84 th EAS CONGRESS May 29 - June 1, 2016 Innsbruck, Austria

Transcription

1 84 th EAS CONGRESS May 29 - June 1, 2016 Innsbruck, Austria Programme Book

2 EAS 2016 AT YOUR FINGERTIPS Download the App for the Full Congress Experience Search EAS 2016 Your all-in-one guide for the duration of the Congress: Access the programme and venue maps Bookmark your preferred sessions and read about your favorite speakers Receive important notifications from the organisers Learn about exhibitors and sponsors, accreditation, and much more 84 th EAS CONGRESS May 29 - June 1, 2016 Innsbruck, Austria Programme Book Organised by Rue François-Versonnex Geneva, Switzerland Tel: Fax: eas@kenes.com

3 84 th EAS CONGRESS CONTENTS Dear friends and Colleagues, Welcome Letter 3 Committees 4 The European Atherosclerosis Society 6 About Innsbruck 8 EAS Keynote Lecture 9 The Anitschkow Prize 10 Young Investigator Awards 11 General Information 13 CME Accreditation 16 Information for Presenters 19 Poster Area Map 22 Programme at a Glance 24 Congress Floor Plan 28 Hall Name Eulogy of Distinguished Scientists 30 Scientific Programme Sunday, May 29, Monday, May 30, Tuesday, May 31, Wednesday, June 1, On behalf of the European Atherosclerosis Society (EAS) and the Austrian Atherosclerosis Society (AAS) we are delighted to welcome you to Innsbruck for the 84th EAS Congress. The congress committees have been working hard on preparing a programme of scientific excellence that will excite and inform the European and Global Atherosclerosis communities. We are particularly proud to announce the certainly inspiring Keynote Lecture by Nobel laureate Michael S. Brown entitled How genes control cholesterol and invaluable contributions by outstanding plenary speakers. The comfortable atmosphere of the congress venue and its impressive setting will provide a unique meeting place for high-level interdisciplinary exchange of newest research highlights and effective networking among participants from more than 70 countries from across the world. The congress will be held at Congress Innsbruck, located next to the scenic river Inn and in walking distance to the city centre and all major hotels. Innsbruck is one of the most beautiful cities in the Alps, surrounded by impressive mountain peaks. Another attraction, of course, are the superb Tyrolean culinary highlights that will be offered during the unique Social Programme and throughout the meeting. Finally, for those with a few days to spare, there are many interesting opportunities to visit Innsbruck s cultural highlights before and after the congress. The 84th EAS congress is accompanied by an International Satellite Symposium on Lp(a) two days ahead of the main congress, again bringing together world experts in this small but exciting and emerging field of an extraordinary atherogenic lipoprotein. On behalf of the organising committee, we welcome you to Innsbruck for a memorable and inspiring congress. Science at a Glance Presentations 81 Poster Presentations, Monday May 30, Poster Presentations, Tuesday, May 31, Index of Authors 181 Recognition, Acknowledgements and Commercial Support 217 Acknowledgements 219 Industry Sponsored Sessions 222 Educational Grant 228 Exhibition Information 229 List of Sponsors and Exhibitors 231 Alberico L. Catapano EAS President Geesje Dallinga-Thie Chair, Programme Scientific Committee Seppo Ylä-Herttuala Co-Chair, Programme Scientific Committee Hans Dieplinger Congress Chair Florian Kronenberg Congress Chair 2 3

4 84 th EAS CONGRESS COMMITTEES CONGRESS CHAIRs Hans Dieplinger, Austria Florian Kronenberg, Austria EAS EXECUTIVE COMMITTEE Alberico L. Catapano, Italy, President Olov Wiklund, Sweden, Vice President M. John Chapman, France, Past President Petri Kovanen, Finland, Secretary & Award Committee Chair Jan Borén, Sweden, Treasurer Lale Tokgözoglu, Turkey, President Elect Christoph J. Binder, Austria Geesje Dallinga-Thie, The Netherlands Børge Nordestgaard, Denmark Arnold von Eckardstein, Switzerland Michal Vrablík, Czech Republic LOCAL ORGANISING COMMITTEE Hans Dieplinger, Innsbruck, Congress Chair Florian Kronenberg, Innsbruck, Congress Co-Chair Christoph Binder, Vienna Benjamin Dieplinger, Linz Christoph Ebenbichler, Innsbruck Bernhard Föger, Bregenz Gerhard Kostner, Graz Dagmar Kratky, Graz Bernhard Paulweber, Salzburg Ruth Prassl, Graz Andreas Ritsch, Innsbruck Wolfgang Schneider, Vienna Herbert Stangl, Vienna Ernst Steyrer, Graz Gerd Utermann, Innsbruck Rudolf Zechner, Graz SCIENTIFIC PROGRAMME COMMITTEE Geesje Dallinga-Thie, The Netherlands, Chair Seppo Ylä-Herttuala, Finland, Co-Chair Eric Bruckert, France Alberico L. Catapano, Italy Hans Dieplinger, Austria Jörg Heeren, Germany Dimitris Kardassis, Greece Florian Kronenberg, Austria Chris Packard, UK Erik Stroes, The Netherlands Arnold von Eckardstein, Switzerland Counselling Members Gerhard Kostner, Austria Wolfgang Schneider, Austria CONGRESS COMMITTEE Marja-Ritta Taskinen, Finland, Chair Jan Borén, Sweden Hans Dieplinger, Austria Danilo Norata, Italy Chris Packard, UK APPRECIATION AND THANKS We would like to thank the reviewers of the submitted abstracts for their valuable help and assistance. FACULTY LIST Afonyuskin Taras, Austria Alitalo Kari, Finland Armitage Jane, UK Assmann Gerd, Germany Averna Maurizio, Italy Banach Maciej, UK Besseling Joost, The Netherlands Binder Christoph J., Austria Borén Jan, Sweden Bossano Prescott Eva, Denmark Boulanger Chantal M., France Brouwer Ingeborg A., The Netherlands Brown Mark J., USA Brown Michael, USA Bruckert Eric, France Bujo Hideaki, Japan Caligiuri Giuseppina, France Carmeliet Peter, Belgium Catapano Alberico, Italy Chapman M. John, France Colhoun Helen, UK Dallinga-Thie Geesje, The Netherlands de Meyer Guido R.C., Belgium Després Jean-Pierre, Canada Dieplinger Benjamin, Austria Dieplinger Hans, Austria Ebenbichler Christoph J., Austria El-Osta Assam, Australia Farinaro Eduardo, Italy Ferri Nicola, Italy Föger Bernhard, Austria Fu Jingyuan, The Netherlands Gaetano Carlo, Germany Gaudet Daniel, Canada Gordts Philip, USA Graham Ian, Ireland Herz Joachim, USA Heeren Jörg, Germany Hersberger Martin, Switzerland Hobbs Helen, USA Hoefer Imo, The Netherlands Hoffmann Michael, Germany Humphries Steve, UK Hunt Steve, Qatar Jauhainien Matti, Finland Kararigas Georgios, Germany Kardassis Dimitris, Greece Karpe Fredrik, UK Koenig Wolfgang, Germany Kollerits Barbara, Austria Kostner Gerhard, Austria Kotseva Kornelia, UK Kovanen Petri, Finland Kratky Dagmar, Austria Kronenberg Florian, Austria Kuivenhoven Jan Albert, The Netherlands Lambert Gilles, France Lamina Claudia, Austria Laufs Ulrich, Germany Letourneur Didier, France Luetjohann Dieter, Germany Ley Klaus, USA Lichtenstein Alice H., USA Lutgens Esther, The Netherlands Mach Francois, Switzerland Maegdefessel Lars, Sweden März Winfried, Germany Malik Vasanti, USA Mangelsdorf David, USA Manolio Teri, USA Marsche Gunther, Austria Martinez Laurent O., France Matsuzawa Yuji, Japan McCormick Sally, New Zealand Moschetta Antonio, Italy Moulin Philippe, France Müller Thomas, Austria Nicholls Stephen, Australia Norata Giuseppe Danilo, Italy Nordestgaard Børge, Denmark Öörni Katariina, Finland Packard Chris, UK Parini Paolo, Sweden Pasterkamp Gerard, The Netherlands Paulweber Bernhard, Austria Pechlaner Raimund, Austria Piepoli Massimo, Italy Poirier Steve, Canada Prassl Ruth, Austria Ray Kausik K., UK Reaven Peter D., USA Ripatti Samuli, Finland Ritsch Andreas, Austria Rudling Mats, Sweden Ryan Robert O., USA Sanjana Neville, USA Schmid Johannes, Austria Schneider Markus, Germany Schneider Wolfgang, Austria Scharbagl Hubert, Austria Scheja Ludger, Germany Schunkert Heribert, Germany Seed Mary, UK Stangl Herbert, Austria Steinhagen-Thiessen Elisabeth, Germany Steyrer Ernst, Austria Stojakovic Tatjana, Austria Stroes Erik, The Netherlands Suhre Karsten, Qatar Stuling Thomas, Austria Taskinen Marja-Riitta, Finland Tawakol Ahmed, USA Titze Jens M., Germany Tokgözoglu Lale, Turkey Tschöp Matthias, Germany Ulmer Hanno, Austria Utermann Gerd, Austria van Gaal Luc, Belgium von Eckardstein Arnold, Switzerland Vrablik Michal, Czech Republic Watts Gerald, Australia Wiklund Olov, Sweden Willeit Peter, UK Ylä-Herttuala Seppo, Finland Yvant-Charvet Laurent, France Zambon Alberto, Italy Zechner Rudolf, Austria Zelcer Noam, The Netherlands Zimmermann Robert, Austria 4 5

5 84 th EAS CONGRESS The European Atherosclerosis Society The European Atherosclerosis Society (EAS) was founded in 1964 with the aim of advancing and exchanging knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease. For more than 50 years the Society s expertise has been used to teach clinicians how to manage lipid disorders and how to prevent atherosclerosis. By offering to our members access to educational materials, and opportunities to take part in Congress and courses, and by providing a forum in which new developments can be discussed, EAS contributes to the development of knowledge in the field, and ultimately to the improved treatment of persons with cardiovascular disease and lipid disorders. In recent years the Society has made a particular effort to recruit young scientists and clinicians also from other related disciplines. The European Atherosclerosis Society s goal is to provide a framework for concerted scientific and clinical discussion of new developments in basic research, diagnosis and therapy of atherosclerosis. What we do at a glance EAS is active in the publication of Guidelines and Consensus Position Papers, and its official Journal is Atherosclerosis. Through a regular series of Featured Commentaries EAS puts into perspective topical issues of relevance to our members. The Society organizes an annual Congress for approximately 2000 delegates, and runs a programme of Advanced Courses for both basic scientists and clinicians. EAS Academy is the Society's online e-learning resource, containing a range of educational material and self-teaching programmes. EAS is co-organiser of the European Lipoprotein Club (ELC) annual Scientific meeting. EAS coordinates the FH Studies Collaboration, working to establish an international registry of observational studies on FH. Why should I become an EAS member? Continue your professional development with EAS educational activities - Advanced courses & EAS Academy EAS membership offers opportunities to deepen your theoretical skills and/or practical knowledge, which you can then apply in your own research or clinical practice. The Society organises educational activities such as Advanced Courses (many CME accredited by EBAC), and offers a wealth of online learning material, such as webcasts, videos and quizzes, on the Society's educational platform, EAS Academy. As an EAS member, you have access to the very latest uploaded material, EAS Academy's Premium content. Stay well informed with EAS publications EAS membership makes it easier for those working in the field to stay abreast of the latest developments in the field. In addition to access to the Society's own publications of Consensus position papers and Guidelines, EAS membership includes complimentary access to Atherosclerosis Journal (worth ca. 300 ), and members receive by newsletters and featured commentaries on topical issues. Interact with leading experts in the field at EAS Congress The participants at EAS annual Congress are world leaders in atherosclerosis research and clinical practice, and the size and format of the Congress lends itself to networking and interaction. EAS members are encouraged to submit their findings as an abstract to Congress, where they can participate at significantly reduced registration fee (savings of up to 100 compared to non-member fees). Apply for grants and prizes as an EAS member EAS members may apply for the Society's travel grants to attend Congress, and, where eligible, may apply for the Society's Prizes. Great value membership benefits at affordable annual subscription rates EAS' aim is to provide access to learning that will help our members to manage lipid disorders and to prevent and treat atherosclerosis. We keep our annual membership subscription rates low 40 (persons over 35) or 20 (persons 35 or younger) so that as many as possible can afford to become members. How to become an EAS member If you're not an EAS member and would like to become one, you should complete the application form and pay the annual subscription fee. Once your application is approved, and the subscription payment processed, you become eligible for membership benefits for one year at 6 7

6 84 th EAS CONGRESS EAS KEYNOTE LECTURE ABOUT innsbruck Innsbruck is the capital city of the federal state of Tyrol in western Austria. It is located in the Inn Valley at the junction with the Wipptal (Sill River), which provides access to the Brenner Pass, some 30 kilometers (19 mi) south of Innsbruck. Located in a broad valley between high mountains, it is an internationally renowned winter sports centre. Innsbruck serves as an ideal place for skiing in winter, and mountaineering in summer. There are several ski resorts around Innsbruck as well as nearby, which include the Axamer Lizum, Patscherkofel, Igls, Seefeld, Tulfes and Stubai Valley. The city of Innsbruck is suffused with the spirit of the Habsburg dynasty. The Habsburgs legacy in Innsbruck is sumptuous and palatial majestic and has left many architectural landmarks in the city. The Keynote Lecture at EAS Congress 2016 is given by Michael S. Brown, Paul J. Thomas Professor of Molecular Genetics and Director of the Jonsson Center for Molecular Genetics at University of Texas Southwestern, Dallas, USA. Dr. Brown and his long-time colleague, Dr. Joseph L. Goldstein, are recognised as the discoverers of the low density lipoprotein (LDL) receptor, which controls the level of cholesterol in blood and in cells. Drs. Brown and Goldstein have received many awards for this work, including the U.S. National Medal of Science and the Nobel Prize for Medicine or Physiology in Working together, Drs. Brown and Goldstein showed that familial hypercholesterolaemia is caused by genetic defects in the LDL receptor, which disrupt the normal regulation of cholesterol metabolism. Their studies led to the elucidation of the mechanism by which this receptor carries LDL particles into cells through coated pits and coated vesicles. These LDL receptor studies provided clear evidence for selective uptake of macromolecules into cells, giving rise to the concept of receptor-mediated endocytosis. More recently, study of another genetic disease called Niemann-Pick C (NPC), has provided insights into how cholesterol is transported from one organelle to another, which underlie the consistency in cholesterol concentration in the plasma membrane. Extensive studies showed that both the NPC1 and NPC2 proteins have the capacity for binding LDL cholesterol. Whereas binding of cholesterol to NPC2 is rapid, occurring within minutes, binding to NPC1 is extremely slow, requiring several hours to reach equilibrium. However, this process can be accelerated when cholesterol is delivered by NPC2. Based on these findings, it was proposed that NPC2 extracts cholesterol from LDL in the lysosome and then transfers it to the N-terminal domain of membrane-bound NPC1 for insertion into the lysosomal membrane, currently being tested in the laboratory of Professor Brown. The work of Drs. Brown and Goldstein has not only been the stimulus for new thinking about cholesterol homeostasis, but also has led to the development of new concepts in biology. Specifically, these include selective sorting of proteins within the plasma membrane, a prerequisite for receptor-mediated endocytosis; receptor-mediated endocytosis and receptor recycling; and, finally, the concept of feedback regulation of receptors. Michael Brown graduated in 1962 from the College of Arts and Sciences of the University of Pennsylvania, with chemistry as his major subject, and subsequently obtained his M.D. degree in 1966 at the same university. He was an intern and resident at the Massachusetts General Hospital, where he met Joseph L. Goldstein, a fellow intern; the two established the friendship and mutual respect that led to their long-term scientific collaboration. Dr. Brown subsequently completed a postdoctoral fellowship at the National Institutes of Health, before moving to UT Southwestern, becoming Professor in The remainder of this story has been instrumental in changing how hypercholesterolaemia is managed, and paving the way for innovative new therapeutic agents targeting LDL cholesterol. 8 9

7 84 th EAS CONGRESS THE ANITSCHKOW PRIZE YOUNG INVESTIGATOR AWARDS The Anitschkow prize recipient 2016 is Professor Peter Carmeliet, Professor at the Katholieke Universiteit Leuven (Leuven, Belgium). The Anitschkov lecture entitled Endothelial Cell Metabolism: A Novel Player in Atherosclerosis? Basic Principles and Therapeutic Opportunities will be part of the Congress Opening Ceremony. professor Peter Carmeliet Peter Carmeliet is a physician and professor at the Katholieke Universiteit Leuven (Leuven, Belgium). He is former director ( ) of the Vesalius Research Center, VIB - KU Leuven and is heading the Laboratory of Angiogenesis and Vascular Metabolism at the VRC. His research interests are vasculogenesis, angiogenesis, and vascular endothelial growth factors. His research group has sought to elucidate the molecular basis of angiogenesis with the aim of translating their findings to therapeutic concepts and ultimately novel treatments. Latest findings indicate that the efficacy of current antiangiogenic therapy in cancer is limited by intrinsic refractoriness and acquired drug resistance. To overcome this problem, his research team pioneered the study of endothelial cell metabolism during vessel sprouting. Professor Carmeliet is the recipient of numerous awards, including InBev-Baillet Latour health prize (2010), Ernst Jung-Priz für Medizin (2010), the Blaise Pascal Medal in Medicine and Life Sciences by the European Academy of Sciences (2011), the Münster Heart Center Award (2015), and award of the Noble title of Baron, granted by King Filip of Belgium (2015). These annual awards are presented by EAS for outstanding publications by young scientists in the field of Atherosclerosis steve poirier In 2003, Steve joined the team of Dr. Nabil Seidah at the Clinical Research Institute of Montreal the same year the laboratory published the identification of PCSK9 and its link to familial hypercholesterolemia. Over the years, he actively designed and performed key experiments as well as collaborated with international researchers to accomplish important studies in the highly competitive field of PCSK9 biology in cardiovascular diseases. Cited by more than 850 publications, those manuscripts have questioned and revisited published papers that supported the fact that PCSK9 had only one target and that it was acting exclusively via an extracellular route. He was the first to show that PCSK9 has other important targets towards LDLR family members and revealed the existence of an intracellular route for PCSK9-induced LDLR degradation. In addition, he also made many other significant contributions in the field of PCSK9 such as the identification of the two known natural inhibitors of PCSK9 namely AnxA2 (extra-hepatic) and GRP94 (hepatic) now used as precursors for the design of lipid-lowering agents with high therapeutic potentials. He also showed that the cytosolic adaptor AP-1A is directly implicated in the intracellular trafficking of Niemann-Pick type C proteins and revealed the first evidence and mechanism by which the cancer drug 5-Azacytidine favorably perturbs lipid and cholesterol metabolism. Together with his great scientific partner Dr. Gaétan Mayer (CSO), he is the co-founder and CEO of Monogenic Pharmaceuticals a Montreal Heart Institute-based biotech primarily developing 4 distinct unprecedented and highly innovative therapeutic pipelines to lower circulating LDL- Cholesterol and cardiovascular diseases by specifically targeting PCSK

8 84 th EAS CONGRESS GENERAL INFORMATION YOUNG INVESTIGATOR AWARDS Joost Besseling Dr. Besseling started Med School at the University of Amsterdam (the Academic Medical Center) in 2004 and obtained his medical degree in Subsequently, he started his PhD research under the guidance of Prof. Kastelein, Dr. Hovingh and Dr. Hutten. He worked on studies focused on different aspects of familial hypercholesterolemia and published in highly cited peer reviewed journals, such as Lancet and JAMA. He specifically focused on the diagnosis, consequence and treatement of FH and as such showed that FH patients are relatively protected from diabetes mellitus. Moreover, he developed a new prediction model for carriership of an FH mutation, and investigated the consequence of CETP inhibition in these patients. In January 2016, he started his residency to become a board certified specialist in internal medicine, and in October 2016, he will defend his PhD thesis on familial hypercholesterolemia. VENUE Congress und Messe Innsbruck GmbH Rennweg Innsbruck, Austria OFFICIAL LANGUAGE The official language of the Congress is English. All presentations will be made in English. CLOTHING Clothing is informal for all occasions. REGISTRATION DESK HOURS The Registration Desk will be situated at the North Entrance, ground level of the convention center, as follows: Sunday, May 29 10:00 21:00 Monday, May 30 07:30 19:40 Tuesday, May 31 08:00 18:30 Wednesday, June 1 08:00 12:30 EXHIBITION OPENING HOURS Sunday, May 29 17:30 end of Welcome Reception Monday, May 30 10:00 17:30 Tuesday, May 31 10:00 17:30 Wednesday, June 1 10:00 12:30 CONGRESS NAME BADGE Upon registration you will receive your name badge. You are kindly requested to wear your badge during all sessions and events. EAS 2016 app Install the EAS 2016 interactive mobile App to your smartphone and portable devices to access all the Congress information you could need during the Congress: See the overview of sessions, speakers and exhibitors Create your own programme for the event, including bookmarking the sessions you wish to attend Receive real-time updates Download the EAS App now to enhance your congress experience! (available on the App Store or Google Play)

9 84 th EAS CONGRESS EAS 2016 E-Book EAS 2015 Final Programme E-Book is available online and can be viewed and downloaded at: This e-book offers a green alternative to the printed programme book, provides delegates a convenient and enjoyable way to access congress content on the move and is designed to provide a user friendly interface on any mobile device. EAS is dedicated to implementing innovative and environmentally-friendly technology. The programme book can be downloaded as a PDF file from the congress website. REFRESHMENTS Coffee and refreshments will be served to Congress participants in the Exhibition Area from May 29-June 1, as indicated in the Programme. Cash Bars will be available next to the Exhibition Area. internet access WiFi is available for congress participants throughout the public areas. In order to log in please use the following user name and password: User name: eas-2016 Password: eas-2016 Free internet and facilities will be available in the exhibition area during the exhibition opening hours only. Congress abstracts will also be available for viewing from these stations. Please be considerate of fellow participants when using these facilities. CONGRESS ABSTRACTS The congress abstracts will be published online in the Atherosclerosis Journal following the congress. MOBILE PHONES AND PHOTOGRAPHY Participants are kindly requested to keep their mobile phones switched off in session halls and refrain from taking pictures during sessions. Cloak Room A cloak room will be available for participants on Wednesday, June 1st at the Innfoyer. LIABILITY AND INSURANCE The Congress Secretariat and Organisers cannot accept liability for personal accidents or loss of or damage to private property of participants. Participants are advised to take out their own personal travel and health insurance for their trip. SAFETY AND SECURITY Please do not leave bags or suitcases unattended at any time, whether inside or outside the session halls. Hotels strongly recommend that you use their safety deposit boxes for your valuables. WEBCASTING A selection of sessions will be webcast and will be available on the Society website after the Congress. CONGRESS organisers 84th EAS Congress Rue François-Versonnex 7, 1207 Geneva, Switzerland Tel: Fax: eas@kenes.com SMOKING POLICY The 84th EAS Congress is a Non-Smoking event and participants are requested to refrain from smoking in the venue

10 84 th EAS CONGRESS CME ACCREDITATION EDUCATIONAL OBJECTIVES After participating in this educational event, learners should be able to: Address individual needs in compliance with their Continuous Professional Development (CPD) plan. Exchange ideas and knowledge in the field of Atherosclerosis and related cardiovascular conditions across continents, institutions, and individuals. Discuss the innovative new therapeutic agents targeting LDL cholesterol. Identify possible programmatic collaborations to more effectively address regional, national and local responses to Atherosclerosis around the world and overcome barriers that limit access to prevention, care and services. Discuss the latest scientific advantages in the field of Atherosclerosis and related cardiovascular conditions. Summarise the latest research outcomes in the field of Atherosclerosis and related cardiovascular conditions. TARGET AUDIENCE Specialists in the field of atherosclerosis, clinical chemistry, diabetes, endocrinology, primary care and more. ACCREDITATION STATEMENT AND CREDIT DESIGNATION European Board for Accreditation in Cardiology (EBAC) An application was made to the European Board for Accreditation in Cardiology (EBAC) for CME accreditation of this event. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). American Medical Association (AMA) Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits. Information on the process to convert EACCME credit to AMA credit can be found at www. ama-assn.org/go/internationalcme. Royal College of Physicians and Surgeons of Canada Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. For more information, visit: EBAC Accredited Educational Programme EBAC Accredited Educational Programmes will be taking place during the Congress as follows: EBAC Accredited Educational Programme: Diet and prevention of cardiovascular disease. Symposium at EAS 2016 Innsbruck Sunday, May 29, 2016, 14:00-15:30 This session is supported by an unrestricted educational grant from BASF, Raisio and Unilever. EBAC Accredited Educational Programme: Gene therapy and lipoprotein lipase deficiency. Symposium at EAS 2016 Innsbruck Sunday, May 29, 2016, 14:00-15:00 This session is supported by an unrestricted educational grant from Chiesi. EBAC Accredited Educational Programme: Gene therapy and lipoprotein lipase deficiency. Symposium at EAS 2016 Innsbruck Monday, May 30, 2016, 13:00-14:00 This session is supported by an unrestricted educational grant from Meda (Rottapharm). EBAC Accredited Educational Programme: Low HDL high triglyceride, diabetic dyslipidaemia. Symposium at EAS 2016 Innsbruck Tuesday, May 31, 2016, 13:00-14:00 This session is supported by an unrestricted educational grant from Mylan. EBAC Accredited Educational Programme: Lysosomal Acid Lipase Deficiency. Symposium at EAS 2016 Innsbruck Tuesday, May 31, 2016, 13:00-14:00 This session is supported by an unrestricted educational grant from Alexion. In compliance with EBAC/ EACCME guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest that might cause a bias in the presentations. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities. CREDIT BREAKDOWN Day Sunday, May 29 Monday, May 30 Tuesday, May 31 Total Credits: Maximum Credits CREDIT BREAKDOWN Day Monday, May 30 Tuesday, May 31 Wednesday, June 1 Total Credits: Maximum Credits

11 84 th EAS CONGRESS INFORMATION FOR PRESENTERS TO RECEIVE YOUR CME/CPD CERTIFICATE The CME/CPD certificate will be available after completing the online evaluation and credit claiming procedure. The process takes about 5 minutes. We thank you for your feedback as it is an important part of CME/CPD accreditation and helps improve future educational offerings. Before June 29, 2016: 1. Access the online system via any of the following Please note that web browsers Mozilla Firefox 2.X or higher, or Google Chrome are recommended - Visit the CME/CPD Accreditation page on the event website - Follow the link in the sent at the end of the event 2. Complete the anonymous online evaluation 3. Complete the credit claim form and submit 4. The CME/CPD certificate will be available for download; fill-in and retain for your personal records DISCLOSURE AND RESOLUTION OF PERSONAL CONFLICTS OF INTEREST In accordance with CME/CPD accreditation criteria and standards for commercial support to ensure balance, independence, objectivity, and scientific rigor, those in control of the educational content must disclose potential or actual conflicts of interest. Disclosure information is evaluated and conflicts of interest resolved. Disclosure is made to participants prior to the activity. Participants will be asked on the evaluation to assess the objectivity and independence of the event. INDUSTRY SUPPORT DISCLOSURE This event is supported, in part, by funding from industry. All support is managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support. Appropriate acknowledgement of all supporting organizations is made in the Programme guide, on the event website, and with signage during the event. Disclosure is made to participants prior to the activity. Aegerion Pharmaceuticals Chiesi Akcea Therapeutics Denka Seiken Alexion Amgen BASF European FH Network FH Score Fuji Film/ Sonosite IBL Kaneka Pharma Kowa Meda Pharma Merck MSD Mercodia Mylan Numares Pfizer Raisio Randox Regeneron Sanofi Unilever Wisepress ORAL PRESENTATIONS Data Presentation: A speakers ready room will be available throughout the entire Congress for speakers. The room is located on the 1st Level (Maximilian). If using a PowerPoint presentation (or any other PC based application, such as PDF), please note you need to bring it on USB Memory stick and load it on one of the Congress computers in the Speakers Ready Room at least 1 hour before the start of the session. The recommended format for PPT presentations is 16:9. Please make sure to prepare your presentation accordingly. Please note that the Congress computers in the session halls are being supplied with Office 2010 (at least). If combining video films with PowerPoint, please make sure to check it in the session hall where your lecture is taking place during the break prior to your session, at least 30 minutes before the start of the session - even after checking it in the Speakers Ready Room. Alternatively you may supply your own laptop computer. In such a case please confirm that it has a VGA socket for external signal and come to check it first in the Speakers Ready Room as soon as you arrive and later on in the session hall where your lecture is taking place during the break prior to your session, at least 30 minutes before the start of the session. Important note for Apple Mac users: In order to use MAC presentations on a PC compatible computer please note that you need to prepare it according to the instructions below, before bringing it to the Speakers Ready Room: 1. Use a common font, such as Arial, Times New Roman, Verdana etc. (special fonts might be changed to a default font on a PowerPoint based PC). 2. Insert pictures as JPG files (and not TIF, PNG or PICT - these images will not be visible on a PowerPoint based PC). Alternatively you may use your own Macintosh laptop computer. In such a case please confirm you provide it with a VGA adaptor for external signal, advise the operators in the Speakers Ready Room about it as soon as you arrive and later on test it in the session hall where your lecture is taking place during the break prior to your session, at least 30 minutes before the start of the session 18 19

12 84 th EAS CONGRESS SCIENCE AT A GlANCE PRESENTATIONS EAS is proud to have Science at a Glance E-Poster sessions that will be located in the Exhibition area, providing the unique opportunity for convivial scientific discussions and exchange. For further details please refer to the Overview of these Sessions. OVERVIEW OF SCIENCE AT A GLANCE E-POSTER SESSIONS Session I, Monday, May 30, :00-14:00 Session Topic Session Chair E-Poster Station Poster # Lipids and Lipoproteins Jörg Heeren, Germany Station A SaG001-SaG008 Vascular Biology I Genetic, Omics and in silico Approaches Guido de Meyer, Belgium Station B SaG009-SaG016 Neville Sanjana, USA Station C SaG017-SaG024 CV Risk Factors and Atherosclerosis I Yuji Matsuzawa, Japan Station D SaG25-SaG032 Session II, Monday, May 30, :00-15:00 Session Topic Session Chair E-Poster Station Poster # Experimental Cadiovascular Medicine I Nutrition, Nutraceuticals and Cardiovascular Disease Paolo Parini, Sweden Station A SaG033-SaG040 Alice H. Lichtenstein, USA Station B SaG041-SaG048 Pharmacology of Dyslipidemia Maurizio Averna, Italy Station C SaG049-SaG056 Imaging in Vascular Dysfunction and Myocardial Infarction Wolfgang Koenig, Germany Station D SaG057-SaG064 Session III, Tuesday, May 31, :00-14:00 Session Topic Session Chair E-Poster Station Poster # CV risk factors and Atherosclerosis II Winfried März, Germany Station A SaG065-SaG072 Vascular Biology II Herbert Stangl, Austria Station B SaG073-SaG080 Insulin Resistance, Diabetes, Metabolic Syndrome and Obesity Hypertension, Liver and Chronic Renal Disease Gerald Watts, Australia Station C SaG081-SaG088 TBA Station D SaG089-SaG096 Session IV, Tuesday, May 31, :00-15:00 Session Topic Session Chair E-Poster Station Poster # Experimental Cadiovascular Medicine II Immunity and Atherosclerosis Emerging Aspects in Pharmacological Treatment of Primary and Secondary Dyslipidemia Matti Jauhiainen, Finland Giuseppina Caligiuri, France Benjamin Dieplinger, Austria Station A SaG097-SaG104 Station B SaG105-SaG112 Station C SaG113-SaG120 Vascular Biology III Joachim Herz, USA Station D SaG121-SaG128 POSTER PRESENTATIONS Posters will be on display in 2 shifts. Please check the Scientific Programme to see the exact poster board number, date, and time of the poster discussion groups. The organisers are not responsible for any posters that have not been removed by the end of sessions on Wednesday, June 1. Poster Shift I Posters may be mounted from 17:30 on Sunday, May 29, 2016 and should remain on display until Monday, May 30, 2016 at 18:30. Poster Shift II Posters may be mounted from 08:30 on Tuesday, May 31, 2016 and should remain on display until Wednesday, June 1, 2016 at 12:30. Authors are asked to actively participate in both the poster sessions on the day in which their poster was allocated to. Poster sessions will take place on Monday, May 30 from 13:00-14:00, 17:00-18:00 and Tuesday, May 31 from 13:00-14:00, 17:00-18:

13 84 th EAS CONGRESS Poster Area Map POSTER OVERVIEW Please note that posters of Abstract presenters that were not registered to the congress by the deadline were not allocated poster boards. Such abstract presenters are requested to approach the poster help desk to be allocated an available poster board on-site. To: Nikolai N. Anitschkow (Tirol) To: Nikolai N. Anitschkow (Tirol) Poster Shift I Monday, May 30, 2016 Session Time Topic Poster Board 13:00-14:00 Vascular Biology: Endothelium and Smooth Muscle Cells Vascular Biology: Macrophages, Inflammation, Immunity Vascular Biology: Myocardial Inf arction, Stroke, Peripheral Vascular Disease Vascular Biology: Immune Disease and Cardiovascular Pathologies Lipoproteins and Lipid Metabolism: ApoB Containing Lipoproteins Lipoproteins and Lipid Metabolism: Lipoprotein Metabolism :00-18:00 Lipoproteins and Lipid Metabolism: Lp(a) Lipoproteins and Lipid Metabolism: HDL CVD Risk Factors Poster Shift II Tuesday, May 31, 2016 Session Time Topic Poster Board 13:00-14:00 Metabolic Abnormalities and Atherosclerosis: Diabetes Metabolic Abnormalities and Atherosclerosis: Adipose Tissue Metabolic Abnormalities and Atherosclerosis: Kidney Metabolic Abnormalities and Atherosclerosis: NASH and Liver Abnormalities Dyslipidemias: Dyslipidemias, Screening and Treatment :00-18:00 Dyslipidemias: Treatment Dyslipidemias: Coagulation Dyslipidemias: Endothelial Dysfunction Genetics, Nutrition, Biomarkers: Genetics, Gene Regulation Genetics, Nutrition, Biomarkers: Nutrition Genetics, Nutrition, Biomarkers: Biomarkers Genetics, Nutrition, Biomarkers: Guidelines and Miscellaneous Please note that posters of abstract presenters that were not registered to the Congress by the deadline were not allocated poster boards. Such abstract presenters are requested to approach the poster help desk to be allocated an available poster board on-site

14 84 th EAS CONGRESS Programme at a Glance Monday, May 30, 2016 Exhibition & Posters Area Nikolai N. Anitschkow (Tirol) Karl Landsteiner (Innsbruck) Carl von Rokitansky (Brussel) Wilhelm Auerswald (Strassburg) Plenary Session Company Sponsored Session Workshop EBAC Accredited Session Science at a Glance Session Poster Walk Session Young Investigators Session Other Oral Communication Session Social Event 08:30-10:30 Plenary Session: Integrative Approach in Atherosclerosis 10:30-11:00 Coffee Break, Exhibition and Poster Viewing Sunday, May 29, 2016 Exhibition & Posters Area Nikolai N. Anitschkow (Tirol) Karl Landsteiner (Innsbruck) Carl von Rokitansky (Brussel) 12:00-13:30 12:30-13:30 Meet the Expert Supported Session Not included in the CME/CPD programme 13:30-14:00 Break Wilhelm Auerswald (Strassburg) Workshop 1.1 Novel Aspects of Pathogenesis in Atherosclerosis Workshop 2.1 Lipoproteins and Extracellular Matrix 11:00-11:45 Advanced Clinical Seminar Debate on Statin Associated Muscle Symptoms (SAMS) - A Problem for Clinicians or a Problem with Clinicians? 11:45-12:30 Advanced Clinical Seminar Role of Nutrition in Disease Pathology Workshop 3.1 Novel Therapies 14:00-15:30 EBAC Accredited Educational Programme Diet and Prevention of Cardiovascular Disease 15:30-16:00 Break 16:00-17:30 Educational Symposium Supported Session Not included in the CME/CPD programme 17:30-18:00 Break 18:00-19:45 Opening Ceremony, including the Anitschkow Lecture 19:45 20:45 Welcome Reception 14:00-15:00 EBAC Accredited Educational Programme Gene Therapy and Lipoprotein Lipase Deficiency 12:30-15:00 Break, Exhibition and Poster Viewing 13:00-14:00 Science at a Glance Session I 13:00-14:00 Poster Walk Session I 14:00-15:00 Science at a Glance Session II 13:00 14:30 Educational Symposium Supported Session Not included in the CME/CPD programme :30 EAS- ESC Joint Workshop Sex differences in Cardiovascular Diseases 16:30-17:00 Coffee break, Exhibition and Poster Viewing 17:00-18:30 17:00-18:00 Poster Walk Session II Young Investigator Session Vascular Biology and Inflammation 13:00 14:30 Educational Symposium Supported Session Not included in the CME/CPD programme Workshop 1.2 Therapeutic and Diagnostic Targeting of the Arterial Wall Young Investigator Session Lipids and Lipoproteins Metabolism 13:00-14:00 EBAC Accredited Educational Programme Nutraceuticals with Lipid Lowering: Who Can Benefit? Workshop 2.2 Adipose Tissue Liver Axis Young Investigator Session Clinical Epidemiology and Pharmacology 15:00-15:45 Late Breaking: Basic Science 15:45-16:30 Young Investigator Award Session Oral Communication Session Vascular Biology 18:40-19:40 Keynote Lecture 24 25

15 84 th EAS CONGRESS Tuesday, May 31, 2016 Wednesday, June 1, 2016 Exhibition & Posters Area Nikolai N. Anitschkow (Tirol) Karl Landsteiner (Innsbruck) Carl von Rokitansky (Brussel) Wilhelm Auerswald (Strassburg) Exhibition & Posters Area Karl Landsteiner (Innsbruck) Carl von Rokitansky (Brussel) Wilhelm Auerswald (Strassburg) Fritz Pregl (Freiburg) 08:30-10:30 Plenary Lecture: Lipid Biology, New Insights 10:30-11:00 Coffee Break, Exhibition and Poster Viewing 11:00-12:30 Workshop 1.3 Cellular Stress Response in Atherosclerosis 12:30-15:00 Break, Exhibition and Poster Viewing 13:00 14:00 Science at a Glance Session III Workshop 2.3 Gut- Liver Axis 13:00-14:30 Educational Symposium Supported Session Not included in the CME/CPD programme ICCR-EAS Joint Session Management of Cardiometabolic Risk; Where Do We Stand? 13:00-14:00 EBAC Accredited Educational Programme Low HDL High Triglyceride, Diabetic Dyslipidaemia Workshop 3.2 Vascular Aging and Atherothrombosis 13:00-14:00 EBAC Accredited Educational Programme Lysosomal Acid Lipase Deficiency 08:30-10:30 Plenary Session: Future Therapeutic Challenges 10: Coffee Break, Exhibition and Poster Viewing 11:00-12:30 Workshop 1.4 Inflammation Immunity and Atherosclerosis Workshop 3.4 Biology of CVD Risk Workshop 4.4 New Guidelines on Prevention of Cardiovascular Disease in Clinical Practice Workshop 2.4 Novel Role of Lipoprotein Receptors 13:00-14:00 Poster Walk Session III 14:00 15:00 Science at a Glance Session IV 14:00-14:45 Supported Session Special Lecture Not included in the CME/CPD programme 14:10-14:55 Supported Session Not included in the CME/CPD programme 14:10-14:55 Supported Session Meet the Expert Not included in the CME/CPD programme :30 Workshop 3.3 Genetics in Risk Factor Prevention and Treatment Late Breaking: Clinical Science 15:00-16:30 EAS Initiatives Update Session (open to all) Advanced Clinical Seminar Economics and Guidelines/ Technology of the Future 16:30-16:50 EAS General Assembly 16:30-17:00 Coffee Break, Exhibition and Poster Viewing 17:00-18:30 17:00-18:00 Poster Walk Session IV Workshop 3.5 Epigenetics and Gene Regulation Oral Communication Session Imaging, Biomarkers Oral Communication Session Intracellular Lipid Young Investigator Session Novel pathways in 26 27

16 84 th EAS CONGRESS CONGRESS FLOOR PLAN Level 0 Level 2 Level 1 Level

17 84 th EAS CONGRESS HALL NAME EULOGY OF DISTINGUISHED SCIENTISTS Nikolai N. Anitschkow ( ) Professor of the Department of Pathological Physiology of the Military Medical Academy St. Petersburg, Russia In 1913, experimental pathologist Dr. Nikolai N. Anitschkow showed that simply feeding to rabbits purified cholesterol dissolved in sunflower oil induced vascular lesions closely resembling those of human atherosclerosis, both grossly and microscopically. Controls fed with only the sunflower oil showed no lesions. It is fair to say that this paper marked the beginning of the modern era of atherosclerosis research. Dr. Anitschkow was not only a keen-eyed structural pathologist and a careful experimentalist; he thought in terms of function and time-related pathogenesis. However, the landmark studies by Dr. Anitschkow were largely rejected at the time. An important reason for this was that the findings were inconsistent with the prevailing view of atherosclerosis. It was generally accepted to be an inevitable accompaniment of aging (the senescence hypothesis ). If the full significance of his findings had been appreciated at the time, we might have saved more than 30 years in the long struggle to settle the cholesterol controversy. In honor of Dr. Nikolai N. Anitschkow, the Anitschkow Prize in Atherosclerosis Research awarded annually by the EAS recognizes outstanding research in the field of atherosclerosis and linked metabolic disturbances. Karl Landsteiner ( ) Karl Landsteiner, Austrian pathologist, studied medicine at the University of Vienna. In 1896 he became an assistant in the Hygiene Institute at Vienna where he was interested in the mechanisms of immunity and in the nature of antibodies. From 1898 till 1908 he held the post of assistant in the University Department of Pathological Anatomy in Vienna, in 1911 he became Professor of Pathological Anatomy in the University of Vienna. He showed that the cause of poliomyelitis could be transmitted to monkeys by injecting into them material prepared by grinding up the spinal cords of children who had died from this disease. His work laid the foundations of our knowledge of the cause and immunology of poliomyelitis. Landsteiner made numerous contributions to both pathological anatomy, histology and immunology, all of which showed, not only his meticulous care in observation and description, but also his biological understanding. But his name will no doubt always be honoured for his discovery in 1901 of the blood groups, for which he was given the Nobel Prize for Physiology or Medicine in In 1875 Landois had reported that, when man is given transfusions of the blood of other animals, these foreign blood corpuscles are clumped and broken up in the blood vessels of man with the liberation of haemoglobin. In Landsteiner pointed out that a similar reaction may occur when the blood of one human individual is transfused, not with the blood of another animal, but with that of another human being, and that this might be the cause of shock, jaundice, and haemoglobinuria that had followed some earlier attempts at blood transfusions. His suggestions, however, received little attention until, in 1909, he classified human blood into the now well-known A, B, AB, and O groups and showed that transfusions between individuals of groups A or B do not result in the destruction of new blood cells and that this catastrophe occurs only when a person is transfused with the blood of a person belonging to a different group. Earlier, in , Landsteiner had suggested that, because the characteristics which determine the blood groups are inherited, the blood groups may be used to decide instances of doubtful paternity. In 1922, he accepted a post in the Rockefeller Institute for Medical Research in New York. It was here that he did further work on the blood groups which greatly extended the number of these groups, and studied bleeding in the new-born, leading to the discovery of the Rh-factor in blood, which relates the human blood to the blood of the rhesus monkey

18 84 th EAS CONGRESS Karl Baron von Rokitansky ( ) Austrian pathologist whose endeavours to establish a systematic picture of the sick organism from nearly 100,000 autopsies 30,000 of which he himself performed helped make the study of pathological anatomy a cornerstone of modern medical practice and established the New Vienna School as a world medical centre during the latter half of the 19th century. A professor of pathological anatomy at the Vienna General Hospital, he inspired the Bohemian student Ignaz Semmelweis, later a martyr to the cause of antiseptic medical practice, to take up the study of medicine and afterward supported him in his struggle to eliminate childbed fever by cleaning up Europe s maternity wards. First to detect bacteria in lesions of malignant endocarditis, an often rapidly fatal inflammation of the membrane lining the inner walls of the heart, Rokitansky created the basis for a differentiation of lobar pneumonia (originating in the lower lobe of the lung) and lobular pneumonia, or bronchopneumonia (originating in the finer subdivisions of the branched bronchial tree). He made a fundamental study of acute yellow atrophy of the liver (now known as Rokitansky s disease), established the micropathology of pulmonary emphysema (a condition of the lung characterized by enlarged air spaces separated from the terminals of the bronchial tree), and first described spondylolisthesis, the forward displacement of one vertebra over another. Wilhelm Auerswald ( ) Wilhelm Auerswald, Austrian physiologist, graduated from medical school at the University of Vienna in Auerswald became assistant at the Physiological Institute of the University of Vienna in Under the later-appointed Director Carl Schwarz-Wendl Auerswald could finish his habilitation in Physiology in 1950 and was established in 1968 as the successor to Gustav Schubert. His scientific work includes 370 publications in the fields of physiology and pathology of blood proteins, nutrition, thrombosis, atherosclerosis, aerospace- and work physiology. It was Auerswald s concern to make his research results available for practical medicine; he provided valuable pioneering work in the fields of plasma replacement, productions of vaccines (first Poliomyelitis vaccine in Austria) and immunoglobulins (first intravenous application). His blood coagulation studies gained high international reputation. In his teaching Auerswald was anxious to consider physiology as medical basic science with strong and immediate reference to the bedside; he also succeded in renaming his workplace into the Department of Medical Physiology. Its translation and adaptation of the Textbook of Physiology 32 33

19 34 Fritz Pregl ( ) Fritz Pregl, Austrian physiologist and chemist, studied medicine at the University of Graz and received his M.D. In 1894, he became assistant lecturer for physiology and histology under Alexander Rollett, taking over the chair when Rollett died in During this time Pregl also acquired a thorough knowledge of all branches of chemistry under the guidance of Professor Skraup. He started investigating the components of albuminous bodies and the analysis of bile acids. His work, however, was handicapped by the lack of sufficient starting materials and this fact impelled him to look for methods requiring smaller amounts when making quantitative analyses of elements in compounds. The years , whilst professor at the University of Innsbruck, were almost entirely devoted to developing the method of quantitative organic micro-analysis. Pregl continued this work when he was recalled to Graz in Initially Pregl s scientific work had been mainly in the fields of physiology and physiological chemistry; later he turned to the study of the constitution of chemical compounds, in particular the investigation of bile acids. By 1912 he was able, by using his own methods of quantitative micro-analysis, to make measurements of carbon, hydrogen, nitrogen, sulphur, and halogen, using only 5-13 mg of starting materials with results as accurate as those obtained by macro-analysis. Later he perfected his techniques so that as little as 3-5 mg were adequate. Pregl also contributed a number of micromethods for measuring atomic groups and developed a series of apparatus, including a sensitive microbalance, necessary for his work. The greatest honour was the award of the Nobel Prize for Chemistry by the Swedish Academy of Sciences in The Nobel Committee pointed out that it was not for a discovery, but for modifying and improving existing methods that Pregl was awarded the prize. Following the Nobel Prize for Chemistry in 1923, chemists from all over the world came to the Medico- Chemical Institute in Graz to study Pregl s techniques of quantitative organic micro-analysis under his guidance. 84 th EAS CONGRESS May 29 - June 1, 2016 Innsbruck, Austria Scientific Programme Sunday, May 29,

20 Sunday, May 29, 2016 Sunday, May 29, :30-13:30 C. von Rokitansky Hall Industry Symposium: Meet the Expert Supported Session. Not included in the CME/CPD Programme. For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme. 13:30-14:00E exhibition & Poster Area Break 37

21 Sunday, May 29, :00-15:30 C. von Rokitansky Hall EBAC Accredited Session: Diet and Prevention of Cardiovascular Disease This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s); Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). EAS have independently organised all matters related to this 90-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from BASF, Raisio and Unilever in support of the Programme. Chair: E. Bruckert (France) 1 14:00 SHOULD SATURATED FAt BE TARGETED FOR The PREVENTION Of CARDIOVASCULAR DISEASE? 2 A.H. Lichtenstein (USA) 14:20 SUGAR INTAKE AND CARDIOVASCULAR DISEASE - SHOULD IT BE The NEXT FIGHT TO DECREASE CVD? 3 J.P. Després (Canada) 14:40 PLANT STEROL AND STANOLS AND CARDIOVASCULAR DISEASE. IMPACT Of ENRICHED FOODS AND CHOLESTEROL-LOWERING DRUGS 4 J. Chapman (France) 15:00 ROLE Of MICROBIOTA ON CARDIOVASCULAR DISEASE 5 J. Fu (Netherlands) 15:20 PANEL DISCUSSION 6 A.H. Lichtenstein (USA) J.P. Després (Canada) 7 J. Chapman (France) 8 J. Fu (Netherlands) 9 14:00-15:00W w. Auerswald Hall EBAC Accredited Session: Gene Therapy and Lipoprotein Lipase Deficiency This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s); Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Chiesi in support of the Programme. Chair: J. Borén (Sweden) 10 Chair: M. Averna (Italy) 11 14:00 GENETIC SEVERE HYPERTRIGLYCERIDEMIA 12 A. Zambon (Italy) 14:15 GENETIC THERAPY FOR LIPOPROTEIn LIPASE DEFICIENCY 13 E. Stroes (Netherlands) 14:45 CASE REPORT 14 E.S. Thiessen (Germany) 14:45 CONCLUSION AND DISCUSSION 15 15:30-16:00E exhibition & Poster Area Break 16:00-17:30N n. Anitschkow Hall Industry Symposium: Company Sponsored Session Supported Session. Not included in the CME/CPD Programme. For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme. 17:30-18:00E exhibition & Poster Area Break

22 18:00-19:45N n. Anitschkow Hall Plenary: Opening Ceremony, including the Anitschkow Lecture Chair: A. Catapano (Italy) 16 Chair: H. Dieplinger (Austria) 17 Chair: F. Kronenberg (Austria) 18 18:00 WELCOME FROM EAS PRESIDENT 19 A. Catapano (Italy) 84 th EAS CONGRESS May 29 - June 1, 2016 Innsbruck, Austria 40 18:03 WELCOME FROM IAS PRESIDENT 20 Y. Matsuzawa (Japan) 18:06 WELCOME FROM MAYOR Of INNSBRUCK 21 C. Oppitz-Plörer (Austria) 18:09 WELCOME FROM PRESIDENT Of The MEDICAL UNIVERSITY Of INNSBRUCK 22 H. Fritsch (Austria) 18:12 WELCOME FROM AUSTRIAN ATHEROSCLEROSIS SOCIETY & CONGRESS CHAIR 23 H. Dieplinger (Austria) 18:15 ACKNOWLEDGEMENT Of JOURNAL EDITOR-IN-CHIEF, PROFESSOR STEVE HUMPHRIES 24 A. Catapano (Italy) 18:20 MUSICAL INTERLUDE 25 18:30 INTRODUCTION TO ANITSCHKOW PRIZE WINNER 26 A. Catapano (Italy) 18:35 ANITSCHKOW LECTURE: ENDOTHELIAL CELL METABOLISM: A NOVEL PLAYER In ATHEROSCLEROSIS? BASIC PRINCIPLES AND THERAPEUTIC OPPORTUNITIES 27 P. Carmeliet (Belgium) 19:25 CLOSING REMARKS AND INVITATION TO WELCOME RECEPTION 28 F. Kronenberg (Austria) 19:30 MUSICAL INTERLUDE 29 19:45-20:45E exhibition Area Welcome Reception Scientific Programme Monday, May 30,

23 Aurelio, A.; Durante, A. (Milan) Key journals in Cardiologyogy International Journal of Cardiovascular Medicine, Surgery, Pathology and Pharmacology Editorial 41 Utilization of Statins: Guiding Principles and the New United States Guidelines Hennekens, C.H.; Gelb, I.J. (Boca Raton, Fla.) Editorial Comments 13 Systemic Inflammatory Response following Transcatheter Aortic Valve Implantation Paraskos, J.A. (Worcester, Mass.) 51 Hyperthyroid Atrial Fibrillation: Does It Matter for Stroke Risk? Poulin, M.-F.; Doukky, R. (Chicago, Ill.) Review 62 Contrast-Induced Nephropathy in Percutaneous Coronary Interventions: Pathogenesis, Risk Factors, Outcome, Prevention and Treatment Original Research 1 Allitridin Reduces IKr Current by Disrupting the Trafficking of Human Ether-à-Go-Go-Related Gene Channels Li, G.; Cheng, G.; Wu, J.; Ma, S.; Zhang, A.; Han, W.; Sun, C. (Xi an) 15 Synergistic Restoring Effects of Isoproterenol and Magnesium on KCNQ1-Inhibited Bradycardia Cell Models Cultured in Microelectrode Array Kim, S.K.; Pak, H.-N.; Park, Y. (Seoul) 25 Thrombin Generation and Platelet Reactivity at Hospital Discharge and 6-Month Outcome after the Acute Coronary Syndrome in Diabetic and Nondiabetic Patients Kuliczkowski, W.; Szewczyk, M.; Kaczmarski, J.; Sztohryn, E.; Greif, M.; Pres, D. (Zabrze); Fortmann, S.D. (Towson, Md.); Poloński, L. (Zabrze); Serebruany, V. (Towson, Md.) 34 Assessment of Characteristics of Neointimal Hyperplasia after Drug-Eluting Stent Implantation in Patients with Diabetes Mellitus: An Optical Coherence Tomography Analysis Tian, F.; Chen, Y.; Liu, H.; Zhang, T.; Guo, J.; Jin, Q. (Beijing) 43 Rat Induced Pluripotent Stem Cells Protect H9C2 Cells from Cellular Senescence via a Paracrine Mechanism Zhang, Y. (Suzhou); Wang, D. (Haerbin); Cao, K.; Chen, M. (Nanjing); Yang, X.; Tao, Y. (Suzhou) 54 Autoantibodies to Oxidized Low-Density Lipoprotein in Patients with Aortic Regurgitation: Association with Aortic Diameter Size Shimoni, S.; Bar, I.; Zilberman, L.; George, J. (Rehovot) Novel Insights from Clinical Experience 9 Transcatheter Aortic Valve Implantation for a Failed Bio-Bentall in Patients with Marfan Syndrome Beigel, R.; Siegel, R.J.; Kahlon, R.S.; Jilaihawi, H.; Cheng, W.; Makkar, R.R. (Los Angeles, Calif.) Monday, May 30, 2016 Monday, May 30, :30-10:30N n. Anitschkow Hall Plenary: Integrative Approach in Atherosclerosis Chair: A. Catapano (Italy) 30 Chair: H. Dieplinger (Austria) 31 8:30 GENETIC PROTECTION FROM CORONARY ARTERY DISEASE: The ROLE Of ABCG5 AND ABCG8 32 H. Hobbs (USA) 9:00 GWAS FOR CORONARY ARTERY DISEASE 33 H. Schunkert (Germany) 9:30 LEADING The WAY TO GENETICS AND PHARMACOGENOMICS In The CLINIC 34 T. Manolio (USA) 10:00 EPIGENETICS In ATHEROSCLEROSIS 35 A. El-Osta (Australia) Editor-in-Chief J.S. Borer (New York, N.Y.) An invaluable aid in understanding and treating heart disease Cardiology features: First reports on original clinical, preclinical and fundamental research Turning Basic Research into Clinical Success Clinical Trial Design Topical comprehensive reviews in selected areas of cardiovascular disease Editorial Comments Editor-in-Chief U. Pohl (Munich) A source of current research The Journal of Vascular Research publishes original articles and reviews of scientific excellence in vascular and microvascular biology, physiology and pathophysiology. The scope of the journal covers a broad spectrum of vascular and lymphatic research, including vascular structure, vascular function, haemodynamics, mechanics, cell signalling, intercellular communication, growth and differentiation. 10:30-11:00E exhibition & Poster Area Coffee Break, Exhibition & Poster Viewing KI

24 Monday, May 30, :00-12:30N n. Anitschkow Hall Workshop 1.1: Novel Aspects of Pathogenesis in Atherosclerosis Chair: C.J. Binder (Austria) 36 Chair: S. Ylä-Herttuala (Finland) 37 11:00 BEYOND VASCULAR INFLAMMATION: RECENT ADVANCES In UNDERSTANDING ATHEROSCLEROSIS 38 K. Ley (USA) 11:25 B-CELLS AND ATHEROSCLEROSIS 39 C.J. Binder (Austria) 11:50 REGULATORY T CELLS FROM PATIENTS WITH ATHEROSCLEROSIS HAVE ENHANCED SUPPRESSION FUNCTION DUE TO INCREASED EFFECTOR/ RESTING RATIO AND PRO-INFLAMMATORY SKEWING 40 I.E. Dumitriu, P. Baruah, J.C. Kaski (United Kingdom) 12:03 CONTROL Of ATHEROSCLEROSIS BY AN APOE RECEPTOR-DEPENDENT NEUROMODULATOR 41 J. Herz (USA) 12:16 DYNAMIN-RELATED PROTEIn 1 INHIBITION REDUCES OSTEOGENIC DIFFERENTIATION INDUCED TYPE 1 COLLAGEN SECRETION AND PREVENTS HUMAN VASCULAR CELL CALCIFICATION 42 M. Rogers, N. Maldonado, J. Hutcheson, C. Goettsch, M. Aikawa, E. Aikawa (USA) 11:00-12:30 K. Landsteiner Hall Workshop 2.1: Lipoproteins and Extracellular Matrix Chair: J. Borén (Sweden) 43 Chair: P. Gordts (USA) 44 11:00 POSTPRANDIAL HYPERLIPIDEMIA, ENDOTHELIAL DYSFUNCTION AND CARDIOVASCULAR RISK: FOCUS ON INCRETINS 45 P.D. Reaven (USA) 11:30 The ROLE Of PROTEOGLYCANS In HEPATIC TRIGLYCERIDE-RICH LIPOPROTEIn METABOLISM: ROLE Of ACOCIII AND APOAV 46 P. Gordts (USA) 12:00 INCREASED LIPOPROTEIn BINDING TO ARTERIAL PROTEOGLYCANS AND NORMAL MACROPHAGE CHOLESTEROL EFFLUX CAPACITY DEFINE The PRO-ATHEROGENIC FEATURE Of CKD DYSLIPIDEMIA 47 M. Pedrelli, P. Stenvinkel, M.E. Minniti, K. Emma, A. Dikkers, S. Ebtehaj, M. Gomaraschi, P. Barany, A.R. Qureshi, G. Camejo, B. Lindholm, K. Oörni, U. Tietge, L. Calabresi, E. Hurt-Camejo, P. Parini (Sweden) 12:15 BROWN AND BEIGE ADIPOCYTE ACTIVITY CONTROLS METABOLIC FLUX THROUGH The HDL COMPARTMENT 48 N. Schaltenberg, A. Bartelt, J. Clara, A. Worthmann, C. Lisa M., R. Franz, H. Markus, N. Stefan K., S. Ludger, J. Heeren (Germany) 11:00-11:45 C. von Rokitansky Hall Advanced Clinical Seminar 4.1: Debate on Statin Associated Muscle Symptoms (SAMS) - A Problem for Clinicians or a Problem with Clinicians? Chair: C. Packard (United Kingdom) 49 11:00 LESSONS FROM CLINICAL EXPERIENCE 50 U. Laufs (Germany) 11:20 LESSONS FROM CLINICAL TRIALS 51 J.M. Armitage (United Kingdom) 11:40 DISCUSSION

25 Monday, May 30, :45-12:30 C. von Rokitansky Hall Workshop 4.2: Role of Nutrition in Disease Pathology Chair: E. Bruckert (France) 53 Chair: J.M. Titze (Germany) 54 11:45 ROLE Of SODIUM In ATHEROSCLEROSIS 55 J.M. Titze (Germany) 12:05 SATURATED FAt In The DIET: GOOD OR BAD? 56 I. Brouwer (Netherlands) 12:25 DISCUSSION 57 11:00-12:30W w. Auerswald Hall Workshop 3.1: Novel Therapies Chair: F. Mach (Switzerland) 58 Chair: D. Gaudet (Canada) 59 11:00 ANTI-INFLAMMATORY INTERVENTIONS VERSUS INTENSIVE LDL LOWERING 60 F. Mach (Switzerland) 11:25 COMPARATIVE EFFECTS Of CHOLESTERYL ESTER TRANSFER PROTEIn INHIBITION, STATIn AND EZETIMIBE THERAPY ON ATHEROGENIC AND PROTECTIVE LIPID FACTORS: The ACCENTUATE TRIAL 61 S. Nicholls, K. Ray, C. Ballantyne, L. Beacham, D. Miller, G. Ruotolo, J. Riesmeyer (Australia) 11:50 A NOVEL COMBINATORIAL NON-VIRAL VECTOR TO TREAt FAMILIAL HYPERCHOLESTEROLAEMIA (FH) 62 A. Kerr, L. Tam, M. Cioroch, A. Hale, G. Douglas, K. Channon, R. Wade-Martins (United Kingdom) 12:03 CURRENT STATUS-PHASE I TRIAL Of CELL-TRANSPLANTATION THERAPY WITH ALLOGENEIC ADIPOSE TISSUE-DERIVED MULTILINEAGE PROGENITOR CELLS In SEVERE FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS UNDERGOING LDL-APHERESIS 63 M. Koseki, S. Ayami, T. Okada, T. Kobayashi, M. Asaji, R. Kawase, M. Nishida, Y. Sakata, S. Yamashita (Japan) 12:16 NOVEL INTRANASAL ANTI-CETP VACCINE AGAINST The DEVELOPMENT Of ATHEROSCLEROSIS AND FATTY LIVER DISEASE 64 J. Mas-Oliva, B. Delgado-Coello, K. Méndez-Acevedo (Mexico) 12:30-15:00E exhibition & Poster Area Break, Exhibition & Poster Viewing 13:00-14:00E exhibition Area Science at a Glance Session I 13:00-14:00 Kristall Foyer Poster Walk Session I 46 47

26 Monday, May 30, :00-14:30N n. Anitschkow Hall Industry Symposium: Company Sponsored Session Supported Session. Not included in the CME/CPD Programme. For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme. 13:00-14:30 K. Landsteiner Hall Industry Symposium: Company Sponsored Session Supported Session. Not included in the CME/CPD Programme. For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme. 13:00-14:00 C. von Rokitansky Hall EBAC Accredited Session: Nutraceuticals with Lipid Lowering Activity: Who Can Benefit? This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s); Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Meda (Rottapharm) in support of the Programme. Chair: P. Kovanen (Finland) 65 Chair: G. Assmann (Germany) 66 14:00-15:00E exhibition Area Science at a Glance Session II 15:00-16:30N n. Anitschkow Hall EAS-ESC Joint Workshop: Sex Differences in Cardiovascular Diseases Chair: I. Hoefer (Netherlands) 71 Chair: L. Tokgözoglu (Turkey) 72 15:00 PUBLIC HEALTH PERSPECTIVES ON CARDIOVASCULAR CARE FOR MEN AND WOMEN 73 K. Kotseva (United Kingdom) 15:22 SEX DIFFERENCES In HEART DISEASE In CLINICAL PRACTICE 74 E. Bossano Prescott (Denmark) 15:45 SEX-SPECIFIC BIOMARKERS FOR CARDIOVASCULAR DISEASES 75 B. Nordestgaard (Denmark) 16:07 SEX-SPECIFIC GENOMIC AND PROTEOMIC REGULATION In CARDIOVASCULAR DISEASE 76 G. Kararigas (Germany) 13:00 GUIDELINES In PRIMARY PREVENTION 67 E. Farinaro (Italy) 13:15 TO BRIDGE The GAP BETWEEN LIFESTYLE AND PHARMACOLOGICAL TREATMENT: DO WE HAVE AN UNMET NEED? 68 B. Paulweber (Austria) 13:30 PLANT NUTRACEUTICALS FOR The TREATMENT Of HYPERCHOLESTEROLEMIA: The AVAILABLE CLINICAL DATA 69 E. Bruckert (France) 13:45 DISCUSSION AND CONCLUSION

27 Monday, May 30, :00-16:30 K. Landsteiner Hall Workshop 1.2: Therapeutic and Diagnostic Targeting of the Arterial Wall Chair: E. Stroes (Netherlands) 77 Chair: A. Tawakol (USA) 78 15:00 NANOMEDICINE AS DIAGNOSTIC TOOL FOR CARDIOVASCULAR DISEASE 79 D. Letourneur (France) 15:25 NON-INVASIVE IMAGING Of ATHEROSCLEROTIC BURDEN AND INFLAMMATION 80 A. Tawakol (USA) 15:50 INCREASED ARTERIAL WALL INFLAMMATION In PATIENTS WITH FAMILIAL DYSBETALIPOPROTEINEMIA 81 S. Verweij, S. Bernelot Moens, J. Kroon, J. Schnitzler, E. Stroes (Netherlands) 16:03 GENE THERAPY REDUCES ANGIOPLASTY INDUCED CORONARY RESTENOSIS In A HIGH CHOLESTEROL SWINE MODEL 82 D. Agrawal, P. Gunasekar, C. Boosani, V. Swier, M. Radwan, M. Del Core, W. Hunter (USA) 16:16 SPOTTY CALCIFICATION AS A MARKER Of VULNERABLE PLAQUE: NOVEL FINDINGS FROM IN-VIVO STUDY In SURVIVORS Of CARDIAC ARREST AND IN-VITRO STUDY In AUTOPTIC SCD PATIENTS 83 J. Pu, P. Zhang, G.S. Mintz, X. Ma, B. He (China) 15:00-16:30 C. von Rokitansky Hall Workshop 2.2: Adipose Tissue Liver Axis Chair: M. Taskinen (Finland) 84 Chair: F. Karpe (United Kingdom) 85 15:00 BIOLOGY Of ADIPOSE TISSUE PHENOTYPE AND ITS LINK TO DISEASE 86 F. Karpe (United Kingdom) 15:25 APO AV, BEYOND TRIGLYCERIDES 87 R.O. Ryan (USA) 15:50 FGF21 LOWERS PLASMA TRIGLYCERIDES BY ACCELERATING LIPOPROTEIn CATABOLISM In WHITE AND BROWN ADIPOSE TISSUES 88 C. Schlein, S. Talukdar, M. Heine, A.W. Fischer, L.M. Krott, S.K. Nilsson, M.B. Brenner, J. Heeren, L. Scheja (Germany) 16:03 OAT2 DEPLETION IMPROVES INSULIn SENSITIVITY AND HEPATIC STEATOSIS 89 P. Parini, C. Pramfalk, O. Ahmed, L. Larsson, F. Karpe, M. Neville, M. Eriksson (Sweden) 16:16 SHORT-TERM COLD EXPOSURE MODULATES HUMAN VLDL AND HDL METABOLISM 90 K. Nahon, G. Hoeke, L. Bakker, D. Drettwan, P. Pagel, I. Jazet, J. Berbée, M. Boon, P. Rensen (Netherlands) 50 51

28 Monday, May 30, :00-15:45W w. Auerswald Hall Late Breaking: Basic Science Chair: J. Herz (USA) 91 Chair: R. Zechner (Austria) 92 15:00 FLOW PERTURBATION MEDIATES NEUTROPHIL RECRUITMENT AND POTENTIATES ENDOTHELIAL INJURY VIA TLR2 In MICE. A NOVEL In VIVO APPROACH FOR PROBING The PATHOPHYSIOLOGY Of SUPERFICIAL EROSION 93 G. Franck, G. Sausen, T. Mawson, M. Salinas, G. Masson, A. Cole, M. Beltrami- Moreira, Y. Chatzizisis, Y. Tesmenitsky, E. Swartz, G. Sukhova, F. Swirski, M. Nahrendorf, E. Aikawa, K. Croce, P. Libby (USA) 15:15 The ATYPICAL CADHERIn FAT1 SUPPRESSES MITOCHONDRIAL RESPIRATION TO LIMIT SMOOTH MUSCLE CELL RESPONSE TO VASCULAR INJURY 94 N. Sibinga, L.L. Cao, D. Riascos-Bernal, P. Chinnasamy, C. Dunaway, M. Pujato, A. Fiser (USA) 15:30 The CORONARY ARTERY DISEASE RISK ASSOCIATED GENE PLPP3/PPAP2B SUPPRESSES ATHEROSCLEROSIS In MICE 95 A. Morris, P. Mueller, J. Brandon, L. Yang, S. Smyth (USA) 15:45-16:30W w. Auerswald Hall Young Investigator Award Session Chair: P. Kovanen (Finland) 96 Chair: G. Dallinga-Thie (Netherlands) 97 15:45 GRP94 REGULATES CIRCULATING CHOLESTEROL LEVELS THROUGH BLOCKADE Of PCSK9-INDUCED LDLR DEGRADATION 98 S. Poirier (Canada) 16:05 ASSOCIATION BETWEEN FAMILIAL HYPERCHOLESTEROLEMIA AND PREVALENCE Of TYPE 2 DIABETES MELLITUS 99 J. Besseling (Netherlands) 17:00-18:30N n. Anitschkow Hall Young Investigator Session: Vascular Biology and Inflammation Chair: K. Öörni (Finland) 100 Chair: L.O. Martinez (France) :00 IRON ACCELERATES CARDIOVASCULAR DISEASE: The IMPORTANCE Of MAINTAINING IRON BALANCE 102 F. Vinchi, A. Simmelbauer, S. Altamura, B. Galy, M.W. Hentze, M. Muckenthaler (Germany) 17:15 INCREASED APOA-I TRANSCRIPTION BY BET INHIBITOR JQ1(+) ACTS INDEPENDENTLY FROM PPAR-ALPHA ACTIVATION AND IS LINKED TO ER-STRESS INHIBITION 103 S.E. Van der Krieken, H.E. Popeijus, R.P. Mensink, J. Plat (Netherlands) 17:30 PHOSPHATIDYLSERINE IMPROVES ANTI-INFLAMMATORY FUNCTION Of RECONSTITUTED HDL In MACROPHAGES VIA SR-BI-, Akt- AND p38 MAPK-DEPENDENT PATHWAYS 104 M. Darabi, E. Tubeuf, M. Lhomme, I. Guillas-Baudouin, C. Dauteuille, M. Patel, T. Huby, E.L. Gautier, K.A. Rye, P. Lesnik, W. Le Goff, A. Kontush (France) 17:45 CCAAT/ENHANCER BINDING PROTEIn DELTA CONTRIBUTES TO LIPID ACCUMULATION In M1 MACROPHAGES Of BLOOD VESSEL LESIONS 105 H.Y. Lai, L.W. Hsu, P.Y. Liu, J.M. Wang (Taiwan) 18:00 INHIBITION Of The CHOLESTEROL SYNTHESIS PATHWAY PREVENTS TRAINED INNATE IMMUNITY 106 S. Bekkering, S. Bernelot Moens, S. Verweij, J. Roeters van Lennep, J. Van Tuijl, L. Joosten, E. Stroes, M. Netea, N. Riksen (Netherlands) 18:15 SELECTIVE DONOR ENDOTHELIAL HEPARAN SULFATE MODIFYING ENZYME NDST1 DELETION SIGNIFICANTLY BLOCKS REJECTION AFTER RENAL TRANSPLANT 107 S. Ambadapadi, H. Chen, D. Wakefield, S. Morshed, W. Clapp, A. Lucas (USA) 16:30-17:00E exhibition & Poster Area Coffee Break, Exhibition & Poster Viewing 17:00-18:00 Kristall Foyer Poster Walk Session II 52 53

29 Monday, May 30, :00-18:30 K. Landsteiner Hall Young Investigator Session: Lipids and Lipoprotein Metabolism Chair: L. Scheja (Germany) 108 Chair: A. Ritsch (Austria) :00 PARAOXONASE 1 (PON1) MAINTAINS CELLULAR CHOLESTEROL HOMEOSTASIS VIA The REGULATION Of CHOLESTEROL EFFLUX 110 S. Ikhlef, H. Berrougui, A. Khalil (Canada) 17:15 A UBIQUITOUS TRANSCRIPTION FACTOR INFLUENCES DIET-INDUCED THERMOGENESIS AND SENSITIZES BAt TO NORADRENERGIC STIMULI IMPROVING CARDIOMETABOLIC HEALTH 111 P.P. Laurila, J. Soronen, S. Kooijman, M. Boon, M.R. Taskinen, V. Olkkonen, S. Ripatti, P. Kovanen, P. Rensen, M. Jauhiainen (Finland) 17:30 CALCIUM DEPENDENT ENDOCYTOSIS AND RECYCLING Of LIPOPROTEIN(A) In HEPG2 CELLS 112 M. SHARMA, G. Redpath, S. McCormick (New Zealand) 17:45 PLASMA CETP IS DERIVED FROM HEPATIC KUPFFER CELLS RATHER THAN ADIPOSE TISSUE 113 L. Blauw, R. De Mutsert, Y. Wang, H. Lamb, A. De Roos, F. Rosendaal, W. Jukema, S. Van der Tuin, S. Rensen, R. Shiri-Sverdlov, B. Atanasovska, J. Fu, W. Buurman, J.W. Greve, M. Hofker, K. Willems van Dijk, P. Rensen (Netherlands) 18:00 In VIVO INHIBITION Of NUCLEAR FACTOR Of ACTIVATED T CELLS (NFAT) RESTORES MICROVASCULAR ENDOTHELIAL FUNCTION In DIABETIC MICE 114 E. Garcia-Vaz, A. Mc Neilly, J. Gallagher, R. Mc Crimmon, F. Khan, M.F. Gomez (Sweden) 18:15 OXYSTEROLS, 24S-HYDROXYCHOLESTEROL AND 27-HYDROXYCHOLESTEROL, In SUBJECTS WITH GENETIC HYPERCHOLESTEROLEMIA NEGATIVE FOR LDLR/APOB/PCSK9/APOE MUTATIONS. ASSOCIATION WITH LIPIDS AND CAROTID ATHEROSCLEROSIS 115 L. Baila-Rueda, A. Cenarro, I. Lamiquiz-Moneo, R. Mateo-Gallego, A.M. Bea-Sanz, S. Perez-Calahorra, V. Marco-Benedi, F. Civeira (Spain) 17:00-18:30 C. von Rokitansky Hall Young Investigator Session: Clinical Epidemiology and Pharmacology Chair: K. Kotseva (United Kingdom) 116 Chair: P.D. Reaven (USA) :00 APABETALONE (RVX-208) DECREASES ATHEROGENIC, THROMBOTIC AND INFLAMMATORY MEDIATORS In VITRO AND In PLASMA Of PATIENTS WITH CARDIOVASCULAR DISEASE (CVD). 118 N. Wong, E. Kulikowski, S. Wasiak, D. Gilham, C. Calosing, T. Laura, C. Halliday, J. Johansson, M. Sweeney (Canada) 17:15 IMPACT Of DIABETES, INSULIn RESISTANCE AND CETP INHIBITION ON CIRCULATING PCSK9 LEVELS In PATIENTS At HIGH CARDIOVASCULAR RISK: The ILLUMINATE STUDY 119 B. Arsenault, F. Tabet, W. Bao, F. Petrides, G.K. Hovingh, S.M. Boekholdt, D. DeMicco, K.A. Rye, D. Waters, J. Kastelein, P. Barter, G. Lambert (Canada) 17:30 CLINICAL CHARACTERISTICS AND LONG-TERM CLINICAL OUTCOMES Of PATIENTS WITH TYPICAL RESTING CHEST PAIn ACCORDING TO The TYPES Of VASOMOTOR RESPONSE TO AN ACETYLCHOLINE PROVOCATION TEST 120 E.M. Lee, H.S. Seo, M.H. Choi, H.K. Kim, S.Y. Lee, N.H. Kim, D.O. Kang, C.U. Choi, J.W. Kim, E.J. Kim, S.W. Rha, C.G. Park, D.J. Oh (Republic of Korea) 17:45 RESPONSE TO TREATMENT AND OCCURRENCE Of CARDIOVASCULAR (CV) COMPLICATIONS In PATIENTS WITH AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA (ARH): A RETROSPECTIVE ANALYSIS 121 L. D'Erasmo, I. Minicocci, L. Masana, J. Roeters van Lennep, M. Harada-Shiba, S. Muntoni, P. Pintus, S. Bertolini, C. Sirtori, L. Calabresi, C. Pavanello, M. Averna, A.B. Cefalù, D. Noto, A. Pacifico, G. Pes, R. Fellin, E. Manzato, S. Zambon, M. Arca (Italy) 18:00 ASSOCIATION Of PERIPHERAL BLOOD MONONUCLEAR CELLS ADENYLATE CYCLASE-ASSOCIATED PROTEIn 1 mrna WITH CORONARY ARTERY DISEASE 122 M. Sopic, J. Joksić, V. Spasojević Kalimanovska, D. Kalminaovska Oštrić, K. Anđelković, Z. Jelić Ivanović (Serbia) 18:15 FILAGGRIn MUTATIONS AS RISK FACTORS FOR ISCHEMIC STROKE In The GENERAL POPULATION 123 A. Varbo, B.G. Nordestgaard, M. Benn (Denmark) 54 55

30 17:00-18:30W w. Auerswald Hall Oral Communication Session: Vascular Biology Chair: L. Yvant-Charvet (France) 124 Chair: K. Ley (USA) :00 SELECTIVE HDL-RAISING GENE TRANSFER COUNTERACTS The DEVELOPMENT Of PRESSURE OVERLOAD-INDUCED CARDIOMYOPATHY In MICE 126 R. Amin, I. Muthuramu, F. Jacobs, B. De Geest (Belgium) 84 th EAS CONGRESS May 29 - June 1, 2016 Innsbruck, Austria 17:15 BONE MARROW-SPECIFIC SIRT6 DELETION INCREASES ATHEROGENESIS BY INCREASING MACROPHAGE SCAVENGER RECEPTOR T. Arsiwala, L. J. van Tits, M. Miranda, K. Nussbaum, J. Weber, S. Stivala, J. H. Beer, M. Greter, B. Becher, M. O. Hottiger, R. Mostoslavsky, J. Auwerx, T. F. Lüscher, C. M. Matter (Switzerland) 17:30 T CELL-SPECIFIC CD40L CONTRIBUTES TO ATHEROSCLEROSIS 128 C. Bürger, H. Winkels, C. Spitz, S. Meiler, S. Reim, C. Weber, E. Lutgens, N. Gerdes (Germany) 17:45 STRUCTURAL REMODELING AND GLUCOSE METABOLISM IMPAIRMENT At EARLY ATHEROSCLEROSIS: IN-SITU AORTA ALTERATIONS AND PLASMA TRANSLATION. 129 M. Martin-Lorenzo, L. Gonzalez-Calero, A.S. Maroto, P.J. Martinez, A. Heredero, G. Aldamiz-Echevarria, F. Vivanco, G. Alvarez-Llamas (Spain) 18:00 LIVER-SPECIFIC ABLATION Of HNF-4α In MICE IS ASSOCIATED WITH CHANGES In PLASMA LIPOPROTEIn PROFILES AND The EXPRESSION Of GENES INVOLVED In LIPOPROTEIn METABOLISM 130 E. Thymiakou, D. Kardassis (Greece) 18:15 HEPATOCYTE-SPECIFIC PPAP2B ABLATION INCREASES PLASMA LEVELS Of SEVERAL MINOR PRO-ATHEROGENIC LIPID SPECIES AND WORSENS ATHEROSCLEROSIS In APOE-/- MICE 131 M. Busnelli, S. Manzini, M. Hilvo, C. Parolini, G.S. Ganzetti, F. Dellera, K. Ekroos, M. Jänis, C.R. Sirtori, R. Laaksonen, G. Chiesa (Italy) 56 18:40-19:40N n. Anitschkow Hall Plenary: Keynote Lecture Chair: A. Catapano (Italy) 132 Chair: W.J. Schneider (Austria) :40 HOW GENES CONTROL CHOLESTEROL 134 M.S. Brown (USA) Scientific Programme Tuesday, May 31,

31 Tuesday, May 31, 2016 Tuesday, May 31, :30-10:30N n. Anitschkow Hall Plenary: Lipid Biology, New Insights Chair: G. Kostner (Austria) 135 Chair: O. Wiklund (Sweden) 136 8:30 PATHOPHYSIOLOGY Of INTERCELLULAR AND INTRAVASCULAR LIPOLYSIS 137 R. Zechner (Austria) 9:00 ADIPOSE TISSUE BROWNING AND METABOLIC HEALTH 138 J. Heeren (Germany) 9:30 NUCLEAR RECEPTORS In LIPID METABOLISM 139 D. Mangelsdorf (USA) 10:00 ANGIOGENESIS AND ENDOTHELIAL CELL DYSFUNCTION In ATHEROSCLEROSIS: A NOVEL TARGET FOR TREATMENT 140 P. Carmeliet (Belgium) 10:30-11:00 exhibition & Poster Areater Area Coffee Break, Exhibition & Poster Viewing 59

32 Tuesday, May 31, :00-12:30N n. Anitschkow Hall Workshop 1.3: Cellular Stress Response in Atherosclerosis Chair: G.R.Y. De Meyer (Belgium) 198 Chair: R. Prassl (Austria) :00 MICTOPARTICLES In ATHEROSCLEROSIS 200 C.M. Boulanger (France) 11:25 ROLE Of AUTOPHAGY In VASCULAR DISORDERS 201 G.R.Y. De Meyer (Belgium) 11:50 HYPERCHOLESTEROLEMIA ALTERS The microrna PROFILE Of VASCULAR SMOOTH MUSCLE CELL-DERIVED MICROPARTICLES 202 D. De Gonzalo Calvo, A. Cenarro, F. Civeira, V. Llorente-Cortés (Spain) 12:03 A FUNCTIONAL GENETIC VARIANT In The LIPID DROPLET-ASSOCIATED PROTEIn PERILIPIn 2 (PLIN2) AFFECTS CHOLESTEROL CONTENT AND AUTOPHAGY In HUMAN PRIMARY MACROPHAGES TREATED WITH OXLDL 203 E. Ehrenborg, P. Gustafsson, O. Werngren, M. Pedrelli, P. Parini, J. Magné (Sweden) 12:16 EXTRACELLULAR LIPID PARTICLES ACCUMULATING In HUMAN CAROTID ARTERY INTIMA INDUCE STERILE INFLAMMATION In MACROPHAGES 204 S. Lehti, I. Belevich, S.D. Nguyen, P. Lindsberg, E. Jokitalo, P.T. Kovanen, K. Oörni (Finland) 11:00-12:30 K. Landsteiner Hall Workshop 2.3: Gut - Liver Axis Chair: A. Moschetta (Italy) 205 Chair: D. Kardassis (Greece) :00 The GUT MICROBIOME ENDOCRINE ORGAN: BACTERIALLY SIGNALS DRIVING CARDIO-METABOLIC DISEASES 207 M.J. Brown (USA) 11:25 INTESTINAL NUCLEAR RECEPTORS In LIPID REGULATION 208 A. Moschetta (Italy) 11:50 A MARCH6 AND IDOL E3 UBIQUITIn LIGASE CIRCUIT UNCOUPLES CHOLESTEROL SYNTHESIS FROM LIPOPROTEIn UPTAKE In HEPATOCYTES 209 A. Loregger, E. Cook, J. Nelson, M. Moeton, L. Sharpe, S. Engberg, M. Karimova, G. Lambert, N. Zelcer (Netherlands) 12:03 BUTYRATE VIA The GUT-BRAIn CIRCUIT REDUCES APPETITE AND ACTIVATES BROWN ADIPOSE TISSUE 210 Y. Wang, L. Zhuang, C. Yi, C.K. Chuang, S. Kooijman, K. Willems van Dijk, A.K. Groen, P.C.N. Rensen 12:16 NON-ALCOHOLIC FATTY LIVER DISEASE AS A CAUSE Of ISCHEMIC HEART DISEASE: A MENDELIAN RANDOMIZATION STUDY AND META-ANALYSIS Of 170,998 INDIVIDUALS 211 B. Lauridsen, S. Stender, T. Kristensen, K. Kofoed, B. Nordestgaard, A. Tybjærg-Hansen (Denmark) 60 61

33 Tuesday, May 31, :00-12:30 C. von Rokitansky Hall Workshop: ICCR-EAS Joint Session: Management of Cardiometabolic Risk; Where Do We Stand? Chair: J.P. Després (Canada) 212 Chair: J. Chapman (France) :00 MANAGEMENT Of SUBJECTS At HIGH CARDIOMETABOLIC RISK - WHERE DO WE FALL? 214 J.P. Després (Canada) 11:22 DOES The HEALTHY METABOLICALLY OBESE PHENOTYPE EXIST? 215 L. Van Gaal (Belgium) 11:45 TRANSLATING NUTRITIONAL SCIENCE INTO CLINICAL PRACTICE 216 V. Malik (USA) 12:07 NAFLD - The NOVEL TREAt FOR VASCULAR DISEASE 217 M. Taskinen (Finland) 11:00-12:30W w. Auerswald Hall Workshop 3.2: Vascular Aging and Atherothrombosis Chair: C. Gaetano (Germany) 218 Chair: B. Föger (Austria) :00 VASCULAR PROGENITOR CELLS, LYMPHATICS, ANGIOGENESIS AND ATHEROSCLEROSIS 220 A. Kari (Finland) 11:25 SIRTUINS In CARDIOVASCULAR DISEASE 221 C. Gaetano (Germany) 11:50 PENTRAXIn 3 DEFICIENCY IS ASSOCIATED WITH INCREASED ARTERIAL THROMBOSIS In ANIMAL MODELS 222 F. Bonacina, S. Barbieri, L. Cutuli, P. Amadio, A. Doni, M. Sironi, S. Tartari, B. Bottazzi, C. Garlanda, E. Tremoli, A. Mantovani, A.L. Catapano, G.D. Norata (Italy) 12:03 HDL MODULATES CARDIAC GLUCOSE METABOLISM AND INFLAMMATION AND IMPROVES CARDIAC FUNCTION AFTER MYOCARDIAL ISCHEMIA- REPERFUSION INJURY 223 B. Kingwell, S. Heywood, A. Richart, D. Henstridge, K. Alt, H. Kiriazis, A. Carey, H. Kammoun, H. Begum, L. Delbridge, P. Meikle, C. Hagemeyer, M. Febbraio, X.J. Du, A. Siebel (Australia) 12:16 DIET-INDUCED OBESITY REQUIRES SIGNALLING THROUGH TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTOR 1 (TRAF-1) In ADIPOCYTES 224 D. Wolf, N. Anto Michel, I. Hilgendorf, Bode, A. Zirlik (Germany) 12:30-15:00E exhibition & Poster Area Break, Exhibition & Poster Viewing 13:00-14:00E exhibition Area Science at a Glance Session III 13:00-14:00 Kristall Foyer Poster Walk Session III 62 63

34 Tuesday, May 31, :00-14:30 K. Landsteiner Hall Industry Symposium: Company Sponsored Session Supported Session. Not included in the CME/CPD Programme. For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme. 13:00-14:00 C. von Rokitansky Hall EBAC Accredited Session: Low HDL High Triglyceride, Diabetic Dyslipidaemia This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s); Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Mylan in support of the Programme. Chair: O. Wiklund (Sweden) :00 DIABETIC DYSLIPIDEMIA 226 A. Zambon (Italy) 13:20 TRIGLYCERIDE, REMNANTS AND ATHEROSCLEROSIS 227 B. Nordestgaard (Denmark) 13:40 CONCLUSION AND DISCUSSION :00-14:00W w. Auerswald Hall EBAC Accredited Session: Lysosomal Acid Lipase Deficiency This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s); Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Alexion in support of the Programme. Chair: E. Bruckert (France) 229 Chair: P. Kovanen (Finland) :00 LIPID METABOLISM ABNORMALITIES In GENERAL WITH DIFFERENTIAL DIAGNOSIS INCLUDING ALSO LAL-D 231 T. Stulnig (Austria) 13:20 LIPID METABOLISM ABNORNALITIES In LAL-D AS A LYSOSOMAL STORAGE DISEASE WITH A FOCUS ON SPECIFIC SIGNS AND SYMPTOMS 232 M. Averna (Italy) 13:40 CONCLUSION AND DISCUSSION :00-15:00E exhibition Area Science at a Glance Session IV 14:00-14:45N n. Anitschkow Hall Industry Symposium: Special Lecture Supported Session. Not included in the CME/CPD Programme. For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme. 14:10-14:55 C. von Rokitansky Hall Industry Symposium: Company Sponsored Session Supported Session. Not included in the CME/CPD Programme. For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme

35 Tuesday, May 31, :05-14:50W w. Auerswald Hall Industry Symposium: Meet the Expert Supported Session. Not included in the CME/CPD Programme. For programme details please refer to the Recognition, Acknowledgements & Commercial Support section in the final Programme. 15:00-16:30N n. Anitschkow Hall Workshop 3.3: Genetics in Risk Factor Prevention and Treatment Chair: G. Utermann (Austria) 234 Chair: S. Ripatti (Finland) :00 GENETIC DISCOVERIES FOR LIPID GENETIC TRAITS. LESSON LEARNED FROM FAMILIES AND The GENERAL POPULATION 236 S. Ripatti (Finland) 15:20 LOSS-OF-FUNCTION MUTATIONS In APOC3, REMNANT CHOLESTEROL, LDL CHOLESTEROL, AND RISK Of ISCHEMIC VASCULAR DISEASE 237 A.B. Jørgensen, R. Frikke-Schmidt, B. Nordestgaard, A. Tybjaerg-Hansen (Denmark) 15:34 LEUKOCYTE TELOMERE LENGTH, GENETICALLY DETERMINED, IS CAUSALLY ASSOCIATED WITH The PROGRESSION Of CAROTID INTIMA- MEDIA THICKNESS AND INCIDENCE Of CARDIOVASCULAR EVENTS 238 A. Baragetti, J. Palmen, K. Garlaschelli, L. Grigore, S. Humphries, A.L. Catapano, P.J. Talmud, N. Giuseppe Danilo (Italy) 15:48 DEEP SEQUENCING IDENTIFIES DNA METHYLATION DEPENDENT GENES IMPLICATED In DIABETIC COMPLICATIONS 239 I. Khurana, A. El-Osta (Australia) 16:02 PLEIOTROPIC MOLECULAR TARGETS Of COXIBS REVEALS NOVEL GENOMIC LOCI CONFERRING CORONARY ARTERY DISEASE RISK 240 I. Brænne, C. Willenborg, B. Reiz, L. Zeng, V. Tragante do Ó, T. Meitinger, N.J. Samani, T. Kessler, F.W. Asselbergs, J. Erdmann, H. Schunkert (Germany) 15:00-16:30 K. Landsteiner Hall Late Breaking: Clinical Science Chair: P. Moulin (France) 242 Chair: M. Vrablik (Czech Republic) :00 A PILOT STUDY Of MBX-8025 In The TREATMENT Of HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HoFH) 244 D. Gaudet, S. Saheb, E. Bruckert, J. De Graaf, G. Langslet, J.C. Tardif, S. Bergheanu, A. Steinberg, Y.J. Choi, R. Martin, C. McWherter, J. Kastelein, P. Boudes (USA) 15:15 AFFITOPE-BASED ANTI-PCSK9 (PROPROTEIn CONVERTASE SUBTILISIN/ KEXIn TYPE 9) VACCINE (AT04A) REDUCES ATHEROSCLEROSIS In APOE*3LEIDEN.CETP MICE 245 G. Galabova, C. Juno, J.W.A. Van der Hoorn, E.J. Pieterman, M. Pouwer, C. Landlinger, J.W. Jukema, H.M.G. Princen, G. Staffler (Austria) 15:30 TREATMENT ADHERENCE TO The PROPROTEIn CONVERTASE SUBTILISIN/ KEXIn TYPE 9 INHIBITOR ALIROCUMAB In SIX ODYSSEY PHASE 3 CLINICAL STUDIES WITH TREATMENT DURATION Of WEEKS 246 M. Farnier, H.M. Colhoun, W.J. Sasiela, J. Edelberg, G. Asset, J.G. Robinson (France) 15:45 SAFETY AND EFFICACY Of EVINACUMAB, A MONOCLONAL ANTIBODY TO ANGPTL3, In PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SINGLE-ARM, OPEN-LABEL, PROOF-OF- CONCEPT STUDY 247 D. Gaudet, D.A. Gipe, E. Khoury, R. Pordy, W. Sasiela, K.C. Chan 16:00 DYNAMIC CHANGES In MR SIGNALS Of INTRAPLAGUE HEMORRHAGE ARE STRONGLY CORRELATED WITH PLAQUE PROGRESSION: A SERIAL IMAGING STUDY ON CAROTID ATHEROSCLEROSIS 248 J. Sun, J. Liu, N. Balu, D. Hippe, K. William, A. Wang, G. Canton, T. Hatsukami, C. Yuan (USA) 16:15 MORTALITY In RELATION TO GLYCAEMIC STATUS In PATIENTS WITH PERIPHERAL ARTERIAL DISEASE 249 I.D. Hjellestad, E. Søfteland, R.M. Nilsen, E.S. Husebye, T. Jonung (Norway) 16:16 INVESTIGATION Of MULTIPLE DYSLIPIDEMIAS In A LARGE AUSTRIAN PEDIGREE BY GENETIC RISK SCORES AND EXOME SEQUENCING 241 E. Nikkola, A. Ko, R.M. Cantor, R. Muxel, N. Matikainen, S. Söderlund, M.M. Motazacker, J.A. Kuivenhoven, J. Boren, F. Kronenberg, W. Schneider, A. Palotie, M. Laakso, M.R. Taskinen, P. Pajukanta (USA) 66 67

36 Tuesday, May 31, :00-16:30 C. von Rokitansky Hall EAS Initiatives Update Session (open to all) Chair: A. Catapano (Italy) 250 Chair: O. Wiklund (Sweden) :00 WELCOME AND OVERVIEW Of EAS ACTIVITIES 252 A. Catapano (Italy) 15:15 FHSC UPDATE 253 K.K. Ray (United Kingdom) 15:30 CONSENSUS ACTIVITIES HIGHLIGHT- CONSENSUS ON FASTING/ NONFASTING LIPID ANALYSES (WITH EFLM) 254 B. Nordestgaard (Denmark) 15:45 EDUCATIONAL ACTIVITIES HIGHLIGHT- ADVANCED COURSES & EAS ACADEMY ACCREDITED PROGRAMMES 255 L. Tokgözoglu (Turkey) 15:55 OTHER ACTIVITIES: GUIDELINES & CONSENSUS UPDATE 256 A. Catapano (Italy) 16:05 OTHER ACTIVITIES: JOURNAL 257 A. von Eckardstein (Switzerland) 16:15 Q&A 258 A. Catapano (Italy) 15:00-16:30W w. Auerswald Hall Advanced Clinical Seminar: Economics and Guidelines/ Technology of the Future Chair: M. Banach (Poland) 259 Chair: G. Dallinga-Thie (Netherlands) :00 PHARMACO-ECONOMICS - HOW TO EXPLORE IT 261 G. Corrao (Italy) 15:30 CrisprCas9 TECHNOLOGY AS A NEW STRATEGY FOR TARGET DISCOVERY 262 N. Sanjana (USA) 16:00 WHAt DID WE LEARN FROM Lp(a)? SUMMARY Of The SATELLITE MEETING 263 G. Kostner (Austria) 16:30-16:50 C. von Rokitansky Hall EAS General Assembly (Members Only) 16:30-17:00E exhibition & Poster Area Coffee Break, Exhibition & Poster Viewing 17:00-18:00 Kristall Foyer Poster Walk Session IV 17:00-18:30N n. Anitschkow Hall Workshop 3.5: Epigenetics and Gene Regulation Chair: L. Maegdefessel (Sweden) 264 Chair: A. El-Osta (Australia) :00 The EMERGING ROLE Of micrornas In CARDIOVASCULAR DISEASE 266 L. Maegdefessel (Sweden) 17:25 IDENTIFICATION Of HISTONE DEACETYLASE 3 AS A MOLECULAR BRAKE Of WHITE ADIPOSE TISSUE BROWNING 267 M. Crestani, A. Ferrari, E. Fiorino, R. Long, N. Mitro, G. Cermenati, A. Mai, D. Caruso, E. De Fabiani, S.W. Hiebert (Italy) 17:38 HYPERCHOLESTEROLEMIA TRANSFORMS HIGH-DENSITY LIPOPROTEINS- MEDIATED TRNA-DERIVED SMALL RNA INTERCELLULAR COMMUNICATION 268 R. Allen, D. Michell, W. Zhu, S. Zhao, Q. Sheng, L. MacRae, K. Vickers (USA) 17:51 QUAKING POST-TRANSCRIPTIONALLY PROMOTES DIFFERENTIATION Of MONOCYTES INTO PRO-ATHEROGENIC MACROPHAGES BY CONTROLING PRE-MRNA SPLICING AND GENE EXPRESSION 269 R.G. De Bruin, L. Shiue, J. Prins, A. Djaramshi, H. De Boer, W.S. Fagg, J. Van Gils, J. Duijs, C. Van Kooten, J.W. Jukema, H. Van Esch, T.J. Rabelink, H. Kazan, E.A.L. Biessen, M. Ares Jr., A.J. Van Zonneveld, E. Van der Veer (Netherlands) 18:09 INNATE IMMUNE CELL ACTIVATION In SYMPTOMATIC AND ASYMPTOMATIC ATHEROSCLEROSIS In HUMANS In VIVO 270 S. Bekkering, I. Van den Munckhof, T. Nielen, J. Rutten, J. De Graaf, L. Joosten, M. Netea, M. Gomes, N. Riksen (Netherlands) 68 69

37 Tuesday, May 31, :00-18:30 K. Landsteiner Hall Oral Communication Session: Imaging, Biomarkers and Clinical Epidemiology Chair: D. Letourneur (France) 271 Chair: B. Paulweber (Austria) :00 ULTRA-SMALL POSITIVE AND NEGATIVE DUAL CONTRAST IRON OXIDE NANOPARTICLES FOR MOLECULAR IMAGING Of CARDIOVASCULAR DISEASE 273 H. Ta, Z. Li, K. Peter, C. Hagemeyer, A. Whittaker (Australia) 17:15 COMPUTED TOMOGRAPHY ANGIOGRAPHY DERIVED COMPARED TO INVASIVE FRACTIONAL FLOW RESERVE ASSESSMENT. A META-ANALYSIS. 274 S. Baumann, M. Renker, S. Hetjens, T. Becher, D. Loßnitzer, I. Akin, M. Borggrefe, U.J. Schoepf (Germany) 17:30 PLASMA CERAMIDES IDENTIFY RESIDUAL CARDIOVASCULAR RISK In STATIn TREATED CORONARY ARTERY DISEASE PATIENTS 275 R. Laaksonen, K. Ekroos, M. Sysi-Aho, T. Vihervaara, D. Kauhanen, M. Hilvo, R. Hurme, E. Ringdal Pedersen, G. Tell, O. Nygård (Finland) 17:45 In TYPE 2 DIABETES MELLITUS The GLP-1 EFFECTS ON PLATELETS ARE IMPAIRED 276 C. Barale, C. Frascaroli, F. Cavalot, A. Guerrasio, I. Russo (Italy) 18:00 INCREASED F2-ISOPROSTANE OXIDATIVE STRESS In CORONARY ARTERY DISEASE (CAD) PATIENTS WITH POOR ASPIRIN-INDUCED THROMBOXANE B2 INHIBITION 277 L.R. Lopez, T. Bottiglieri, A. Vasudevan, C. Swift, R. Schiffmann, P.A. McCullough (USA) 18:15 ASYMMETRIC DIMETHLYARGININE DIRECTLY PROMOTES CHRONIC KIDNEY DISEASE PROGRESSION: EVIDENCE FROM A MENDELIAN RANDOMIZATION APPROACH In The GCKD STUDY 278 M. Schneider, M. Mieth, S. Titze, F. Kronenberg, Y. Li, R. Maas, K.U. Eckardt (Germany) 17:00-18:30 C. von Rokitansky Hall Oral Communication Session: Intracellular Lipid Metabolism Chair: D. Kratky (Austria) 279 Chair: J. Heeren (Germany) :00 AN UNEXPECTED ROLE Of AUTOPHAGY In TARGETING FUNCTIONAL MITOCHONDRIAL ATP SYNTHASE TO The PLASMA MEMBRANE: ITS ROLE In HDL ENDOCYTOSIS 281 L.O. Martinez, G. Cardouat, S. Fried, S. Najib (France) 17:15 α/β HYDROLASE DOMAIN-CONTAINING 6 (ABHD6) DEGRADES The LATE ENDOSOMAL/LYSOSOMAL LIPID BIS(MONOACYLGLYCERO)PHOSPHATE 282 R. Zimmermann (Austria) 17:30 CONVERGENT SIGNALING PATHWAYS CONTROLLED BY LRP1 CYTOPLASMIC AND EXTRACELLULAR DOMAINS LIMIT CELLULAR CHOLESTEROL ACCUMULATION 283 P. Boucher, Z. El Asmar, J. Terrand, M. Jenty, L. Host, M. Mlih, A. Zerr, H. Justiniano, R. Matz L., C. Boudier, E. Scholler, J.M. Garnier, D. Bertaccini, D. Thiersé, C. Schaeffer, V.D. Alain, J. Herz (France) 17:45 MONOGLYCERIDE LIPASE REGULATES ENDOCANNABINOID TONE AND ATHEROSCLEROTIC PLAQUE STRUCTURE In APOLIPOPROTEIn E-DEFICIENT MICE 284 N. Vujic, S. Schlager, T.O. Eichmann, M. Goeritzer, C.T. Madreiter- Sokolowski, S. Schauer, A. Lass, R. Zimmermann, G. Hoefler, W.F. Graier, B. Radovic, D. Kratky (Austria) 18:00 LACK Of ADIPOSE TISSUE LIPOLYSIS PROTECTS AGAINST PRESSURE OVERLOAD-INDUCED HEART FAILURE 285 A. Foryst-Ludwig, J. Salatzki, S. Brix, Z. Ban, J. Grune, R. Klopfleisch, M. Rothe, E. Kershaw, U. Kintscher (Germany) 18:15 A LOSS-OF-FUNCTION VARIANT In OSBPL1A PREDISPOSES TO LOW PLASMA HDL CHOLESTEROL LEVELS AND IMPAIRED CHOLESTEROL EFFLUX CAPACITY 286 J. Van Capelleveen, J. Pirhonen, M.M. Motazacker, M. Weber-Boyvat, M. Jauhiainen, G.K. Hovingh, G.M. Dallinga-Thie, V. Olkkonen (Netherlands) 70 71

38 17:00-18:30W w. Auerswald Hall Young Investigator Session: Novel Pathways in Atherosclerosis Chair: J.A. Kuivenhoven (Netherlands) 287 Chair: R.O. Ryan (USA) :00 REDUCING AMYLOID PROCESSING PREVENTS DIABETES INDUCED VASCULAR DYSFUNCTION. 289 P. Meakin, F. Khan, M. Ashford (United Kingdom) 84 th EAS CONGRESS May 29 - June 1, 2016 Innsbruck, Austria 17:15 A LIPID METABOLITE PROFILE In ATHEROSCLEROTIC PLAQUES ASSOCIATED WITH INCREASED INFLAMMATION AND CARDIOVASCULAR RISK 290 L. Tomas, H. Björkbacka, A. Edsfeldt, A. Danielsson, M. Wigren, H. Grufman, A. Persson, C. Prehn, J. Adamski, J. Nilsson, I. Gonçalves (Sweden) 17:30 A COMPLEX ATHEROSCLEROTIC PHENOTYPE Of MIF GENE-DEFICIENT MICE In AN ATHEROGENIC APOE-/- BACKGROUND UNCOVERS A NOVEL CONNECTION BETWEEN MIF AND B CELLS 291 C. Schmitz, E. Straußfeld, O. El Bounkari, H. Noels, J. Bernhagen (Germany) 17:45 MARKERS Of VULNERABLE PLAQUES In NON-HUMAN PRIMATES UNDER ATHEROGENIC DIET 292 V. Di Cataldo, J. Piraquive Agudelo, A. Geloen, M. Verset, A. Paturet, A. Serusclat, F. Lamberton, D. Ibarolla, F. Lavenne, D. Le Bars, H. Contamin, E. Canet-Soulas (France) 18:00 The ROLE Of INFLAMMATION In The ASSOCIATION BETWEEN ADIPOSITY AND SUBCLINICAL ATHEROSCLEROSIS 293 T. Christen, S. Trompet, K.B. Gast, P.C.N. Rensen, J.A.P. Willems van Dijk, H.J. Lamb, A. De Roos, J.W. Jukema, F.R. Rosendaal, S. Le Cessie, R. De Mutsert (Netherlands) 18:15 The RELATIONSHIP Of NETRIN- 1 EXPRESSION WITH MACROPHAGE INFILTRATION AND POLARIZATION In HUMAN EPICARDIAL ADIPOSE TISSUE AND SEVERITY Of CORONARY ARTERY DISEASE 294 K.M. Gurses, F. Ozmen, D. Kocyigit, N. Yersal, E. Bilgic, E. Kaya, C. Kopru, T. Soyal, S. Doganci, L. Tokgozoglu, P. Korkusuz (Turkey) 72 Scientific Programme Wednesday, June 1,

39 Wednesday, June 1, 2016 Wednesday, June 1, :30-10:30 K. Landsteiner Hall Plenary: Future Therapeutic Challenges Chair: F. Kronenberg (Austria) 295 Chair: L. Tokgözoglu (Turkey) 296 8:30 In INTEGRATIVE OMICS APPROACH In HUMAN DISEASE RESEARCH 297 K. Suhre (Qatar) 9:00 DRUGS FOR METABOLIC DISORDERS AND OBESITY 298 M. Tschöp (Germany) 9:30 The USE Of NOVEL THERAPIES In ATHEROSCLEROSIS: FROM ANTIBODIES TO NANOTECHNOLOGY 299 E. Stroes (Netherlands) 10:00 LESSONS LEARNED FROM EMERGING THERAPIES FOR SEVERE HYPERTRIGLYCERIDEMIA 300 D. Gaudet (Canada) 10:30-11:00E exhibition & Poster Area Coffee Break, Exhibition & Poster Viewing 75

40 Wednesday, June 1, :00-12:30 K. Landsteiner Hall Workshop 1.4: Inflammation, Immunity and Atherosclerosis Chair: G.D. Norata (Italy) 301 Chair: E. Lutgens (Netherlands) :00 TARGETING The ADAPTIVE IMMUNE SYSTEM: A NEW STRATEGY In ATHEROSCLEROSIS 303 E. Lutgens (Netherlands) 11:25 CHOLESTEROL, INFLAMMATION AND IMMUNITY 304 L. Yvant-Charvet (France) 11:50 CD27 CO-STIMULATION FOSTERS REGULATORY T CELL SURVIVAL AND AMELIORATED PROGRESSION Of ATHEROSCLEROSIS. 305 H. Winkels, S. Meiler, C. Spitz, C. Buerger, A. Faussner, J. Borst, C. Weber, E. Lutgens, N. Gerdes 12:03 EARLY ATHEROPROTECTION BY SYK INHIBITION FAILS In ESTABLISHED DISEASE WHEN LOCAL MACROPHAGE PROLIFERATION DOMINATES LESION PROGRESSION 306 A. Lindau, C. Haerdtner, F.K. Swirski, P. Libby, L. Hein, C. Bode, A. Zirlik, I. Hilgendorf (Germany) 12:16 DEFICIENCY Of SECRETED IgM ANTIBODIES CAUSES INCREASED PLASMA IgE LEVELS THAt PROMOTE ATHEROSCLEROSIS 307 D. Tsiantoulas, I. Bot, M. Kiss, B. Bartolini-Gritti, L. Göderle, M. Ozsvar- Kozma, T. Perkmann, K. Hartvigsen, A. Bergthaler, D.H. Conrad, J. Kuiper, Z. Mallat, H. Jumaa, C.J. Binder (Austria) 11:00-12:30 C. von Rokitansky Hall Workshop 3.4: Biology of CVD Risk Chair: H. Colhoun (United Kingdom) 308 Chair: F. Kronenberg (Austria) :00 NOVEL BIOMARKERS FOR CVD In METABOLIC DISORDERS 310 H. Colhoun (United Kingdom) 11:25 CIRCULATING CELLS AND CVD RISK 311 G. Pasterkamp (Netherlands) 11:50 CIRCULATING MICRORNA-122 IS ASSOCIATED WITH INCIDENT METABOLIC SYNDROME AND TYPE-2 DIABETES 312 P. Willeit, X. Yin, D. Kaudewitz, P. Skroblin, A. Zampetaki, A.R. Moschen, C.M. Ramirez, L. Goedeke, N. Rotllan, E. Bonora, A.D. Hughes, P. Santer, C. Fernandez-Hernando, H. Tilg, J. Willeit, S. Kiechl, M. Mayr (United Kingdom) 12:03 ASSOCIATIONS BETWEEN LIPOPROTEIn SUBFRACTIONS AND GENOME- WIDE DNA METHYLATION In KORA F4 313 L. Pfeiffer, R. Wilson, H. Grallert, E. Reischl, A. Peters, C. Gieger, S. Wahl, M. Waldenberger (Germany) 12:16 PLASMA LIPIDOMIC PROFILES IMPROVE UPON CONVENTIONAL RISK FACTORS TO PREDICT CARDIOVASCULAR EVENTS 314 P. Mundra, C. Barlow, N. Mellett, K. Huynh, Z. Alshehry, G. Wong, B. Kingwell, P. Nestel, P. Thompson, D. Sullivan, E. Barnes, J. Simes, A. Tonkin, P. Meikle (Australia) 76 77

41 Wednesday, June 1, :00-12:30W w. Auerswald Hall Workshop: New Guidelines on Prevention of Cardiovascular Disease in Clinical Practice Chair: A. Catapano (Italy) 315 Chair: M. Piepoli (Italy) :00 INTRODUCTION: WHAt IS NEW In THESE GUIDELINES? 318 M. Piepoli (Italy) 11:05 HOW CAN WE IDENTIFY HIGH RISK? 319 I. Graham (Ireland) 11:20 WHAt ARE The RISK FACTOR TARGETS? 320 TBA 11:35 LIPIDS: WHAt IS NEW? 321 A. Catapano (Italy) 11:50 POPULATION APPROACH TO PREVENT CVD 322 E. Bossano Prescott (Denmark) 12:05 PANEL DISCUSSION :25 CONCLUSIONS 324 A. Catapano (Italy) M. Piepoli (Italy) :00-12:30 F. Pregl Hall Workshop 2.4: Novel Role of Lipoprotein Receptors Chair: A. von Eckardstein (Switzerland) 327 Chair: E. Steyrer (Austria) :00 NOVEL ROLE Of ENDOTHELIAL RECEPTORS In ATHEROSCLEROSIS 329 A. von Eckardstein (Switzerland) 11:25 SOLUBLE LR11, A CIRCULATING MARKER FOR ATHEROSCLEROSIS 330 H. Bujo (Japan) 11:50 REGULATION Of HDL-C LEVELS VIA ABCA1: A ROLE FOR LRP1 331 F. Oldoni, J. Van Capelleveen, M.M. Motazacker, J. Heeren, R. Sinke, G. Dallinga-Thie, D. Hui, K. Hovingh, J.A. Kuivenhoven (Netherlands) 12:03 SorLA IS A NOVEL HIGH AFFINITY PCSK9 RECEPTOR THAt INHIBITS ITS INACTIVATION BY FURIN 332 C. Gustafsen, S. Skeldal, S.L. Jensen, O.M. Andersen, C.M. Petersen, P. Madsen, S. Glerup (Denmark) 12:16 UNRAVELLING The MECHANISM AND IMPORTANCE Of BROWN ADIPOSE TISSUE WHOLE LIPOPROTEIn UPTAKE 333 A. Fischer, K. Gottschling, N. Mangels, M. Heine, J. Heeren (Germany) 78 79

42 84 th EAS CONGRESS May 29 - June 1, 2016 Innsbruck, Austria 80 Science at a Glance E-Poster Presentations

43 Science at a Glance CALL FOR PAPERS Atherosclerosis Official Journal of the European Atherosclerosis Society Atherosclerosis publishes original papers and review articles reporting research findings and investigations into all aspects of atherosclerosis, its complications and related diseases. Encompassing: lipoprotein metabolism, disorders of lipid transport, arterial and vascular biology, including vascular imaging and flow studies, cardiovascular stem cell biology, thrombosis and inflammation. Papers covering genetics, metaanalysis and epidemiology of atherosclerosis are of interest, as are dietary studies and investigations into diabetes and hypertension as related to atherosclerosis and cardiovascular risk factors. Publisher, Koos Admiraal, k.admiraal@elsevier.com Editor-in-Chief: A. von Eckardstein If you have a specific question please contact our Editorial Assistant, S. Negrini, Simona.Negrini@usz.ch BENEFITS OF PUBLISHING IN ATHEROSCLEROSIS Seamless electronic editorial system, from online submission to article publication, with clear instructions and online tracking. Improved presentation and the option to enrich your article with graphical abstracts, video, 3D images and linkage of content to relevant databases. Rapid editorial processing and availability of accepted articles (2-3 weeks after acceptance) as articles in press Advance notification of article publication via ScienceDirect s alerting service High visibility, with articles appearing in Scopus and PubMed shortly after publication Unparalleled international readership via ScienceDirect, with 10 million active users monthly from over 120 countries. Over 80,000 Atherosclerosis articles are downloaded every month. Atherosclerosis available via mobile Apps for increased accessibility Authors receive quarterly updates of the number of downloads of their article Open access publishing available BENEFITS OF PUBLISHING IN ATHEROSCLEROSIS Poster # Monday, May 30, :00-14:00E exhibition Area Lipids and Lipoproteins Chair: J. Heeren (Germany) 334 SaG001 SaG002 SaG003 SaG004 SaG005 SaG006 SaG007 SaG008 CONSEQUENCES OF DEFECTIVE LIPOLYSIS IN THE SMALL INTESTINE ON LIPID METABOLISM 335 M. Korbelius, S. Obrowsky, S. Rainer, N. Vujic, D. Kratky (Austria) POSTTRANSCRIPTIONAL REGULATION OF THE LDLR BY ACTH TREATMENT - IMPORTANCE OF PCSK9 IN LIVER WHILE IDOL TAKES THE SCENE IN THE ADRENALS 336 M. Ghosh Laskar, B. Angelin, M. Rudling (Sweden) TNF-ALPHA INDUCES PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) EXPRESSION IN HEPATIC HEPG2 CELL LINE IN A SOCS- 3-DEPENDENT MANNER 337 M. Ruscica, Ricci, C. Macchi, P. Magni, L. Jingwen, A. Corsini, N. Ferri (Italy) A POTENTIAL ROLE OF CHOLESTEROL UPTAKE CAPACITY, A NEW MEASURE FOR HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY, IN CORONARY RISK STRATIFICATION 338 A. Harada, R. Toh, K. Murakami, M. Kiriyama, K. Yoshikawa, T. Kubo, K. Miwa, Y. Irino, K. Mori, N. Tanaka, T. Ishida, K. Hirata (Japan) LOW-DENSITY LIPOPROTEIN UPREGULATE SR-BI THROUGH SP1 SER702 PHOSPHORYLATION IN HEPATIC CELLS 339 L. Wang, F. Yang, Y. Du, J. Zhang, B. Hong (China) SNPS LOCATED IN ABCA1, CETP AND APOA5/A4/C3/A1 ARE ASSOCIATED WITH PLASMA CHOLESTEROL EFFLUX 340 C. Talbot, J. Plat, H. Popeijus, A. Ritsch, R. Mensink IDENTIFICATION OF A NOVEL APOLIPOPROTEIN THAT FACILITATES MTP-MEDIATED LIPID TRANSPORT 341 H. Peng, C.S. Liu, T.Y. Chiu, H.T. Chen, J.J.Y. Yen, H.F. Yang-Yen (Taiwan) BETA CELL-SPECIFIC DELETION OF ABCA1 AND ABCG1 REGULATES THE INCREASE OF SMALL NUCLEOLAR RNAS IN ADIPOCYTES 342 F. Tabet, L. Hou, B. Cochran, L.F. Cuesta Torres, P.J. Barter, K.A. Rye (Australia) Easy online submission at: More information on the types of papers we publish and further instructions for authors can be found at: 83

44 Science at a Glance Poster # 13:00-14:00E exhibition Area Vascular Biology I Chair: G.R.Y. De Meyer (Belgium) 343 Poster # 13:00-14:00E exhibition Area Genetic, Omics and in silico Approaches Chair: N. Sanjana (USA) 352 SaG009 SaG010 HIGH-DENSUTY LIPOPROTEIN PHOSPHOLIPID CONTENT AND APOLIPOPROTEIN A-I LEVEL ARE DETERMINANTS OF CHOLESTEROL EFFLUX CAPACITY IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA 344 M. Ogura, M. Harada-Shiba (Japan) A HIGH-THROUGHPUT SCREENING OF KINASE INHIBITORS IDENTIFIES A REGULATORY ROLE OF VEGF SIGNALING FOR TRANSENDOTHELIAL TRANSPORT OF HIGH-DENSITY LIPOPROTEINS 345 S. Velagapudi, L. Rohrer, A. Von Eckardstein (Switzerland) SaG017 SaG018 GENE EXPRESSION PROFILES OF RECURRENT ACUTE PANCREATITIS RISK IN SEVERE HYPERTRIGLYCERIDEMIA 353 K. Tremblay, D. Gaudet (Canada) EVIDENCE FOR ENHANCED DE NOVO LIPOGENESIS AND UNCOUPLING OF OBESITY FROM TYPE 2 DIABETES RISK IN THE LOW- EXPRESSION VARIANT CARRIERS OF FATTY ACID-BINDING PROTEIN J. Saksi, P. Ijäs, A. Jula, H. Heikkilä, J. Tuimala, O. Dwivedi, T.M. Tuomi, L. Groop, M. Jauhiainen, P. Kovanen, P. Lindsberg (Finland) SaG011 SaG012 SaG013 SaG014 MITOPHAGY ACTS AS A SAFEGUARD MECHANISM AGAINST HUMAN VASCULAR SMOOTH MUSCLE CELL APOPTOSIS INDUCED BY ATHEROGENIC LIPIDS 346 H. Nahapetyan, A. Swiader, J. Faccini, R. D'Angelo, E. Mucher, M. Elbaz, P. Boya, C. Vindis (France) SMOOTH MUSCLE CELLS PCSK9 KNOCK-OUT EXHIBIT AN IMPAIRED RESPONSE TO PDGF STIMULATION 347 S. Marchianò, G. Tibolla, A. Corsini, A.L. Catapano, N. Ferri (Italy) 5-METHOXYTRYPTOPHAN REDUCES NEOINTIMA FORMATION FOLLOWING ARTERIAL INJURY 348 C.H. Chen, Y.C. Ho, H.H. Ho, C.H. Su, S.F. Yet (Taiwan) IMPACT OF FIBRE ORIENTATION IN FIBROUS CAP ON THE MECHANICAL LOADING IN HUMAN CORONARY ATHEROSCLEROTIC PLAQUES 349 Z. Teng, G. Douglas, A. Brown, M. Sutcliffe, J. Gillard (United Kingdom) SaG019 SaG020 SaG021 THE PREVALENCE OF FAMILIAL HYPERLIPIDAEMIA AND HYPER-LIPOPROTEIN(A) IN MUTATION-NEGATIVE FAMILIAL HYPERCHOLESTEROLAEMIA AND ASSOCIATIONS WITH CARDIOVASCULAR EVENTS 355 K. Ellis, J. Pang, D. Chan, A. Hooper, D. Bell, J. Burnett, G. Watts (Australia) THE RS POLYMORPHISM OF THE RECEPTOR-INTERACTING PROTEIN 2 (RIP2) GENE IS ASSOCIATED WITH SUBCLINICAL ATHEROSCLEROSIS. THE GENETICS OF ATHEROSCLEROTIC DISEASE (GEA) MEXICAN STUDY 356 G. Vargas-Alarcon, R. Posadas-Sánchez, J. Angeles-Martínez, E. Alvarez- León, N. Pérez-Hernánez, J.M. Rodríguez-Pérez, J.M. Fragoso, G. Cardoso, T. Villarreal-Molina, C. Posadas-Romero (Mexico) RARE VARIANTS IN ABCG2 IDENTIFIED BY SEQUENCING MAY INFLUENCE THE LIPID RESPONSE TO ROSUVASTATIN TREATMENT 357 M. Hu, J. Chan, B. Tomlinson (Hong Kong- China) SaG015 SaG016 MDM2 E3 LIGASE-MEDIATED UBIQUITINATION AND DEGRADATION OF HDAC1 IN VASCULAR CALCIFICATION 350 H. Kook, D.H. Kwon, G.H. Eom, S. Shin, E.M. Kim, Y.U. Lee, N. Choe (Republic of Korea) IN VITRO MIGRATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) INTO HUMAN HEALTHY AND DISEASED ARTERIES 351 B. Jakic, C. Krapf, M. Buszko, G. Cappellano, M. Grimm, G. Wick (Austria) SaG022 SaG023 CHARACTERISTICS OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN SPAIN 358 R.M. Sánchez-Hernández, M. Stef, S. Perez-Calahorra, F. Almagro, P. Sáenz-Aranzubía, N. Plana, J.T. Real, F. Blanco-Vaca, J.F. Ascaso, F. Civeira, M. Pocovi (Spain) CLINICAL CHARACTERISTICS AND PREVALENCE OF CARDIOVASCULAR DISEASE RISK FACTORS IN SUBJECTS SCREENED FOR FAMILIAL HYPERCHOLESTEROLEMIA - A CROSS SECTIONAL STUDY IN THE NETHERLANDS 359 M.L. Hartgers, J. Besseling, B. Lucius, L. Kutikova, G.K. Hovingh (Netherlands) SaG024 LOOKS LIKE FH BUT IT'S NOT FH - EXTENDED LIPID PROFILE OF PAEDIATRIC CLINICAL FH PATIENTS REVEALS A DIFFERENT LIPID PROFILE IN FH NEGATIVE PATIENTS 360 A.M. Medeiros, M. Bourbon, P. Aguiar (Portugal) 84 85

45 Science at a Glance Poster # 13:00-14:00E exhibition Area CV Risk Factors and Atherosclerosis I Chair: Y. Matsuzawa (Japan) 361 Poster # 14:00-15:00E exhibition Area Experimental Cadiovascular Medicine I Chair: P. Parini (Sweden) 370 SaG025 SaG026 SaG027 SaG028 SaG029 SERUM PHOSPHATIDYLCHOLINE PLASMALOGEN AND ALKYL- PHOSPHATIDYLCHOLINE CONCENTRATIONS ARE INVERSELY ASSOCIATED WITH MYOCARDIAL INFARCTION INCIDENCE IN PATIENTS WITH PERIPHERAL ARTERY DISEASE 362 J. Moxon, R. Jones, G. Wong, D. Liu, J. Weir, R. Behl-Gilhotra, B. Kingwell, P. Meikle, J. Golledge (Australia) SERUM ACYLCARNITINES AND RISK OF INCIDENT TYPE 2 DIABETES IN PATIENTS WITH SUSPECTED STABLE ANGINA PECTORIS - A PROSPECTIVE COHORT STUDY 363 E.W. Rebnord, E. Strand, G.F.T. Svingen, P.R. Njølstad, G. Mellgren, G.S. Tell, R.K. Berge, A. Svardal, O.K. Nygård, E.R. Pedersen (Norway) ANTI-APOLIPOPROTEIN A-1 ANTIBODIES AS A NOVEL CARDIOVASCULAR RISK FACTOR: RESULTS FROM THE COLAUS STUDY 364 N. Vuilleumier (Switzerland) REDUCTION IN PLASMA CHOLESTEROL EFFLUX CAPACITY FROM HUMAN MACROPHAGES IS ASSOCIATED WITH THE APPEARANCE OF CLINICAL FEATURES OF METABOLIC SYNDROME 365 J. Gall, E. Frisdal, R. Bittar, W. Le Goff, E. Bruckert, P. Lesnik, M. Guerin, P. Giral (France) REMNANT CHOLESTEROL PREDICTS CARDIOVASCULAR EVENT RISK IN PATIENTS WITH TYPE 2 DIABETES INDEPENDENTLY FROM THE BASELINE CORONARY ARTERY DISEASE STATE 366 C. Saely, D. Zanolin, P. Rein, A. Vonbank, A. Leiherer, A. Muendlein, H. Drexel (Austria) SaG033 SaG034 SaG035 SaG036 SaG037 SaG038 THE ROLE OF MICRO RNAS AND THEIR TARGETS IN A CAROTID ARTERY INTIMAL HYPERPLASIA 371 Y.U. Lee, N. Choe, E.M. Kim, S. Shin, D.H. Kwon, T. Kook, H. Kook (Republic of Korea) HEPATIC MIRNA EXPRESSION PROFILING IN GENETICALLY MODIFIED MOUSE MODELS OF DIFFERENT ATHEROSCLEROSIS SUSCEPTIBILITY 372 S. Manzini, M. Busnelli, M. Chiara, C. Parolini, F. Dellera, G.S. Ganzetti, D.S. Horner, G. Chiesa (Italy) ESTRADIOL PROTECTS OVARIECTOMIZED FEMALE RATS AGAINST FRUCTOSE RICH DIET INDUCED CARDIAC INFLAMMATION 373 M. Bundalo, M. Zivkovic, G. Koricanac, A. Stankovic (Serbia) IMPACT OF ENDOTHELIAL LIPASE OVEREXPRESSION ON CHOLESTEROL EFFLUX CAPACITY OF SERUM, APOLIPOPROTEIN B-DEPLETED SERUM AND HDL 374 I. Schilcher, A. Hrzenjak, T. Eichmann, T. Stojakovic, H. Scharnagl, G. Marsche, S. Frank (Austria) SR-BI INVOLVED ON PLASMA HDL2-APOA-I RECIRCULATION TO PREb- HDL IN MICE 375 M. Tsujita, T. Yokota, N. Akita, F.J. Gonzalez, S. Yokoyama (Japan) MICE ABUNDANT IN MURICHOLIC BILE ACIDS SHOW RESISTANCE TO DIETARY INDUCED STEATOSIS, WEIGHT GAIN, AND TO IMPAIRED GLUCOSE METABOLISM 376 Y. Bonde, G. Eggertsen, M. Rudling (Sweden) SaG030 SaG031 SaG032 THE PROSPECTIVE RELATIONSHIPS OF CIRCULATING AND URINARY CHOLINE METABOLITES WITH INCIDENT TYPE 2 DIABETES AMONG PATIENTS WITH SUSPECTED STABLE ANGINA PECTORIS 367 G.F.T. Svingen, H. Schartum-Hansen, E.R. Pedersen, P.M. Ueland, G.S. Tell, G. Mellgren, P.R. Njølstad, R. Seifert, E. Strand, T. Karlsson, O.K. Nygård (Norway) ASSOCIATIONS OF TRIGLYCERIDES WITH PERCENT BODY FAT IN ADOLESCENTS: THE PEP FAMILY HEART STUDY 368 T. Bertsch, G.M. Haas, E. Liepold, P. Schwandt (Germany) HEPATITIS C VIRUS (HCV) AND ATHEROSCLEROSIS RISK: A ROLE FOR LOW-DENSITY IMMUNE COMPLEXES? 369 M. Bassendine, S. Nielsen, D. Neely (United Kingdom) SaG039 SaG040 IMPACT OF LITOMOSOIDES SIGMODONTIS ANTIGEN ON T CELL DIFFERENTIATION AND ON THE DEVELOPMENT OF INITIAL ATHEROSCLEROTIC LESIONS IN APOE-KNOCKOUT MICE 377 C. Kühn, M. Tauchi-Brück, J. Ajendra, A. Hörauf, C. Stumpf, S. Achenbach, M. Hübner, B. Dietel (Germany) UNSTABLE LDL - NOVEL MECHANISM OF ATHEROGENESIS AND LINK TO CARDIOVASCULAR DEATHS 378 M. Ruuth, S.D. Nguyen, T. Vihervaara, T.D. Laajala, M. Uusitupa, U. Schwab, M. Savolainen, J. Sinisalo, T. Aittokallio, R. Käkelä, M. Jauhiainen, P. Kovanen, K. Oörni (Finland) 86 87

46 Science at a Glance Poster # 14:00-15:00E exhibition Area Nutrition, Nutraceuticals and Cardiovascular Disease Chair: A.H. Lichtenstein (USA) 379 Poster # 14:00-15:00E exhibition Area Pharmacology of Dyslipidemia Chair: M. Averna (Italy) 388 SaG041 SaG042 SaG043 SaG044 SaG045 SaG046 SaG047 SaG048 MIDDLE-TERM DIETARY SUPPLEMENTATION WITH RED YEAST RICE PLUS COENZYME Q10 IMPROVES LIPID PATTERN, ENDOTHELIAL REACTIVITY AND ARTERIAL STIFFNESS IN MODERATELY HYPERCHOLESTEROLEMIC SUBJECTS 380 A. Cicero, M. Morbini, M. Rosticci, S. D'Addato, E. Grandi, C. Borghi (Italy) INCREASED OXIDATIVE STRESS AND IMPAIRED MITOCHONDRIAL BIOGENESIS AND DYNAMICS ARE IMPROVED BY RICE BRAN ENZYMATIC EXTRACT DIET SUPPLEMENTATION 381 C. Perez Ternero, C. Werner, M. Alvarez de Sotomayor, M.D. Herrera, U. Laufs (Spain) INVESTIGATION OF THE IMPACT OF CROCUS SATIVUS ON THE METABOLIC PROFILE OF DIABETIC RATS 382 P. Konstantopoulos, L.M. Korou, I. Vlachos, I. Doulamis, A. Tzani, S. Fragouli, G. Mastorakos, Ν. Katsilambros, D. Perrea (Greece) LONG-CHAIN METABOLITES OF Α-TOCOPHEROL EMERGE FROM THE SHADOW OF THEIR PRECURSORS: Α-13 -OH AND Α-13 -COOH AS A NEW CLASS OF REGULATORY METABOLITES 383 L. Schmölz, M. Wallert, S. Ciffolilli, S. Kluge, G. Cruciani, M. Glei, O. Werz, F. Galli, M. Birringer, S. Lorkowski (Germany) CONSUMPTION OF POLYUNSATURATED FAT IMPROVES THE SATURATED FATTY ACID-MEDIATED IMPAIRMENT OF HDL ANTIOXIDANT POTENTIAL 384 A. García León, L. Cedó, J. Metso, D. Santos, J.L. Sánchez-Quesada, J. Julve, J. Mora-Brugués, M. Jauhiainen, F. Blanco-Vaca, J.C. Escolà-Gil (Spain) PLASMA LEVELS OF THE PRO-ATHEROGENIC NUTRIENT BIOMARKER TMAO IS INCREASED BY EXPOSURE TO DIOXIN-LIKE POLLUTANTS THROUGH UPREGULATION OF FMO3 385 M. Petriello, J. Hoffman, M. Sunkara, A. Morris, B. Hennig (USA) SOYA-ENRICHED MIXED DIET SIGNIFICANTLY IMPROVES CARDIOVASCULAR AND METABOLIC RISK FACTORS: A RANDOMIZED CONTROLLED TRIAL 386 M. Ruscica, C. Pavanello, B. Morlotti, M. Gomaraschi, C. Vitali, R. Bosisio, C.R. Sirtori, A. Arnoldi, P. Magni (Italy) PREVALENCE AND SECULAR TRENDS IN SUGAR-SWEETENED BEVERAGES SALES IN EUROPE AND THE MIDDLE EAST 387 B. Arsenault, M.R. Taskinen, J.P. Després (Canada) SaG049 SaG050 SaG051 SaG052 SaG053 SaG054 SaG055 SaG056 ATTAINMENT OF ACC/AHA RECOMMENDED LDL-C LOWERING WITH STATIN AND EZETIMIBE STATIN THERAPIES 389 P. Toth, H. Bays, M. Farnier, E. Jensen, J. Tomassini, A. Polis, J. Foody, A. Tershakovec (USA) EFFICACY AND SAFETY OF PITAVASTATIN IN PAEDIATRIC FH COMPARED WITH OTHER STATINS FROM COCHRANE DATABASE 390 M. Harada-Shiba, T. Ohta, A. Ohtake, T. Okada, O. Arisaka, J. Kastelein, I. Luirink (Japan) HOW TO IMPROVE THE CHOLESTEROL-LOWERING EFFICACY OF EZETIMIBE IN STATIN-INTOLERANT PATIENTS IN CLINICAL PRACTICE: A RETROSPECTIVE STUDY 391 A. Cicero, M. Morbini, S. D'Addato, F. Fogacci, M. Rosticci, C. Borghi (Italy) IDENTIFICATION AND MANAGEMENT OF CANADIAN PATIENTS WITH SYMPTOMS OF STATIN INTOLERANCE: RESULTS FROM A REAL-WORLD CLINICAL PRACTICE SURVEY 392 P. Oh, G.K. Hovingh, S.R. Gandra, J. McKendrick, R. Dent, H.M. Wieffer, A.L. Catapano, R.S. Rosenson, E.S.G. Stroes (Switzerland) PCSK9 CIRCULATING LEVELS AND CETP PLASMA ACTIVITY ARE ASSOCIATED INDEPENDENTLY OF LIPID LOWERING THERAPIES 393 J. Girona, D. Ibarretxe, N. Plana, S. Guaita, N. Amigó, M. Heras, L. Masana (Spain) UNDERSTANDING LIPOPROTEIN(A) METABOLISM: REBOUND ANALYSES OF LIPOPROTEIN(A) AND PCSK9 CONCENTRATIONS FOLLOWING REGULAR LIPOPROTEIN APHERESIS TREATMENT (THE LIPARE-STUDY) 394 E. Waldmann, E.M. Ooi, P.H.R. Barrett, D.C. Chan, S.M. Marcovina, G.F. Watts, K.G. Parhofer (Germany) DPP4 INHIBITOR, ANAGLIPTIN, AMELIORATES FASTING AND POSTPRANDIAL HYPERTRIGLYCERIDEMIA 395 M. Sairyo, D. Masuda, T. Kobayashi, H. Matsuda, T. Okada, R. Kawase, K. Nakatani, M. Koseki, T. Ohama, M. Nishida, Y. Sakata, S. Yamashita (Japan) FAMILIAL HYPERCHOLESTEROLEMIA IN PRIMARY CARE IN GERMANY - DIABETES AND CARDIOVASCULAR RISK EVALUATION: TARGETS AND ESSENTIAL DATA FOR COMMITMENT OF TREATMENT (DETECT) STUDY 396 N. Schmidt, B. Schmidt, A. Dressel, U. Fraass, I. Gergei, J. Klotsche, L. Pieper, H. Scharnagel, M.E. Kleber, W. März, H.U. Wittchen, T. Grammer (Germany) 88 89

47 Science at a Glance Poster # 14:00-15:00E exhibition Area Imaging in Vascular Dysfunction and Myocardial Infarction Chair: W. Koenig (Germany) 397 SaG057 SaG058 SaG059 SaG060 SaG061 SaG062 SaG063 A NOVEL TC-99M AND FLUORESCENCE LABELED PEPTIDE AS A MULTIMODAL IMAGING AGENT FOR TARGETING ANGIOGENESIS IN A MURINE HINDLIMB ISCHEMIA MODEL 398 D.W. Kim, S.G. Kim, M.H. Kim, C.G. Kim (Republic of Korea) REPRODUCIBILITY OF ENDOTHELIAL SHEAR STRESS AND LOW DENSITY LIPOPROTEIN TRANSPORT MODELING IN COMPUTED TOMOGRAPHY ANGIOGRAPHIC IMAGING DATA 399 A. Sakellarios, C.V. Bourantas, S.L. Papadopoulou, T. De Vries, P.H. Kitslaar, C. Gyrasis, K.K. Naka, S. Veldhof, G.W. Stone, J.H.C. Reiber, L.K. Michalis, P.W. Serruys, P.J. De Feyter, H.M. Garcia Garcia, D.I. Fotiadis (Greece) USAGE OF NOVEL HYBRID PIXEL DETECTORS FOR NATIVE ATHEROSCLEROTIC PLAQUE IMAGING BY HIGH RESOLUTION X-RAY COMPUTED TOMOGRAPHY 400 A. Zhemchugov, A. Svetlikov, D. Kozhevnikov, G. Shelkov, S. Urazgildeeva, V. Gurevich (Russia) COMPOSITION OF CORONARY PLAQUES BY CT ANGIOGRAPHY: VALIDATION BY NEAR-INFRARED SPECTROSCOPY 401 J.A. Goldstein, R.D. Madder, S. Dixon (USA) ACTIVATED-PLATELET TARGETED FIBRINOLYTIC DRUGS: NOVEL TARGETED-THERANOSTIC MICROBUBBLES FOR SIMULTANEOUS DIAGNOSIS, TREATMENT AND MONITORING USING MOLECULAR ULTRASOUND TECHNOLOGY 402 X. Wang, K. Peter (Australia) CARDIOVASCULAR EVENTS IN PATIENTS TREATED BY LIPOPROTEIN APHERESIS (LA) - ANALYSIS OF POSSIBLE REASONS 403 S. Tselmin, S. Fischer, F. Pistrosch, G. Müller, U. Julius (Germany) THE RELATIONSHIP BETWEEN INSULIN LIKE GROWTH FACTOR-1 AND CORONARY ARTERY CALCIUM SCORE IN CARDIOVASCULAR ASYMPTOMATIC ADULT MEN 404 K.C. Park, M.J. Kim, K.C. Kim, B.H. Choi, K.H. Park, H.C. Cho (Republic of Korea) Poster # Tuesday, May 31, :00-14:00E exhibition Area CV Risk Factors and Atherosclerosis II Chair: W. März (Germany) 406 SaG065 SERUM LEVELS OF ANTI-APOLIPOPROTEIN A-1 IGG ARE ASSOCIATED WITH LONG-TERM DISABILITY AND CEREBRAL LESION VOLUME IN ACUTE ISCHEMIC STROKE PATIENTS 407 N. Satta, F. Carbone, F. Montecucco, J. Virzi, F. Burger, A. Roth, G. Roversi, C. Tamborino, I. Casetta, S. Seraceni, A. Trentini, M. Padroni, F. Dallegri, P. Lalive, F. Mach, E. Fainardi, N. Vuilleumier (Switzerland) SaG066 GLYCATION OF APOA-I LINKS DIABETES AND CVD 408 J. Domingo-Espin, O. Nilsson-Wolanin, J. Dalla-Riva, K. Bernfur, M. Lindahl, J. Lagerstedt (Sweden) SaG067 SaG068 SaG069 SaG070 APOLIPOPROTEIN CII AND CIII: PROGNOSTIC MARKERS OF CARDIOVASCULAR RISK? 409 H. Scharnagl, M.E. Kleber, T.B. Grammer, T. Stojakovic, M.M. Hoffmann, W. März (Austria) SERUM MMP-8 AND TIMP-1 ASSOCIATE WITH INCIDENT CVD EVENTS AND ALL-CAUSE MORTALITY IN A POPULATION-BASED COHORT 410 I. Kormi, A.S. Havulinna, V. Salomaa, T. Tervahartiala, T. Sorsa, P.J. Pussinen (Finland) PLASMA CONCENTRATIONS OF AFAMIN ARE ASSOCIATED WITH THE PREVALENCE AND INCIDENCE OF TYPE 2 DIABETES MELLITUS 411 B. Kollerits, C. Huth, S. Kiechl, C. Lamina, C. Meisinger, C. Herder, L. Kedenko, J. Willeit, B. Thorand, D. Dähnhardt, D. Stöckl, M. Roden, W. Rathmann, B. Paulweber, A. Peters, H. Dieplinger, F. Kronenberg (Austria) OMENTIN-1 AND RISK OF STROKE: RESULTS FROM THE EPIC-POTSDAM COHORT STUDY 412 J. Menzel, R. Di Giuseppe, R. Biemann, C. Wittenbecher, K. Aleksandrova, T. Pischon, A. Fritsche, M.B. Schulze, H. Boeing, B. Isermann, C. Weikert (Germany) SaG ACC/AHA VERSUS 2004 NCEP ATP III GUIDELINES IN THE PREDICTION OF CORONARY ARTERY CALCIFICATION PROGRESSION IN A KOREAN POPULATION 405 C.H. Jung, S. Kim, W.J. Lee, J.Y. Park, C.Y. Park (Republic of Korea) SaG071 AGE, GENDER AND BLOOD LIPID LEVELS: A CHANCE TO IMPROVE CARDIOVASCULAR RISK ASSESSMENT 413 W. Balder, J.K. De Vries, I.M. Nolte, J.A. Kuivenhoven, P.W. Kamphuisen (Netherlands) 90 SaG072 THE ADDED VALUE OF AORTIC PWV BEYOND TRADITIONAL RISK FACTORS IN CARDIOVASCULAR RISK STRATIFICATION 414 B. Benczur, R. Bocskei, A. Cziraki, M. Illyes (Hungary) 91

48 Science at a Glance Poster # 13:00-14:00E exhibition Area Vascular Biology II Chair: H. Stangl (Austria) 415 SaG073 SaG074 SaG075 SaG076 SaG077 SaG078 SaG079 SaG080 ENDOTHELIAL DYNAMIC CHANGES IN CHONDROITIN SULFATE AND DERMATAN SULFATE PROTEOGLYCANS INDUCED BY VERY LOW DENSITY LIPOPROTEINS 416 R.E. Oberkersch, Y. Rasente, S. Yuschak, N. Volpi, G. Calabrese (Argentina) PRO-ATHEROGENIC OXIDIZED-LDL/Β2-GLYCOPROTEIN I COMPLEXES IN CORONARY ARTERY DISEASE PATIENTS ARE ASSOCIATED WITH DISEASE SEVERITY 417 L.R. Lopez, K.P. Bliden, R. Chaudhary, R. Damrongwatanasuk, K.E. Guyer, M.G. Gesheff, C.J. Franzese, U.S. Tantry, P.A. Gurbel (USA) PAI-1 EXPRESSION RENDERS M2 POLARIZED MACROPHAGES PROTEOLYTICALLY QUIESCENT 418 P. Hohensinner, J. Baumgartner, B. Ebenbauer, B. Thaler, D. Konstantin, C. Kaun, S. Stoijkovic, M. Fischer, G. Maurer, K. Huber, J. Wojta (Austria) IN VITRO EVIDENCE OF A PRO-INFLAMMATORY ACTION OF PCSK9 IN THP-1-DERIVED MACROPHAGES 419 C. Ricci, A. Corsini, N. Ferri (Italy) INCREASED MITOCHONDRIAL ROS ACCELERATE ATHEROSCLEROSIS IN MITOCHONDRIAL CATALYTIC ENZYME 3 DEFICIENT MICE 420 S.H. Park, S.K. Hur, J.Y. Yoo, S.J. Jeong, G.T. Oh (Republic of Korea) COMPARATIVE EFFECT OF SILYMARIN AND SILYBIN TREATMENT ON INFLAMMATION AND OXIDATIVE STRESS IN TRANSGENIC SPONTANEOUSLY HYPERTENSIVE RATS OVEREXPRESSING HUMAN C-REACTIVE PROTEIN 421 O. Oliyarnyk, H. Malinska, I. Markova, J. Trnovska, V. Skop, L. Kazdova, R. Vecera, M. Pravenec (Czech Republic) PONATINIB AUGMENTS VASOCONSTRICTION AND ATTENUATES VASORELAXATION IN MOUSE AORTIC RINGS 422 A. Kirsch, R. Kirchmair, S. Frank (Austria) CARDIOVASCULAR RISK FACTORS DIFFER IN INFLAMMATION PATHOLOGY IN PATIENTS WITH CLINICALLY SYMPTOMATIC LOWER LIMB ATHEROSCLEROSIS 423 J. Jalkanen, M. Maksimow, S. Jalkanen, H. Hakovirta (Finland) Poster # 13:00-14:00E exhibition Area Insulin Resistance, Diabetes, Metabolic Syndrome and Obesity Chair: G. Watts (Australia) 424 SaG081 SaG082 BARIATRIC SURGERY-INDUCED WEIGHT LOSS IN MORBIDLY OBESE PATIENTS PROMOTES A FAVORABLE DECREASE IN THE GENE EXPRESSION OF MARKERS OF SUBCUTANEOUS ADIPOSE TISSUE HOMEOSTASIS 425 J. Julve, E. Pardina, R. Ferrer, J. Rossell, J.A. Baena-Fustegueras, J.M. Fort, A. Lecube, J. Peinado-Onsurbe (Spain) EFFECTS OF OBESITY AND BARIATRIC SURGERY ON HDL FUNCTIONALITY AND MICROVASCULAR COMPLICATIONS OF OBESITY 426 Y. Liu, T. Siahmansur, J.D. Schofield, S. Hama, R. Yadav, S. Adam, M. France, S. Kwok, R. Donn, A. Stevens, J. Ho, B.J. Ammori, A. Syed, P.N. Durrington, H. Soran (United Kingdom) SaG083 BODY MASS INDEX AND MORTALITY OVER 3 DECADES 427 S. Afzal, A. Tybjærg-Hansen, G.B. Jensen, B.G. Nordestgaard (Denmark) SaG084 WAIST CIRCUMFERENCE AND BODY MASS INDEX CORRELATE WITH CEREBRAL GLUCOSE METABOLISM IN THE TEMPORAL LOBE IN DIABETIC PATIENTS 428 N. García-Casares, J. García-Arnés, A. Gutiérrez-Cardo, J. Rioja, M.J. Ariza, F. Alfaro, A. Nabrozidis, P. González-Santos (Spain) SaG085 COMPONENTS OF THE METABOLIC SYNDROME AND RISK OF TYPE 2 DIABETES 429 S. Marott, B. Nordestgaard, A. Tybjærg-Hansen, M. Benn (Denmark) SaG086 SaG087 SaG088 THE PLASMA PROTEOME OF TANGIER DISEASE PATIENTS REVEALS PERTURBATIONS OF DIABETIC AND INFLAMMATORY PATHWAYS 430 J. McParland, E. Pashos, D. Rader, M. Cuchel (USA) ROLE OF PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) IN OBESITY AND METABOLIC SYNDROME: BEYOND LDLR TARGETING 431 G. Balzarotti, G. Tibolla, M. Ruscica, M. Stramba-Badiale, A.L. Catapano, D.G. Norata (Italy) DIPEPTIDYL PEPTIDASE-4 INHIBITORS AND PROTECTION AGAINST STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS 432 F. Barkas, M. Elisaf, V. Tsimihodimos, H. Milionis (Greece) 92 93

49 Science at a Glance Poster # 13:00-14:00E exhibition Area Hypertension, Liver and Chronic Renal Disease Chair: A. Zambon (Italy) 433 Poster # 14:00-15:00E exhibition Area Experimental Cadiovascular Medicine II Chair: M. Jauhiainen (Finland) 442 SaG089 SaG090 SaG091 SaG092 SaG093 SaG094 SaG095 PRO-ATHEROGENIC LIPOPROTEIN PROFILE ASSOCIATED WITH WHITE MATTER LESIONS IN CHRONIC KIDNEY DISEASE PATIENTS: A 1H-NMR METABOLOMIC APPROACH 434 N. Amigó, R. Fuertes, C. Cabré, M. Vinaixa, M. Romeu, M. Muñoz, M. Giralt, J. Soler, J. Aquilera, M.T. Compte, X. Correig, A. Martínez-Vea (Spain) ALTERED INFLAMMATORY PARAMETERS AND CHEMERIN LEVELS AFTER RENAL TRANSPLANTATION 435 R. Szentimrei, M. Harangi, H. Lőrincz, E.V. Varga, A. Szentpéteri, P. Fülöp, I. Seres, G. Paragh (Hungary) RENAL DISEASE IS ASSOCIATED WITH MODIFIED PON1 DISTRIBUTION AT HDL SUBCLASSES 436 M. Miljkovic, J. Kotur-Stevuljevic, A. Stefanovic, J. Vekic, A. Zeljkovic, T. Gojkovic, S. Simic-Ogrizovic, V. Spasojevic-Kalimanovska, Z. Jelic- Ivanovic (Serbia) HEPATIC TRANSCRIPTOMIC SIGNATURES IN A MOUSE MODEL OF THE METABOLIC SYNDROME 437 D. Nasias, I. Evangelakos, D. Kardassis (Greece) STRONGLY INCREASING PREVALENCE OF HYPERTENSION BY INCREASING OVERWEIGHT IN CHILDREN AND ADOLESCENTS 438 G.M. Haas, E. Liepold, T. Bertsch, P. Schwandt (Germany) ASSOCIATION OF CORONARY ARTERY CALCIFICATION AND ARTERIAL MICRO-CALCIFICATION OF THE VASCULAR ACCESS IN INCIDENT HEMODIALYSIS PATIENTS 439 B.M. Choi, Y.O. Kim, H.C. Song, Y.B. Lee (Republic of Korea) LIVER DISEASE ALTERS HIGH-DENSITY LIPOPROTEIN COMPOSITION, METABOLISM AND FUNCTION 440 M. Trieb, V. Stadlbauer, R. Birner-Gruenberger, G. Marsche (Austria) SaG097 SaG098 SaG099 SaG100 SaG101 SaG102 SaG103 CONSEQUENCES OF LYSOSOMAL ACID LIPASE DEFICIENCY IN MACROPHAGES 443 M.C. Duta-Mare, B. Radovic, S. Schlager, M. Wegscheider, D. Kolb-Lenz, T. Madl, S. Stryeck, D. Kratky (Austria) PEROXIREDOXIN 1 HAVE PROTECTIVE ROLE IN THE VASCULAR DISEASE BY REGULATING MACROPHAGES 444 S. Kim, S.J. Jeong, G.T. Oh (Republic of Korea) THE ATHEROPROTECTIVE ACTIVITY OF GANODERMA AND ITS ACTION MECHANISM IN MICE 445 F.E. Mo, P.L. Hsu, Y.C. Lin (Taiwan) THE APOE*3LEIDEN.GK+/- MOUSE AS NOVEL TRANSLATIONAL MODEL FOR DYSLIPIDEMIA, TYPE 2 DIABETES AND MACROVASCULAR COMPLICATIONS 446 M. Pouwer, S. Heinonen, M. Behrendt, A.C. Andréasson, E. Pieterman, A. Van den Hoek, W. Jukema, B. Leighton, A.C. Jönsson-Rylander, H. Princen (Netherlands) PPARΓ ACTIVATION ATTENUATES OXIDATIVE STRESS AND IMPROVES CEREBRAL ARTERIES ENDOTHELIAL DYSFUNCTION IN AGING RAT THROUGH UP-REGULATING UCP2 447 P. Wang, G. Cai, F. Wang, P. Zhou, Q. Wang (China) EFFECTS OF CHRONIC INFLAMMATION ON MEGAKARYOCYTE AND PLATELET FUNCTION IN A CONDITIONAL MOUSE MODEL 448 M. Salzmann, M. Haase, C. Arzt, M. Mussbacher, A. Assinger, J.A. Schmid (Austria) GENETIC CORRELATIONS BETWEEN CIRCULATING MIRNAS AND LIPID PROFILES REVEAL NOVEL BIOMARKERS OF CVD RISK 449 L. Michael, S. McAhren, S. Kumar, J. Peralta, H. Kulkarni, W. Gerard, J. Weir, C. Barlow, M. Kowala, P. Meikle, J. Blangero, J. Curran (USA) SaG096 ENHANCED STATUS OF PROTHROMBOGENESIS AND ITS ASSOCIATION WITH SERUM LDL-C LEVELS IN SUBJECTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA 441 N.A. Mohd Kasim, R. Rahmat, S. Abdul Razak, S. Muid, T. Rahman, H. Nawawi (Malaysia) SaG104 ELEVATED LDL AND OXIDATIVE STRESS CONTRIBUTE TO ARRHYTHMOGENIC CARDIOMYOPATHY PHENOTYPIC MANIFESTATION 450 L. Arnaboldi, I. Stadiotti, S. Brambilla, G. Milano, A. Scopece, F. Cattaneo, A. Granata, C. Tondo, A. Corsini, G. Pompilio, E. Sommariva (Italy) 94 95

50 Science at a Glance Poster # 14:00-15:00E exhibition Area Immunity and Atherosclerosis Chair: G. Caligiuri (France) 451 SaG105 SaG106 SaG107 SaG108 SaG109 SaG110 SaG111 SaG112 A NOVEL MECHANISM OF STATINS IN ATHEROSCLEROTIC AND IN HIGH-RISK SUBJECTS: MODULATION OF THE ADIPONECTIN RECEPTOR PATHWAY IN CIRCULATING MONOCYTES 452 K. Gasbarrino, H. Zheng, S.S. Daskalopoulou (Canada) NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND THE RISK OF STROKE IN PATIENTS WITH RHEUMATOID ARTHRITIS 453 Y.R. Chen, H. Fang-I, W. Hsin-Chiao, C. Hung-Yi (Taiwan) THE PROTEIN COMPOSITION OF INTIMA AND MEDIA THORACIC AORTA LAYERS IN ATHEROSCLEROSIS WITH AUTOANTIGENS DETECTION AND IDENTIFICATION USING PROTEOMIC TECHNOLOGIES 454 R. Zhetisheva, V. Naumov, L. Kovalyov, M. Kovalyova, I. Kamenihina, L. Novikova, M. Shogenova, A. Karpov (Russia) EXPRESSION OF E06, A NATURAL MONOCLONAL ANTIBODY TARGETED TO OXIDIZED PHOSPHOLIPIDS (OXPL), ATTENUATES THE PROGRESSION OF AORTIC SCLEROSIS IN AGED HYPERLIPIDEMIC MICE 455 C. Yeang, M.Y. Hung, J. Pattison, K. Bowden, N. Dalton, K.L. Peterson, J.L. Witztum, S. Tsimikas, X. Que (USA) CCL22/ MACROPHAGE-DERIVED CHEMOKINE EXPRESSION VIA HISTAMINE IN THE ATHEROSCLEROSIS 456 S. Kimura, S. Yamada, H. Noguchi, K.Y. Wang, T. Nakayama (Japan) SOLUBLE URIC ACID PROMOTES DEVELOPMENT OF ATHEROSCLEROSIS LESIONS VIA ENHANCEMENT OF INNATE INFLAMMATION IN MICE 457 Y. Kimura, T. Yanagida, A. Onda, K. Asako, H. Kikuchi, H. Kono (Japan) PENTRAXIN 3 PLAYS A KEY ROLE IN THE IMMUNOMODULATION OF DIET INDUCED-OBESITY IN MICE 458 A. Moregola, F. Bonacina, U. Guerrini, E. Bonavita, C. Garlanda, A. Mantovani, A.L. Catapano, G.D. Norata (Italy) REGULATORY CD19+CD24HICD38HI B CELLS ARE DECREASED IN PATIENTS WITH CORONARY ATHEROSCLEROSIS AND HAVE IMPAIRED INTERLEUKIN-10 PRODUCTION IN RESPONSE TO CPG 459 I.E. Dumitriu, P. Baruah, J.C. Kaski (United Kingdom) Poster # 14:00-15:00E exhibition Area Emerging Aspects in Pharmacological Treatment of Primary and Secondary Dyslipidemia Chair: B. Dieplinger (Austria) 460 SaG113 SaG114 SaG115 SaG116 SaG117 SaG118 SaG119 EFFICACY AND SAFETY OF LONG-TERM COADMINISTRATION OF FENOFIBRATE AND EZETIMIBE IN PATIENTS WITH COMBINED HYPERLIPIDEMIA: RESULTS OF THE EFECTL TRIAL 461 S. Oikawa, S. Yamashita, N. Nakaya, J. Sasaki, S. Kono, G. EFECTL Study Investigators (Japan) EFFICACY AND SAFETY OF EVOLOCUMAB IN PATIENTS ON HIGH- VS MODERATE-INTENSITY BACKGROUND STATIN THERAPY 462 H. Soran, A. Lira, R. Dent, I. Bridges, R. Somaratne, M. Koren (United Kingdom) PHARMACODYNAMIC RELATIONSHIP BETWEEN PCSK9, ALIROCUMAB, AND LDL-C LOWERING IN FOUR PHASE 3 ODYSSEY TRIALS WITH/ WITHOUT STATIN BACKGROUND 463 J.G. Robinson, M. Farnier, J.J. Kastelein, E.M. Roth, M.R. Taskinen, H.M. Colhoun, A. Brunet, A.T. DiCioccio, G. Lecorps, R. Pordy, M.T. Baccara-Dinet, C.P. Cannon (USA) OMEGA-3 CARBOXYLIC ACIDS IN SEVERE HYPERTRIGLYCERIDEMIA: EVOLVE II STUDY RESULTS 464 E. Stroes, T. De Bruin, M. Davidson, H. Yang, M. Kvarnstrom, T. Lundstrom (Netherlands) CARDIOVASCULAR EVENT RATES IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): TRIAL ASSESSING LONG-TERM USE OF PCSK9 INHIBITION IN SUBJECTS WITH GENETIC LDL DISORDERS (TAUSSIG) STUDY INTERIM RESULTS 465 F. Raal, C. Kurtz, N. Honarpour, L. Tang, E.A. Stein (South Africa) TRANSITION FROM LDL APHERESIS TO EVOLOCUMAB IN HETEROZYGOUS FH IS EQUALLY EFFECTIVE IN LOWERING LDL- BUT WITHOUT LOWERING HDL CHOLESTEROL 466 A. Hovland, K.T. Lappegård (Norway) THE IMPACT OF SELECTIVE LDL APHERESIS ON SERUM ADIPOKINE LEVELS IN PATIENTS WITH HYPERCHOLESTEROLEMIA 467 V.E. Varga, H. Lőrincz, N. Zsíros, P. Fülöp, I. Seres, G. Paragh, J. Balla, M. Harangi (Hungary) SaG120 THE MECHANISM OF STATIN-INDUCED MODULATION OF VITAMIN D METABOLISM 468 J. Beltowski (Poland) 96 97

51 Poster # 14:00-15:00E exhibition Area Vascular Biology III Chair: J. Herz (USA) 469 SaG121 ACUTE EXPOSURE TO AIR POLLUTION AGGRAVATES ACUTE MYOCARDIAL INFARCTION AND SUBSEQUENT ISCHEMIC HEART FAILURE IN MICE 470 D. Wolf, T. Marchini, N. Anto Michel, D. Dürschmied, I. Hilgendorf, C. Bode, A. Zirlik (Germany) 84 th EAS CONGRESS May 29 - June 1, 2016 Innsbruck, Austria SaG122 EFFECT OF OMEGA-3 FATTY ACID SUPPLEMENTATION ON ARTERIAL ELASTICITY IN PATIETNS WITH FAMILIAL HYPERCHOLESTEROLAEMIA ON STATIN THERAPY 471 D. Chan, J. Pang, P.H.R. Barrett, D.R. Sullivan, T.A. Mori, J.R. Burnett, F.M. Van Bockxmeer, G.F. Watts (Australia) SaG123 THE ABSENCE OF PCSK9 DETERMINES A LOWER NEOINTIMAL FORMATION IN RESPONSE TO PERIVASCULAR CAROTID COLLAR PLACEMENT 472 N. Ferri, G. Tibolla, A. Dhyani, R. Baetta, A. Catapano, A. Corsini (Italy) SaG124 BLOOD LEVEL OF CD45+ PLATELETS AND DEVELOPMENT OF RESTENOSIS AFTER DRUG-ELUTING STENT IMPLANTATION IN PATIENTS WITH CORONARY ARTERY DISEASE 473 Z. Gabbasov, S. Kozlov, I. Melnikov, S. Byazrova, O. Saburova (Russia) SaG125 PLASMA FROM PATIENTS WITH CALCIFIED AORTIC DISEASE TRIGGERS AN OSTEOBLAST-LIKE PHENOTYPE SWITCH IN HUMAN AORTIC VALVE INTERSTITIAL CELLS 474 L. Cattan-Lévy, M.P. Jacob-Lenet, M. Dehoux, C. Deschildre, I. Codogno, M. Morvan, A.T. Gaston, G. Even, J.B. Michel, D. Messika-Zeitoun, A. Nicoletti, G. Caligiuri, J. Khallou-Laschet (France) SaG126 A NOVEL PLAYER IN VASCULAR CALCIFICATION: HYPOXIA INDUCES OSTEOGENIC DIFFERENTIATION AND EXTRACELLULAR MATRIX MINERALIZATION OF VASCULAR SMOOTH MUSCLE CELLS 475 V. Jeney, B. Enikő, T. Emese, T. Andrea (Hungary) 98 SaG127 SaG128 HH RESPONSIVE CELLS CONTRIBUTE TO VSMC ACCUMULATION FOLLOWING VASCULAR INJURY 476 P. Cahill, E. Fitzpatrick, H. Jay-Christian, S. Diana, R. Hakimjavadi, E. Redmond (Ireland) METABOLOMIC PROFILING OF ASCENDING THORACIC AORTIC ANEURYSMS AND DISSECTIONS - IMPLICATIONS FOR PATHOPHYSIOLOGY AND BIOMARKER DISCOVERY 477 C. Doppler, K. Arnhard, J. Dumfarth, K. Heinz, K. Danzl, B. Messner, C. Stern, D. Bernhard (Austria) Poster Presentation - Shift I Sunday, May 29 Monday, May 30

52 Poster Walks Monday Monday, May 30, 2016 Vascular Biology: Endothelium and Smooth Muscle Cells 001 SIGMA-1 RECEPTOR INVOLVEMENT In RHOA/ROCK ACTIVATION AND ENDOTHELIAL DYSFUNCTION INDUCED BY COCAINE 478 C.G. Saez, M.P. Hernández, K. Pereira-Flores, M. Palominos, A. Leguina- Ruzzi, D. Mezzano, J. Pereira (Chile) 002 P38 MITOGEN-ACTIVATED PROTEIn KINASE IS INVOVLED In ARGINASE-II- MEDIATED ENOS-UNCOUPLING In AGING AND OBESITY 479 Y. Yu, J.P. Montani, X. Ming, Z. Yang (Switzerland) 003 SOLUBLE ENDOGLIn EFFECTS ON ENDOTHELIAL CELLS In VITRO 480 M. Varejckova, I. Nemeckova, P. Fikrova, E. Dolezelova, B. Vitverova, P. Nachtigal (Czech Republic) 004 The RhoGEF TRIO REGULATES ANGIOGENIC SPROUTING THROUGH VE-CADHERIN 481 J. Kroon, I. Timmerman, M. Hoogenboezem, S.A. Van de Pavert, E.M. Weijers, P. Koolwijk, J.D. Van Buul (Netherlands) 005 IDENTIFICATION Of FLOW-SENSITIVE GENES DURING EMBRYOTIC VASCULAR DEVELOPMENT 482 C.W. Ni, N. Lawson (United Arab Emirates) 006 The NEURONAL GUIDANCE CUE SEMAPHORIn 3F IS HIGHLY EXPRESSED BY ENDOTHELIAL CELLS UPON LAMINAR FLOW AND INHIBIT MONOCYTE MIGRATION 483 H. Zhang, R.G. De Bruin, W.M.P.J. Sol, E.P. Van der Veer, B.M. Van den Berg, T.J. Rabelink, A.J. Van Zonneveld, J.M. Van Gils (Netherlands) 007 SUPPLEMENTATION WITH A COMBINATION Of L-CITRULLINE AND L-ARGININE RESTORES The PLASMA L-ARGININE CONCENTRATION AND RETARDS ENDOTHELIAL SENESCENCE 484 T. Hayashi, K. Ina, M. Kuzuya (Japan) 008 FICUS DELTOIDEA ENHANCES EXPRESSION Of ENDOTHELIAL NITRIC OXIDE SYNTHASE AND REDUCES ENDOTHELIN-1 ON STIMULATED HUMAN CORONARY ARTERY ENDOTHELIAL CELLS 485 R. Ahmad, T. Rahman, N.A. Mohd Kasim, G.A. Froemming, S. Muid, N.H. Ismail, A.M. Ali, H. Nawawi (Malaysia) 009 ANTI-OXIDANT PROPERTIES Of FENUGREEK AND SAPONINS, AND THEIR EFFECTS ON enos EXPRESSION ON HUMAN CORONARY ARTERY ENDOTHELIAL CELLS. 486 R. Ahmad, T. Rahman, G.A. Froemming, H. Nawawi (Malaysia) 101

53 Poster Walks Monday 010 ANTIOXIDANT PROPERTIES Of SAFFRON AND CROCIn AND THEIR EFFECTS ON ENDOTHELIAL NITRIC OXIDE SYNTHASE EXPRESSION In STIMULATED HUMAN CORONARY ARTERY ENDOTHELIAL CELLS 487 R. Ahmad, N.A. Mohd Kasim, T. Rahman, G.A. Froemming, H. Nawawi (Malaysia) 011 GLYCATED LDL INDUCE ENDOPLASMIC RETICULUM STRESS ALONG WITH The STIMULATION Of VCAM-1 EXPRESSION In HUMAN ENDOTHELIAL CELLS, AND The ENSUING MONOCYTE ADHESION 488 L. Toma, G.M. Sanda, M. Deleanu, C.S. Stancu, A.V. Sima (Romania) 012 ENDOTHELIAL CELL DEATH AND DISASSEMBLY In ATHEROSCLEROSIS 489 S. Paone, G. Atkin-Smith, R. Tixeira, S. Caruso, L. Jiang, I. Poon, M. Hulett (Australia) 013 LEVOROTATORY-AMLODIPINE PLUS FLUVASTATIn CONFER ADDITIVE EFFECTS ON RETARDING ENDOTHELIUM-MESENCHYMAL TRANSITION THROUGH SUPPRESSING ROCK1 EXPRESSION 490 A. Cai, L. Liwen, Z. Yingling, C. Jiyan, L. Xida (China) 014 STUDIES ON The MECHANISM Of ACTION Of The ANTIPROLIFERATIVE EFFECT Of NO-DONORS FUROXANS In SMOOTH MUSCLE CELLS 491 L. Arnaboldi, M. Lombardi, M. Sinelli, B. Rolando, L. Lazzarato, R. Fruttero, A. Gasco, A. Corsini (Italy) 015 The DIACYLGLYCEROL ACETYLTRANSFERASE INHIBITORS XANTHOHUMOL AND AMIDEPSINE D REVEAL LIPID SYNTHESIS AS A PROMOTER Of ANGIOGENESIS 492 K. Astanina, J. Spang, R.T. Hahn, D. Oster, J. Hoppstaedter, A.K. Kiemer (Germany) 016 PROLIFERATION Of ENDOTHELIAL PROGENITOR CELLS BY 11,12-EPOXYEICOSATRIENOIC ACID In I/R INJURED RAT 493 S. Kim, J.K. Chae, J.L. Young, Y.S. Kim, S.H. Lee, S.R. Lee, K.S. Rhee, W.H. Kim, J. Ko (Republic of Korea) 017 HIGH LEVELS Of SOLUBLE ENDOGLIn INDUCE INFLAMMATION AND OXIDATIVE STRESS In AORTA COMPENSATED WITH PRESERVED NO- DEPENDENT VASODILATATION MICE FED HIGH FAt DIET 494 K. Jezkova, J. Rathouska, I. Nemeckova, P. Fikrova, E. Dolezelova, M. Varejckova, B. Vitverova, C. Bernabeu, J.M. Novoa, S. Chlopicki, P. Nachtigal (Czech Republic) 018 MEMBRANE CONTACT SITES In ENDOTHELIAL CELLS 495 A. Kivelä, V. Olkkonen (Finland) 019 ENDOTHELIAL PROGENITOR CELLS BEFORE AND AFTER TREATMENT WITH METFORMIn In PATIENTS WITH FAMILIAL COMBINED HYPERLIPIDEMIA AND INSULIn RESISTANCE 496 C.O. Aragona, E. Imbalzano, V. Cairo, C. Conte, F. Mamone, A. Lo Gullo, M.A. Sardo, A. Saitta, G. Mandraffino (Italy) 020 ENDOTELIAL DYSFUNCTION, BLOOD LIPID SPECTRUM,LEVEL Of LEPTIn AND MASS Of BODY In PATIENT WITH CORONARY HEART DISEASE In COMBINATION WITH HEPATIC STEATOSIS. 497 N. Grechanyk, A. Filippova, A. Kuryata (Ukraine) 021 UNDERSTANDING The INTERACTIVE EFFECTS Of DOXORUBICIn AND RADIOTHERAPY ON ENDOTHELIAL CELL FUNCTION - The ROLE Of JNK 498 G. Hargrave, M. Boyd, R. Plevin (United Kingdom) 022 The CAPACITY Of EL MODIFIED SERUM / APO B DEPLETED SERUM TO PROTECT VASCULAR ENDOTHELIAL FUNCTION 499 S. Radulović, A. Kirsch, I. Schilcher, M. Lechleitner, C. Nusshold, S. Hallström, S. Frank (Austria) 023 ULTRASTRUCTURAL STUDY Of ENDOTHELIUM In ADVANCED CAROTID ARTERY ATHEROSCLEROSIS 500 A. Evdokimenko, T. Gulevskaya, T. Gulevskaya, S. Scrylev, V. Shchipakin, M. Tanashyan (Russia) 024 The ASSESSMENT Of VARIANT DOUBLE FILTRATION PLASMAPHERESIS (DFPP) IMPACT ON The ADHESION MOLECULES CONTENT In STABLE CORONARY ARTERY DISEASE (CAD) PATIENTS AFTER CORONARY STENTING 501 M. Pyatchenkov, V. Tishko, A. Sokolov (Russia) 025 The EFFECTS Of HIV-INFECTION AND ANTI-RETROVIRAL TREATMENT ON ENDOTHELIAL FUNCTION In A SOUTH AFRICAN COHORT 502 N. Mashele, S. Charania, F. Essop, I. Webster, C. Westcott, N. Goswami, P. De Boever, T. Nawrot, H. Strijdom (South Africa) 026 The ROLE Of INHIBITORS Of WNT SIGNALING In CARDIOVASCULAR EVENTS 503 C. Ress, A. Kirschner, M. Paulweber, K. Willeit, L. Kedenko, G. Goebel, K. Rufinatscha, K. Salzmann, G. Staudacher, H. Tilg, B. Igelseder, B. Paulweber, S. Kaser (Austria) 027 The GOOD? The BAD? The UGLY! RETINOIC ACID In MYOCARDIAL INFARCTION 504 K. Danzl (Austria) 028 ARTERIAL STIFFNESS CORRELATES WITH EXTRACELLULAR MATRIX TURNOVER In HEART FAILURE WITH PRESERVED EJECTION FRACTION PATIENTS 505 M. Martínez-Marin, J. Perez-Calvo, C. Josa-Laorden, I. Lacambra-Blasco, I. Gimenez-Lopez, J. Rubio-Gracia, V. Garces-Horna, M. Sanchez-Marteles, F. Ruiz-Laiglesia, P. Samperiz-Legarre, I. Torres-Courchoud, B. Amores- Arriaga, R. Martinez-Marin, C. Sanz-Bescos, F. Roncales-Garcia Blanco (Spain) 029 BYGLICAN EXPRESSION, ARTERIAL STIFFNESS AND PROATHEROGENIC PROFILE In FORMER SMOKERS AFTER 1-YEAR SMOKE CESSATION 506 G. Mandraffino, C.O. Aragona, V. Cairo, F. Mamone, A. Lo Gullo, M.A. Sardo, A. Saitta, E. Imbalzano (Italy)

54 Poster Walks Monday 030 HIGH, NOT LOW LEVELS Of ENDOGENOUS ENDOSTATIn SERUM LEVELS PREDICT EVENT-FREE SURVIVAL In PATIENTS WITH PERIPHERAL ARTERIAL DISEASE 507 B. Zierfuss, C. Herz, C. Höbaus, R. Koppensteiner, G.H. Schernthaner (Austria) 031 HIGH FRUCTOSE CONSUMPTION IMPAIRS AORTIC FUNCTION AND METABOLIC PARAMETERS COMPARED TO GLUCOSE In FEMALE RATS 508 G. Sanguesa, M.D.M. Cascales, S. Shaligram, F. Akther, M. Baena, R. Rahimian, J.C. Laguna, M. Alegret, N. Roglans (Spain) 032 MECHANICAL CONDITIONS AROUND NEOVESSELS In POPLITEAL ATHEROSCLEROTIC PLAQUES - AN ANALYSIS USING FINITE ELEMENT METHOD 509 M. Mocan, M. Bogdan, B. Sorin Nicu (Romania) 033 LASER CONFOCAL MICROSCOPY Of ARTERIAL WALL: ROLE Of SIGNALING MOLECULES In MECHANISMS Of RESTENOSIS 510 I. Kvetnoi, K. Kozlov, E. Sedova, I. Bolotov, V. Polyakova (Russia) 034 HOMOARGININE: A NEW POTENTIAL AVENUE In The MANAGEMENT Of NEOINTIMAL HYPERPLASIA? 511 F. Dellera, G.S. Ganzetti, A. Froio, S. Manzini, M. Busnelli, A. Meinitzer, G. Chiesa, C. Parolini (Italy) 035 SOLUBLE ST2 IS A NOVEL MARKER Of AORTIC STIFFNESS AND ARTERIOSCLEROSIS MEASURED BY INVASIVE HEMODYNAMIC STUDY 512 S.H. Kim, H.L. Kim, W.H. Lim, J.B. Seo, W.Y. Chung, J.H. Zo, H.L. Lee, M.A. Kim, D.G. Park, G.J. An (Republic of Korea) 036 VASCULAR RESPONSES TO INSULIn ARE IMPAIRED AFTER DIET-INDUCED OBESITY WHEREAS RESPONSES TO IGF-1 ARE MAINTAINED 513 G.K. Povlsen, I. Buza, H. Boonen, J. Worm (Denmark) 037 CARDIOMETABOLIC AND VASCULAR EFFECTS Of TREATMENT WITH A FIXED-DOSE COMBINATION ANTI-RETROVIRAL DRUG CONTAINING NUCLEOSIDE AND NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs AND NNRTIs) In ADULT RATS 514 H. Strijdom, N. Goswami, P. De Boever, C. Westcott, T. Ogundipe, F. Everson, A. Genis (South Africa) 038 SHORT-TERM AEROBIC EXERCISE IMPROVES AORTIC STIFFNESS In WOMEN AFTER MENOPAUSE 515 P. Wohlfahrt, J. Pitha, I. Kralova Lesna, O. Auzky, P. Suchanek, P. Stavek (Czech Republic) 039 EFFECTS Of ADIPONECTIn ON VASCULAR PROPERTIES Of CAROTID ARTERY ASSOCIATED WITH MATRIX REMODELING 516 W.C. Tsai, Y.T. Sun (Taiwan) 040 The LABILE IRON POOL AND PARAMETERS Of ARTERIAL WALL ELASTICITY 517 P. Risko, J. Pláteník, R. Buchal, J. Potočková, P. Kraml (Czech Republic) 041 The EFFECT Of HIGH-FAt DIET ON The BARRIER FUNCTIONS AND INFLAMMATORY STATUS Of HUMAN VASCULAR ENDOTHELIAL CELLS 518 P. Gorzelak-Pabis, E. Luczak, K. Wojdan, M. Broncel, M. Chalubinski (Poland) 042 MODIFYING The GUT MICROBIOME WITH POLYPHENOLS AND A LECTIn LIMITED DIET IMPROVES ENDOTHELIAL FUNCTION 519 S. Gundry (USA) 043 GENOMIC REARRANGEMENTS In HUMAN ATHEROSCLEROTIC VASCULAR TISSUES 520 A. Sleptcov, M. Nazarenko, I. Lebedev, N. Skryabin, O. Barbarash, V. Puzyrev (Russia) 044 INTIMA-MEDIA THICKNESS OF THE DESCENDING AORTA IS INFLUENCED BY AORTIC VALVE DISEASE 521 J. Petrini, M. Ring, P. Eriksson, A. Franco-Cereceda, K. Caidahl, M.J. Eriksson (Sweden) Vascular Biology: Macrophages, Inflammation, Immunity 045 EFFECTS OF OXIDAZED LDL IN M2 MACROPHAGES. IMPLICATIONS IN ATHEROSCLEROSIS 522 F. Goncalves, K. Alcantara, V. Moura, P. Nolasco, J. Kalil, M. Hernandez (Brazil) 046 HUMAN MACROPHAGES EXPOSED TO OXIDIZED LDL OR TUNICAMYCIN EXHIBIT INCREASED MMP-9 EXPRESSION, SECRETION AND ACTIVITY BY A MECHANISM INVOLVING ENDOPLASMIC RETICULUM STRESS 523 G.M. Sanda, M. Deleanu, C.S. Stancu, M. Simionescu, A.V. Sima (Romania) 047 RECOMBINANT DOMAIN V OF BETA(2)-GLYCOPROTEIN I INHIBITS OXLDL- INDUCED TF EXPRESSION IN MACROPHAGES 524 Y. Chi, T. Yu, Q. Liu, J. Qin, J. Li, Y. Chen, M. Li (China) 048 REDUCED DIETARY INTAKE OF TLR2 AND TLR4 STIMULANTS FAVOURABLY MODIFIES LIPID AND INFLAMMATORY MARKERS OF CARDIOMETABOLIC RISK IN HEALTHY MEN 525 T. Faraj, C. Erridge (United Kingdom) 049 THE ROLE OF OXIDIZED LOW-DENSITY LIPOPROTEINS AND AUTOANTIBODIES TO THEM IN ATHEROGENESIS IN PATIENTS WITH CORONARY ATHEROSCLEROSIS 526 M. Shogenova, A. Karpov, R. Zhetisheva, V. Masenko, V. Naumov (Russia)

55 Poster Walks Monday 050 CELL-SPECIFIC UPREGULATION OF APOLIPOPROTEIN E GENE EXPRESSION IN MACROPHAGES BY GLUCOCORTICOIDS 527 V.G. Trusca, E.V. Fuior, I.M. Fenyo, I.F. Tudorache, D. Kardassis, M. Simionescu, A.V. Gafencu (Romania) 051 INTERLEUKIN-27 POLYMORPHISMS ARE ASSOCIATED WITH PREMATURE CORONARY ARTERY DISEASE AND INSULIN RESISTANCE. THE GENETICS OF ATHEROSCLEROTIC DISEASE (GEA) MEXICAN STUDY 528 R. Posadas-Sánchez, N. Pérez-Hernández, J.M. Rodríguez-Pérez, J. Angeles-Martínez, C. Posadas-Romero, G. Cardoso-Saldaña, T. Villarreal-Molina, G. Vargas-Alarcón (Mexico) 052 ENZYMATIC DEGRADATION OF 7-KETOCHOLESTEROL (7-KC), A NEW STRATEGY FOR THE TREATMENT OF ATHEROSCLEROSIS 529 I. Perveen, S. Ahmed (Pakistan) 053 HUMAN MONOCYTE-DERIVED MACROPHAGES FROM CORONARY ARTERY DISEASE PATIENTS SHOW AN IMPAIRED PHENOTYPE 530 S. Eligini, S. Fiorelli, N. Cosentino, V. Cavalca, S. Colli, G. Marenzi, E. Tremoli (Italy) 054 AGE-ALBUMIN REDUCES ABCA-1 CONTENT IN MACROPHAGES BY INDUCING ITS MODIFICATION BY AGE AND DEGRADATION BY THE UBIQUITIN-PROTEASOME AND LYSOSOMAL SYSTEM. 531 R. Tallada Iborra, A. Machado-Lima, U. Fabres Machado, L. Rui, E.R. Nakandakare, S. Yokoyama, M. Passarelli (Brazil) 055 MONOCYTE ACTIVATION CORRELATES WITH ATHEROGENIC MITOCHONDRIAL MUTATIONS 532 A. Orekhov, N. Nikiforov, N. Elizova, M. Sazonova, A. Zhelankin, I. Sobenin (Russia) 056 FOXO1 AND NF-κB REGULATE CYCLOOXEGENASE-2 EXPRESSION UNDER LYSOPHOSPHATIDYALCHOLINE TREATMENT IN HUMAN CARDIAC FIBROBLAST 533 H.C. Tseng, C.M. Yang (Taiwan) 057 DIVERGENT EFFECTS OF SODIUM SALICYLATE ON GLUCOSE METABOLISM AND REVERSE CHOLESTEROL TRANSPORT IN OBESITY 534 S. Kajani, M. O'Reilly, W. Guo, F. McGillicuddy (Ireland) 058 PRO-INFLAMMATORY GENE EXPRESSION IN ADIPOSE TISSUE IN PATIENTS WITH ATHEROSCLEROSIS 535 S. Cejková, I. Králová Lesná, J. Froněk, A. Králová, R. Poledne (Czech Republic) 059 RESPONSE GENE TO COMPLEMENT-32 REGULATES TGF-Β EXTRACELLULAR MATRIX EXPRESSION IN HUMAN AORTIC ATHEROSCLEROTIC WALL 536 S.I. Vlaicu, A. Tatomir, D. Boodhoo, A.P. Mekala, C.A. Tegla, V. Rus, H. Rus (Romania) 060 THE ASSOCIATION BETWEEN PLASMA INTERLEUKIN-27 (IL-27) LEVELS AND THE SEVERITY OR INSTABLITY OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CAD 537 K. Miura, E. Saita, N. Suzuki, K. Miyata, N. Ikemura, R. Ohmori, Y. Ikegami, Y. Kishimoto, K. Kondo, Y. Momiyama (Japan) 061 FEATURES OF CELLULAR AND VASCULAR INFLAMMATORY RESPONSE IN PATIENTS WITH UNSTABLE ANGINA AND MYOCARDIAL INFARCTION 538 N. Musikhina, T. Petelina, L. Gapon, O. Irina, V. Kuznetsov (Russia) 062 EVALUATION OF MMP-7 AND TIMP-1 IN PATIENTS WITH CORONARY ATHEROSCLEROSIS 539 C.R. Revnic, C. PENA, S. VOINEA, F. REVNIC, B. PALTINEANU (Romania) 063 RELATIONSHIP BETWEEN MMP-9, TIMP-1, hs CRP AND THE SEVERITY OF ATHEROSCLEROTIC CORONARY ARTERY DISEASE 540 C.R. Revnic, C. PENA, S. PRADA, F. REVNIC, G. PRADA (Romania) 064 INTERMEDIATE DENSITY LIPOPROTEIN IS ASSOCIATED WITH MONOCYTE SUBSET DISTRIBUTION IN PATIENTS WITH STABLE ATHEROSCLEROSIS 541 K. Krychtiuk, S. Kastl, T. Pongratz, G. Goliasch, L. Gaspar, G. Maurer, K. Huber, E. Dostal, S. Pfaffenberger, S. Oravec, J. Wojta, W. Speidl (Austria) 065 THE ROLE OF MYELOID DENDRITIC CELLS, CHEMOKINE CCL17 AND T-CELL RECEPTOR CCR4 IN ATHEROGENESIS 542 A. Karpov, A. Rvatcheva, M. Shogenova, R. Zhetisheva, V. Masenko, V. Naumov (Russia) 066 THE INFLAMMATORY PROCESS AS A RISK FACTOR OF DEVELOPING ATHEROSCLEROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS 543 I. Starodubtseva (Russia) 067 MMP-12 AND TIMPS BEHAVIOUR IN STROKE RELATED TO CAROTID ARTERY STENOSIS 544 N. Cifani, F. Del Porto, L. Ferri, M. Proietta, D. Toni, R. Dito, M. De Michele, A. Falcou, M. Taurino (Italy) 068 ATHEROSCLEROTIC PATIENTS HAVE M1-SKEWED MONOCYTES: COMORBIDITIES AND RISK FACTORS CONTRIBUTE 545 H. Williams, V. Patel, G. Cassorla, N. Pertsoulis, S. Li, J. Fletcher, H. Medbury (Australia) 069 INCREASED GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) IS ASSOCCIATED WITH INFLAMMATION IN OBESE SUBJECTS 546 M. Malczewska-Malec, M. Malczewska-Malec, A. Polus, J. Goralska, U. Razny, A. Dembinska-Kiec, B. Solnica (Poland)

56 Poster Walks Monday 070 INCREASING B1A LYMPHOCYTES THROUGH APRIL OVEREXPRESSION IN APOLIPOPROTEIN E-DEFICIENT MICE STABILIZES ADVANCED ATHEROSCLEROTIC LESIONS BY DECREASING NECROTIC AREA AND INCREASING SMOOTH MUSCLE CELL CONTENT 547 K.H. Zheng, S. Bernelot Moens, S.I. Van Leuven, S. Havik, D. Baeten, E. Stroes (Netherlands) 071 CYTOMEGALOVIRUS DNA LOAD AND T-LYMPHOCYTES ACTIVATION IN ATHEROSCLEROTIC PLAQUES 548 A. Lebedeva, E. Nikitskaya, O. Ivanova, J.C. Grivel, E. Maryukhnich, A. Shpektor, E. Vasilieva, L. Margolis (Russia) 072 INTERLEUKIN-17-RELATED PATHWAYS ARE INVOLVED IN CAROTID ATHEROSCLEROSIS, BUT NOT IN STANFORD-A ACUTE AORTIC DISSECTION 549 F. Del Porto, N. Cifani, L. Ferri, S. Perrotta, R. Dito, M. Iaconi, R. Carletti, M. Proietta, L. Tritapepe, C. Di Gioia, M. Taurino (Italy) 073 ROLE OF T HELPER 17 LYMPHOCYTE SUBPOPOLATIONS IN CRITICAL CAROTID ARTERY STENOSIS 550 M. Proietta, N. Cifani, F. Del Porto, L. Ferri, G. Orgera, S. Perrotta, R. Dito, L. Tritapepe, M. Iaconi, M. Taurino (Italy) 074 INCREASED FREQUENCIES OF CIRCULATING T-HELPERS 17 AND DIMINISHED REGULATORY T-CELLS TO T-HELPERS 17 RATIO PREDICT CAROTID ATHEROSCLEROSIS PROGRESSION 551 A. Filatova, A. Shchinova, E. Pylaeva, A. Potekhina, A. Osokina, M. Tripoten, O. Pogorelova, T. Balakhonova, E. Noeva, E. Klesareva, O. Afanasieva, T. Arefieva (Russia) 075 DECREASED BONE MARROW ACTIVITY MEASURED BY USING 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH CEREBRAL ARTERY ATHEROSCLEROSIS 552 J.M. Kim, L. Eun Seoung, P. Kwang-Yeol, S. Ju Won, J. Keun-Hwa (Republic of Korea) 076 PSORIASIS AND CORONARY ARTERY DISEASE: THE ROLE OF INFLAMMATION 553 P. Altieri, H.L. Banchs, J. Nieves (Puerto Rico) 077 ABSENCE OF FIBRONECTIN-EDA CONTRIBUTES TO SEPSIS OUTCOMES IN A MURINE MODEL 554 A. Dhyani, V.K. Pulakazhi Venu, P. Uboldi, A.F. Muro, A.L. Catapano, D.G. Norata (Italy) 078 HUMAN HERPESVIRUS ACTIVATION IN PATIENTS WITH ACUTE CORONARY SYNDROME 555 E. Nikitskaya, O. Ivanova, M. Elena, G. Jean-Charles, A. Lebedeva, A. Shpektor, L. Margolis, E. Vasilieva (Russia) 079 BACILLE-CALMETTE-GUÉRIN LOWERS PLASMA CHOLESTEROL AND DELAYS ATHEROSCLEROTIC LESION PROGRESSION IN MICE 556 A. Van Dam, S. Bekkering, M. Crasborn, L. Van Beek, S. Van den Berg, F. Vrieling, S. Joosten, V. Van Harmelen, M. De Winther, E. Lutgens, M. Boon, N. Riksen, P. Rensen, J. Berbée (Netherlands) 080 IDENTIFYING FEATURES OF VASCULAR INFLAMMATORY RESPONSE IN PATIENTS WITH MYOCARDIAL INFARCTION USING THE SYNTAX SCORE 557 T. Petelina, N. Musikhina, L. Gapon, I. Osipova, V. Kuznetsov (Russia) 081 REDOX-ACTIVE IRON IN MONOCYTES ISOLATED FROM PATIENTS WITH CHRONIC CARDIOVASCULAR DISEASE 558 P. Kraml, P. Riško, J. Pláteník, J. Potočková (Czech Republic) 082 PATIENTS WITH RHEUMATOID ARTHRITIS SHOWED ALTERED LIPOPROTEIN PROFILE WITH DYSFUNCTIONAL HIGH-DENSITY LIPOPROTEINS TO EXACERBATES INFLAMMATION AND ATHEROSCLEROTIC PROCESS 559 J.Y. Kim, E.Y. Lee, K.H. Cho (Republic of Korea) 083 THE LEVEL OF NITRIC OXIDE REGULATES LIPOCALIN-2 EXPRESSION UNDER INFLAMMATORY CONDITION IN RINM5F BETA-CELLS 560 S.Y. Chang, Y.H. Jo, M.J. Kim (Republic of Korea) 084 DIFFERENTIAL WHITE BLOOD CELL COUNT AND METABOLIC SYNDROME IN JAPANESE MEN 561 Y. Ikeda, N. Hisakawa, T. Ohguro, J. Nishiuchi, Y. Kumon (Japan) 085 NON-HDL CHOLESTEROL RELATES TO PRO-INFLAMMATORY STATUS OF HUMAN VISCERAL ADIPOSE TISSUE 562 R. Poledne, I. Kralova Lesna, A. Kralova, A. Sekerkova, J. Fronek (Czech Republic) 086 EFFECT OF FAT COMPOSITION OF A MEAL ON THE ACUTE POSTPRANDIAL INFLAMMATORY RESPONSE 563 I. Shapira, O. Raz, S. Berliner (Israel) 087 THE RELATIONSHIP BETWEEN HELICOBACTER PYLOR INFECTION AND ARTERIAL STIFFNESS IN ADULTS WITH ABNORMAL GASTRIC ENDOSCOPIC FINDINGS 564 K.C. Park, M.J. Kim, K.S. Park, Y.S. Kim, H.C. Cho, H.R. Sung, K.H. Park, B.H. Choi, K.C. Kim (Republic of Korea) 088 PROTECTIVE EFFECT OF CAROTENOIDS ON CX40 AD CX43 EXPRESSION IN THE LEFT VENTRICLE OF NORMOTENSIVE WISTAR RATS AFTER ADMINISTRATION OF LPS 565 K. Frimmel, J. Krizak, B. Liptak, J. Navarova, V. Knezl, E. Breierova, I. Bernatova, L. Okruhlicova (Slovakia)

57 Poster Walks Monday Vascular Biology: Myocardial Infarction, Stroke, Peripheral Vascular Disease 089 EFFECT OF THROMBOLYTIC THERAPY AND PERCUTANEOUS CORONARY INTERVENTION (PCI) ON INFLAMMATORY MEDIATORS 566 B. Bagheri, A. Garjani, B. Taherkhanchi, B. Sohrabi, F. Mousavi (Iran) 090 EFFECT OF ENDOVASCULAR TREATMENT AT PATIENTS WITH EARLY POSTINFARCTION STENOCARDIA 567 S. Salakhitdinov, M. Kenjaev, S. Abdijalilova, A. Nizomov (Uzbekistan) 091 TERMS OF SUCCESS OF REHABILITATION IN PATIENTS WITH MULTIFOCAL ATHEROSCLEROSIS 568 P. Bondarenko, A. Novikova, M. Ivanov, M. Ermina, M. Chvostova, A. Yadernaya, R. Al-Banna (Russia) 092 INTERSECTED GENES IN HYPERLIPIDEMIA AND CORONARY BYPASS PATIENTS: FEASIBLE BIOMARKERS FOR CORONARY HEART DISEASE 569 Y. Maneerat, K. Prasongsukarn, S. Benjathummarak, W. Dechkhajorn, U. Chaisri (Thailand) 093 MYOCARDIAL STANNING AFTER THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL INFARCTION. 570 M. Kenjaev, S. Kenjaev, S. Abdijalilova, A. Nizomov (Uzbekistan) 094 EARLIEST OUTCOMES OF ACUTE CORONARY SYNDROME IN PATIENTS WITH TYPE 2 DIABETES 571 S. Abdijalilova, M. Kenjaev, L. Botirova, U. Ganiyev, A. Nizomov (Uzbekistan) 095 N-ACETYLCYSTEINE IN A COMBINATION THERAPY REDUCES MYOCARDIAL DAMAGE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND IMPROVES LEFT VENTRICULAR FUNCTION AFTER PERCUTANEOUS CORONARY INTERVENTION. 572 A. Nizomov, B. Toshev, M. Mukhamedova, J. Berdiqulov (Uzbekistan) 096 RELATIONSHIP BETWEEN LIPID DISORDERS AND SEVERITY AND NATURE OF CORONARY ARTERY LESIONS IN MALE PATIENTS WITH CORONARY ARTERY DISEASE 573 V. Kashtalap, O. Barbarash, O. Hryachkova, A. Novitskaya (Russia) 097 PHYSIOLOGICAL AND BIOCHEMICAL PARAMETERS OF HYPERTHYROID RAT HEART DURING ISCHEMIA REPERFUSION 574 C.R. Revnic, C. PENA, F. REVNIC, A.S. NICA, S. PRADA, G. PRADA (Romania) 098 ACUTE ARTERIAL OCCLUSION OF APPARENTLY HEALTHY ARTERIES - A CONCLUSIVE EXPLANATION USING FRACTAL PHYSICS 575 D. Tesloianu, M. Agop, I. Nedelciuc (Romania) 099 AUTOLYSIS IN CAD STEMI ANTEROSEPTOAPICOLATERAL WALL PATIENT, A CASE REPORT 576 P. Sudjana, F. Nugraha, C. Achmad, A. Purnomowati, T. Aprami (Indonesia) 100 VENOUS THROMBOEMBOLISM AND CORONARY SYNDROME 577 A. Babets, A. KURIATA (Ukraine) 101 ASSOCIATION OF BASELINE APOLIPOPROTEIN B AND FRIEDEWALD LDLC WITH LONG-TERM RE-INFARCTION IN HYPERTRIGLYCERIDEMIC PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION 578 M. Hermans, A. Van der Laarse, M. Schalij, F. Romijn, N. Smit, Y. Van der Burgt, W. Jukema, C. Cobbaert (Netherlands) 102 CORRELATION OF HIGH-SENSITIVE CRP, CAROTID INTIMA-MEDIA THICKNESS, AND THE CHRONIC KIDNEY DISEASE OF HEALTHY RESIDENTS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION STUDY (KOPS) 579 Y. Tanaka, M. Shimizu, N. Furusyo, Y. Kato, J. Hayashi (Japan) 103 ATHEROSCLEROTIC SOFT PLAQUE REGRESSION USING TRANSCUTANEOUS LOW-LEVEL COMBINED DUAL-FREQUENCY SONICATION ACCOMPANIED BY HIGH-DOSE ATORVASTATIN AND PESDA MICROBUBBLES ADMINISTRATION 580 H. Mehrad, M. Mokhtari-Dizaji, H. Ghanaati (Iran) 104 INDIVIDUAL ATORVASTATIN DOSES TITRATION TO TREATMENT OF CAROTID PLAQUES IN PATIENTS WITH ARTERIAL HYPERTENSION I-II DEGREE 581 N. Balashenka, V. Podpalov (Belarus) 105 EFFECT OF SHORT-TERM INTENSIVE ROSUVASTATIN THERAPY ON CAROTID ATHEROSCLEROTIC PLAQUE VOLUME IN VERY HIGH CARDIOVASCULAR RISK PATIENTS USING THE THREE-DIMENSIONAL ULTRASOUND 582 Z. Luginova, M. Koshurnikova, E. Solovieva, T. Balakhonova, A. Susekov (Russia) 106 PLEIOTROPIC EFFECTS OF ANTI-ATHEROSCREROTIC CILOSTAZOL ON BRAIN OF STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS (SHR-SP) 583 K. Abe, Y. Omote, T. Yamashita, R. Morihara, Y. Nakano, Y. Ohta (Japan) 107 ASSOCIATION BETWEEN VO2PEAK AND CLAUDICATION WALKING TIME MEASURED DURING WALKING ON A TREADMILL AND IN COMMUNITY SETTINGS OUTDOOR WALK - PILOT STUDY 584 E. Rosłoniec, A. Kulik, J. Trzeciak, P. Mika (Poland) 108 EFFECTS OF NORDIC POLE WALKING ON OXIDATIVE STRESS AND WALKING ABILITIES IN PATIENTS WITH INTERMITTENT CLAUDICATION 585 E. Rosłoniec, M. Więcek, M. Bawelski, M. Maciejczyk, J. Głodzik, P. Mika (Poland)

58 Poster Walks Monday 109 LOW NUMBER OF CIRCULATING CD34 POSITIVE CELL IS ASSOCIATED WITH GREATER PROGRESSION OF CORONARY CALCIUM DETERMINED BY MDCT 586 T. Miyoshi, M. Doi, K. Nakamura, H. Ito (Japan) 110 A GIANT LEFT ATRIUM 587 Y. Saleh, A. Almaghraby, B. Hammad, M. Elbahey, A. Samoka, A. Ghoneem, M. Seleem (Egypt) 111 ARTERIAL STIFFNESS AS A PREDICTOR OF RECOVERY OF LEFT VENTRICULAR SYSTOLIC FUNCTION AFTER ACUTE MYOCARDIAL INFARCTION TREATED WITH PRIMARY PERCUTANEOUS CORONARY INTERVENTION 588 G. Mandraffino, C.O. Aragona, S. Quartuccio, G. Trapani, A. Saitta, M. Vatrano, E. Imbalzano (Italy) 112 EVALUATION OF CHANGES OF GLOBAL LONGITUDINAL STRAIN IN PATIENTS WITH STEMI AFTER MYOCARDIAL REVASCULARIZATION 589 V. Oleynikov, V. Galimskaya, E. Romanovskaya (Russia) 113 ASSESSMENT OF EFFICIENT REVASCULARIZATION ON DYNAMICS OF VELOCITY PARAMETERS IN PATIENTS WITH STEMI 590 V. Oleynikov, V. Galimskaya, E. Romanovskaya, I. Avdeeva (Russia) 114 STRUCTURAL AND FUNCTIONAL PROPERTIES OF THE MAJOR ARTERIES IN PATIENTS WITH CORONARY HEART DISEASE AND HEALTHY SUBJECTS 591 V. Oleynikov, A. Khromova, L. Salyamova (Russia) 115 LIVER DYSFUNCTION AND 18F-NAF ATHEROSCLEROTIC PLAQUE UPTAKE - ANALYSIS IN HIGH-CARDIOVASCULAR RISK INDIVIDUALS 592 M. Santos, M. Castelo-Branco, R. Silva, A. Gomes, P. Donato, J. Ferreira, C. Domingues, M. Pego, L. Gonçalves, M.J. Ferreira (Portugal) 116 THE RELATIONSHIP BETWEEEN CALCIFIED PLAQUES AND RESTENOSIS AFTER CAROTID ENDARTERECTOMY 593 H. Katano, K. Yamada, M. Mase (Japan) 117 ASSOCIATION BETWEEN SERUM ZINC LEVEL AND CAROTID ATHEROSCLEROSIS WITHOUT PLAQUE 594 M. Park (Republic of Korea) 118 PLAQUE CHARACTERISATION AND ANALYSIS IN THE RISK STRATIFYING PATIENTS WITH SYMPTOMATIC CAROTIS STENOSIS 595 D. Vanoli, P. Lindqvist (Sweden) 119 AREA MEASUREMENT OF CAROTID PLAQUE COMPARING B-MODE, DOPPLER COLOR AND CONTRAST-ENHANCED ULTRASOUND IMAGING 596 E. Nyman, D. Vanoli, C. Grönlund, U. Näslund, P. Lindqvist (Sweden) 120 DO STROKE PATIENTS WITH NORMAL CAROTID ARTERIES REQUIRE TEE FOR EXCLUSION OF RELEVANT AORTIC PLAQUE? 597 B. Muinjonov, E. Giyazitdinova (Uzbekistan) 121 QUANTIFICATION OF MICROVESSELS DENSITY IN CAROTID PLAQUE BY CONTRAST-ENHANCED ULTRASOUND WITH HISTOPATHOLOGIC VALIDATION 598 A. Evdokimenko, L. Druina, A. Chechetkin, S. Scrylev, T. Gulevskaya, M. Tanashyan (Russia) 122 REFERENCE VALUES FOR LOCAL ONE-POINT CAROTID STIFFNESS BY ECHO-TRACKING IN A LARGE POPULATION OF HEALTHY SUBJECTS 599 S. Favretto, S. Carerj, J. Jaroch, K. Łoboz-Grudzień, F. Antonini-Canterin, C. Zito, E. Bossone, M. PIrisi, O. Vriz (Italy) 123 INVESTIGATION OF PROTOPORPHYRIN IX-MEDIATED SONODYNAMIC THERAPY ON INTERMEDIATE STAGE ATHEROSCLEROSIS USING A NEW COMPUTERIZED B- MODE ULTRASOUND ANALYZING METHOD 600 H. Mehrad, M. Farhoudi (Iran) 124 NON-INVASIVE HIGH-FREQUENCY ULTRASOUND USING INTIMA AND INTIMA/MEDIA THICKNESS RATIO (BUT NOT CIMT), CORRECTLY MONITORED EXPECTED BENEFICIAL VASCULAR EFFECTS OF MENOPAUSAL HORMONE THERAPY 601 T. Naessen, M. Larsson (Sweden) 125 LIMITATIONS OF CONTRAST-ENHANCED ULTRASOUND WITH EVALUATION OF NEOVASCULARISATION IN THE ATHEROSCLEROTIC PLAQUE 602 A. Evdokimenko, L. Druina, A. Chechetkin, M. Tanashyan, T. Gulevskaya, S. Scrylev (Russia) 126 COMPARISON OF THE RESULTS OF CORONARY ANGIOGRAPHY AND PARAMETERS OF LOCAL RIGIDITY OF COMMON CAROTID ARTERY IN PATIENTS WITH CORONARY HEART DISEASE 603 V. Oleynikov, L. Salyamova, A. Khromova, N. Burko (Russia) 127 EFFICACY OF SCREENING OF SUBCLINICAL AORTAL ATHEROSCLEROSIS IN WORKING-AGE POPULATION DEPENDING ON INVESTIGATIONAL METHODS. 604 N. Koziolova, A. Chernyavina (Russia) 128 SUBCLINICAL CAROTID AND CEREBRAL ATHEROSCLEROSIS SCREENING IN WORKING-AGE POPULATION: EFFICACY OF DIFFERENT INVESTIGATIONAL METHODS. 605 N. Koziolova, A. Chernyavina (Russia) 129 RETINAL VASCULAR CALIBER, OCULAR BLOOD FLOW AND ENDOTHELIN-1 LEVEL IN BLOOD SERUM IN PATIENTS WITH SUBCLINICAL ATHEROSCLEROSIS 606 N. Adzhemian, V. Neroev, T. Kiseleva, M. Ezhov, N. Balatskaya, N. Ilina, V. Tankovskiy (Russia)

59 Poster Walks Monday 130 INVESTIGATING THE FEASIBILITY OF B-MODE ULTRASONOGRAPHY ACCOMPANIED BY PESDA MICROBUBBLES ADMINISTRATION FOR ACCURATE VISUALIZATION OF INTRAPLAQUE NEOVASCULARIZATION 607 H. Mehrad, M. Mokhtari-Dizaji, H. Ghanaati (Iran) 131 SUBCLINICAL ATHEROSCLEROSIS AND COGNITIVE IMPAIRMENT IN UZBEKISTAN 608 D. Akramova, A. Umarov (Uzbekistan) 132 THE RELATIONSHIP BETWEEN NONALCOHOLIC HEPATIC STEATOSIS AND CAROTID ATHEROSCLEROSIS AT THE ELDERLY 609 A. Capisizu, A. Zamfirescu, R. Dascalescu, O. Stanciu, S.M. Aurelian (Romania) 133 RELATIONSHIP BETWEEN THE CHOLESTEROL AND TRIGLYCERIDE CONTENT OF LIPOPROTEIN SUBCLASSES AND CAROTID INTIMA MEDIA THICKNESS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION STUDY 610 N. Furusyo, M. Shimizu, Y. Kato, Y. Tanaka, J. Hayashi (Japan) 134 CONFOCAL DUAL-PULSED ELECTROHYDRAULIC SHOCK WAVE THERAPY ACCOMPANIED BY PESDA MICROBUBBLES AND ATORVASTATIN ADMINISTRATION REDUCE THE ATHEROSCLEROTIC INTRAPLAQUE NEOVESSELS IN THE RABBIT CAROTID ARTERY 611 H. Mehrad, S.A. Seyedikhosroshahi (Iran) Vascular Biology: Immune Disease and Cardiovascular Pathologies 135 EVALUATION OF SERUM CHEMERIN LEVEL IN PATIENTS WITH HASHIMOTO S THYROIDITIS 612 E. Berta, M. Harangi, V.E. Varga, H. Lőrincz, I. Seres, E.V. Nagy, G. Paragh, M. Bodor (Hungary) 136 RISK FACTORS OF ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH THYROID GLAND LESION 613 R. Sayfutdinov, O. Bugrova, K. Nagornova, M. Dobrolubov, N. Artemova (Russia) 137 CARDIOVASCULAR MORTALITY AND MORBIDITY IN A GROUP OF PATIENTS WITH HIV DIAGNOSIS 614 E. Sifuentes Diaz, M. Monsalvo Hernando, C. Palomar Muñoz, N. Caro Gomez, E. Lopez Tinoco, R. Toro (Spain) 138 ARE CARDIOVASCULAR RISK FACTORS THE NEW THREAT TO HIV PATIENTS? 615 M. Monsalvo, E. Sifuentes Diaz, A. Caceres Gestoso, P. Perez Guerrero, I. Tinoco Racero, A. De los Santos Moreno (Spain) 139 SYSTEMIC LUPUS ERYTHEMATOSUS FLARE-UP IS ASSOCIATED WITH INCREASED 5-YEARS CAROTID INTIMA-MEDIA THICKNESS PROGRESSION 616 A. Baragetti, M. Magnoni, K. Garlaschelli, L. Grigore, M. Berteotti, I. Scotti, E. Bozzolo, A. Berti, A.A. Manfredi, E. Ammirati, A.L. Catapano, G.D. Norata (Italy) 140 PREVALENCE OF INCREASED ARTERIAL STIFFNESS AND PERIPHERAL ARTERIAL DISEASE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS 617 K. Tziomalos, I. Gkougkourelas, A. Sarantopoulos, E. Bekiari, E. Makri, N. Raptis, K. Tselios, M. Pantoura, A. Hatzitolios, P. Boura (Greece) 141 PREVALENCE OF INCREASED ARTERIAL STIFFNESS AND PERIPHERAL ARTERIAL DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS 618 K. Tziomalos, I. Gkougkourelas, A. Sarantopoulos, E. Bekiari, N. Raptis, E. Makri, K. Tselios, M. Pantoura, A. Hatzitolios, P. Boura (Greece) 142 ARTERIAL STIFFNESS IN A BLACK SOUTH AFRICAN COHORT INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) 619 C.M. Fourie, J.M. Van Rooyen, H.W. Huisman, C.M. Mels, W. Smith, R. Kruger, S. Botha, L. Lammertyn, L. Gafane, A.E. Schutte (South Africa) Lipoproteins and Lipid Metabolism: ApoB Containing Lipoproteins 143 DEVELOPMENT OF A NOVEL HOMOGENEOUS ASSAY FOR REMNANT LIPOPROTEINS 620 N. Satoh, M. Ikaida, Y. Ito (Japan) 144 MOST OF THE HEPATIC TRIGLYCERIDE LIPASE (HTGL) IS BOUND TO APOE-RICH HDL IN POST-HEPARIN PLASMA 621 K. Nakajima, S. Usui, R. Shinohata, K. Miyashita, S. Imamura, J. Kobayashi, T. Machida, H. Sumino, M. Murakami (Japan) 145 NOVEL ROLE OF A TRIGLYCERIDE-SYNTHESIZING ENZYME: DGAT1 AT THE CROSSROAD BETWEEN TRIGLYCERIDE AND CHOLESTEROL METABOLISM 622 V. Sachdev, C. Leopold, R. Bauer, J.V. Patankar, J. Iqbal, S. Obrowsky, M. Doktorova, M. Goeritzer, B. Scheicher, D. Kolb, G. Hoefler, A.V. Turnbull, A. Zimmer, M.M. Hussain, A.K. Groen, D. Kratky (Austria) 146 THE ROLE OF ANGPTL3 IN HUMAN LIPOPROTEIN METABOLISM 623 A. Tikka, J. Metso, M. Jauhiainen (Finland) 147 ASSOCIATION OF THE POSTPRANDIAL CHYLOMICRON TRIGLYCERIDE/ ApoB INDEX AND CARDIOVASCULAR EVENTS 624 H. Scharnagl, C. Werner, T. Stojakovic, W. März, U. Laufs (Austria)

60 Poster Walks Monday 148 SYSTEMATIC ASSAY OF LIPOPROTEIN LIPASE ACTIVITY AND MASS IN COHORT OF PATIENTS WITH HISTORY OF TYPE V HYPERLIPIDEMIA 625 O. Marmontel, M. Di Filippo, S. Nony, C. Marcais, C. Caussy, S. Charriere, A. Sassolas, P. Moulin (France) 149 APOLIPOPROTEIN C-III GLYCOFORMS CORRELATE HETEROGENEOUSLY WITH PLASMA LIPID PROFILE IN SUBJECTS WITH CORONARY ARTERY DISEASE 626 C. Chiariello, A. Castagna, N. Martinelli, P. Guarini, M. Manfredi, E. Ranzato, S. Martinotti, E. Marengo, D. Cecconi, O. Olivieri (Italy) 150 PLASMA APOLIPOPROTEIN CIII LEVELS AND INCIDENT CORONARY ARTERY DISEASE RISK: THE EPIC-NORFOLK PROSPECTIVE POPULATION STUDY. 627 J. Van Capelleveen, S.J. Bernelot Moens, X. Yang, N.T. Wareham, K.T. Khaw, E.S.G. Stroes, J.L. Witztum, G.K. Hovingh, S.M. Boekholdt, S. Tsimikas (Netherlands) C MIRISTIC ACID AND 3H CHOLESTEROL UPTAKE STUDIES IN AGING RABBIT AORTA AND HEART MUSCLE.THE IMPACT OF SERUM FACTORS FROM PATIENTS WITH LIPID METABOLIC DISORDERS 628 C.R. Revnic, C. Pena, F. Revnic, S. Voinea, B. Paltineanu (Romania) 152 LDL SUBFRACTIONAL ANALYSIS: A LABORATORY DIAGNOSTIC ASSAY IN PATIENTS WITH CAROTID AND CORONARY ATHEROSCLEROSIS 629 N. Gavrilova, V. Metelskaya, I. Ozerova, E. Yarovaya, S. Boytsov (Russia) 153 THERMAL STABILITY OF HUMAN PLASMA LDL(-): A PARADOXICAL BEHAVIOR OF LDL AGGREGATION 630 A. Rull, S. Jayaraman, A. Rivas, M. Pérez Cuellar, J. Ordóñez Llanos, J.L. Sánchez Quesada, O. Gursky (Spain) 154 LIPOPROTEINS FROM CORD BLOOD OF SMALL BABY FOR GESTATIONAL AGE SHOWED ELEVATED TRIGLYCERIDE AND DIMINISHED APOA-I CONTENT WITH MORE PRO-ATHEROSCLEROTIC AND PRO- INFLAMMATORY ACTIVITY 631 S.M. Kim, C. Kyung-Hyun (Republic of Korea) 155 POLOXAMERS INHIBIT ASSOCIATION OF MULTIPLY MODIFIED LDL, BUT DO NOT REDUCE THEIR ATHEROGENIC POTENTIAL 632 A. Melnichenko, N. Elizova, A. Orekhov (Russia) 156 MULTIPLE MODIFICATION OF LDL CIRCULATING IN BLOOD OF ATHEROSCLEROTIC PATIENTS 633 A. Orekhov, I. Sobenin, A. Melnichenko (Russia) 157 COMPARABILITY STUDY OF CANDIDATE REFERENCE METHODS FOR LDL-P MEASUREMENTS 634 N. Clouet Foraison, S. Vaslin-Reimann, C. Cobbaert, P. Gillery, V. Delatour (France) 158 THE DETERMINATION OF APOLIPOPROTEIN B BY CALCULATION AND BY MEASUREMENT ON SET OF DYSLIPIDEMIC PATIENTS 635 L. Cibickova, R. Gasko, H. Vaverkova, D. Karasek (Czech Republic) 159 ADIPONECTIN AS A BLOCKER OF OXIDIZED LDL 636 A. Kakino, Y. Fujita, T. Sawamura (Japan) 160 STRUCTURAL CHANGES INDUCED BY ACIDIC PH IN HUMAN APOLIPOPROTEIN B A. Benito-Vicente, J.A. Fernández-Higuero, J.C.G. Milicua, A. Etxebarria, H. Ostolaza, J.L.R. Arrondo, C. Martin (Spain) 161 OXIDIZED LOW-DENSITY LIPOPROTEINS AND LECTIN-LIKE OXIDIZED LDL RECEPTOR-1 ARE POSITIVELY ASSOCIATED TO PCSK9 IN TYPE 2 DIABETES MELLITUS 638 Y. Nekaies, B. Baudin, S. Kalbousi, M. Sakly, N. Attia (France) 162 LIPIDOMICS OF PLASMA, LIVER AND AORTA OF PCSK9-KO MICE 639 G. Chiesa, M. Busnelli, C. Parolini, S. Manzini, G.S. Ganzetti, F. Dellera, M. Suoniemi, M. Hilvo, R. Hurme, K. Ekroos, C.R. Sirtori, R. Laaksonen (Italy) 163 SUBFRACTIONAL DISTRIBUTION OF APO B-CONTAINING LIPOPROTEINS: A NEW MARKER FOR DETECTION OF INDIVIDUAL CARDIOVASCULAR RISK 640 V. Metelskaya, I. Ozerova, N. Gavrilova, E. Yarovaya, S. Boytsov (Russia) Lipoproteins and Lipid Metabolism: Lipoprotein Metabolism 164 NOVEL CHIMERAS PROVIDE INSIGHT INTO STRUCTURE/FUNCTION ACTIVITY IN APOLIPOPROTEIN E3 AND APOLIPOPROTEIN AI 641 V. Narayanaswami, M. Lek, N. Ibe, W. Beck, J. Bielicki, P. Weers (USA) 165 EFFECTS OF TUMOR BEARING ON SERUM AND LIVER LIPID LEVELS IN SATO LUNG CARCINOMA (SLC)-IMPLANTED RATS: EFFECT OF A DIFFERENCE IN IMPLANTED CELL NUMBERS 642 M. Kawasaki (Japan) 166 EFFECTS OF ROSUVASTATIN ON GENE EXPRESSION OF LIVER LDL-R, PCSK9, SREBP-2, AND LRP1 IN OVARIECTOMIZED RATS SUBMITTED OR NOT TO VOLUNTARY EXERCISE 643 J.M. Lavoie, E.T. Ngo Sock, G. Mayer (Canada) 167 BLOOD LEVELS OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IN MEN OF DIFFERENT POPULATION SUBGROUPS AND ITS RELATIONSHIP WITH UNFAVORABLE LONG-TERM PROGNOSIS 644 K. Astrakova, Y. Ragino, E. Shakhtshneider, S. Astrakov, M. Voevoda (Russia)

61 Poster Walks Monday 168 LDL RECEPTOR (LDLR) EXPRESSION AND FUNCTION IN HUMAN PANCREATIC BETA CELLS 645 A. Thedrez, R. Scharfmann, P. Parnet, E. Nobécourt, G. Lambert (France) 169 HIGH INTAKE OF SODIUM CHLORIDE EXACERBATES DEGRADATION OF HUMAN LIPOPROTEINS AND IMPAIRMENT OF REPRODUCTIVE CAPACITY VIA TESTICULAR TOXICITY IN ZEBRAFISH 646 E.Y. Lee, K.H. Cho (Republic of Korea) 170 MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN THE ISCHEMIC HEART 647 M. Klevstig, M. Scharin Täng, M. Ståhlman, M. Levin, J. Borén (Sweden) 171 STABLE ISOTOPE KINETIC STUDY OF APOLIPOPROTEIN M IN HEALTHY SUBJECTS 648 M. Croyal, M. Chétiveaux, K. Ouguerram, S. Billon-Crossouard, E. Nobécourt, M. Krempf (France) 172 HEPATOSTEATOSIS AND ESTROGEN INCREASE APOLIPOPROTEIN O PRODUCTION IN THE CHICKEN 649 B. Schmidinger, A. Weijler, W.J. Schneider, M. Hermann (Austria) 173 NORMALIZATION OF LIPOPROTEIN PROFILE DURING PREGNANCY IN LCAT DEFICIENCY 650 A. Ossoli, E. Hanna, S. Simonelli, R. Mullan, S. Chamney, J. Chestnutt, F. Stewart, G. Franceschini, L. Calabresi (Italy) 174 CHARGED RESIDUES IN THE C-TERMINAL DOMAIN OF APOLIPOPROTEIN A-I MEDIATE OLIGOMERIZATION 651 P. Weers, V. Narayanaswami, L. Fuentes, J. Horn, R. Ellena, K. Cong (USA) 175 EFFECTS OF APOE VARIANTS ON PLTP INTERACTION AND ACTIVATION OF LOW AND HIGH ACTIVITY FORMS OF PLTP 652 M. Jauhiainen, I. Dafnis, J. Metso, V. Zannis, A. Chroni (Finland) 176 HIGH-PERFORMANCE GEL PERMEATION CHROMATOGRAPHY ANALYSIS DEMONSTRATES ATHEROGENIC PROPERTIES OF LIPOPROTEINS IN PATIENTS WITH CHOLESTERYL ESTER TRANSFER PROTEIN DEFICIENCY 653 T. Okada, T. Ohama, M. Okazaki, H. Matsuda, M. Sairyo, Y. Zhu, R. Kawase, D. Masuda, M. Koseki, M. Nishida, Y. Sakata, S. Yamashita (Japan) 177 COMPARISON OF FATTY ACID COMPOSITION OF SUBCUTANEOUS, PERICARDIAL AND EPICARDIAL ADIPOSE TISSUE AND ATRIAL TISSUE IN PATIENTS WITH HEART DISEASE 654 R. Bülow Eschen, J. Gu, J.J. Andreasen, A. Andreasen, S. Lundbye- Christensen, E. Berg Schmidt (Denmark) 179 MYRISTIC ACID PLASMA LEVELS ARE STRONGLY CORRELATED WITH TRIGLYCERIDE AND APOLIPOPROTEIN C-III PLASMA CONCENTRATION IN A COHORT OF SUBJECTS WITH OR WITHOUT CORONARY ARTERY DISEASE 656 G. Speziali, D. Cecconi, N. Martinelli, O. Olivieri, A. Castagna, P. Guarini (Italy) 180 SPHINGOMYELIN CONTENT OF ERYTHROCYTE MEMBRANES IS IN LINEAR ASSOCIATION WITH MEMBRANES LOADING WITH CHOLESTEROL IN CORONARY ARTERY DISEASE PATIENTS. 657 G. Chalikias, P. Kikas, I. Drosos, M. Pavlaki, A. Thomaidis, S. Konstantinides, D. Tziakas (Greece) 181 COMPLEX PHOSPHOLIPIDS ASSOCIATE WITH ARTERIAL NOREPINEPHRINE, NON-ESTERIFIED FATTY ACIDS AND HEART RATE, MARKERS OF SYMPATHETIC NERVE SYSTEM IN METABOLIC SYNDROME SUBJECTS INDEPENDENTLY OF INSULIN RESISTANCE 658 P. Nestel, N. Straznicky, A. Anwar, M. Pyush, P. Meikle (Australia) 182 ATHEROGENIC INDEX OF PLASMA FOR PREDICTION OF FUTURE CARDIOVASCULAR DISEASE IN PREDIABETES AND DIABETES POPULATION 659 P. Regmi, B. Baral, M. Raut, M.P. Khanal (Nepal) 183 INVESTIGATION OF LPL INDEPENDENT PATHWAYS OF TG-RICH LIPOPROTEIN METABOLISM IN LPL DEFICIENCY 660 D. Gaudet, D. Brisson, K. Tremblay (Canada) 184 EFFECT OF SALSALATE ON METABOLIC SYNDROME-RELATED PARAMETERS AND ACTIVITY OF BROWN ADIPOSE TISSUE IN WISTAR AND HEREDITARY HYPERTRIGLYCERIDEMIC RATS 661 V. Skop, J. Trnovska, M. Huttl, H. Malinska, I. Markova, O. Oliyarnyk, L. Kazdova (Czech Republic) 185 SPECIFIC CIRCULATING PHOSPHOLIPIDS, ACYLCARNITINES, AMINO ACIDS AND BIOGENIC AMINES ARE AEROBIC EXERCISE MARKERS 662 T. Felder, S. Ring-Dimitriou, S. Auer, S. Soyal, L. Kedenko, M. Rinnerthaler, J. Cadamuro, E. Haschke-Becher, E. Aigner, B. Paulweber, W. Patsch (Austria) 186 HETEROGENEITY OF PLASMA LOW DENSITY LIPOPROTEINS AND HIGH DENSITY LIPOPROTEINS: SOME GENDER PECULIARITIES IN SUBFRACTIONAL DISTRIBUTION 663 V. Metelskaya, I. Ozerova, N. Gavrilova, S. Boytsov (Russia) 187 IDENTIFICATION OF A NOVEL LXR TARGET 664 E.C.L. Cook, J.K. Nelson, V. Sorrentino, N. Zelcer (The Netherlands) 178 DIETARY SATURATED FATTY ACIDS AGGRAVATE PRESSURE OVERLOAD- INDUCED CARDIOMYOPATHY IN MICE IN THE ABSENCE OF CARDIAC STEATOSIS 655 I. Muthuramu, R. Amin, N. Singh, A. Postnov, O. Gheysens, P. Van Veldhoven, B. De Geest (Belgium)

62 Poster Walks Monday Lipoproteins and Lipid Metabolism: Lp(a) 188 PROGNOSTIC VALUE OF COMBINED LIPOPROTEIN(A) AND HOMOCYSTEINE IN ANGIOGRAPHICALLY PROVEN PATIENTS WITH CORONARY ARTERY DISEASE 665 S.W. Kwon, H.M. Kwon (Republic of Korea) 189 LIPOPROTEIN(A) MEASUREMENT AND ASSOCIATION WITH MEDICAL HISTORY IN SECONDARY CARE LIPID CLINICS 666 K.E. Shipman, A.J. Lawson, W. Alkaaby, A.F. Jones, R. Cramb (United Kingdom) 190 ELEVATED LIPOPROTEIN(A) AND ISCHEMIC STROKES- A CASE REPORT 667 P. Moriarty, N. Sehar, L. Denney, F. Perez-Marques, A. Panchal, P. Luna (USA) 191 RATIONALE AND DESIGN OF A CLINICAL TRIAL TO ASSESS LP(A) LOWERING WITH IONIS-APO(A)-LRX IN PATIENTS UNDERGOING APHERESIS FOR ELEVATED LP(A) AND RECURRENT CARDIOVASCULAR EVENTS 668 P.M. Moriarty, E.S. Thiessen, J.L. Witztum, N.J. Viney, S. Tsimikas (USA) 192 PREVALENCE OF LPA SINGLE NUCLEOTIDE POLYMORPHISMS AND ISOFORMS IN PATIENTS ENROLLED IN A PHASE 2 IONIS-APO(a)Rx CLINICAL TRIAL 669 E.S. Stroes, F.M. Van der Valk, D. Gaudet, I. Gouni-Berthold, N.P. Riksen, E. Steinhagen-Thiessen, B. Isermann, B. Nordestgaard, N.J. Viney, S. Marcovina, S.G. Hughes, J. Tami, S. Xia, J.L. Witztum, S. Tsimikas (Netherlands) 193 NATURAL TEMPORAL VARIABILITY IN Lp(a) LEVELS IN PATIENTS ENROLLED IN THE PLACEBO ARMS OF IONIS-APO(a)Rx ANTISENSE OLIGONUCLEOTIDE CLINICAL TRIALS 670 N.J. Viney, S. Marcovina, J. Tami, S. Xia, J.L. Witztum, S. Tsimikas (USA) 194 PROGNOSTIC VALUE OF SERUM LIPOPROTEIN(A) LEVELS ON LONG- TERM MORTALITY IN A LARGE SAMPLE OF SUBJECTS IN PRIMARY CARDIOVASCULAR PREVENTION: DATA FROM THE BRISIGHELLA HEART STUDY 671 F. Fogacci, S. D'Addato, A.F.G. Cicero, E. Bertagnin, S. Palmisano, L. D'Agostini, E. Grandi, M. Giovannini, C. Borghi (Italy) 195 A SYSTEMATIC REVIEW AND META-ANALYSIS COMPARING THE EFFECTS OF STATINS AND FIBRATES ON PLASMA LIPOPROTEIN(A) LEVELS 672 A. Sahebkar, L.E. Simental-Mendía, M. Banach, M.C. Serban, G.F. Watts (Iran) 196 DEFINING THE MECHANISM OF LIPOPROTEIN(A) [LP(A)] LOWERING BY ALIROCUMAB IN TRANSGENIC MOUSE MODELS 673 C. Yeang, P. Miu, S. Green, X. Yang, M.Y. Hung, J.L. Witztum, S. Tsimikas (USA) 197 LIPOPROTEIN(A)-CHOLESTEROL (LP(A)-C) LEVELS DETERMINED BY VERTICAL AUTO PROFILE (VAP) CORRELATES WEAKLY WITH LP(A) MASS BUT MODESTLY WITH HDL-C: IMPLICATIONS FOR APPROPRIATE INTERPRETATION OF CLINICAL DATA 674 C. Yeang, S. Tsimikas (USA) 198 LIPOPROTEIN(a) AND INSULIN RESISTANCE: A POSSIBLE INVERSE RELATIONSHIP BETWEEN TWO WELL-KNOWN CARDIOVASCULAR RISK FACTORS 675 C.O. Aragona, E. Imbalzano, V. Cairo, F. Mamone, A. Lo Gullo, M.A. Sardo, A. Saitta, G. Mandraffino (Italy) 199 A NOVEL MODIFIED LIPID TETRAD INDEX AS PREDICTOR OF PREMATURE CORONARY ARTERY DISEASE IN INDIANS 676 S. Das (India) 200 CIRCULATING LIPOPROTEIN (A) [LP(A)] LEVELS AND RISK OF CARDIOVASCULAR DISEASE: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY 677 R. Hoogeveen, W. Sun, V. Salim, B. Christie (USA) 201 THE ROLE OF Lp(a) LEVELS AND APOPROTEIN(a) PHENOTYPE IN THE DEVELOPMENT OF ATHEROSCLEROSIS IN PATIENTS WITH CORONARY ARTERY DISEASE 678 D. Labudovic, K. Toseska-Trajkovska, S. Alabakovska, J. Bogdanska, S. Jovanova (FYR Macedonia) 202 LIPOPROTEIN(a) AND T-HELPER CELLS AS INDEPENDENT PREDICTORS OF RAPID PROGRESSION OF CAROTID ATHEROSCLEROSIS 679 O. Afanasieva, E. Pylaeva, T. Arefieva, E. Klesareva, M. Afanasieva, A. Potekhina, A. Shchinova, T. Balakhonova, O. Pogorelova, M. Tripoten, S. Pokrovsky (Russia) 203 POPULATION AND ASSAY THRESHOLDS FOR THE PREDICTIVE VALUE OF LIPOPROTEIN(A) FOR RISK OF CORONARY ARTERY DISEASE: THE EPIC- NORFOLK PROSPECTIVE POPULATION STUDY 680 R. Verbeek, S.M. Boekholdt, R.M. Stoekenbroek, G.K. Hovingh, J.L. Witztum, N.J. Wareham, M.S. Sandhu, K.T. Khaw, S. Tsimikas (Netherlands) 204 STATUS OF INFLAMMATION, ENDOTHELIAL ACTIVATION AND PROTHROMBOGENESIS AMONG NEGRITOS AND MALAYS WITH METABOLIC SYNDROME 681 S.S. Mokhtar, N.A. Mohd Mokhsin, F. Mohd Nor, S.A. Shaari, H. Nawawi, B.P. Hoh, T. Rahman (Malaysia) 205 ELEVATED LIPOPROTEIN(A) LEVELS RESULT IN A HIGH CARDIOVASCULAR RISK A PROSPECTIVE ANALYSIS OF A LIPIDOLOGY OUTPATIENTS UNIT 682 U. Schatz, S. Fischer, U. Julius, S.R. Bornstein, S. Tselmin (Germany)

63 Poster Walks Monday 206 PROFILE OF CIRCULATING mirnas IN PATIENT WITH HIGH Lp(a) TREATED BY LDL/Lp(a) APHERESIS 683 D. Dlouha, J. Pitha, Z. Eretova, O. Viklicky, A. Parikova (Czech Republic) 207 FAMILIAL HYPERCHOLESTEROLEMIA (FH) WITH ELEVATED LIPOPROTEIN(a) (Lp(a)) LEVELS AND AGGRESSIVE CORONARY HEART DISEASE: A CASUISTIC APPROACH 684 A. Dybvig, A. Græsdal (Norway) 208 LIPOPROTEIN(a) IS A PREDICTOR OF ONE-YEAR VEIN GRAFT OCCLUSIONS IN STABLE ANGINA PATIENTS RECEIVED LIPOPROTEIN APHERESIS FOR REFRACTORY HYPERCHOLESTEROLEMIA AFTER CORONARY ARTERY BYPASS GRAFTING 685 R. Adzhiev, M. Ezhov, O. Afanasieva, S. Pokrovsky (Russia) 209 LIPOPROTEIN(A) LEVEL AS A PREDICTOR OF LONG-TERM CARDIOVASCULAR OUTCOMES AFTER PERCUTANEOUS CORONARY INTERVENTIONS 686 M. Mitroshkin, M. Ezhov, M. Safarova, O. Afanasieva, Y. Matchin, S. Pokrovsky (Russia) 210 EFFECT OF NIACIN ON LIPOPROTEIN SUBFRACTIONS CONCENTRATION IN PATIENTS WITH ELEVATED LIPOPROTEIN(a) 687 E. Utkina, O. Afanasieva, N. Artemieva, M. Ezhov, I. Adamova, Y. Berestetskaya, S. Pokrovsky (Russia) Lipoproteins and Lipid Metabolism: HDL 211 FUNCTIONAL DIFFERENCES BETWEEN APOLIPOPROTEIN E- AND APOLIPOPROTEIN A-I- CONTAINING HDL PARTICLES 688 S. Filou, E. Karavia, C. Constantinou, E. Zvintzou, K. Kypreos (Greece) 212 APOA-I DEPLETION IN CHOW-FED APOEKO MICE SEVERELY WORSENS CORONARY ATHEROSCLEROSIS DEVELOPMENT 689 G.S. Ganzetti, M. Busnelli, C. Parolini, S. Manzini, F. Dellera, C.R. Sirtori, G. Chiesa (Italy) 213 EVALUATION OF NOVEL APOA-I TWO-SITE IMMUNOASSAYS 690 J. Lövgren, P. Negi, T. Heikkilä, T. Tallgren, K. Pettersson, M. Jauhiainen, U. Lamminmäki (Finland) 214 EICOSAPENTAENOIC ACID (EPA) MEMBRANE INCORPORATION REDUCES ABCA1-DEPENDENT CHOLESTEROL EFFLUX IN UNLOADED AS WELL AS IN CHOLESTEROL-LOADED PRIMARY HUMAN MACROPHAGES THROUGH DIFFERENT MECHANISMS 691 N. Fournier, S. Tardivel, B. Vedie, J.F. Benoist, F. Allaoui, J.L. Paul (France) 215 EFFECTS OF MODERATE AND EXCESS ALCOHOL CONSUMPTION ON THE REVERSE CHOLESTEROL TRANSPORT IN VIVO 692 D. Greco, L. Mele, A. Piemontese, S. Battista, A. Poli, F. Bernini, I. Zanotti (Italy) 216 PROBUCOL OXIDIZED PRODUCTS, SPIROQUINONE AND DIPHENOQUINONE, PROMOTE REVERSE CHOLESTEROL TRANSPORT IN MICE 693 K. Shiotani, E. Yakushiji, M. Ayaori, T. Nishida, S. Takiguchi, H. Uto-Kondo, M. Sasaki, M. Yogo, T. Komatsu, R. Lu, S. Yokoyama, K. Ikewaki (Japan) 217 INFLAMMATION POTENTLY SUPPRESSES ABCA1-MEDIATED CHOLESTEROL EFFLUX FROM MACROPHAGES, AND NOT ADIPOCYTES, VIA ACTIVATION OF JAK/STAT PATHWAY 694 M. O'Reilly, M. Goodwin, O. Ansmidte, H. Roche, F. McGillicuddy (Ireland) 218 IDENTIFICATION OF A NOVEL UPREGULATOR OF ABCA1 AND SRB1 EXPRESSION WITH THE ACTION OF REGULATING CHOLESTEROL METABOLISM IN VITRO AND IN VIVO 695 S. Si, Y. Xu, C. Liu, P. Liu, X. Wang, B. Hong (China) 219 ELEVATED LEVELS OF LECITHIN:CHOLESTEROL ACYLTRANSFERASE (LCAT) ARE ASSOCIATED WITH REDUCED ATHEROMA BURDEN AN IVUS STUDY 696 D. Rhainds, C. Gebhard, M. Cossette, M.C. Guertin, E. Rhéaume, J.C. Tardif (Canada) 220 EVALUATION OF HDL CHOLESTEROL EFFLUX CAPACITY (CEC) AFTER CONSUMPTION OF AN INNOVATIVE PASTA ENRICHED WITH BIOACTIVE COMPONENTS AND FUNCTIONAL PROBIOTICS 697 E. Cipollari, F. Zimetti, M.P. Adorni, N. Ronda, D. Angelino, N. Pellegrini, F. Bernini, E. Favari (Italy) 221 AEROBIC EXERCISE TRAINING DOES NOT SYSTEMATICALLY AFFECT MACROPHAGE GENE EXPRESSION INVOLVED IN REVERSE CHOLESTEROL TRANSPORT AND CHOLESTEROL EFFLUX IN CETP TRANSGENIC MICE 698 P.R. Pinto, K.S. Silva, D.J. Gomes, A. Machado-Lima, R.T. Iborra, G.S. Ferreira, E.C.R. Quintao, E.R. Nakandakare, U.F. Machado, M.L.C. Corrêa-Giannella, S. Catanozi, M. Passarelli (Brazil) 222 HDL CHOLESTEROL EFFLUX IS NOT PREDICTIVE OF CARDIOVASCULAR RISK IN DIABETIC PATIENTS ON HEMODIALYSIS 699 C. Kopecky, S. Ebtehaj, B. Genser, C. Wanner, M.D. Saemann, U. Tietge (Austria) 223 XANTHOHUMOL, A PRENYLATED FLAVONOID IN HOPS, PROMOTES MACROPHAGE REVERSE CHOLESTEROL TRANSPORT IN HAMSTER 700 H. Hirata, H. Uto-Kondo, M. Ogura, M. Ayaori, K. Ikewaki (Japan)

64 Poster Walks Monday 224 FAT-ACTIVATED ER STRESS INDUCES THE REDUCTION OF ABCG5/8 EXPRESSION IN THE SMALL INTESTINE AND LIVER OF HYPERLIPIDEMIC HAMSTERS AND THE APPEARANCE OF DYSFUNCTIONAL HDL 701 C.S. Stancu, M.G. Carnuta, G.M. Sanda, L. Toma, M. Deleanu, L.S. Niculescu, M. Simionescu, A.V. Sima (Romania) 225 ASSOCIATIONS BETWEEN LIPID SUBFRACTIONS AND SERUM MYELOPEROXIDASE LEVELS IN UNTREATED HYPERLIPIDEMIC PATIENTS 702 A. Szentpéteri, H. Lőrincz, N. Zsíros, V.E. Varga, I. Seres, M. Katkó, P. Fülöp, G. Paragh, M. Harangi (Hungary) 226 ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN SUBCLASSES WITH CAROTID INTIMA-MEDIA THICKNESS:SHIMANE CoHRE STUDY 703 Y. Notsu, T. Nabika, S. Yano, A. Nagai (Japan) 227 HIGH DENSITY LIPOPROTEINS EXERT PRO-INFLAMMATORY EFFECTS ON MACROPHAGES VIA PASSIVE CHOLESTEROL DEPLETION AND PKC-NF-KB/ STAT1-IRF1 SIGNALING 704 E. Van der Vorst, K. Theodorou, Y. Wu, M. Hoeksema, P. Goossens, C. Bursill, L. Huitema, S. Tas, M. Gijbels, K. McDaniels, C.C. Wang, M. Leitges, T. Lawrence, L. Touqui, J. Plat, M. Van Eck, K.A. Rye, M. De Winther, E. Biessen, M. Donners (Germany) 228 RELATIONSHIP BETWEEN FRAMINGHAM SCORE, HDL-CHOLESTEROL AND C-REACTIVE PROTEIN AT ELDERLY PATIENTS 705 S. Opris, G. Constantin, M. Grigorie (Romania) 229 THE LIPID FRACTIONS AS RISK FACTORS FOR ATHEROSCLEROSIS IN DIFFERENT AGE GROUPS IN BOSNIAN POPULATION 706 B. Pojskic, E. Stimjanin, L. Pojskic, H. Selimovic, A. Macic-Dzankovic, S. Palo, I. Sisic (Bosnia and Herzegovina) 230 METRICS OF HIGH-DENSITY LIPOPROTEIN FUNCTION AND HOSPITAL MORTALITY IN ACUTE HEART FAILURE PATIENTS 707 I. Potočnjak, V. Degoricija, M. Trbušić, S. Dokoza Terešak, B. Radulović, G. Pregartner, B. Andrea, B. Tiran, G. Marsche, S. Frank (Austria) 231 CAUSAL LINK BETWEEN SERUM AMYLOID A AND OXIDATIVE DAMAGES TO HIGH-DENSITY LIPOPROTEIN 708 S. Jayaraman, C. Haupt, O. Gursky (USA) 232 INFLUENCE OF HDL-CHOLESTEROL LEVELS ON HDL PARTICLES LIPID COMPOSITION IN HEALTHY INDIVIDUALS. AN NMR-BASED LIPIDOMIC STUDY 709 C. Kostara, V. Tsimihodimos, E. Bairaktari, M. Elisaf (Greece) 233 HIGH-DENSITY LIPOPROTEIN (HDL) FUNCTION AND SUBCLASS DISTRIBUTION IN OBESE AND NORMAL-WEIGHT BLACK AND WHITE AFRICAN WOMEN. 710 N. Woudberg, J. Goedecke, D. Blackhurst, M. Frias, R. James, L. Opie, S. Lecour (South Africa) 234 SMALL, DENSE HDL DISPLAY POTENT VASORELAXING ACTIVITY, REFLECTING THEIR ELEVATED CONTENT OF S1P 711 L. Persègol, M. Darabi, C. Dauteuille, M. Lhomme, R. Salvayre, A. Nègre- Salvayre, S. Monier, A. Kontush (France) 235 ESTIMATION OF HDL ANTIOXIDATIVE ACTIVITY IN SUBJECTS WITH ACUTE CORONARY SYNDROME 712 H. Thakkar, V. Vincent, A. Roy, S. Singh, L. Ramakrishnan, A. Singh (India) 236 HDL-SPHINGOMYELIN REDUCTION AFTER WEIGHT LOSS BY AN ENERGY-RESTRICTED DIET IS ASSOCIATED WITH THE IMPROVEMENT OF METABOLIC SYNDROME COMPONENTS IN OVERWEIGHT PATIENTS 713 O. Pérez-Méndez, M. Martínez-Ramírez, M. Madero (Mexico) 237 A PHASE III MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (TANGO) TO EVALUATE CER-001 ON CAROTID ATHEROSCLEROSIS (VESSEL WALL AREA) IN PATIENTS WITH FAMILIAL PRIMARY HYPOALPHALIPOPROTEINAEMIA 714 E. Stroes, R. Benghozi, J.L. Dasseux, J. Genest, H. Ginsberg, C. Keyserling, E. Leitersdorf, P. Raggi, A. Von Eckardstein (Netherlands) 238 VITAMIN D STATUS AND HDL FUNCTIONALITY IN HEALTHY PRE- MENOPAUSAL WOMEN 715 F. Zimetti, D. Kocyigit, D. Greco, M.P. Adorni, N. Ronda, K.M. Gurses, S.H. Oguz, A. Gurlek, L. Tokgozoglu (Italy) 239 STATUS OF INFLAMMATION AND ENDOTHELIAL ACTIVATION IN SUBJECTS WITH LOW HIGH DENSITY LIPOPROTEIN CHOLESTEROL AMONG ABORIGINES IN MALAYSIA 716 N.A. Mohd Mokhsin, W.N.H. Wan Ahmad, F.H. Sakri, N.A. Mohd Kasim, N. Mohd Nasir, S. Abdul Razak, M. Md Yasin, A. Mohd Ismail, T. Rahman, H. Nawawi (Malaysia) 240 EFFECT OF STATINS ON HDL IN FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS 717 M. Licona-Rashid, R. Yahya, D. Wattimena, J. Roeters van Lennep, C. Christoffersen, E. Sijbrands, A. Verhoeven, M. Mulder (Netherlands) 241 HDL AS A CRUCIAL INDICATOR OF AN EARLY CLINICAL MANIFESTATION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA 718 S. Urazgildeeva, M.V. Muzalevskaya, A.V. Tregubov, T.V. Nekrasova, V.S. Gurevich (Russia) 242 ENDOTHELIAL PROTECTIVE PROPERTIES OF HDL IMPROVE EARLY AFTER ROUX-EN-Y GASTRIC BYPASS BUT NOT AFTER DIET-INDUCED WEIGHT LOSS: THE SUPERIOR CARDIOMETABOLIC BENEFITS OF RYGB 719 E. Osto, E. McLoughlin, P. Doytcheva, M. Charakida, L. Van Gaal, J. Deanfield, T. Lüscher (Switzerland)

65 Poster Walks Monday 243 EFFECTS OF BARIATRIC SURGERY ON HIGH-DENSITY LIPOPROTEIN SUBTYPES 720 G. Rega-Kaun, C. Kaun, E. Dostal, S. Oravec, M. Prager, J. Wojta, W. Speidl (Austria) 244 INTERLEUKIN-6 REDUCES PARAOXONASE-1 ACTIVITY IN A DOSE- DEPENDENT MANNER; EVIDENCE FOR A POTENTIAL NOVEL LIPOPROTEIN-BASED MODULATORY MECHANISM 721 A. Abedpour Dehkordi, H. Nayeri, G.A. Naderi, N. Jafari Dinani, M. Boshtam (Iran) 245 TERMINALIA ARJUNA MODULATES LIPID EFFLUX AND INFLAMMATION IN HYPERCHOLESTEROLEMIC RABBITS 722 V. Dhawan, R. Rather, D. Trikha (India) CVD Risk Factors 246 ELEVATED NEUTROPHILS, MONOCYTES AND WHITE CELL COUNTS IN PATIENTS WITH MYOCARDIAL INFARCTION COMPARED WITH STABLE CORONARY ARTERY DISEASE 723 I. Trakarnwijitr, B. Li, H. Adams, J. Layland, J. Garlick, A. Wilson (Australia) 247 THE RISK FACTORS OF ATHEROSCLEROSIS IN ROMA POPULATION IN SOUTH BOHEMIA 724 V. Adamkova, J. Hubacek, D. Novakova, V. Adamek, V. Lanska, V. Tothova (Czech Republic) 248 LIPOPROTEIN PHENOTYPE IN NAïVE PATIENTS WITH KLINEFELTER SYNDROME 725 A. Antonucci, A. Bonaldo, P. Scarinzi, M. Barichello, P. Bigolin, N. Caretta, M. Ghezzi, R. Selice, M. Terrin, D. Vianello, R. Marin, A. Ferlin, C. Foresta, E. Manzato, F. Fabris, S. Bertocco, S. Zambon, A. Zambon (Italy) 249 RISK OF DEMENTIA HOSPITALISATION ASSOCIATED WITH CARDIOVASCULAR RISK FACTORS IN MIDLIFE AND OLDER AGE: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY 726 B. Muinjonov, E. Giyazitdinova (Uzbekistan) 250 PULSE WAVE VELOCITY IS CORRELATED WITH THE SERUM N-TERMINAL FRAGMENT OF BRAIN NATRIURETIC PEPTIDE LEVEL INDEPENDENTLY OF CENTRAL BLOOD PRESSURE AND THE AUGMENTATION INDEX 727 M. Shimizu, N. Furusyo, Y. Kato, Y. Tanaka, J. Hayashi (Japan) 251 ATHEROSCLEROTIC LESIONS OF AORTO-ILIAC SEGMENT AND LONG- TERM CONSEQUENCES OF RECONSTRUCTIVE OPERATIONS 728 A. Kozireva, M. Ivanov, P. Bondarenko, M. Ermina, D. Kozhevnikov, P. Puzdriak, A. Yadernaya, A. Kebryakov (Russia) 252 COMBINED EFFECTS OF ADIPONECTIN AND VISCERAL FAT ON THE RISK OF METABOLIC SYNDROME 729 K.H. Ha, D.J. Kim, H.C. Kim (Republic of Korea) 253 THE NEED TO CREATE AWARENESS TOWARDS CHOLESTEROL 730 J. Frutuoso, M. Bourbon (Portugal) 254 CORONARY ARTERY DISEASE AS A RISK FOR DEVELOPING TYPE 2 DIABETES MELLITUS 731 C. Saely, A. Vonbank, P. Rein, D. Zanolin, A. Leiherer, A. Muendlein, H. Drexel (Austria) 255 C-REACTIVE PROTEIN SIGNIFICANTLY PREDICTS CARDIOVASCULAR EVENTS BOTH IN PERIPHERAL ARTERIAL DISEASE PATIENTS WITH AND IN PERIPHERAL ARTERIAL DISEASE PATIENTS WITHOUT THE METABOLIC SYNDROME 732 A. Vonbank, C. Saely, P. Rein, D. Zanolin, A. Leiherer, H. Drexel (Austria) 256 PRO B-TYPE NATRIURETIC PEPTIDE SIGNIFICANTLY PREDICTS FUTURE VASCULAR EVENTS IN PERIPHERAL ARTERIAL DISEASE PATIENTS WITH TYPE 2 DIABETES 733 A. Vonbank, C. Saely, P. Rein, D. Zanolin, A. Leiherer, H. Drexel (Austria) 257 OVERWEIGHT IN CHILDREN OF PATIENTS WITH EARLY CORONARY HEART DISEASE: RELATION TO OWN AND PARENTAL CHARACTERISTICS` 734 M. Konnov, A. Deev (Russia) 258 AGE-DEPENDENCE OF THE MAGNITUDE OF LIPID PROFILE VARIABLES RESEMBLANCE BETWEEN FIRST DEGREE RELATIVES IN FAMILIES OF PATIENTS WITH EARLY CORONARY HEART DISEASE 735 M. Konnov, A. Deev, N. Gratsiansky (Russia) 259 THE EFFECT OF MOXONIDINE ON LIPID PROFILE OF PATIENTS WITH ARTERIAL HYPERTENSION, GRADE 1 AND E. Karlafti, A. Hatzitolios, T. Didangelos, M. Baltatzi, G. Koliakos, A. Kalkavouri, E. Liorda, V. Chasiotis, C. Savopoulos (Greece) 260 RISK OF INCIDENT HYPERTENSION ACCORDING TO METABOLIC HEALTH AND OBESITY: DEFINITION OF METABOLIC HEALTH DOES NOT MATTER 737 C.H. Jung, W.J. Lee, J.Y. Park, C.Y. Park, S. Kim (Republic of Korea) 261 BRACHIAL-ANKLE PULSE WAVE VELOCITY IS ASSOCIATED WITH COMPOSITE CAROTID AND CORONARY ATHEROSCLEROSIS IN A MIDDLE- AGED ASYMPTOMATIC POPULATION 738 H.J. Joo, S.A. Cho, J.Y. Cho, S. Lee, J.H. Park, S.H. Hwang, S.J. Hong, C.W. Yu, D.S. Lim (Republic of Korea) 262 SUSTAINED METABOLIC SYNDROME AFTER LIFESTYLE COUNSELING WAS ASSOCIATED WITH HIGHER RISK OF SUBCLINICAL CORONARY ATHEROSCLEROSIS 739 H.J. Joo, S.A. Cho, J.Y. Cho, S. Lee, J.H. Park, S.H. Hwang, S.J. Hong, C.W. Yu, K.J. An, D.S. Lim (Republic of Korea)

66 Poster Walks Monday 263 ASSOCIATION OF Pro12Ala PPARγ AND -308G/A TNFα WITH PPARγ AND TNFα mrna LEVELS IN VISCERAL ABDOMINAL TISSUE IN FERTILE WOMEN IN RUSSIA 740 A. Kopytova, T. Usenko, V. Miroshnikova, E. Bazhenova, M. Nikolaev, A. Panteleeva, I. Semenova, A. Neimark, E. Baranova, S. Pchelina (Russia) 264 CAN NON-CHOLESTEROL STEROLS AND LIPOPROTEIN SUBCLASSES DISTRIBUTION PREDICT DIFFERENT PATTERNS OF CHOLESTEROL METABOLISM AND STATIN THERAPY RESPONSE? 741 T. Gojković, S. Vladimirov, V. Spasojević-Kalimanovska, A. Zeljković, J. Vekić, D. Kalimanovska-Oštrić, Z. Jelić-Ivanović (Serbia) 265 SERUM LIPID PROFILE ON ADMISSION FOR ISCHEMIC STROKE/ TRANSIENT ISCHEMIC ATTACK 742 T. Vassalo, F. Faria, T. Duarte, I. Colaço, D. Cruz, J.L. Ducla Soares (Portugal) 266 DETERMINATION OF FACTORS CONTRIBUTING TO ATHEROSCLEROTIC DISEASE PROGRESSION IN PATIENTS WITH SYMPTOMATIC PERIPHERAL ARTERIAL DISEASE (PAD) 743 L.P. Zielinski, M.M. Chowdhury, B.P. Worsfold, S.C. Harrison, J.R. Boyle, P.D. Hayes, P.A. Coughlin (United Kingdom) 267 COMPLIANCE INITIATIVES IN MANAGEMENT OF PATIENTS WITH CORONARY ARTERY DISEASE AND PARKINSONISM SYNDROME 744 A. Shalaeva, N. Dadabaeva, M. Bozorboev, G. Kasimdjanova (Uzbekistan) 268 HEART RATE TURBULENCE AS A MORTALITY PREDICTOR IN 5 YEARS STUDY IN PATIENTS WITH CRORONARY HEART DISEASE 745 N. Zagidullin, D. Gareeva, I. Lackman, I. Sagitov, S. Zagidullin (Russia) 269 EFFECTS OF ASTHMA SEVERITY ON CHANGE OF PRESSURE OF PULMONARY ARTERY IN PATIENTS WITH ARTERIAL HYPERTENSION 746 A. Odegova, E. Tarlovskaya (Russia) 274 EPICARDIAL FAT THICKNESS IS ASSOCIATED WITH HIGHER VAGAL TONE 751 S. Lee, Y.S. Lee, B. Kim (Republic of Korea) 275 PREVALENCE OF RISK FACTORS AND CARDIOVASCULAR DISEASES IN EMPLOYEES OF A SINGLE PLANT IN DIFFERENT AGE GROUPS 752 R. Allanov, R. Rakhimov, E. Shalaeva, N. Dadabaeva (Uzbekistan) 276 CHADS2 AND CHA2DS2-VASC SCORES PREDICT CARDIOVASCULAR DISEASE IN STATIN-TREATED INDIVIDUALS WITHOUT ATRIAL FIBRILLATION 753 F. Barkas, E. Klouras, G. Liamis, M. Elisaf, E. Liberopoulos (Greece) 277 ACCURATE CARDIOVASCULAR EVENT RISK ESTIMATION CAN BE OBTAINED USING CORONARY ARTERY SCAN 754 M. Gracia, D. Craiem, A. Simon (Spain) 278 THE ASSOCIATION OF AN ELEVATED SERUM ENDOSTATIN LEVEL AND CAROTID ATHEROSCLEROSIS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION STUDY (KOPS) 755 Y. Kato, M. Shimizu, N. Furusyo, Y. Tanaka, J. Hayashi (Japan) 279 SERUM ENDOSTATIN IS CORRELATED TO RENAL FUNCTION INDEPENDENTLY OF CAROTID ATHEROSCLEROSIS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION STUDY (KOPS) 756 Y. Kato, M. Shimizu, N. Furusyo, Y. Tanaka, J. Hayashi (Japan) 280 SYSTEMATIC REVIEW OF HERPES ZOSTER AND ITS ASSOCIATION WITH CARDIOVASCULAR EVENTS 757 N. Erskine, H. Tran, L. Levin, C. Ulbricht, R. Goldberg (USA) 281 EXPOSURE TO CARDIOVASCULAR DISEASE RISK FACTORS IN CHILDHOOD IS ASSOCIATED WITH INCREASED CAROTID EXTRA MEDIAL THICKNESS IN ADULTHOOD: THE CHILDHOOD DETERMINANTS OF ADULT HEALTH STUDY 758 H. West, M. Skilton, B. Fraser, T. Dwyer, A. Venn, C. Magnussen (Australia) 270 CLINICAL CHARACTERISTICS OF PATIENTS ON HEMODIALYSIS WITH PERIPHERAL ARTERIAL DISEASE 747 N. Aoyama (Japan) 271 ASSOCIATIONS BETWEEN OSTEOPOROSIS AND SIGNIFICANT CORONARY ARTERY DISEASE IN ASYMPTOMATIC POSTMENOPAUSAL WOMEN 748 S.N. Lee (Republic of Korea) 272 ADJUSTED NECK CIRCUMFERENCE AND METABOLIC SYNDROME: RESULTS FROM THE BRISIGHELLA HEART STUDY 749 E. Bertagnin, S. D'Addato, F. Fogacci, S. Palmisano, L. D Agostini, A.F.G. Cicero, M. Giovannini, M. Rosticci, C. Borghi (Italy) 273 NON-CORONARY ATHEROSCLEROSIS PREVALENCE ACCORDING TO THE DATA OF THE ADULT POPULATION SCREENING 750 R. Khokhlov, L. Tribuntseva, V. Burlachuk, L. Khokhlov (Russia) 282 CANDIDATE GENE POLYMORPHISMS RELATED TO LIPID AND CARBOHYDRATE METABOLISM SHOW AN ASSOCIATION WITH RISK FACTOR COMPONENTS OF THE METABOLIC SYNDROME IN ASIAN INDIANS. 759 T. Maistry (South Africa) 283 CLINICAL CHARACTERISTICS AND LDL-CHOLESTEROL MANAGEMENT IN PATIENTS WITH CARDIOVASCULAR EVENT AND/OR DIABETES IN THE NETHERLANDS 760 E. Heintjes, J. Kuiper, B. Lucius, F. Penning-van Beest, L. Kutikova, A. Liem, R. Herings (Switzerland) 284 WAIST-HIP-RATIO AND 1-YEAR CLINICAL OUTCOME IN PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME 761 H.W. Lee, T.J. Hong, J.H. Choi, B.W. Kim (Republic of Korea)

67 Poster Walks Monday 285 GLOMERULAR FILTRATION RATE (GFR) MODERATES THE PROTECTIVE EFFECT OF MEDITERRANEAN DIET AGAINST CARDIOVASCULAR INCIDENCE: 10-YEAR FOLLOW-UP ( ) OF THE ATTICA STUDY 762 E. Georgousopoulou, C. Pitsavos, D. Panagiotakos, C. Chrysohoou, I. Skoumas, M. Chatzigeorgiou, D. Tousoulis, C. Stefanadis (Greece) 286 PLAQUE CHARACTERIZATION AND REMODELING BY CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY AND CORONARY EVENTS 763 S.U. Kwon (Republic of Korea) 287 DURATION OF DIABETES IS AN INDEPENDENT DETERMINANT AND INTERACTED WITH GENDER FOR ACUTE MYOCARDIAL INFARCTION 764 Y.D. Jiang (Taiwan) 288 PRESENCE OF CAROTID PLAQUES AND CARDIOVASCULAR DISEASE EVENTS: A PROSPECTIVE STUDY 765 A. Bea, E. Jarauta, R. Mateo-Gallego, S. Perez-Calahorra, V. Marco-Benedi, I. Lamiquiz-Moneo, L. Baila-Rueda, A. Cenarro, F. Civeira (Spain) 289 TWO-GENERATION CARDIOVASCULAR DISEASE PREVALENCE IN FAMILIAL HYPERCHOLESTEROLEMIA 766 R. Mateo-Gallego, S. Perez-Calahorra, M. Laclaustra, N. Plana, C. Lahoz, J. Pedro-Botet, J.F. Ascaso, A. Vila Belmonte, P. Valdivielso, A. Brea, F. Civeira (Spain) 290 RAPID RISE IN PREVALENCE OF HYPERTENSION IN YOUNG IN NATIONAL CAPITAL REGION (NCR) OF DELHI, INDIA 767 A. Roy, P.A. Praveen, R. Amarchand, D. Prabhakaran, A. Krishnan, K.S. Reddy (India) 291 VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL, BLOOD PRESSURE, AND HEART RATE: THE GAIN IN CONTEXT OF CIRCUMSTANCES 768 E. Pello, T. Kouznetsova, Y. Nikitin, J. Staessen (Russia) 292 IMPROVING CARDIOVASCULAR PREVENTION IN PATIENTS WITH HIGH CARDIOVASCULAR RISK THROUGH AN INNOVATIVE APPROACH: THE COACHING CARE MODEL 769 S. Mosteoru, K. Kotseva, O.C. Cosor, L. Gaita, R. Pleava, A. Dumitrescu, G. Mut-Vitcu, D. Gaita, S. Mancas, D. Wood (Romania) 293 OVERWEIGHT/OBESITY AND CORONARY HEART DISEASE: AGE DEPENDENCIES IN METABOLIC MEDIATION 770 J. Fritz, S. Strohmaier, G. Nagel, H. Concin, H. Ulmer (Austria) 294 DECREASED SERUM LEVELS OF SOLUBLE DIPEPTIDYL PEPTIDASE IV ARE ASSOCIATED WITH ALL-CAUSE DEATH IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE 771 M.T. Howanietz, C.T. Herz, C. Höbaus, R. Koppensteiner, G.H. Schernthaner (Austria) 295 FACTORS PREDICTING SURVIVAL OVER TWO DECADES OF OBSERVATION AFTER PERIPHERAL PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY: A RETROSPECTIVE STUDY 772 M. Schneider, C. Herz, C. Höbaus, R. Koppensteiner, G.H. Schernthaner (Austria) 296 ANALYSIS OF THE DIRECT CAUSES OF DEATH IN PATIENTS WITH ACUTE STEMI TREATED WITH PRIMARY PCI FROM 2005 TO Y.H. Li, P.T. Lee, T.H. Chao, W.C. Tsai (Taiwan) 297 KLOTHO GENE POLYMORPHISMS ARE ASSOCIATED WITH PROGRESSION OF ATHEROMATOSIS IN PATIENTS WITH CKD. RESULTS OF TWO YEARS FOLLOW-UP OF THE NEFRONA COHORT 774 M. Gracia, A. Betriu, M. Martínez, D. Arroyo, M. Abajo, E. Fernández, J.M. Valdivielso (Spain) 298 RHEUMATOID ARTHRITIS AND ATHEROSCLEROSIS: WHY IS IMPORTANT TO EVALUATE THIS? 775 M. Parvu, S. Coman, S. Voidazan (Romania) 299 COMPARISON OF COMBINED THERAPY OF CAD ACCOMPANIED BY GASTRODUODENAL PATHOLOGY 776 Y. Balandina, Z. Simonova, Y. Tarlovskaya (Russia) 300 INCREASED VISCERAL FAT AND LOWER MUSCLE STRENGTH ASSOCIATED WITH ACUTE MYOCARDIAL INFARCTION 777 E. Okuyan, B. Ayca, S. Varol (Turkey) 301 HIGH PREVALENCE OF CVD RISK FACTORS AND UNSATISFACTORY CONTROL OF LDL-C LEVELS IN 40-YEARS-OLD MEN AND 50-YEARS-OLD WOMEN IN THE CZECH REPUBLIC 778 Z. Chmelik, M. Vrablík (Czech Republic) 302 PLASMA METHIONINE IS NOT ASSOCIATED WITH RISK OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH SUSPECTED STABLE ANGINA PECTORIS 779 I. Dhar, V. Lysne, P. Ueland, A. McCann, O. Nygård (Norway) 303 THE DIFFERENCE IN BLOOD PRESSURE READINGS BETWEEN ARMS AND CARDIOVASCULAR RISK: AN URBANITE INDIAN STUDY 780 P. Bhasin, S. Kapoor (India) 304 ASSOCIATION BETWEEN PREPROCEDURAL NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS WITH THE INFLAMMATORY RESPONSE FOLLOWING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION 781 F. Rached, F. Brito Jr, C. Garzillo, T. Nascimento, M.A. Perin, C.V. Serrano Jr (Brazil)

68 Poster Walks Monday 305 THE INCIDENCE AND SEVERITY OF ANGINA PECTORIS IN PATIENTS AFTER ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (OPTIMA II) 782 N. Logunova, Y. Karpov, V. Buza, D. Tomilova (Russia) 306 HYBRID INTERVENTION ON FEMOROPOPLITEAL ARTERIAL SEGMENT IN COMPARISON WITH CONVENTIONAL SURGICAL TECHNIQUE 783 P. Puzdriak, V. Shlomin, Y. Didenko, Y. Yurtaev, M. Ivanov, P. Bondarenko, R. Magomedov (Russia) 307 PREVALENCE OF CARDIOVASCULAR RISK FACTORS IN MIDDLE-AGED SUBJECTS OF HIGH RISK LITHUANIAN POPULATION 784 S. Kutkiene, M. Petrylaite, Z. Petrulioniene (Lithuania) 308 MULTIPLE CORONARY FISTULAE INTO LEFT VENTRICLE AS A RARE CAUSE OF MYOCARDIAL ISCHEMIA 785 A. Averkova, K. Savostyanov, D. Zateyshchikov (Russia) 309 SUBCLINICAL MANIFESTATIONS OF ATHEROSCLEROSIS IN HYPERTENSIVE FEMALES WITH RHEUMATOID ARTHRITIS AND ITS RELATIONSHIP WITH THE ADIPONECTIN LEVEL, INSULIN RESISTANCE, ENDOTHELIAL FUNCTION 786 O. Sirenko, O. Kuryata, T. Lysunets (Ukraine) 310 THE PREVALENCE OF CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS AND LEUCOENCEPHALOPATHY (CADASIL) IN UZBEKISTAN 787 B. Muinjonov, E. Giyazitdinova (Uzbekistan) T MRI REVEALS DIFFUSE IRON DEPOSITION IN PUTAMEN AND CAUDATE NUCLEUS IN CADASIL 788 B. Muinjonov, E. Giyazitdinova (Uzbekistan) 316 PATHOPHYSIOLOGICAL MECHANISMS FOR PRESERVING GRAFT PATENCY IN PATIENTS WITH COMPROMISED OUTFLOW TRACT AFTER DISTAL RECONSTRUCTION 793 A. Zotikov, Z. Adyrkhaev, V. Mitish, N. Ascerov, A. Kozhanova, A. Ivandaev, M. Abdulgamidov, A. Pokrovsky (Russia) 317 OUTDOOR AIR POLLUTION AND ISCHEMIC STROKE SEVERITY: AN ECOLOGICAL STUDY IN THESSALONIKI 794 N. Kakaletsis, K. Tziomalos, C. Savopoulos, M. Riga, S. Bouziana, M. Spanou, S. Kostaki, S. Angelopoulou, K. Karatzas, I.A. Hatzitolios (Greece) 318 GENDER FEATURES OF MYOCARDIAL INFARCTION AND STROKE RISK IN GENERAL POPULATION WITH VITAL EXHAUSTION IN RUSSIA / SIBERIA: WHO PROGRAM MONICA-PSYCHOSOCIAL 795 V. Gafarov, E. Gromova, I. Gagulin, D. Panov, A. Gafarova, M. Voevoda (Russia) 319 RELATIONSHIP OF STRESS WITH METABOLIC SYNDROME AND CORONARY HEART DISEASE IN MIDDLE-AGED POLICE OFFICERS 796 M. Janczura, J. Dropinski, A. Stanisz, K. Kotula-Horowitz, R. Rosa, T. Domagala (Poland) 320 PRELIMINARY RESULTS OF THE EGYPTIAN CARDIOVASCULAR RISK FACTORS PROJECT:MULTICENTER OBSERVATIONAL STUDY OF THE PATTERN OF RISK FACTOR PROFILE IN EGYPTIAN PATIENTS WITH ACUTE CORONARY SYNDROME 797 W. Hamed, A. Reda, A. El-Kersh, A. Shalaby, M. Beshay (Egypt) 312 TENASCIN-C DEFICIENCY ATTENUATES ABDOMINAL AORTIC ANEURYSM FORMATION 789 A.K. Schaefer, F. Nagel, P. Kaiser, D. Santer, K. Trescher, A. Kiss, B.K. Podesser (Austria) 313 A CASE OF FATAL OBSTRUCTIVE SHOCK 790 A. Almaghraby, Y. Saleh, B. Hammad, A. Samoka, M. Elbahey, M. Seleem (Egypt) 314 CARDIOVASCULAR RISK FACTORS IN WOMEN AND MEN 791 A. Nikolova, M. Milanova (Bulgaria) 315 CAROTID INTIMA-MEDIA THICKNESS AS A PROGNOSTIC RISK MARKER OF DEMENTIA AT THE ELDERLY 792 R. Dascalescu, A. Zamfirescu, S.M. Aurelian, O. Stanciu, A. Capisizu (Romania)

69 Poster Walks Monday Abstract not Registered 400 THE ZINC-SUPPLEMENTED TO RABBITS FED A HIGH CHOLESTROL DIET DELAYS THE PROGRESSION OF ATHEROSCLEROSIS 798 Y. Al mohy (Kingdom of Saudi Arabia) 401 EVALUATION OF THE SAFETY AND EFFICACY OF STATIN IN ELDERLY PATIENTS 799 R. Alves, C. Gonçalves, N. Borges Jr (Brazil) 402 CD34+ BONE MARROW DERIVED CELLS INHIBIT INTIMAL HYPERPLASIA IN MOUSE MODEL OF VASCULAR INJURY 800 S. Ananthaseshan, E. Kurzejamska, M. Lazarczyk, P. Religa (Sweden) 403 ESCHERICHIA COLI LIPOPOLYSACCHARIDE AND CPG MAY AFFECT ATHEROGENESIS THROUGH THE MODULATION OF ENDOTHELIAL BARRIER AND TOLEROGENIC PHENOTYPE OF APOLIPOPROTEIN B100- PULSED DENDRITIC CELLS 801 M. Chalubinski, K. Wojdan, E. Luczak, P. Gorzelak, G. Katarzyna, B. Maciej, G. Adrian, R. Karolina, C. Magdalena, B. Marlena (Poland) 404 MODIFICATIONS OF LOW DENSITY LIPOPROTEIN IN ATHEROSCLEROSIS 802 G.I. Constantin, S. Opris (Romania) 405 ISCHEMIC HEART DISEASE AND EARLY DIAGNOSIS. STUDY ON THE PREDICTIVE VALUE OF 2D STRAIN 803 G. Dattilo, A. Lamari, M. Casale, E. Imbalzano, P. Busacca, C. De Gregorio, G. Di Bella (Italy) 406 REDUCED AVAILABILITY OF DIETARY CHOLESTEROL IN INFANCY PROGRAMS THE INTESTINAL CHOLESTEROL ABSORPTION DURING ADULTHOOD IN MICE 804 L.G. Dimova, J.F. De Boer, T. Plösch, H.J. Verkade, U.J.F. Tietge (Netherlands) 407 CARDIOVASCULAR RISK AND PROINFLAMMATORY CYTOKINES IN PATIENTS WITH METABOLIC SYNDROME 805 R. Dragut, E. Rusu, R. Nan, H. Popescu, F. Rusu, M. Jinga, A. Cursaru, L. Grosu, G. Radulian (Romania) 408 IS HIGH-DENSITY LIPOPROTEIN SUITABLE PREDICTOR FOR DEVELOPMENT OF METABOLIC SYNDROME: A 10-YEAR FOLLOW-UP IN ADULTS 806 M. Gharipour, M. Sadeghi, N. Sarrafzadegan (Iran) 409 VIOLATIONS IN THE LEVEL OF SERUM LIPIDS APPEAR AT ALL PATIENTS WITH PROSTATITIS THAT IS ASSOCIATED WITH DECREASE IN THE LEVEL OF THE FREE TESTOSTERONE 807 A. Govorin, D. Zaytsev (Russia) 410 ON THE DEVELOPMENT OF ANTI-ATHEROSCLEROTIC DRUGS ON THE BASIS OF NATURAL PRODUCTS USING CELL CULTURES 808 S. Jargin (Russia) 411 POSSIBLE ASSOCIATION BETWEEN COMMON CAROTID ARTERY LUMEN DIAMETER AND VASCULAR FUNCTION IN NATURAL POPULATIONS OF SHE MINORITY FROM FUJIAN PROVINCE IN CHINA 809 H. Liu, H. Yongqiang, W. Hongyu, L. Jinbo (China) 412 Identification of Cofilin-1 Induces G0/G1 Arrest and Autophagy in Angiotensin-(1-7)-treated Human Aortic Endothelial Cells from itraq Quantitative PROTEOMICS 810 W.Y. Lo, H.J. Wang (Taiwan) 413 HYPOTHYROIDISM IS THE INDEPENDENT FACTOR OF ATHEROSCLEROSIS 811 O. Kupchynskaya, N. Tsyrulneva, O. Gulkevych, V. Bezrodnyi, M. Mospan, A. Logvinenko (Ukraine) 414 DYSLIPIDEMIA IN PATIENTS WITH HEART FAILURE AND HYPOTHYROIDISM 812 A. Logvinenko (Ukraine) 415 THE ROLE OF OXIDATIVE STRESS ON AMYLOID-LIKE PROTEIN FORMATION AND AORTIC VALVE CALCIFICATION 813 I. Mamarelis, E. Koutoulakis, C. Kotoulas, V. Mamareli, V. Dritsa, J. Anastassopoulou (Greece) 416 IMPACT OF THE LIPID AND ANTHROPOMETRIC PARAMETERS ON THE LDL(-) AND AUTOANTIBODIES ANTI-LDL(-) 814 A.P.Q. Mello, I.T. Silva, N.R.T. Damasceno (Brazil) 417 LIFESTYLE - THE SILENT KILLER, LEADING TO CARDIOVASCULAR EVENTS ACROSS CONTINENTS IN YOUNG APPARENTLY HEALTHY INDIANS 815 R. Narain, A. Pulikal, S. Sharma (United Kingdom) 418 BURDEN OF CARDIOVASCUlaR RISK IN YOUNG, APPARENTLY HEALTHY INDIANS IN UK & INDIA. TIME FOR INTERVENTION? 816 R. Narain, S. Sharma (United Kingdom) 419 RELATIONSHIP OF CAROTID AND FEMORAL ARTERY INTIMA-MEDIA THICKNESS WITH HISTOPATHOLOGIC ARTERIAL ATHEROSCLEROSIS IN CHRONIC KIDNEY DISEASE 817 N. Nezami, K. Ghabili, B. Shokouhi, M. Mirchi, M. Gojazadeh, S. Ghorashi, M.K. Tarzamni (USA) 420 IN VIVO/EX VIVO INTEGRATED IMAGING MODEL FOR CORONARY AND CAROTID PLAQUE RISK ASSESSMENT: A PROOF OF CONCEPT STUDY 818 G. Pelosi, D. Panetta, A. Sakellarios, N. Filipovic, T. Exarchos, V. Federico, C. Fiorentini, A. Gennaro, S. Rocchiccioli, P.A. Salvadori, M.G. Trivella, D. Fotiadis, O. Parodi (Italy) 421 SYNTAX SCORE AS A MARKER OF PLURIDISTRICTUAL ATHEROSCLEROSIS 819 G. Polizzi, S. Evola, S. Novo, V. Evola (Italy)

70 422 PERCUTANEOUS TRANSVENOUS MITRAL COMMISSUROTOMY IN PATIENTS WITH CALCIFIC MITRAL STENOSIS : IMMEDIATE AND IN- HOSPITAL CLINICAL, ECHOCARDIOGRAPHIC AND HEMODYNAMIC OUTCOME 820 T. Rahman, A.A.S. Majumder, M.Z. Ali (Bangladesh) 423 THE EFFECT OF PINACIDIL ON HUMAN SAPHENOUS VEINS OBTAINED FROM THE PATIENTS WITH AND WITHOUT DIABETES MELLITUS TYPE J. Rajkovic, M. Peric, R. Novakovic, D. Nezic, V. Djokic, V. Zivanovic, V. Kanjuh, H. Heinle, L. Gojkovic-Bukarica (Serbia) 424 SR-BI antagonises the S1P/S1PR2-mediated pro-inflammatory effects induced by ox-ldl in HUVECS 822 K. Ren, Y.J. Lu, X. Liu, Q.H. Zhang, Z.C. Mo, Z.L. Tang, Y. Jiang, X.S. Peng, G.H. Yi (China) 84 th EAS CONGRESS May 29 - June 1, 2016 Innsbruck, Austria ApoA-I induces S1P release from endothelial cells through ABCA1 and SR-BI in a positive feedback manner. 823 K. Ren, X. Liu, R. Suo, S.L. Xiong, Q.H. Zhang, Z.C. Mo, Z.L. Tang, J. Yue, X.S. Peng, G.H. Yi (China) 426 TGF-β down-regulates apolipoprotein M expression via the TAK1-JNK-c-Jun pathway in HepG2 CELLS 824 K. Ren, X. Liu, Z.C. Mo, Q.H. Zhang, Z.L. Tang, Y. Jiang, X.S. Peng, G.H. Yi (China) 427 THE HYPERCHOLESTEROLEMIC SWINE MODEL OF ATHEROGENESIS: STATISTICAL APPROACHES TO MOLECULAR MARKERS AND PLAQUE MORPHOLOGY ASSOCIATION 825 S. Rocchiccioli, G. Pelosi, A. Cecchettini, E. Capobianco, M.G. Trivella (Italy) 428 A NEW MARKER FOR ST ELEVATION MYOCARDIAL INFARCTION: PRESEPSIN? 826 F.N. Turhan caglar, N. Isikssacan, I. Biyik, F. Akturk, S. Opan, H. Cebe, I. Ungan, O. Karakaya (Turkey) 429 THE ROLE OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION ON ENDOTHELIAL CELLS: OXIDATIVE STRESS AND VASCULAR DYSFUNCTION. 827 A. Wanschel, E. Lorza, A. Paiva, J. Stravinsky, D. Gabriel, T. Rentz, D. Guizoni, A. Davel, A. Salerno, H. Oliveira (Brazil) 430 THE EFFECT OF OXIDIZED CHOLESTEROL ON BARRIER FUNCTIONS AND IL-10 MRNA EXPRESSION IN HUMAN INTESTINAL EPITHELIUM CO- CULTURED WITH DENDRITIC CELLS IN THE TRANSWELL SYSTEM 828 K. Wojdan, M. Chalubinski, P. Gorzelak, M. Borowiec, M. Broncel (Poland) 431 IMPROVEMENT OF HIGH-DENSITY LIPOPROTEIN FUNCTIONALITY BY CO- CONSUMPTION OF HIGH DOSAGE VITAMIN C AND CLOVE VIA CETP INHIBITION 829 J.A. Yoo, K.H. Cho 432 IMPACT OF AN ABDOMINAL AORTIC CALCIFICATION ON THE MORPHOLOGY OF LOW LIMB ARTERY ATHEROSCLEROSIS 830 V. Zelinskiy, M. Melnikov, V. Andreev, S. Alexandra (Russia) Poster Presentation - Shift II Tuesday, May 31 Wednesday, June 1

71 Poster Walks tuesday Tuesday, May 31, 2016 Metabolic Abnormalities and Atherosclerosis: Diabetes 001 MODY TYPE DIABETES MELLITUS AND COGNITIVE IMPAIRMENT 831 B. Muinjonov, E. Giyazitdinova (Uzbekistan) 002 POLYMORPHISM IN GENES INVOLVED IN LIPID METABOLISM IN MODY PATIENTS 832 E. Shakhtshneider, A. Ovsyannikova, A. Kurilshikov, D. Ivanoshchuk, O. Rymar, Y. Ragino, M. Voevoda (Russia) 003 METABOLIC CONTROL IN TYPE 2 DIABETIC PATIENTS 833 B. Orhan (Turkey) 004 ONE-YEAR RESULTS OF A MULTIDISCIPLINARY SCREENING PROGRAM FOR DIABETES, CARDIOVASCULAR AND PULMONARY DISEASES AMONG 67-YEARS OLD CITIZENS IN VIBORG MUNICIPAL, DENMARK 834 A. Høgh, M. Dahl, J. S. Lindholt (Denmark) 005 DIFFERENCES IN LIPID PROFILE CONTROL AMONG DIABETIC PATIENTS AT VERY HIGH CARDIOVASCULAR RISK ACCORDING TO THEIR CLINICAL FEATURES 835 D. García Fuertes, E. Villanueva Fernández, M. Crespín Crespín, F.J. Castillo Bernal, I. Guerado Espinosa, M.C. Castro Jiménez, A. Rodríguez Cubero (Spain) 006 FACTORS RELATED TO THE APPEARANCE OF MAJOR EVENTS DURING FOLLOW-UP OF DIABETIC PATIENTS AT VERY HIGH CARDIOVASCULAR RISK 836 M. Crespín Crespín, D. García Fuertes, E. Villanueva Fernández, F.J. Castillo Bernal, A. Rodríguez Cubero, I. Guerado Espinosa, M.C. Castro Jiménez (Spain) 007 CONTROL OF CARDIOVASCULAR RISK FACTORS IN A NON-SELECTED COHORT OF DIABETIC PATIENTS AT VERY HIGH CARDIOVASCULAR RISK 837 E. Villanueva Fernández, D. García Fuertes, M. Crespín Crespín, F.J. Castillo Bernal, M.C. Castro Jiménez, A. Rodríguez Cubero, I. Guerado Espinosa (Spain) 008 THE IMPORTANCE OF HDL CHOLESTEROL LEVELS IN DIABETIC INDIVIDUALS : 9.2-YEAR SURVEY OF CARDIOVASCULAR EVENTS 838 K. Ina, T. Hayashi, M. Kuzuya (Japan) 009 CONCORDANCE OF GLUCOSE BASED AND OF HbA1c BASED DIAGNOSES OF DIABETES IN PATIENTS WITH ESTABLISHED CORONARY ATHEROSCLEROSIS - A COMPARISON BETWEEN MEN AND WOMEN 839 C. Saely, D. Zanolin, P. Rein, A. Vonbank, A. Leiherer, A. Muendlein, H. Drexel (Austria) 139

72 Poster Walks tuesday 010 ASSOCIATION OF INSULIN RESISTANSE WITH CAROTID INTIMA-MEDIA THICKNESS AND BRACHIAL FLOW-MEDIATED DILATION IN THE SUBJECTS WITH METABOLIC SYNDROME 840 T. Domagala, M. Janczura, K. Kotula-Horowitz, J. Dropinski, T. Iwaniec, J. Zagajewski, A. Stanisz (Poland) 011 ASSOCIATION OF INSULIN RESISTANCE, AS DETERMINED BY HOMEOSTASIS MODEL ASSESSMENT (HOMA), WITH METABOLIC SYNDROME AMONG MIDDLE-AGED SUBJECTS 841 M. Janczura, K. Kotula-Horowitz, T. Iwaniec, A. Stanisz, J. Dropinski, T. Domagala (Poland) 012 DYSLIPIDEMIA WITH AND WITHOUT INSULIN RESISTANCE: SIMILARITIES AND DIFFERENCES 842 I. Pchelin, N. Hudiakova, A. Shishkin, O. Vasilkova (Russia) 013 DYSLIPIDEMIA CONTROL IN TYPE 2 DIABETES: EXPERIENCE OF A PORTUGUESE CENTRE IN THE LAST DECADE 843 J. Sequeira Duarte, C. Tavares Bello, R. Fonseca, R. Ferreira, M. Oliveira, C. Saraiva, C. Gouveia, F. Santos, J. Azinheira, C. Vasconcelos (Portugal) 014 CORRELATION BETWEEN HOMOCYSTEINE AND TYPE-2 DIABETES MELLITUS COMPLICATIONSCORRELATION BETWEEN HOMOCYSTEINE AND TYPE-2 DIABETES MELLITUS COMPLICATIONS 844 M. Akhvlediani, M. Emukhvari, N. Zabakhidze, T. Kvantaliani (Georgia) 015 SERUM APOLIPOPROTEIN B48 CONCENTRATION IS HIGH IN PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE AND INCREASES AFTER ORAL GLUCOSE INGESTION IN PATIENTS WITH DIABETES MELLITUS 845 D. Masuda (Japan) 016 FASTING INSULIN LEVELS PREDICT FATAL CARDIOVASCULAR (CVD) EVENTS MORE ACCURATELY THAN ANY OTHER MARKER OF GLUCOSE METABOLISM. THE 10-YEAR FOLLOW-UP OF THE ATTICA STUDY ( ) 846 E. Georgousopoulou, D. Panagiotakos, C. Chrysohoou, I. Skoumas, A. Laskaris, C. Stefanadis, C. Pitsavos (Greece) 017 ALTERATIONS OF METABOLIC PARAMETERS AND ANTIOXIDANT ENZYMES IN DIABETIC AGING FEMALE RAT BRAIN: NEUROPROTECTIVE ROLE OF METFORMIN 847 P. Kumar, N. Baquer (India) 018 CARDIO- AND NEPHROPROTECTIVE EFFECTS OF EZETIMIBE/ SIMVASTATIN COMBINATION IN TYPE 2 DIABETES MELLITUS 848 R. Sayfutdinov, O. Bugrova, O. Boeva (Russia) 020 DOES TYPE 2 DIABETES ASSOCIATE ATHEROSCLEROTIC PROCESS? 850 D. Gabrielyan, L. Gabrielyan, A. Artemova, D. Zhokhov, M. Ivanov, P. Bondarenko, M. Ermina, A. Yadernaya (Russia) 021 SEVERITY OF ATHEROSCLEROTIC LESIONS AND FOOT SYNOVIAL TENDON COMPLEX INJURY AS FACTORS OF SEPSIS DEVELOPMENT IN PATIENTS WITH DIABETIC FOOT 851 E. Shalaeva, B. Janabaev, Q. Matmurotov, U. Kasimov, U. Pulatov, A. Bobabekov (Uzbekistan) 022 RELATIONSHIP BETWEEN CAROTID ARTERY INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH DIABETES 852 V. Vasilkova, T. Mokhort, E. Naumenko (Belarus) 023 SERUM LEVELS OF SOLUBLE RECEPTOR FOR ADVANCED END PRODUCTS ARE ASSOCIATED WITH RESTENOSIS OCCURRENCE IN PATIENTS WITH DIABETES MELLITUS AFTER DRUG-ELUTING STENT IMPLANTATION 853 S. Kozlov, Z. Gabbasov, S. Byazrova, O. Saburova, V. Masenko (Russia) 024 EFFECT OF THE EDUCATION IN HOSPITALIZATION OF DIABETIC INDIVIDUALS FOR DIABETES CONTROL AND PREVENTION OF COMPLICATIONS AS A TOOL OF HOSPITAL AND CLINIC COOPERATION 854 T. Hayashi, K. Ina, M. Kuzuya (Japan) 025 BMI IS NOT AN IMPORTANT FACTOR FOR THE DEVELOPMENT OF SUBCLINICAL ATHEROSCLEROSIS IN ELDERLY DIABETIC SUBJECTS WITH METABOLIC SYNDROME 855 G. Yoshino, H. Yoshino, T. Ann, K. Kawakami, T. Akiyama, Y. Inoue (Japan) 026 RESVERATROL AND QUERCETIN PROTECT ISOLATED MOUSE CORPORA CAVERNOSA FROM IN VITRO-INDUCED DIABETIC ERECTILE DYSFUNCTION 856 C. Boydens, B. Pauwels, L. Vandendaele, J. Van de Voorde (Belgium) 027 DIABETIC VASCULAR DISEASE AND MATURITY-ONSET DIABETES OF THE YOUNG 857 J.M. Mafra, G. Gaspar, M. Bourbon (Portugal) 028 RELATIONSHIP BETWEEN 25 HYDROXY-VITAMIN D AND ANKLE BRACHIAL INDEX IN TYPE 2 DIABETIC PATIENTS 858 S. Lahiani, I. Oueslati, K. Bouzid, K. Khiari, S. Ghezaiel, H. Ben Ahmed, H. Belhadj Hassen, H. Baccar, J. Abdelmoula, N. Ben Abdallah (Tunisia) 029 ANKLE BRACHIAL INDEX IN THE PREDICTION OF CORONARY HEART DISEASE IN TYPE 2 DIABETIC PATIENTS 859 K. Bouzid, H. Ben Ahmed, I. Oueslati, S. Lahiani, K. Khiari, N. Khessairi, J. Belagha, S. Ghezaiel, N. Ben Abdallah, H. Baccar, J. Abdelmoula (Tunisia) 019 ROLE OF NEW ADIPOKINES IN THE PATHOGENESIS OF ATHEROSCLEROSIS IN MORBIDLY OBESE SUBJECTS 849 A. Gentili, P. Trayhurn, S.Y. Alomar, M.S. Zaibi, S. De Vuono, M.A. Ricci, A. Alaeddin, D. Siepi, M. Boni, G. Vaudo, G. Lupattelli (Italy) 030 CARDIOVASCULAR EFFECTS OF INCRETINS IN PATIENTS WITH TYPE 1 DIABETES 860 M. Arutyunova, A. Glazunova, S. Martynov, I. Klephortova, A. Ilyin, O. Manchenko, I. Ulianova, M. Shamkhalova, M. Shestakova (Russia)

73 Poster Walks tuesday 031 SEVERITY OF CORONARY ARTERY STENOSIS IN PATIENTS WITH CRITICAL PERIPHERAL ARTERY DISEASE UNDERGOING HIGH AMPUTATION 861 E. Shalaeva, B. Janabaev, B. Babadjanov, Q. Matmurotov, U. Kasimov, U. Pulatov, A. Bobabekov (Uzbekistan) 032 HIGH PREVALENCE OF NON DIPPERS HYPERTENSIVE DIABETIC PATIENTS: THE ROLE OF AMBULATORY BLOOD PRESSURE MONITORING IN EFFECTIVE TREATMENT 862 V. Manea, C. Pop, L. Pop (Romania) 033 THE IMPACT OF BARIATRIC SURGERY ON CARDIOMETABOLIC PROFILE AND ADIPOKINE LEVELS 863 F. Reis de Azevedo Rabello, S. Santoro dos Santos Pereira, M.L. Corrêa- Giannella, D. Giannella Neto, E. Sant'Anna Melo, B. Caramelli (Brazil) 034 BARIATRIC SURGERY IMPROVES LIPID PROFILE IN MORBIDLY OBESE PATIENTS BY LOWERING LDL-C AND INCREASING HDL-C AND THE LARGE HDL-PARTICLES 864 C.A. Kjellmo, T. Nestvold, K.T. Lappegård, A. Hovland, M. Mathisen (Norway) 035 EFFECTS OF BARIATRIC SURGERY ON MICROVASCULAR DYSFUNCTION AND METABOLIC PROFILE IN MORBID OBESITY 865 M. Naeimi Kararoudi, G. Lupattelli, S. Ministrini, V. Bianconi, M.A. Ricci, S. De Vuono, P. Mariani, A. Moriconi, M. Boni, E. Mannarino, L. Pasqualini (Italy) 036 FACTORS DETERMINING AND STRATEGIES FOR IMPROVING TREATMENT ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES MELIITUS: DOCTOR, COMMUNITY PHARMACIST AND PATIENT PERSPECTIVES. ADHERI2 STUDY. 866 E. Labrador-Barba, A. Hernández-Mijares, M. Rodríguez-de Miguel, M.J. Faus-Dader, M.L. Orera-Peña, F.J. Alonso Moreno (Spain) 037 PREVALENCE OF 25 HYDROXY-VITAMIN D DEFICIENCY AND ITS CORRELATION WITH GLYCEMIC CONTROL IN DIABETIC PATIENTS 867 S. Lahiani, K. Bouzid, I. Oueslati, K. Khiari, N. Bchir, A. Melki, A. Bartkiz, H. Ben Ahmed, H. Baccar, J. Abdelmoula, N. Ben Abdallah (Tunisia) 038 COMBINED DEVELOPMENT OF MACROVASCULAR AND CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES ASSOCIATED WITH POLYMORPHISM OF TNF-α GENE 868 O. Vikulova, N. Lebedeva, A. Zheleznyakova, A. Nikitin, M. Shamkhalova, M. Shestakova (Russia) 039 FEATURES OF VASCULAR REMODELING AND METABOLIC DISORDERS IN PATIENS WITH ESSENTIAL HYPERTENSION AND CONCOMITANT TYPE 2 DIABETES DEPENDING ON GENETIC POLYMORPHISM PPARγ2 869 A. Shalimova, A. Belovol, L. Bobronnikova, M. Kochueva (Ukraine) 040 NEUTROPHIL/LYMPHOCYTE RATIO AND VASCULAR INFLAMMATION IN OBESE WOMEN 870 B. Ilincic, M. Djeric, E. Stokic, R. Mijovic, S. Nikolic, Z. Stosic (Serbia) 041 GENE FOR CONNEXIN 37 IS ASSOCIATED WITH ATHERSCLEROTIC CHANGES IN WOMEN WITH DIABETES MELLITUS TYPE J. Piťha, P. Pithova, P. Stavek, J.A. Hubacek, O. Auzky, T. Neskudla, T. Pelikanova, M. Kvapil (Czech Republic) 042 LpPLA2 IN GESTATIONAL DIABETES MELLITUS - A PROTECTIVE SYSTEM FOR PLACENTA AND FETUS? 872 C. Wadsack (Austria) 043 CINNAMALDEHYDE ATTENUATES HIGH GLUCOSE-INDUCED OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION AS AN Nrf2 ACTIVATOR 873 F. Wang, P. Wang, J. Wan, J. Hou, P. Zhou (China) 044 ASSOCIATION OF DIFFERENT CHOLESTEROL HOMEOSTASIS PATTERNS WITH ABDOMINAL OBESITY IN PATIENTS WITH CORONARY ARTERY DISEASE 874 S. Vladimirov, T. Gojković, V. Spasojević-Kalimanovska, A. Zeljković, J. Vekić, D. Kalimanovska-Oštrić, Z. Jelić-Ivanović (Serbia) 045 ASSOCIATION BETWEEN NT-PROBNP AND VISCERAL ADIPOSITY 875 J. Suwa (Japan) 046 INCREASED INFLAMMATORY EFFECT ON MONOCYTES OF ELECTRONEGATIVE LDL AND DECREASED PROTECTION BY HDL FROM POORLY CONTROLLED TYPE 2 DIABETIC PATIENTS 876 M. Estruch-Alrich, I. Miñambres, J.L. Sánchez-Quesada, A. Pérez-Pérez, J. Ordóñez-Llanos, S. Benítez (Spain) 047 TRANSGENIC OVEREXPRESSION OF THE NRF2 AMELIORATES INSULIN RESISTANCE AND CHANGES FATTY ACIDS IN MEMBRANE PHOSPHOLIPIDS IN SPONTANEOUSLY HYPERTENSIVE RATS 877 I. Markova, H. Malinska, O. Oliyarnyk, L. Kazdova, M. Pravenec (Czech Republic) 048 HYPOLIPIDEMIC THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: ANALYSIS TYPICAL APPROACHES 878 I. Sapozhnikova, E. Tarlovskaya (Russia) 049 DIABETES AWARENESS AMONG CORONARY DISEASE PATIENTS DIFFERS SIGNIFICANTLY BETWEEN MEN AND WOMEN 879 C. Saely, D. Zanolin, A. Vonbank, A. Leiherer, H. Drexel (Austria) 050 INDIAN DIABETES RISK SCORE (IDRS) FOR TYPE 2 DIABETES MELLITUS SCREENING IN YOUNG ADULTS: EFFECT OF YOGA AND MEDITATION 880 V. Sharma (India) 051 ASSOCIATION OF RED CELL DISTRIBUTION WIDTH WITH CORONARY ARTERY DISEASE IN PATIENTS WITH DIABETES IN MULTI-ETHNIC SINGAPORE 881 C. Chiong, Y.J. Chee, X. Gao, R. Dalan (Singapore)

74 Poster Walks tuesday 052 PREDICTORS OF 10-YEAR MORTALITY ARE DIFFERENT IN DIABETIC AND NON-DIABETIC PATIENTS WITH CHRONIC LOWER EXTREMITY PERIPHERAL ARTERIAL DISEASE 882 T. Mueller, F. Hinterreiter, W. Poelz, M. Haltmayer, B. Dieplinger (Austria) 053 HAND GRIP STRENGTH SIGNIFICANTLY PREDICTS CARDIOVASCULAR EVENT RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS 883 P. Rein, C. Saely, A. Vonbank, D. Zanolin, A. Leiherer, H. Drexel (Austria) 054 TELMISARTAN ATTENUATES HYPERGLYCEMIA-AGGRAVATED VCAM- 1 EXPRESSION AND MONOCYTES ADHESION IN TNFα-STIMULATED ENDOTHELIAL CELLS BY INCREASING GSK3β-SER9 PHOSPHORYLATION 884 D.H. Cho, J.E. Lee, K.H. Song (Republic of Korea) 055 GENETIC VARIANTS AND LIPID TRAITS IN THE HONG KONG CHINESE PATIENTS WITH TYPE 2 DIABETES 885 M. Hu, C. Tam, W.Y. So, J. Chan, B. Tomlinson, R. Ma (Hong Kong- China) 056 ANTIATHEROGENIC EFFECT OF METFORMIN IN TWO MOUSE LINES WITH DIFFERENT SUSCEPTIBILITY TO GLUCOSE INTOLERANCE 886 A. Asai, Y. Shuto, M. Nagao, T. Miyazawa, H. Sugihara, S. Oikawa (Japan) Metabolic Abnormalities and Atherosclerosis: Adipose Tissue 057 EPICARDIAL FAT,CARDIAC CHAMBERS AND CORONARY CALCIFICATION IN HYPERTENSIVE PATIENTS 887 A. Almusawi, H. Nafakhi, H. Alnafakh, A. Albasri (Iraq) 058 ADIPOKINES AND CYTOKINES SERUM LEVELS IN CHILDREN AND ADOLESCENTS AND ITS RELATIONSHIP WITH OBESITY 888 C. Rodriguez-Leal, M. Monsalvo-Hernando, I. Tinoco-Racero, E. Segura, N. Caro, M. Lagares Carballo, A. Perez, C. Perez, M. Rodriguez -Rosety, T. Pery, A. Mangas, T. Rocio (Spain) 059 INDUCIBILITY OF TRIGLYCERIDE TURNOVER IN WHITE FAT A MARKER OF LEAN PHENOTYPE 889 K. Adamcova, P. Flachs, P. Zouhar, K. Bardova, M. Svobodova, P. Janovska, A. Keenan, L. Madsen, J. Jones, K. Kristiansen, J. Kopecky (Czech Republic) 060 RELATIONSHIP OF ORPHAN RECEPTOR RORA AND CHOLESTEROL TRANSPORTERS ABCA1 AND ABCG1 EXPRESSION IN VISCERAL ADIPOSE TISSUE 890 V. Miroshnikova, A. Panteleeva, E. Demina, T. Usenko, E. Bazhenova, I. Semenova, O. Berkovich, E. Baranova, S. Pchelina (Russia) 061 EPICARDIAL FAT AND BMI RELATIONSHIPS WITH CORONARY ATHEROSCLEROTIC MARKERS IN PATIENTS WITH CORONARY CALCIUM SCORE >0: THE EFFECT OF AGE AND GENDER 891 A. Albasri, H. Nafakhi, A. Almusawi, H. Alnafakh (Iraq) 062 COLD-INDUCED CHANGES IN WHITE ADIPOSE TISSUE OF A/J AND C57BL/6J MICE 892 K. Bardova, P. Flachs, K. Adamcova, M. Svobodova, J. Kopecky (Czech Republic) 063 RELATION BETWEEN EPICARDIAL FAT TISSUE AND INFLAMMATORY MARKERS IN PREGNANTS WITH PREECLAMPSIA 893 H.A. Cakmak, B. Dincgez Cakmak, C. Yayla Abide, E. Inci Coskun, M. Erturk (Turkey) 064 LIPOSOMES FOR MICRORNA DELIVERY TO HUMAN ADIPOCYTES 894 G. Schratter, M. Karbiener, G. Almer, H. Mangge, M. Scheideler, R. Prassl (Austria) 065 OVARIECTOMY AFFECTS SUBSTRATE UTILIZATION IN BROWN ADIPOSE TISSUE AND INDUCES LIVER DICARBONYL STRESS IN RATS 895 J. Trnovska, H. Malinska, V. Skop, L. Kazdova (Czech Republic) 066 EFFECT OF BMI ON EPICARDIAL FAT,CARDIAC CHAMBERS AND CORONARY CALCIFICATION CORRELATIONS 896 H. Alnafakh, H. Nafakhi, A. Albasri, A. Almusawi (Iraq) Metabolic Abnormalities and Atherosclerosis: Kidney 067 ARE WE FOLLOWING THE GUIDELINES TO PREVENT CONTRAST INDUCED ACUTE KIDNEY INJURY? A CLINICAL AUDIT ON PATIENTS WITH CHRONIC KIDNEY DISEASE(CKD) UNDERGOING CORONARY ANGIOGRAM 897 V. Kanthasamy, S. Gill (United Kingdom) 068 EFFECT OF RECOMMENDED DIETARY PROTEIN RESTRICTION ON THE PROGRESSION OF KIDNEY DISEASE 898 C. Visinoni, A. Baragetti, I. Baragetti, C. Biazzi, K. Garlaschelli, L. Grigore, C. Pozzi, N. Giuseppe Danilo, C. Alberico L (Italy) 069 VERY MILD RENAL ENDOTHELIAL DAMAGE AND GLOMERULAR HYPERFILTRATION MAY PRECEDE INCIDENT HYPERTENSION IN THE JAPANESE GENERAL POPULATION: THE WATARI STUDY 899 M. Munakata, T. Hattori, S. Konno (Japan) 070 EARLY BIOMARKERS OF CHRONIC KIDNEY DISEASE IN DIABETIC PATIENTS 900 Z. Zuraeva, O. Mikhaleva, O. Vikulova, A. Ilyin, M. Shamkhalova, M. Shestakova (Russia)

75 Poster Walks tuesday 071 CHOLESTEROL LEVELS AND GLOMERULAR FILTRATION RATE - IS THERE ANY ASSOCIATION? 901 J. Frutuoso, M. Bourbon (Portugal) 072 HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND CONTRAST- INDUCED ACUTE KIDNEY DISEASE IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION 902 Y. Liu, L. Hua-Long, W. Dengxuan, Z. Jianbin, C. Shiqun, D. Chong-Yang, C. Ping-Yan, T. Ning, C. Ji-Yan (China) 073 EVALUATION OF THE ASSOCIATION OF PLASMA PENTRAXIN 3 LEVELS WITH TYPE 2 DIABETES AND DIABETIC NEPHROPATHY IN PATIENTS WITH RENAL FAILURE. 903 P. Miarka, M. Walus-Miarka, D. Fedak, M. Kuzniewski, A. Pietrzycka, E. Wieczorek-Surdacka, P. Jasik, B. Przepiorkowska-Hoyer, M. Kapusta, B. Idzior-Walus, W. Sulowicz (Poland) 074 CARDIOMETABOLIC RISK IN PATIENTS WITH CHRONIC RENAL DISEASE RELATED TO HYPERTRIGLYCERIDEMIA-LOW HDL -CHOLESTEROL ASSOCIATION 904 R. Toro, I. Tinoco, B. Ruiz-Estevez, C. Rodriguez-Leal, E. Segura, N. Caro, C. Perez, I. Garcia, D. Gomez -Villarejo, M. Rodriguez-Rosety, M. Lagares, A. Mangas (Spain) 075 CORRELATION OF THYROID STIMULATING HORMONE TO KIDNEY FUNCTION OF HEALTHY RESIDENTS: RESULTS FROM THE KYUSHU AND OKINAWA POPULATION STUDY (KOPS) 905 Y. Tanaka, M. Shimizu, N. Furusyo, Y. Kato, J. Hayashi (Japan) 076 EX VIVO ORGAN-PRESERVING SURGERY ON KIDNEYS FOR RENAL CELL CARCINOMA AND RENAL ARTERY ANEURYSMS 906 A. Teplov, A. Zotikov, A. Gritskevich, Z. Adyrkhaev, S. Pyanikin, I. Timina, I. Pyatkova, A. Kozhanova, A. Ivandaev, A. Pokrovsky (Russia) 077 ISHCEMIC PRECONDITIONING IN CONTRAST-INDUCED NEPHROPATHY PROPHYLACTICS IN PATIENTS WITH MILD CHRONIC KIDNEY FAILUTE 907 N. Zagidullin, A. Dunaeva, E. Sherbakova, S. Zagidullin (Russia) 078 CHARACTERISTICS OF LONG-TERM SURVIVORS IN A DIABETIC DIALYSIS PATIENT COLLECTIVE (4D STUDY) 908 S. Triebswetter (Germany) 079 EVALUATION OF CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC KIDNEY DISEASE 909 I. Oueslati, S. Lahiani, K. Bouzid, K. Khiari, H. Kaaroud, E. Elfaleh, A. Bartkiz, N. Ben Abdallah, J. Abdelmoula (Tunisia) 080 ADULT RELAPSING FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) MAINTAINED IN PARTIAL REMISSION FOLLOWING LIPOPROTEIN APHERESIS: CASE STUDY 910 A. Haikal, N. Sehar, L. Denney, P. Moriarty (USA) 081 SURGICAL TREATMENT OF ANEURYSM AND ARTERIOVENOUS FISTULA OF RENAL ARTERIES 911 A. Zotikov, A. Gritskevich, Z. Adyrkhaev, I. Timina, I. Pyatkova, V. Cigankov, A. Varava, A. Kozhanova, A. Ivandaev, M. Demina, A. Pokrovsky (Russia) Metabolic Abnormalities and Atherosclerosis: NASH and Liver Abnormalities 082 APO-B48 IN PATIENTS WITH TYPE 2 DIABETES AND NON-ALKOHOLIC FATTY LIVER DISEASE 912 B. Idzior-Waluś, M. Walus-Miarka, A. Trojak, P. Miarka, M. Kapusta (Poland) 083 ASSOCIATION BETWEEN SERUM MONOCYTE CHEMOATTRACTANT PROTEIN-1(MCP-1) LEVELS, INSULIN RESISTANCE AND SUBCLINICAL ATHEROSCLEROSIS IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS 913 N. Leach, S.C. Vesa, T. Alexescu, E. Dronca, V. Negrean, S. Dorel P. (Romania) 084 CARDIOMETABOLIC RISK FACTORS IN YOUNG V/S MIDDLE-AGED PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE 914 R. Ivanova, C. Marinova, A. Alexiev, L. Mateva (Bulgaria) 085 CONTINUOUS GRADING OF EARLY FIBROSIS IN NAFLD USING LABEL-FREE IMAGING 915 J. Pirhonen, J. Arola, S. Sädevirta, P. Luukkonen, S.M. Karppinen, T. Pihlajaniemi, A. Isomäki, M. Hukkanen, H. Yki-Järvinen, E. Ikonen (Finland) 086 THE ROLE OF VITAMIN D3 IN HIGH FAT DIET INDUCED FATTY LIVER DISEASE AND OBESITY. 916 R. Kheder, J. Hobkir, M. Browning, C. Stover (United Kingdom) 087 COMPARATIVE ANALYSIS OF SERUM LIPIDS IN PATIENTS WITH CHRONIC HEPATITIS C, NONALCOHOLIC FATTY LIVER DISEASE, AND HEALTHY CONTROLS 917 R. Ivanova, I. Valkov, C. Marinova, A. Alexiev, K. Antonov, D. Jelev, L. Mateva (Bulgaria) 088 LIPID-MODIFYING EFFECTS OF CURCUMIN IN PATIENTS WITH NON- ALCOHOLIC FATTY LIVER DISEASE 918 Y. Panahi, P. Kianpour, R. Mohtashami, R. Jafari, A. Sahebkar (Iran) 089 EFFECTS OF BODY WEIGHT ON HEPATIC STEATOSIS IN ESSENTIAL HYPERTENSION 919 C.H. Chou, W.C. Tsai (Taiwan) 090 HEPATIC STEATOSIS IS INDEPENDENTLY ASSOCIATED WITH ERECTILE DYSFUNCTION: ONE MORE LINK BETWEEN THE LIVER AND CARDIOVASCULAR RISK? 920 F. Rached, A. Laurinavicius, R. Conceição, R. Santos (Brazil)

76 Poster Walks tuesday Dyslipidemias: Dyslipidemias, Screening and Treatment 091 PREVALENCE OF DIABETES MELLITUS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA 921 S. Perez-Calahorra, R. Mateo-Gallego, N. Plana, J.P. Botet-Montoya, J.F. Ascaso, C. Lahoz, F. Almagro, R.M. Sánchez-Hernández, I. Lamiquiz- Moneo, F. Civeira (Spain) 092 FAMILIAL HYPERCHOLESTEROLEMIA (FH) IN CHILDREN AND ADOLESCENTS: OPTIMIZATION OF DETECTION FOR EARLY TREATMENT 922 E. De Faria (Brazil) 093 DIAGNOSTIC PERFORMANCE OF VARIOUS FAMILIAL HYPERCHOLESTEROLAEMIA CRITERIA COMPARED TO THE DUTCH LIPID CLINIC CRITERIA IN AN ASIAN POPULATION 923 S. Abdul Razak, R. Rahmat, N.A. Mohd Kasim, T. Abdul Rahman, S. Muid, N. Mohd Nasir, Z. Ibrahim, S. Kasim, H. Nawawi (Malaysia) 094 DUTCH SCORE AND CASCADE SCREENING FOR THE IDENTIFICATION OF PATIENTS AFFECTED BY HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 924 S. Sperlongano, C. Garaffa, F. Natale, F. Fimiani, E. Garaffa, L. D'Acierno, M. Laringe, G. Limongelli, G. Piccinocchi, P. Calabrò (Italy) 095 RETROSPECTIVE OBSERVATIONAL STUDY ON THE DIAGNOSIS AND THERAPY OF THE FH ON A SAMPLE OF REAL WORLD POPULATION 925 C. Garaffa, F. Natale, S. Sperlongano, F. Fimiani, M. Laringe, L. D'Acierno, E. Garaffa, G. Limongelli, G. Piccinocchi, P. Calabrò (Italy) 096 INTERNATIONAL COMPARISON OF PRIMARY CARE KNOWLEDGE AND PRACTICES OF FAMILIAL HYPERCHOLESTEROLAEMIA (FH) 926 G.F. Watts (Australia) 097 INTERNATIONAL COMPARISON OF SERVICES AND FACILITIES FOR THE CARE OF FAMILIAL HYPERCHOLESTEROLAEMIA (FH) 927 G.F. Watts (Australia) 098 SWITCH TO ROSUVASTATIN VERSUS ADDITION OF EZETIMIBE IN PATIENTS RECEIVING ATORVASTATIN: EFFECT ON URINE 8-ISOPROSTANE LEVELS 928 E. Klouras, C. Tellis, F. Barkas, E. Liberopoulos, M. Elisaf, A. Tselepis (Greece) 099 CASCADE GENETIC SCREENING FOR FAMILIAL HYPERCHOLESTEROLEMIA IN WEST SIBERIA 929 E. Shakhtshneider, K. Makarenkova, D. Ivanoshchuk, P. Orlov, Y. Ragino, M. Voevoda (Russia) 100 LIPID CLINIC EXPERIENCE OF GENOTYPING FOR FAMILIAL HYPERCHOLESTEROLAEMIA 930 K. Shipman, R. Cramb (United Kingdom) 101 CAROTID PLAQUES AND INTIMA-MEDIA THICKNESS - ARE THE SAME RISK FACTORS IN MEN AND WOMEN WITH FAMILIAL HYPERCHOLESTEROLEMIA? 931 M. Walus-Miarka, B. Idzior-Walus, D. Czarnecka, M. Kloch-Badełek, W. Wojciechowska, M. Kapusta (Poland) 102 SEVERE FAMILIAL HYPERCHOLESTEROLEMIA: PREVALENCE AND CHARACTERIZATION OF PATIENTS PRESENTING FOR CARDIAC CATHETERIZATION 932 B. Zafrir, C. Shapira, G. Lavie, D.A. Halon, M.Y. Flugelman (Israel) 103 THE CT CORONARY CALCIUM SCORE IN FAMILIAL HYPERCHOLESTEROLAEMIA: COMPARISON BETWEEN PATIENTS WITH FH MUTATIONS AND THOSE WITH NO IDENTIFIED MUTATION 933 S. Chaudhuri, M. Labib, A. Abeysekera (United Kingdom) 104 THE UK PAEDIATRIC FAMILIAL HYPERCHOLESTEROLAEMIA (FH) REGISTER: PRELIMINARY DATA 934 S. Humphries, J. Cooper, U. Ramaswami (United Kingdom) 105 CASE REPORT: HYPERCHOLESTEROLEMIC PATIENT WITH NEW HOMOZYGOUS LDLR MUTATION AND SEVERE EARLY CORONARY HEART DISEASE 935 T. Grenkowtiz, U. Kassner, N. Buchmann, N. El-Zidy-Ibrahim, D. Spira, I. Demuth, E. Steinhagen-Thiessen (Germany) 106 FAMILIAL HYPERCHOLESTEROLAEMIA - GEOMAPPING OF THE BASELINE LDL LEVELS AND CHARACTERISATION OF LDL RECEPTOR MUTATIONS FOR PATIENTS DIAGNOSED IN THE NORTH WALES SCREENING PROGRAMME M. De Soysa, R. Gingell, Y.P. Teoh (United Kingdom) 107 ESTABLISHMENT OF A NATIONWIDE CASCADE SCREENING PROGRAM AND REGISTER FOR FAMILIAL HYPERCHOLESTROLEMIA IN GERMANY - CARE HIGH 937 N. Schmidt, W. März, T. Grammer (Germany) 108 EPISODIC MEMORY PERFORMANCE IN YOUNG ADULTS WITH FAMILIAL HYPERCHOLESTEROLEMIA 938 M. Mauri, N. Cuenca, R.M. Borrallo, E. Romero, J. Ottino, I. García-García, M.A. Jurado, M. Garolera (Spain) 109 CARRIERS OF THE LDL RECEPTOR MUTATIONS WITHIN THE EXON 12 IN GENERAL POPULATION 939 J. Hubacek, A. Fellnerova, D. Dlouha, L. Schwarzova, V. Adamkova (Czech Republic) 110 TARGETED NEXT-GENERATION SEQUENCING OF THE LDLRAP1 GENE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA 940 D. Ivanoshchuk, E. Shakhtshneider, K. Makarenkova, P. Orlov, Y. Ragino, M. Voevoda (Russia)

77 Poster Walks tuesday 111 FH CLINICS - TWO SHORT YEARS OF EXPERIENCE 941 I. Colaço, T. Vassalo, F. Faria, D. Cruz, J.L. Ducla Soares (Portugal) 112 ACHIEVEMENT OF EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) TARGETS WITH LOMITAPIDE, A MICROSOMAL TRANSFER PROTEIN INHIBITOR IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA (HOFH) 942 H. Phillips, M. Ager, A. Hutchings (United Kingdom) 113 USING PERCENTILES TO DIAGNOSE FAMILIAL HYPERCHOLESTEROLEMIA IN PORTUGAL 943 A. Pereira, A.C. Alves, A.M. Medeiros, C. Mariano, M. Bourbon (Portugal) 114 LOW-DENSITY LIPOPROTEIN GENE SCORE TO IDENTIFY POLYGENIC FORMS OF FAMILIAL HYPERCHOLESTEROLEMIA IN A SPANISH POPULATION 944 J.M. Martín-Campos, J. Julve, N. Plana, R. Figueras, E. Esteve, M. Mauri, M. Bueno, A. Caixàs, E. Llargués, A. Vila, C. Morales, C. Soler, J. Argimón, J. Mayos, J. Grau, A. Zamora, L. Matas, L. Vila, L. Masana, F. Blanco-Vaca (Spain) 115 GENETIC ANALYSIS OF FAMILIAL HYPERCHOLESTEROLAEMIA IN IBEROAMERICAN COUNTRIES 945 J. Chora, P. Mata, R. Santos, A. Cárdenas Vázquez, M. Stoll, L. Schreier, A. Cuevas, A.C. Alves, A.M. Medeiros, L. Perez Isla, C. Jannes, A. Pereira, N. Dell'Oca, X. Reyes, P. Corral, V. Bañares, T. Magaña-Torres, C. Aguilar- Salinas, R. Alonso, M. Bourbon (Argentina) 116 IDENTIFICATION OF A NEW MUTATION IN THE N-TERMINAL REGION OF THE APOLIPOPROTEIN B GENE IN FAMILIAL HYPERCHOLESTEROLEMIA 946 M. Abifadel, S. Elbitar, Y. Ghaleb, G. Peloso, N. Stitziel, P. El Khoury, J.P. Rabes, V. Carreau, E. Bruckert, S. Kathiresan, M. Varret, C. Boileau (France) 117 PRELIMINARY RESULTS OF RUSSIAN FAMILIAL HYPERCHOLESTEROLEMIA REGISTRY 947 I.V. Sergienko, A.A. Ansheles, A.B. Popova, M.I. Voevoda, V.S. Gurevich, V.V. Henkel, V.V. Kukharchuk, M.V. Ezhov (Russia) 118 CLINICAL CHARACTERISTICS OF COMMON PCSK9 GAIN-OF- FUNCTION E32K VARIANT WITH HIGHER TG ELEVATION, AND DOUBLE HETEROZYGOTES WITH COMMON PCSK9 VARIANTS AND LDLR MUTATIONS 948 A. Nohara, M.A. Kawashiri, H. Tada, M. Yoshida, M. Mori, C. Nakanishi, K. Yagi, A. Inazu, M. Yamagishi, H. Mabuchi (Japan) 121 D374Y MUTATION IN THE PCSK-9 GENE IN TURKISH PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: LONG TERM FOLLOW-UP WITH GOOD CLINICAL COURSE 951 M. Kayıkcıoglu, E.K. Kocabas, A.T. VARDARLI, Z. EROGLU, H. DOKMEN, N. SALMAN, S. PAYZIN, L.H. CAN (Turkey) 122 ATHEROSCLEROSIS IN MONOGENIC FAMILIAL HYPERCHOLESTEROLEMIA VERSUS POLYGENIC HYPERCHOLESTEROLEMIA 952 M. Sharifi, A. Gallivan, D. Harvey, L. Ka Wah, J. Cooper, M. Futema, S.E. Humphries, D. Nair (United Kingdom) 123 FIRST PCSK-9 MUTANT PATIENT IN TURKEY 953 E. Kaya Kocabas, M. Kayikcioglu, A. Tetik Vardarli, Z. Eroglu (Turkey) 124 GENETIC EPIDEMIOLOGY OF ARH IN SICILY 954 R. Spina, V. Valenti, V. Ingrassia, M.P. La Spada, C. Scrimali, G. Misiano, D. Noto, O. Palesano, G.I. Altieri, V. Licata, F. Fayer, C.M. Barbagallo, A.B. Cefalù, M. Averna (Italy) 125 CONSTRUCTION OF A NEW FAMILIAL HYPERCHOLESTEROLAEMIA VARIANT DATA BASE: A SYSTEMATIC REVIEW FOR A 2015 UPDATE 955 S. Azevedo, J.R. Chora, A.C. Alves, A.M. Medeiros, M. Bourbon (Portugal) 126 MOLECULAR BASIS OF FAMILIAL HYPERCHOLESTEROLEMIA IN POLAND UPDATE FROM THE POLISH NATIONAL CENTRE OF DIAGNOSTICS AND TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA 956 M. Chmara, M. Zuk, A. Mickiewicz, A. Brandt, K. Chlebus, J. Kubalska, J. Bautembach-Minkowska, M. Stroniawska-Woźniak, M. Bednarska- Makaruk, L. Kłosiewicz-Latoszek, A. Rynkiewicz, M. Mysliwiec, M. Gruchala, J. Limon, B. Wasag (Poland) 127 MORTALITY OF CARDIOVASCULAR DISEASE IN PATIENTS WITH GENETICALLY VERIFIED FAMILIAL HYPERCHOLESTEROLEMIA 957 K. Retterstøl, J. Igland, L. Ose, K.B. Holven, T.P. Leren, M.B. Veierød, L. Mundal (Norway) 128 HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH) IN CHILDREN: AN ITALIAN EXPERIENCE 958 F. Guaraldi, M.D. Di Taranto, C. Giacobbe, G. Fortunato, O. Guardamagna (Italy) 119 PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 (PCSK9) V4I VARIANT WITH LDLR MUTATIONS MODIFIES THE PHENOTYPE OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 949 M. Hori, N. Ohta, A. Takahashi, M. Ogura, H. Makino, T. Tamanaha, Y. Miyamoto, M. Harada-Shiba (Japan) 129 GENETIC ANALYSIS OF FAMILIAL HYPERCHOLESTEROLEMIA IN MEXICO 959 A. Vazquez Cardenas, M.T. Magaña Torres, Y. Sanchez Lopez, T. Hernandez Flores, A.G. Colima Fausto, J.R. González Garcia, F. Escalante, D. Gonzalez Marines, C. Aguilar Salinas, M. Bourbon (Mexico) YEARS OF EXPERIENCE WITH CHILDREN AFFECTED WITH 120 HEREDITARY DEFECT OF APOLIPOPROTEIN B ANALYSIS OF GROUP HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): A CASE OF PATIENTS TREATED WITH STANDARD PERORAL LIPID-LOWERING SERIES OF NINE PATIENTS 960 THERAPY IN ST. ANNE S UNIVERSITY HOSPITAL BRNO 950 K. Widhalm, K. Derfler, G. Kostner, O. Helk (Austria) O. Kyselak, V. Soska (Czech Republic)

78 Poster Walks tuesday 131 PROGRAM STRATEGIES FOR FAMILIAL HYPERCHOLESTEROLEMIA IN URUGUAY 961 M. Stoll, X. Reyes, N. Dell Oca, F. Machado, A. Ressia, G. Fernandez, Zelarayán M(1) (Uruguay) 132 EFFECT OF APOE GENOTYPE ON LDL CHOLESTEROL LEVELS IN FH AND FDB PATIENTS: IS THERE SEX-SPECIFICALLY PROTECTIVE GENOTYPE? 962 L. Schwarzova, A. Horinek, J. Hubacek, M. Vrablik, T. Freiberger, L. Tichy, H. Vaverkova, R. Ceska (Czech Republic) 133 GENETIC AND PHENOTYPIC CHARACTERIZATION OF LDL- RECEPTOR IN PATIENTS WITH A CLINICAL DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA: TWO NOVEL MUTATIONS 963 C. Pavanello, C. Tarlarini, S. Penco, L. Calabresi, S. Castelnuovo, G. Mombelli, C. Sirtori (Italy) 134 THE R46L POLYMORPHISM OF PCSK9 GENE AND LIPID PROFILE IN CAUCASIAN POPULATION OF RUSSIA 964 K. Astrakova, E. Shakhtshneider, D. Ivanoshchuk, Y. Ragino, S. Astrakov, M. Voevoda (Russia) 135 FAMILIAL HYPERCHOLESTEROLAEMIA IN PRIMARY CARE: AWARENESS, KNOWLEDGE AND PRACTICES AMONG PRIMARY CARE DOCTORS IN MALAYSIA 965 A.S. Ramli, N.A. Mohd Mokhsin, S. Abdul Razak, M. Md Yasin, Z. Ismail, N.A. Mohd Kasim, T. Rahman, H. Nawawi (Malaysia) 136 PERCEPTIONS ON HEALTH COMMUNICATION, SYMPTOMS AND CAUSES IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA TREATED IN SPECIALIST CLINICS 966 N.A. Mohd Mokhsin, S. Abdul Razak, A.S. Ramli, M. Md Yasin, N.A. Mohd Kasim, S.S. Kasim, T. Rahman, H. Nawawi (Malaysia) 137 CARDIOVASCULAR DISEASE RESEARCH BY USING DATA FROM ELECTRONIC HEALTH RECORDS 967 L. Majnaric, S. Sabanovic (Croatia) 138 LDL APHERESIS IN CHILDREN WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A CASE SERIES 968 I. Luirink, A. Wiegman, B. Hutten, J. Groothoff (Netherlands) 139 EVALUATION OF PLASMA-FED LIPID APHERESIS IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA. 969 P. Downie, G. Bayly, L. Hart, S. Douglas, J. Griffin (United Kingdom) 140 LOMITAPIDE IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA - FIRST EXPERIENCES IN CLINICAL PRACTICE 970 A. Vogt (Germany) 141 ANALYSIS OF CANDIDATE SINGLE NUCLEOTIDE VARIATIONS ASSOCIATED WITH POLYGENIC HYPERCHOLESTEROLEMIA IN FAMILIES WITH THE CLINICAL DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA 971 I. Lamiquiz Moneo, M.R. Perez-Ruiz, E. Jarauta, M.T. Tejedor, L. Baila-Rueda, A.M. Bea, R. Mateo-Gallego, A. Cenarro, F. Civeira (Spain) 142 STUDY OF APOB MUTATIONS AND FAMILIAL HYPERCHOLESTEROLEMIA PHENOTYPES 972 J. Bassani Borges, G. Medeiros Bastos, T.K. Almendros Afonso, E. Da Silva Rodrigues, H. Strelow Thurow, T. Dominguez Crespo Hirata, A. Arpad Faludi, R. Marques Gonçalves, R. Dominguez Crespo Hirata, M. Hiroyuki Hirata (Brazil) 143 FUNCTIONAL ANALYSIS OF MUTATIONS LOCATED IN THE LDL RECEPTOR SIGNAL SEQUENCE CODING REGION 973 T. Freiberger, J. Pavlouskova, K. Reblova, L. Tichy, L. Fajkusova (Czech Republic) 144 ATTAINMENT OF LDL-C TREATMENT TARGET IN FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS: A THEORETICAL MODEL EXPLORING EFFICACY OF CURRENT AND NOVEL LIPID LOWERING THERAPIES 974 M.L. Hartgers, J. Besseling, G.K. Hovingh (Netherlands) 145 CARDIOVASCULAR DISEASE IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA SUBJECTS ON STATIN TREATMENT 975 V. Marco-Benedi, S. Perez-Calahorra, N. Plana, J.C. Pedro-Botet, J. Ascaso, C. Lahoz, F. Almagro, E. Ros, A. Brea, M. Suarez-Tembra, R.M. Sanchez- Hernández, A. Vila Belmonte, F. Civeira (Spain) 146 LONG-TERM TREATMENT WITH EVOLOCUMAB HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS: RESULTS FROM THE TRIAL ASSESSING LONG-TERM USE OF PCSK9 INHIBITION IN SUBJECTS WITH GENETIC LDL DISORDERS (TAUSSIG) 976 E.A. Stein, T. Sampietro, R. Santos, M. Harada-Shiba, E. Bruckert, D. Blom, G.K. Hovingh, P. Couture, V. Blaha, M. Farnier, O. Descamps, H. Soran, S. Kasichayanula, J. Gibbs, C. Kurtz, L. Tang, N. Honarpour, S.M. Wasserman, F.J. Raal (South Africa) 147 LIPID-LOWERING THERAPY AND TARGET ATTAINMENT AMONG HYPELIPIDEMIC INDIVIDUALS WITH OR WITHOUT FAMILIAL HYPERCHOLESTEROLEMIA: EVIDENCE FROM A LIPID CLINIC 977 F. Barkas, E. Klouras, T. Dimitriou, G. Liamis, E. Liberopoulos, M. Elisaf (Greece) 148 INCIDENCE OF CARDIOVASCULAR DISEASE AMONG INDIVIDUALS WITH AND WITHOUT FAMILIAL HYPERCHOLESTEROLEMIA ATTENDING A LIPID CLINIC 978 F. Barkas, E. Klouras, T. Dimitriou, G. Liamis, M. Elisaf, E. Liberopoulos (Greece)

79 Poster Walks tuesday 149 CHANGES IN PLASMA LIPOPROTEIN SUBFRACTIONS IN PATIENTS WITH POLYGENIC HYPERCHOLESTEROLEMIA, FAMILIAL COMBINED HYPERLIPOPROTEINEMIA, AND FAMILIAL HYPERCHOLESTEROLEMIA AFTER ATORVASTATIN 979 B. Muinjonov, E. Giyazitdinova (Uzbekistan) 150 PREVALENCE OF DYSLIPIDAEMIA AMONG ADULTS AGED YEARS IN IRELAND: THE IRISH LONGITUDINAL STUDY ON AGEING (TILDA) 980 C. Murphy, E. Shelley, T. Fahey, R.A. Kenny (Ireland) 151 IMPACT OF SOCIAL AND CLINICAL PARAMETERS ON NON-HDL CHOLESTEROL IN SCHOOL CHILDREN 981 A. Pereira, F. Guarnieri, A.P.Q. Mello, R. Santos Filho, T.L.R. Martinez (Brazil) 152 STATIN PRESCRIPTION PATTERNS, ADHERENCE, AND ATTAINMENT OF CHOLESTEROL TREATMENT GOALS IN CLINICAL CARE IN ELDERLY WITH HYPERLIPIDEMIA AND CORONARY HEART DISEASE: A RUSSIAN OBSERVATION STUDY 982 M. Bubnova, D. Aronov (Russia) 153 STUDY OF THE PREVALENCE OF DYSLIPIDEMIAS IN CHILDREN AND ADOLESCENTS ATTENDED BY THE NATIONAL HEALTH SYSTEM IN CAMPINAS - SÃO PAULO - BRAZIL 983 E. De Faria, E.I. Gomes, V.H. Zago, E.S. Parra, N.B. Panzoldo, G. Redezuk (Brazil) 154 CLINICAL MANAGEMENT AND QUALITY OF LIFE IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA UNDERGOING LIPID- APHERESIS IN TURKEY: FIRST RESULTS OF A NATION-WIDE SURVEY (A-HIT REGISTRY) 984 M. Kayıkcıoglu, L. Tokgozoglu, S. Pirildar, M. Yilmaz, L. Kaynar, M. Aktan, R. Durmus, A. Temizhan, O. Ozcebe, T. Akyol, H. Okutan, S. Sag, B. Altunkeser, M. Yenercag, E. Kurtoglu, S. Demircioglu, O. Salcioglu, M. Demir, H. Yilmaz, O. (Turkey) 155 FUNCTIONALLY CHARACTERIZATION OF LDLR MISSENSE ALTERATIONS FOUND IN CLINICAL FH PATIENTS 985 A.C. Alves, S. Azevedo, A. Benito-Vicente, A. Etxebarria, P. Barros, A.M. Medeiros, C. Martin, M. Bourbon (Portugal) 156 GENETIC VARIANTS OF PCSK9 GENE IN CORONARY ARTERY DISEASE AMONG SOUTH INDIAN PATIENTS 986 M. Ganesan (India) 157 FAMILIAL COMBINED HYPERLIPIDEMIA IN CHILDREN: BIOCHEMICAL CHARACTERIZATION IN PEDIATRIC AGE 987 F. Abello, E. Barabesi, A. Bosusco, O. Guardamagna, D. Vianello, A. Zambon (Italy) 158 VALIDATION OF SERUM ApoB/CHOLESTEROL AND ApoB/NON-HDL CHOLESTEROL RATIOS AS SCREENING TESTS FOR TYPE III HYPERLIPIDAEMIA 988 C. Boot, E. Holmes, D. Neely, F. Jenkinson, H. Datta, L. Hughes (United Kingdom) 159 TREATMENT OF THERAPY-REFRACTORY HYPERCHOLESTEROLEMIA WITH PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 ANTIBODIES (PCSK9-I) IN CARDIOVASCULAR HIGH RISK PATIENTS - EFFECTIVITY AND SAFETY IN CLINICAL ROUTINE 989 T. Hollstein, D. Spira, N. Buchmann, N. El-Zidy Ibrahim, T. Bobbert, E. Steinhagen-Thiessen, U. Kassner (Germany) 160 SEARCHING FOR THE ELUSIVE FAMILIAL HYPERCHOLESTEROLAEMIA GENE MUTATIONS FOR INDEX PATIENTS - USING HISTORICAL LABORATORY LDL-C RESULTS IN PRIMARY CARE. A NORTH WALES EXPERIENCE. 990 Y.P. Teoh, R. Gingell (United Kingdom) 161 HIGH TRIGLYCERIDES, LOW HDL CHOLESTEROL AND A LOW LDL CHOLESTEROL PER APOLIPOPROTEIN B RATIO PREDICT INCIDENT DIABETES IN PATIENTS WITH ESTABLISHED CORONARY ARTERY DISEASE 991 C. Saely, P. Rein, A. Vonbank, D. Zanolin, A. Leiherer, A. Muendlein, H. Drexel (Austria) 162 CARDIOVASCULAR COMORBIDITIES LINKED TO OBESITY IN FORMER ATHLETES FROM TRANSYLVANIA 992 V. Negrean, O. Orășan, T. Alexescu, N. Leach, I. Para, M. Milaciu (Romania) 163 E_LIPID: CHARACTERIZATION OF THE LIPID PROFILE IN THE PORTUGUESE POPULATION 993 C. Mariano, M. Antunes, Q. Rato, M. Bourbon (Portugal) 164 SEVERE HYPERCHOLESTEROLEMIA IN HOSPITAL PRACTICE-SINGLE CENTRE EXPERIENCE IN SINGAPORE 994 S. Dissanayake, S.P. Li Tin, J.F. Choi Wan, M.S. Wong, S. Tavintharan (Singapore) 165 HIGH PREVALENCE OF FAMILIAL HYPERCHOLESTEROLEMIA IN ARGENTINA: RESULTS OF THE FIRST DETECTION PROGRAM. 995 P. Corral, G.I. López, A. Cristaldi, J.C. Tuseddo, L. Cacciagiú, G. Berg, L. Schreier (Argentina) 166 NETWORK ANALYSIS APPROACH TO FIND NEW CANDIDATE GENES AND PATHWAYS INVOLVED IN THE PATHOPHYSIOLOGY OF FAMILIAL HYPERCHOLESTEROLEMIA 996 N. Rossi, M. Bourbon, F. Enguita (Portugal) 167 PARAMETRES OF ARTERIAL REMODELING IN FAMILAL HYPERCHOLESTEROLEMIA PATIENTS 997 V. Korneva, T. Kuznettsova (Russia)

80 Poster Walks tuesday Dyslipidemias: Treatment 168 EFFECTS OF DIFFERENT DOSES OF ATORVASTATIN ON PLATELET AGGREGATION, ENDOTHELIAL FUNCTION, LEVELS OF SEROTONIN, ANGIOTENSIN II, BLOOD PRESSURE, CEREBRAL BLOOD FLOW IN HYPERTENSIVE PATIENTS WITH HYPERLIPIDEMIA 998 M. Bubnova, D. Aronov, E. Semenova (Russia) 169 EFFECT OF STATIN ON FASTING BLOOD SUGAR LEVEL; COMPARISONS OF KINDS OF STATINS AND ASSOCIATED PARAMETERS 999 C.J. Kim, M.A. Kim (Republic of Korea) 170 DIFFERENT ROLE OF ACHIEVED LDL-CHOLESTEROL AND HS-CRP LEVEL IN FUTURE CARDIOVASCULAR DISEASE OUTCOMES IN NON- PERCUTANEOUS CORONARY INTERVENTION PATIENTS WITH ONGOING STATIN THERAPY OF MODERATE INTENSITY 1000 M.H. Hyun, E. Lee, B.G. Choi, H.S. Seo, J.O. Na, C.U. Choi, H.E. Lim, J.W. Kim, S.W. Rha, E.J. Kim, C.G. Park, D.J. Oh (Republic of Korea) 171 COMPARISON THE EFFECT ON FASTING BLOOD SUGAR BETWEEN ATORVASTATIN, ROUSUVASTATIN AND PITAVASTATIN IN KOREAN POPULATION 1001 Y.S. Lee, Y.W. Park, S.P. Hong, J.B. Lee, J.K. Ryu, J.Y. Choi, K.S. Kim (Republic of Korea) 172 COMPARISON OF LIPID MANAGEMENT BETWEEN ELDERLY AND NON- ELDERLY PATIENTS WITH AND WITHOUT CORONARY HEART DISEASE (CHD) 1002 N. Kume, R. Shimizu, H. Torii, D. Yasuda, Y. Hiraoka, T. Hashida (Japan) 173 STATIN ESCAPE PHENOMENON: DOES IT REALLY EXIST? EVIDENCE FROM A LIPID CLINIC 1003 F. Barkas, E. Klouras, T. Dimitriou, M. Elisaf, E. Liberopoulos (Greece) 178 IMPACT OF FENOFIBRATE THERAPY ON ENDOTHELIAL FUNCTION IN THE SUBJECTS WITH METABOLIC SYNDROME 1008 K. Kotula-Horowitz, M. Janczura, T. Iwaniec, R. Rosa, J. Zagjewski, T. Domagala (Poland) 179 THE EFFICACY OF EVOLOCUMAB AND OTHER LIPID-LOWERING THERAPIES (LLT) FOR THE MANAGEMENT OF LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C): A SYSTEMATIC REVIEW AND NETWORK META- ANALYSIS (NMA) 1009 G. Worthy, S.R. Gandra, I. Bridges, G. Worth, R. Dent, L.I. Cheng, C. Forbes, S. Deshpande, J. Ross, J. Kleijnen, E.S.G. Stroes (Netherlands) 180 EFFICACY AND SAFETY OF FIXED-DOSE COMBINATION OF OLMESARTAN MEDOXOMIL AND ROSUVASTATIN IN KOREAN PATIENTS WITH HYPERTENSION AND DYSLIPIDEMIA 1010 S.H. Kim, H.L. Lee, W.H. Lim, H.L. Kim, J.B. Seo, W.Y. Chung, J.H. Zo, M.A. Kim, H.S. Kim (Republic of Korea) 181 THE EFFECTS OF ALIROCUMAB ON LDL CHOLESTEROL LEVELS IN PATIENTS RECEIVING STATINS 1011 H. Habibinejad (Iran) 182 TESTOSTERONE UNDECANOATE IMPROVES LIPID PROFILE IN PATIENTS WITH TYPE 1 DIABETES AND HYPOGONADOTROPHIC HYPOGONADISM. RESULTS FROM TEST-T1D RANDOMIZED CLINICAL TRIAL J.J. Chillarón, J. Pedro-Botet, M. Fernández-Miró, M. Albareda, L. Vila, D. Benaiges, J.A. Flores Le-Roux (Spain) 183 EFFECT OF TOCILIZUMAB ON CARDIAC BIOMARKERS HIGH-SENSITIVITY TROPONIN T AND NT-PROBNP IN RHEUMATOID ARTHRITIS: POST HOC ANALYSIS OF A RANDOMISED CONTROLLED TRIAL 1013 P. Welsh, K. Tuckwell, N. Sattar (United Kingdom) 174 EFFECTS OF LOW-DOSE VS. MODERATE-DOSE PITAVASTATIN ON LONG- TERM CARDIOVASCULAR EVENTS IN KOREAN PATIENTS WITH CORONARY ARTERY DISEASE REQUIRING STENT IMPLANTATION: PROSPECTIVE, 3-YEAR FOLLOW-UP TRIAL 1004 D.S. Lim, H.J. Kim, Y.C. Kim, B.G. Kang, S.M. Jeon, S.J. Hong, J.Y. Cho, S.H. Lee, H.J. Joo, J.H. Park, C.W. Yu (Republic of Korea) 175 GENE VARIANTS ASSOCIATED WITH STATIN-INDUCED MYOPATHY: DETERMINATION IN A CZECH POPULATION 1005 J. Petrkova, L. Kocourkova, V. Zizkova, M. Taborsky, M. Petrek (Czech Republic) 176 THE SAFETY OF STATINS IN PATIENTS WITH CHRONIC KIDNEY DISEASE 1006 Y.K. Cho (Republic of Korea) 177 ONE YEAR PERSISTENCE OF ATORVASTATIN AND AMLODIPINE FIXED DOSE COMBINATION VERSUS ATORVASTATIN THERAPY 1007 G. Simonyi, F. Tamás (Hungary) 184 CCAAT/ENHANCER BINDING PROTEIN DELTA CONTRIBUTES TO AN EARLIER PHASE OF PRO-INFLAMMATORY RESPONSE IN DOXORUBICIN RELATED CARDIOMYOPATHY 1014 J.T. Wen, L.W. Hsu, P.Y. Liu (Taiwan) 185 EFFECT OF ENDOTOXIN AND NATURAL CAROTENOIDS ON AORTIC ENDOTHELIAL TIGHT JUNCTIONS OCCLUDIN EXPRESSION 1015 J. Krizak, K. Frimmel, E. Breierova, R. Sotnikova, J. Navarova, I. Bernatova, L. Okruhlicova (Slovakia) 186 EFFECT OF DHA/EPA SUPPLEMENTATION ON ENDOTHELIAL DAMAGE MARKERS. THE BIOCLAIMS STUDY 1016 J. Góralska, M. Malczewska-Malec, U. Razny, A. Zdzienicka, A. Gruca, A. Chabowski, M. Sanak, A. Dembinska-Kiec, B. Solnica (Poland)

81 Poster Walks tuesday 187 IN VITRO PHARMACOLOGICAL EVALUATION OF MULTITARGET THROMBOXANE PROSTANOID RECEPTOR/ COX-2 AGENTS: A POSSIBLE STRATEGY TO SOLVE THE CARDIOVASCULAR ISSUES OF COXIBS 1017 M. Hoxha, C. Buccellati, V. Capra, C. Cena, A. Sala, M. Bertinaria, G. Rovati (Italy) 188 THE USE OF N-ACETYLCYSTEINE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND DIASTOLIC LEFT VENTRICULAR DYSFUNCTION, IN ACCORDANCE WITH THE LEVEL OF HIGH-SENSITIVITY C-REACTIVE PROTEIN A. Nizomov, B. Toshev, J. Berdiqulov (Uzbekistan) 189 THREE TIMES A WEEK AND FIVE TIMES A WEEK WALKING EXERCISE FREQUENCIES ARE EQUALLY EFFECTIVE IN IMPROVING WALKING CAPACITY IN EXPERIMENTAL PERIPHERAL ARTERY DISEASE 1019 M. Pellegrin, J. Lavier, K. Bouzourene, L. Mazzolai (Switzerland) 190 SONODYNAMIC THERAPY OF THE RABBIT CAROTID ARTERY NEOINTIMAL HYPERPLASIA USING LOW- LEVEL COMBINED ELECTROHYDRAULIC SHOCK WAVES AND ULTRASONIC WAVES ACCOMPANIED BY PROTOPORPHYRIN IX ADMINISTRATION 1020 H. Mehrad, B. Mahvi (Iran) 191 A NOVEL COMPOUND (D-47), THE HYPOLIPIDEMIC EFFECTS AND THE MECHANISM IN AN ANIMAL MODEL OF HYPERCHOLESTEROLEMIA (WHHLMI RABBIT) 1021 S. Tamura, Y. Yu, T. Nakagawa, R. Nagasaka, T. Tsunoda, K. Ogawa, M.O. Tori, T. Koike, M. Shiomi (Japan) 192 NOVEL ROLE OF BERBERINE IN LOX1-MEDIATED ENDOTHELIAL DYSFUNCTION 1022 A. Cicero, C. Caliceti, P. Rizzo, R. Ferrari, F. Fortini, G. Aquila, J. Shehu, E. Leoncini, L. Zambonin, B. Rizzo, M. Guardigli, A. Roda, S. Hrelia (Italy) 193 EXPERIENCE OF TAKAYASU`S ARTERITIS SURGICAL TREATMENT 1023 A. Pokrovskiy, A. Zotikov, V. Kulbak, E. Burtceva (Russia) 194 DOWN-REGULATION OF THE CHEMOKINE (C-C MOTIF) RECEPTOR 9 (CCR9) CONTRIBUTES TO THE ATHEROSCLEROSIS-LOWERING ACTIVITY OF THE ANGIOTENSIN-CONVERTING ENZYME INHIBITOR CAPTOPRIL 1024 J. Abd Alla, A. Langer, U. Quitterer (Switzerland) 195 INCIDENCE OF VALVULAR HEART DISEASE AFTER COMBINATION OF DOPAMIN AGONISTS WITH STATINS 1025 E. Giyazitdinova, B. Muinjonov, G. Rakhimbayeva, Y. Musayeva (Uzbekistan) 196 HYPOLIPIDEMIC EFFECT OF RHEOPHERESIS AND RESTORATION OF RETINAL PHOTORECEPTOR JUNCTION 1026 M. Blaha, E. Rencova, H. Langrova, M. Lanska, A. Stepanov, V. Blaha (Czech Republic) 197 REMNANT CHOLESTEROL REDUCTION BY EZETIMIBE AND SIMVASTATIN DOES NOT AFFECT BILIARY LIPID CONCENTRATION IN GALLSTONE PATIENTS 1027 M. Eriksson, O. Ahmed, U. Gustafsson, K. Littman, S. Sahlin, C. Pramfalk, P. Parini (Sweden) 198 CROSS-CLASS SERINE PROTEASE INHIBITOR SERP-2 BLOCKS LIVER ISCHEMIA REPERFUSION INJURY 1028 S. Ambadapadi, H. Chen, J. Fuentes, S. Morshed, J. Davids, B. Marques, A. Lucas (USA) 199 STATIN THERAPY REDUCES PHOSPATE LEVELS IN DIALYSIS PATIENTS: RESULTS FROM THE EPIDEMIOLOGICAL VITAMIN K ITALIAN STUDY (VIKI STUDY) 1029 C. Panzavolta, L. Benvegnù, A. Aghi, M. Biolo, S. Giannini, M. Noale, G. Tripepi, M. Plebani, N. Veronese, P. Messa, M. Rossini, M. Gallieni, S. Sella, F. Fabris, E. Manzato, L. Previato, S. Bertocco, A. Zambon, M. Fusaro, S. Zambon (Italy) Dyslipidemias: Coagulation 200 PLASMA ADVANCED OXIDIZED PROTEIN PRODUCTS PROMOTE PLATELET- ENDOTHELIAL CROSSTALK AND ENDOTHELIAL TISSUE FACTOR EXPRESSION 1030 G. Marsche, A. Heinemann, L. Pasterk (Austria) 201 PLASMA FIBRINOGEN IS AN IMPORTANT CLINICAL MARKER FOR PROSPECTIVE ALL-CAUSE MORTALITY IN THE LIFEWAYS CROSS- GENERATION COHORT STUDY 1031 R. Somerville, K. Viljoen, S. McKey, A. Shrivastava, J. Mehegan, R. Segurado, C. Murrin, C. Kelleher (Ireland) 202 ADJUSTING FOR THE INFLUENCE OF THE HEMATOCRIT LEVEL IMPROVES THE PROGNOSTIC VALUE OF THE VERIFYNOW P2Y12 ASSAY 1032 J.W. Suh, Y.G. Kim, Y.S. Cho, T.J. Youn, I.H. Chae (Republic of Korea) 203 PLATELET-ASSOCIATED TISSUE FACTOR AS A NEW MECHANISM INVOLVED IN THE PROTHROMBOTIC PHENOTYPE OF STABLE ANGINA PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) 1033 L. Rossetti, P. Canzano, M. Mapelli, D. Trabattoni, F. Santilli, G. Davì, A. Lualdi, E. Tremoli, M. Camera (Italy) 204 IMPACT OF TYPE-2 DIABETES MELLITUS (T2DM) ON THE PLATELET TRANSCRIPTOME PROFILE IN STABLE ANGINA (SA) PATIENTS 1034 L. Rossetti, M. Brambilla, P. Canzano, L. Piacentini, E. Bono, M. Mapelli, D. Trabattoni, A. Lualdi, G. Colombo, E. Tremoli, M. Camera (Italy)

82 Poster Walks tuesday 205 NTEGRIN αιιbβ3 AS POTENTIAL BIOMARKER OF HIGH ON-TREATMENT PLATELET REACTIVITY TO CLOPIDOGREL IN PATIENTS WITH AN ACUTE CORONARY SYNDROME 1035 A. Gkourogianni, M. Tsoumani, I. Ntallas, D. Tsoukatos, I. Goudevenos, A. Tselepis (Greece) 206 THE COMBINATION OF N-ACETYLCYSTEINE WITH FIBRINOLYTIC THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME A. Nizomov (Uzbekistan) 207 FEASIBILITY OF TARGETING THROMBUS USING FOCUSED- ELECTROHYDRAULIC SHOCK WAVES ACCOMPANIED BY SIMULTANEOUSLY B-MODE ULTRASOUND IMAGING IN THE RABBIT MODEL OF COMMON CAROTID ARTERY ATHEROTHROMBOTIC OCCLUSION 1037 H. Mehrad (Iran) 208 NON-INVASIVE TREATMENT OF THE RABBIT CAROTID ARTERY ATHEROTHROMBOTIC OCCLUSION USING COMBINED Nd:YAG LASER AND PULSED- FOCUSED ULTRASOUND ACCOMPANIED BY THROMBOLYTIC AGENT ADMINISTRATION 1038 H. Mehrad, A. Akrami (Iran) 209 PROTHROMBOTIC PHENOTYPE IN HYPERTENSION: CONTRIBUTION OF MEGAKARYOCYTE- AND PLATELET-ASSOCIATED TISSUE FACTOR EXPRESSION IN STROKE-PRONE RATS 1039 M. Brambilla, P. Gelosa, L. Rossetti, L. Castiglioni, P. Canzano, S. Luigi, E. Tremoli, M. Camera (Italy) 214 INFLUENCE OF CARBOHYDRATE METABOLISM DISORDERS ON STRUCTURAL AND FUNCTIONAL PROPERTIES OF THE LARGE ARTERIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS 1044 N. Burko, L. Salyamova, Y. Tomashevskaya, V. Oleynikov (Russia) 215 THE PROGNOSTIC IMPORTANCE OF ENDOTHELIAL DYSFUNCTION IN METABOLIC SYNDROME WITH CORONARY ARTERY DISEASE 1045 T. Ueda (Japan) 216 VASCULAR AGE - A HELPFUL TOOL IN ASSESSING CARDIOVASCULAR RISK 1046 A. Dumitrescu, S. Mosteoru, L. Gaita, R. Pleava, D. Gaita (Romania) 217 REMOTE ISCHEMIC PRECONDITIONING AND ENDOTHELIAL FUNCTION IN HEALTHY VOLUNTEERS 1047 N. Ryazankina, M. Vagida, V. Manchurov, A. Lebedeva, A. Arakelyan, J.C. Grivel, L. Margolis, E. Vasilieva, A. Shpektor (Russia) 218 THE ENDOTHELIAL FUNCTION IMPROVEMENT ON STATIN THERAPY IN TYPE 2 DIABETES ASSOCIATED WITH TNFα G(308)A AND G(238)A POLYMORPHIC MARKERS 1048 N. Lebedeva, O.K. Vikulova, A.G. Nikitin, M.S. Shamkhalova, M.V. Shestakova (Russia) 219 BENEFICIAL EFFECT OF AZILSARTAN AND AMLODIPINE ON ENDOTHELIAL FUNCTION IN HYPERTENSIVE PATIENTS 1049 T. Nishida, M. Ayaori, K. Shiotani, H. Uto-Kondo, M. Sasaki, T. Komatsu, Y. Endo, M. Ito, M. Ishizuka, M. Sakurada, K. Ikewaki (Japan) 210 SILENCING ANTICOAGULANT PROTEIN C CAUSES SPONTANEOUS ATHEROTHROMBOSIS IN APOE KNOCKOUT MICE 1040 A.B. Ouweneel, M. Heestermans, R.A.F. Verwilligen, M. Van Eck, B.J.M. Van Vlijmen (Netherlands) Dyslipidemias: Endothelial Dysfunction 211 LOW-FLOW MEDIATED CONSTRICTION INCORPORATED INDICES AS INDICATORS OF CARDIOVASCULAR RISK IN SMOKERS 1041 N. Norioka, Y. Takemoto, M. Kobayashi, A. Makuuchi, J. Yoshikawa, Y. Yamazaki, Y. Kamiyama, T. Shuto, M. Yoshiyama (Japan) 212 ENDOTHELIAL SHEAR RATE IN PATIENTS WITH CAROTID ATHEROSCLEROSIS 1042 V. Genkel, A. Salashenko, O. Alekseeva, M. Denisenko, I. Shaposhnik (Russia) 213 ANALYSIS OF BIOLOGICAL, STRUCTURAL AND FUNCTIONAL MARKERS OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH ARTERIAL HYPERTENSION, TREATED WITH ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS CIRCULATING PROGENITOR CELLS IN HYPERTENSIVE SUBJECTS: EFFECTIVENESS OF A TREATMENT WITH OLMESARTAN IN IMPROVING CELL NUMBER AND MIRS PROFILE BESIDES EXPECTED PHARMACOLOGICAL EFFECTS 1050 G. Mandraffino, C.O. Aragona, E. Imbalzano, V. Cairo, F. Mamone, M.A. Sardo, A. Saitta (Italy) Genetics, Nutrition, Biomarkers: Genetics, Gene Regulation 221 A CASE OF SEVERE CHYLOMICRONAEMIA SYNDROME, IN A PATIENT WITH NORMAL LIPOPROTEIN LIPASE ACTIVITY, DUE TO A PREVIOUSLY UNIDENTIFIED MUTATION IN THE GPIHBP1 GENE 1051 P. Downie, G. Bayly (United Kingdom) 222 MOLECULAR ANALYSIS OF GENES INVOLVED IN LIPOPROTEIN LIPASE DEFICIENCY IN SLOVAK PATIENTS WITH FAMILIAL CHYLOMICRONEMIA 1052 D. Gabcova, D. Stanikova, M. Huckova, V. Bzduch, J. Stanik, I. Klimes, K. Raslova, D. Gasperikova (Slovakia) M. Andor, V. Buda, C. Cristescu, M. Voicu, L. Suciu, C. Muntean, M. Tomescu (Romania)

83 Poster Walks tuesday 223 DISSECTION OF CLINICAL AND GENE EXPRESSION SIGNATURES OF FAMILIAL VS MULTIFACTORIAL CHYLOMICRONEMIA 1053 D. Gaudet, D. Brisson, K. Tremblay (Canada) 224 A NOVEL HOMOZYGOUS MUTATION IN GPD1 LEADING TO SEVERE HYPERTRIGLYCERIDEMIA 1054 J. Levels, R. Piña-Aguilar, J. Peter, G.M. Dallinga-Thie (Netherlands) 225 IDENTIFICATION AND CHARACTERIZATION OF TWO NOVEL MUTATIONS IN THE LPL GENE CAUSING TYPE I HYPERLIPOPROTEINEMIA 1055 P. Pingitore, S.M. Lepore, C. Pirazzi, R.M. Mancina, B.M. Motta, L. Valenti, K.E. Berge, K. Retterstøl, T.P. Leren, O. Wiklund, S. Romeo (Sweden) 226 STATINS UPREGULATE microrna-122 IN HepG2 CELLS 1056 A. Etxebarria, X. Moreno, A. Benito-Vicente, S. Jebari, U. Galicia, H. Ostolaza, C. Martin (Spain) 227 THE HYPERTRIGLYCERIDEMIC EFFECT OF APOC3 3'UTR VARIANT SST1 IS NOT MEDIATED BY A HEPATIC OR INTESTINAL MIRNA REGULATION 1057 M. Dancer, C. Marcais, C. Caussy, M. Di filippo, P. Moulin, S. Charrière (France) 228 PLASMA LIPOPROTEINS OF PATIENTS WITH GENETIC LAL DEFICIENCY ARE ENRICHED IN CHOLESTERYL ESTERS: RELEVANCE OF CHOLESTEROL ESTERIFICATION BY LCAT 1058 M. Gomaraschi, L. Arnaboldi, F. Abello, C. Pavanello, F. Zimetti, E. Favari, L. Calabresi, O. Guardamagna (Italy) 229 LYSOSOMAL ACID LIPASE DEFICIENCY IN GREECE: A RARE INBORN ERROR OF METABOLISM PRESENTING WITH DYSLIPIDAIMIA AND LIVER DISEASE 1059 E. Drogari, V. Mollaki, H. Christomanou, K. Stamatelopoulos, N. Manolaki (Greece) 230 WILL FAMILIAL HYPERCHOLESTEROLAEMIA COHORTS HIDE MANY MORE LISOSOMAL ACID LIPASE DEFICIENCY PATIENTS? 1060 J.R. Chora, A.C. Alves, A.M. Medeiros, C. Mariano, G. Loubarinhas, A. Guerra, H. Mansilha, M. Bourbon (Portugal) 231 SCREENING OF LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS WITH SEVERE DYSLIPIDEMIA AND PREMATURE CORONARY HEART DISEASE 1061 O. Azevedo, N. Marques, H. Antunes, P. Azevedo, M. Oliveira, D. Bento, J. Guedes, B. Marmelo, R. Faria, E. Correia (Portugal) 232 GENETIC VARIANTS OF ABO BLOOD GROUP WITH CORONARY ARTERY DISEASE AMONGST INDIANS 1062 P. Chawla, T. Ashavaid, C. Ponde, R. Rajani, A. Deshpande, R. Sawant (India) 234 NFE2L2 RS CC GENOTYPE SIGNIFICANTLY INCREASED THE RISK OF CARDIOVASCULAR DISEASE: A CASE-CONTROL STUDY IN AN ARSENIASIS-ENDEMIC AREA IN TAIWAN 1064 T. Chia-Yin, C. Hung-Yi, H. Fang-I (Taiwan) 235 THE GG GENOTYPE OF VITAMIN D METABOLISM-RELATED GENE DHCR7 rs IS MORE PREVALENT IN THE INDIANS AND ASSOCIATED WITH HIGHER OXIDATIVE STRESS INDEX IN SINGAPORE 1065 R. Dalan, H. Liew, L.L. Goh, X. Gao, D. Chew, B.O. Boehm (Singapore) 236 ASSOCIATION OF THE HETEROPLASMY LEVEL OF MUTATION IN GENE MT-CYB WITH CAROTID ATHEROSCLEROSIS IN WOMEN 1066 V. Sinyov, M. Sazonova, M. Chicheva, N. Nikitina, I. Sobenin, A. Orekhov (Russia) 237 SINGLE NUCLEOTIDE POLYMORPHISMS AT THE HYDROXY-METHYL- GLUTARYL-COA REDUCTASE GENE LOCUS SIGNIFICANTLY PREDICT CARDIOVASCULAR EVENTS IN CORONARY PATIENTS WITH TYPE 2 DIABETES 1067 A. Leiherer, A. Muendlein, C. Saely, E. Kinz, P. Rein, A. Vonbank, P. Fraunberger, H. Drexel (Austria) 238 Rs MARKER AT THE MTHFD1L GENE PREDICT CARDIOVASCULAR MORTALITY IN MALES AFTER ACUTE CORONARY SYNDROME 1068 J. Hubacek, V. Stanek, R. Poledne, V. Adamkova, J. Pitha (Czech Republic) 239 PHENOTYPE OF VULNERABLE ATHEROSCLEROTIC PLAQUES SHOWS STRONG ASSOCIATION WITH SINGLE NUCLEOTIDE POLYMORPHISM ALLELES OF COMMON RISK VARIANTS FOR CORONARY ARTERY DISEASE 1069 R. Furtmair, C. Kuehn, C. König, A. Ekici, L. Klinghammer, S. Achenbach, A. Reis, M. Tauchi, B. Dietel (Germany) 240 GENETIC DETERMINATION OF THE ATHEROSCLEROTIC PLAQUE STABILITY 1070 I. Goncharova, M. Golubenko, O. Makeeva, V. Kashtalap, N. Tarasenko, A. Markov, V. Puzyrev (Russia) 241 MAY THE TRANSCRIPTIONAL ACTIVITY OF TRANSFORMING GROWTH FACTOR BETA 1 GENE BE A MARKER FOR EARLY STAGES FOR CORONARY ATHEROSCLEROSIS? 1071 J. Dąbek, M. Bałys, J. Piotrkowicz, J. Głogowska-Ligus, Z. Gąsior (Poland) 242 ASSOCIATION OF SERUM CAROTENOID CONCENTRATION WITH SINGLE NUCLEOTIDE POLYMORPHISMS IN APOE, BCMO1, NPC1L1, CD36, GSTP1, ABCG5, FABP1, FABP2 AND LIPC GENES 1072 A. Mazeikiene, D. Karciauskaite, N. Burokiene, Z. Daunoravicius, Z.A. Kucinskiene, V. Kucinskas (Lithuania) 233 GPER P.P16L POLYMORPHISM IS NOT ASSOCIATED WITH ALTERED LIPID PHENOTYPES AND CIMT PROGRESSION- A PLIC STUDY 1063 A. Dhyani, A. Baragetti, K. Garlaschelli, F. Pellegatta, L. Grigore, D. G.Norata, A.L. Catapano (Italy) 243 A TOOL FOR QUANTITATIVE MEASUREMENT OF PROATHEROGENIC HETEROPLASMIC MUTATIONS OF MITOCHONDRIAL DNA 1073 I. Sobenin, K. Mitrofanov, A. Orekhov (Russia)

84 Poster Walks tuesday 244 CREATION OF CYBRID LINES OF MONOCYTE ORIGIN WITH HIGH HETEROPLASMY LEVEL FOR MITOCHONDRIAL GENOME MUTATION M.1555G>A 1074 M. Sazonova, V. Sinyov, A. Ryzhkova, T. Shkurat, N. Demakova, N. Nikitina, I. Sobenin, A. Orekhov (Russia) 245 DETECTION OF THRESHOLD HETEROPLASMY LEVEL OF mtdna IN LYPOFIBROUS PLAQUES OF HUMAN AORTIC INTIMA 1075 A. Ryzhkova, M. Sazonova, V. Sinyov, E. Galitsyna, V. Barinova, N. Nikitina, I. Sobenin, A. Orekhov (Russia) 246 PROATHEROGENIC MUTATIONS OF MITOCHONDRIAL DNA IN PATIENTS WITH METABOLIC SYNDROME 1076 I. Sobenin, M. Sazonova, V. Orekhova, A. Zhelankin, A. Orekhov, A. Postnov (Russia) 247 MITOCHONDRIAL DNA MUTATIONS ASSOCIATED WITH CAROTID ATHEROSCLEROSIS: NGS DATA 1077 I. Sobenin, A. Zhelankin, Z. Khasanova, V. Orekhova, A. Orekhov, A. Postnov (Russia) 248 ROLES OF ORPHAN NUCLEAR RECEPTORS IN CARDIAC HYPERTROPHY 1078 G.H. Eom, D.H. Kwon, S. Shin, Y.U. Lee, E. Kim, N. Choe, Y.S. Nam, H. Kook (Republic of Korea) 249 ROLE OF GENETIC POLYMORPHISMS AT THE ADIPONECTIN GENE IN REGULATION OF ADIPONECTIN GENE EXPRESSION AND CIRCULATING ADIPONECTIN LEVELS 1079 L. Kedenko, W. Patsch, I. Kedenko, S.M. Patsch, S. Coassin, F. Kronenberg, F. Krempler, B. Paulweber, C. Lamina (Austria) 250 LOW LDL-CHOLESTEROL, PCSK9 AND HMGCR GENETIC VARIATION, AND RISK OF NEURODEGENERATIVE DISEASE: A MENDELIAN RANDOMIZATION STUDY 1080 M. Benn, B. Nordestgaard, R. Frikke-Schmidt, A. Tybjærg-Hansen (Denmark) 251 RELATIONSHIP BETWEEN CIRCULATING microrna-30c WITH LIPOPROTEINS, THEIR CIRCULATORY TRAFFICKING AND EFFECT OF STATINS 1081 R. Sodi, J. Eastwood, L. Denby, I. Godber, M. Caslake, C.J. Packard (United Kingdom) 252 HYPERGLYCEMIA INCREASES MICRORNAS IN CIRCULATING HDL FROM ACUTE CORONARY SYNDROME PATIENTS AND MODULATES MIRNA PROCESSING MACHINERY IN HUMAN MACROPHAGES 1082 L.S. Niculescu, N. Simionescu, G.M. Sanda, M.G. Carnuta, C.S. Stancu, A.C. Popescu, R.M. Popescu, A. Vlad, D.R. Dimulescu, M. Simionescu, A.V. Sima (Romania) 253 IS PLASMA MICRORNA p A NEW POTENTIAL BIOMARKER FOR ACUTE MYOCARDIAL INFARCTION 1083 E. Coskunpinar, H.A. Cakmak, A.K. Kalkan, N. Ozan Tiryakioglu, T. Araz, Z. Ongen (Turkey) 254 DOES THE GENE EXPRESSION OF NUCLEAR FACTOR KAPPA B IN PATIENTS WITH EARLY STAGES OF CORONARY ATHEROSCLEROSIS DIFFERS FROM HEALTHY INDIVIDUALS 1084 J. Dąbek, M. Bałys, J. Głogowska-Ligus, J. Piotrkowicz, Z. Gąsior (Poland) 255 ENDOTOXIN STRESS-INDUCED APOLIPOPROTEIN E GENE DOWNREGULATION IN MACROPHAGES IS REDUCED BY METFORMIN 1085 E.V. Fuior, S. Stavri, V.G. Trusca, I.F. Tudorache, M. Simionescu, D. Kardassis, A.V. Gafencu (Romania) 256 DNA METHYLATION AND COPY NUMBER EVENTS IN ATHEROSCLEROTIC LESIONS 1086 M. Nazarenko, A. Markov, A. Sleptcov, I. Lebedev, N. Skryabin, O. Barbarash, V. Puzyrev (Russia) 257 GENE THERAPY: CASE STUDY ON THE FIRST LIPOPROTEIN LIPASE DEFICIENCY PATIENT TREATED WITH ALIPOGENE TIPARVOVEC IN GERMANY 1087 U. Kassner, T. Hollstein, M. Wühle-Demuth, I. Demuth, E. Steinhagen- Thiessen (Germany) 258 MAJOR ADIPOKINES AND -420 C>G RESISTIN GENE POLYMORPHISHM AS PREDICTORS OF ACUTE ISCHEMIC STROKE SEVERITY AND IN-HOSPITAL OUTCOME 1088 S. Bouziana, K. Tziomalos, A. Goulas, T.A. Vyzantiadis, A. Panderi, A. Hatzitolios (Greece) 259 PPAR-ALPHA GENE HAPLOTYPES, ARSENIC EXPOSURE AND RISK OF CARDIOVASCULAR DISEASE 1089 F.I. Hsieh, S.H. Lin, C.F. Huang, H.Y. Chiou (Taiwan) Genetics, Nutrition, Biomarkers: Nutrition 260 ABNORMAL BALGHAM MUNZIQ, A UIGHUR HERBAL MEDICINE FORMULA, HAS BEEN RECENTLY SHOWN TO POSSESS EXTENSIVE CARDIOVASCULAR PHARMACOLOGICAL ACTIVITIES 1090 D. Xilifu, A. Nurmuhammat, U. Halmurat (China) 261 EFFECTS OF RAMADAN FASTING ON BIOLOGICAL PARAMETERS IN PATIENTS WITH CARDIOVASCULAR RISK FACTORS 1091 K. Bouzid, W. Hmaidi, Y. Molahedh, H. Ben Ahmed, A. Bartkiz, H. Baccar, J. Abdelmoula (Tunisia)

85 Poster Walks tuesday 262 INCREASING ADHERENCE OF CONSUMERS TO DIET & LIFESTYLE CHANGES TO LOWER (LDL) CHOLESTEROL: THE ACT STUDY 1092 T.E. SIALVERA, P. Farajian, E.A. Trautwein, A. Papadopoulou, S. Efstathiou, G. Goumas, I. Dimakopoulos, K. Papavasiliou, A. Koutsouri, A. Zampelas (Greece) 263 NUTRITIONAL MODULATION OF THE TOXICITY OF ENVIRONMENTAL POLLUTANTS: IMPLICATIONS IN ATHEROSCLEROSIS 1093 B. Hennig, M. Petriello (USA) 264 DIETARY POLYUNSATURATED FATTY ACID AND FRAMINGHAM RISK SCORE : ANALYSIS OF THE KOREA NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (KNHAENS 2013) 1094 N.S. Joo, B. Choi, S.I. Jung (Republic of Korea) 265 VITAMIN D STATUS AND BIOMARKERS OF ENDOTHELIAL ACTIVATION IN OBESE INDIVIDUALS 1095 B. Ilincic, E. Stokic, M. Djeric, N. Eremic, D. Popovic, Z. Stosic (Serbia) 266 EFFECTS OF VITAMIN E OR LIPOIC ACID SUPPLEMENTATION ON FASTING OXYPHYTOSTEROL CONCENTRATIONS IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE OR TYPE II DIABETES 1096 S. Baumgartner, R.P. Mensink, G. Haenen, A. Bast, C. Binder, O. Bekers, C. Husche, D. Lütjohann, J. Plat (Netherlands) 267 EFFECTIVENESS OF A LOW GLYCEMIC INDEX SOLUBLE PLANT POWDER, AS A LOW-CALORIE REPLACEMENT MEAL, IN OVERWEIGHT AND OBESE PATIENTS 1097 R. Volpe, A. Bianco, F. Pacioni, E. Schiavetto (Italy) 268 SUSTAINED NUTRITIONAL COUNSELING IMPROVES DIETARY INTAKE IN PARENTS AND THEIR CHILDREN OVER 5 YEARS: THE PEP FAMILY HEART STUDY 1098 P. Schwandt, E. Liepold, M. Heinzel-Gutenbrunner, T. Bertsch, G.M. Haas (Germany) 269 SPANISH OBESE CHILDREN AND BIOCHEMICAL PARAMETERS : NON- HEALTHY NUTRITIVE PATTERNS 1099 C. Rodriguez-Leal, B. Ruiz-Estevez, E. Segura, I. Tinoco-Racero, N. Caro, C. Perez, I. Garcia-Campanario, A. Perez, M. Quezada-Feijoo, A. Mangas, R. Toro (Spain) 270 LONG-TERM MAGNESIUM SUPPLEMENTATION IMPROVES ARTERIAL STIFFNESS IN OVERWEIGHT AND OBESE ADULTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INTERVENTION STUDY 1100 P.J. Joris, J. Plat, S.J.L. Bakker, R.P. Mensink (Netherlands) 271 THIRTEEN YEAR FOLLOWUP OF MANAGING PATIENTS WITH KNOWN CORONARY ARTERY DISEASE USING A LECTIN-LIMITED, HIGH DOSE OLIVE OIL AND POLYPHENOL RICH DIET 1101 S. Gundry, J. Epstein (USA) 272 SERUM CONTENT OF OLEIC ACID IS ASSOCIATED WITH HIGHER PLATELET-, ENDOTHELIAL- AND LEUKOCYTE-DERIVED CIRCULATING MICROPARTICLES IN NORWEGIAN NORMOLIPIDEMIC ELDERLY PATIENTS AFTER AN ACUTE MYOCARDIAL INFARCTION 1102 G. Chiva-Blanch, V. Bratseth, K. Laake, P. Myhre, H. Arnesen, S. Solheim, E. Berg-Schmidt, L. Badimon, I. Seljeflot (Spain) 273 PLANT STANOL SUPPLEMENTATION LOWERS CETP-MASS, BUT NOT CETP-ACTIVITY, IN HEALTHY SUBJECTS 1103 C. Talbot, J. Plat, A. Ritsch, R. Mensink (Netherlands) 274 PLASMA FAT-SOLUBLE VITAMIN AND CAROTENOID CONCENTRATIONS AFTER PLANT STEROL AND PLANT STANOL ESTER CONSUMPTION A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS 1104 S. Baumgartner, R. Ras, E. Trautwein, R.P. Mensink, J. Plat (Netherlands) 275 HAZELNUT-ENRICHED DIET IMPROVES LIPID PROFILE, FATTY ACID COMPOSITION OF ERYTHROCYTES MEMBRANE AND MARKERS OF OXIDATIVE STRESS IN CHILDREN WITH PRIMARY DYSLIPIDEMIA: A RANDOMIZED CONTROL TRIAL 1105 V. Deon, C. Del Bo', A. Bosusco, S. Vendrame, M. Porrini, P. Simonetti, O. Guardamagna, P. Riso (Italy) 276 PLASMA PLANT STEROLS AND PLANT STEROL INTAKE VARY ACROSS PLANT-BASED DIETARY PATTERNS AMONG ADULTS FROM NORTH AMERICA 1106 D. Luetjohann, K. Jaceldo-Siegl, R. Sirirat, E. Haddad (Germany) 277 LOW-FAT DIETARY TREATMENT ENRICHED WITH SOY PROTEIN IN CHILDREN AFFECTED WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM A RANDOMIZED- CONTROLLED PILOT STUDY 1107 O. Helk, K. Widhalm (Austria) 278 ANGIOGRAPHIC AND ANTIOXIDANT CHANGES AFTER SUPPLEMENTATION WITH HERACLEUM PERSICUM EXTRACT: RESULTS OF A RANDOMIZED CONTROLLED TRIAL 1108 A. Sahebkar, Y. Panahi, H. Taghipour (Iran) 279 DO DIET AND EXERCISE INFLUENCE IN AN ATHLETIC POPULATION?: NEW CLUES OF THE ENTERO-INSULAR AXIS 1109 C. Rodriguez-Leal, V. Aragon, I. Tinoco-Racero, E. Segura, B. Ruiz-estevez, E. Sanchez-Orellana, C. Perez, M. Monsalvo Hernando, N. Caro, A. Perez, I. Garcia-Campanario, A. Mangas, R. Toro (Spain) 280 EVALUATION OF ACTUAL CONSUMPTION OF PULSE REDUCING DRUGS IN PATIENTS AFTER ACUTE CORONARY SYNDROME 1110 T. Chudinovskikh, E. Tarlovskaya (Russia)

86 Poster Walks tuesday 281 EFFECTS OF RAMADAN FASTING ON CLINICAL AND BIOCHEMICAL PARAMETERS FOR TYPE 2 DIABETICS 1111 K. Bouzid, Y. Molahedh, W. Hmaidi, N. Mchirgui, A. Bartkiz, E. Talbi, N. Ben Abdallah, A. Bahlous, J. Abdelmoula (Tunisia) 282 COMPARISON OF EFFECTS OF DIABETIC ENTERAL NUTRITION AND STANDARD ENTERAL NUTRITION ON POSTPRANDIAL LEVEL OF GLYCEMIA, FREE FATTY ACIDS AND GLUCAGON-LIKE PEPTIDE J. Visek, A. Ticha, L. Sobotka, V. Blaha (Czech Republic) 283 REGULATION OF HYPOTHALAMIC GENE EXPRESSION BY DNA METHYLATION IS INFLUENCED BY PARENTAL DIET DURING PREGNANCY AND LINKED TO OFFSPRING'S RISK OF OBESITY 1113 I. Khurana, A. Kaspi, M. Ziemann, T. Block, T. Connor, B. Spolding, A. Cooper, P. Zimmet, A. El-Osta, K. Walder (Australia) 284 INORGANIC NITRATE DOES NOT AFFECT GLUCOSE AND INSULIN REGULATION BUT LOWERS OXIDATIVE STRESS IN OBESE ADULTS DURING ACUTE HYPERGLYCAEMIA 1114 A. Ashor (United Kingdom) 285 EFFECT OF DIFFERENT ORAL GLUCOSE LOADS ON THE ANTIOXIDANT, INFLAMMATORY AND PLATELET RESPONSE OF HEALTHY VOLUNTEERS 1115 A. Mikellidi, D. Papadopoulou - Pozatzidou, E. Bachti, C. Xenaki, S. Antonopoulou, C. Demopoulos, T. Nomikos (Greece) 286 INCREASED BILE ACID AND CHOLESTEROL SYNTHESES AND PCSK9 IN MORBID OBESITY ARE RAPIDLY NORMALIZED FOLLOWING ACUTE CALORIC RESTRICTION 1116 S. Straniero, F. Rosqvist, D. Edholm, M. Sundbom, U. Risérus, M. Rudling (Sweden) 287 SUPPRESSION OF DNA DAMAGE BY DIETARY SUPPLEMENT WHICH CONTAINS PLANT EXTRACTS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL 1117 L. Gavriil, C. Argyrou, I. Malagaris, E. Fragopoulou (Greece) 288 IMPACT OF OIL AND PROTEINS DERIVED FROM ANTARCTIC KRILL ON ATHEROSCLEROSIS DEVELOPMENT IN APOEKO MICE 1118 C. Parolini, F. Dellera, G.S. Ganzetti, S. Manzini, M. Busnelli, M.S. Ramsvik, B. Bjorndal, I. Bruheim, R.K. Berge, G. Chiesa (Italy) 291 ENDOTOXIN AND OMEGA-3 FATTY ACIDS EFFECTS ON ENDOTHELIAL OCCLUDIN EXPRESSION IN RAT HEART 1121 J. Dienova, K. Frimmel, L. Okruhlicova (Slovakia) 292 LOW-SALT DIET INDUCES ATHEROSCLEROSIS INDEPENDENT OF LOWERING BLOOD PRESSURE IN HYPERTENSIVE MICE 1122 S. Catanozi, F. Fusco, D. Gomes, K. Bispo, V. Toledo, D. Barbeiro, V. Capelozzi, L. Furukawa, A.P. Velosa, W. Teodoro, J. Heimann, E. Quintao, M. Passarelli, E. Nakandakare (Brazil) 293 LIQUID FRUCTOSE SUPPLEMENTATION IN WESTERN DIET-FED C57BL/6N MICE CAUSES LIVER CHOLESTEROL LOADING WITHOUT CHANGING CALORIE INTAKE AND BODY WEIGHT 1123 M. Baena, G. Sangüesa, M. González, M. Alegret, N. Roglans, J.C. Laguna (Spain) 294 THE IMPACT OF DIETARY SUPPLEMENTATION OF VERNONIA CALVOANA LEAVES ON SERUM LIPID PROFILE AND HAEMATOLOGICAL INDICES IN ALBINO WISTAR RATS 1124 G. Egbung, I. Atangwho (Nigeria) 295 FERULIC ACID FROM RICE BRAN ENZYMATIC EXTRACT IS RESPONSIBLE FOR ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITIES 1125 C. Perez Ternero, B. Bermudez Pulgarin, A. Macia, M.J. Motilva, M.D. Herrera, M. Alvarez de Sotomayor (Spain) 296 POTENTIAL PROTECTIVE EFFECTS OF DUNALIELLA SALINA ON DEHP- INDUCED MMP-2 AND MMP-9 EXPRESSION VIA MAPK, ERK1/2, AKT, AND NF-κB PATHWAYS IN VASCULAR SMOOTH MUSCLE CELLS 1126 M.F. Shih, J.Y. Cherng (Taiwan) 297 RiBOSE-CYSTEINE INCREASES GLUTATHIONE-BASED ANTIOXIDANT STATUS AND REDUCES ATHEROSCLEROSIS IN apoe-deficient MICE 1127 S. McCormick, T. Kader, C. Porteous, G. Jones, N. Dickerhof (New Zealand) 298 ANTIPLATELET EFFECT OF THE MAIN TRITERPENOIDS OF AN OLIVE LEAF EXTRACT 1128 M. Tsoumani, V. Kontogianni, T. Kellici, T. Mavromoustakos, I. Gerothanassis, A. Tzakos, A. Tselepis (Greece) 289 INVESTIGATION OF CHIOS MASTIC GUM EFFECT ON METABOLIC PROFILE IN STREPTOZOTOCIN-INDUCED DIABETIC MICE 1119 A. Tzani, I. Georgiadis, L.M. Korou, P. Konstantopoulos, G. Agrogiannis, I. Vlachos, I. Doulamis, N. Katsilambros, D. Perrea (Greece) 290 ANTI-HYPERLIPIDEMIC POTENTIAL OF EMBLICA OFFICINALIS IN HIGH FAT FED RATS: UP-REGULATION OF PPARS 1120 B. Variya, S. Patel, A. Bakrania (India)

87 Poster Walks tuesday Genetics, Nutrition, Biomarkers: Biomarkers 299 URINARY LIVER-TYPE FATTY ACID-BINDING PROTEIN IS ASSOCIATED WITH AORTIC STIFFNESS IN MALE CORONARY ARTERY DISEASE PATIENTS 1129 K. Paapstel, M. Zilmer, J. Eha, K. Tootsi, A. Piir, J. Kals (Estonia) 300 IMPACT OF ALKALINE PHOSPHATASE ON IN-HOSPITAL MORTALITY AND 1-YEAR CLINICAL OUTCOME IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERWENT PRIMARY PERCUTANEOUS CORONARY INTERVENTION 1130 P.C. Oh, K. Woong Chol, M. Jeonggeun, S. Jon, P. Hyun Woo, J. Ho-Jun, K. Tae-Hoon, P. Sang-Don, K. Sung Woo, S. Soon Yong, L. Kyounghoon, H. Seung Hwan, A. Taehoon, S. Eak Kyun (Republic of Korea) 301 THE GENERATION OF MALONDIALDEHYDE-POSITIVE MICROVESICLES 1131 F. Puhm, T. Afonyushkin, C. Binder (Austria) 302 LEUKOARAIOSIS IS UNRELATED TO CAROTID STENOSIS OR RISK FACTORS FOR ATHEROSCLEROSIS 1132 B. Muinjonov, E. Giyazitdinova (Uzbekistan) 303 VARIABILITY AND TEMPORAL TREND OF VICORDER-ESTIMATED PULSE WAVE VELOCITY 1133 A.K. Mistri, P. Connell, T. Robinson (United Kingdom) 304 EVALUATION OF OXIDATIVE STRESS INDEX AND ITS CORRELATION WITH TRADITIONAL CARDIOVASCULAR RISK FACTORS, INFLAMMATION AND CAROTID INTIMA MEDIA THICKNESS IN DIABETES AND HEALTHY SUBJECTS 1134 R. Dalan, H. Liew, L.L. Goh, X. Gao, D.E. Chew, B.O. Boehm, M.K.S. Leow (Singapore) 305 PLASMA ARGININE/ADMA RATIO IS A SENSITIVE RISK MARKER FOR ATHEROSCLEROSIS: SHIMANE CoHRE STUDY 1135 S. Yano, Y. Notsu, A. Nagai, T. Nabika (Japan) 306 THE ALANINE AMINOTRANSFERASE/ ASPARTATE AMINOTRANSFERASE RATIO PREDICTS FUTURE CARDIOVASCULAR EVENTS IN PATIENTS WITH ESTABLISHED CORONARY ARTERY DISEASE AND HOMA INSULIN RESISTANCE 1136 A. Vonbank, C. Saely, P. Rein, D. Zanolin, A. Leiherer, H. Drexel (Austria) 307 IMPACT OF AGE ON THE CARDIOVASCULAR EVENT RISK CONFERRED BY HbA1c IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE 1137 A. Vonbank, C. Saely, D. Zanolin, P. Rein, A. Leiherer, H. Drexel (Austria) 308 ProBNP STRONGLY PREDICTS FUTURE MACROVASCULAR EVENTS IN ANGIOGRAPHIED CORONARY PATIENTS WITH AS WELL AS IN THOSE WITHOUT TYPE 2 DIABETES 1138 P. Rein, C. Saely, A. Vonbank, D. Zanolin, A. Leiherer, H. Drexel (Austria) 309 THE LEVEL OF EOSINOPHIL CATIONIC PROTEIN IS CORRELATE WITH SEVERITY OF CORONARY ATEROSCLEROSIS 1139 F. Byazrova, V. Lopukhova, V. Buza, K. Zykov, Y. Karpov (Russia) 310 SIMPLE MORTALITY PROGNOSTIC RISK CALCULATOR FOR PATIENTS WITH ACUTE CORONARY SYNDROME 1140 N. Zagidullin, E. Travnikova, B. Zagidullin, R. Zulkarneev, S. Zagidullin (Russia) 311 THE INVERSE ASSOCIATION BETWEEN PLASMA ENDOGLIN LEVELS AND THE SEVERITY OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH STABLE CAD 1141 E. Saita, K. Miura, N. Suzuki, K. Miyata, N. Ikemura, R. Ohmori, Y. Ikegami, Y. Kishimoto, K. Kondo, Y. Momiyama (Japan) 312 NITRIC OXIDE-RELATED CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH MAJOR DEPRESSION 1142 A. Meinitzer, S. Zelzer, H. Mangge, G. Almer, R. Prassl, O. Amouzadeh- Ghadikolai, C. Robier, A. Baranyi (Austria) 313 BRANCHED-CHAIN AMINO ACID PROFILES INDICATE CARDIO METABOLIC RISK INDEPENDENT OF BODY MASS INDEX 1143 S. Zelzer, A. Meinitzer, D. Enko, G. Almer, R. Prassl, H. Mangge (Austria) 314 STATUS OF NOVEL CARDIOVASCULAR RISK FACTOR AND CARDIOVASCULAR DISEASE RISK IN AN URBAN DELHI POPULATION-A PILOT STUDY 1144 V. Sharma, R. Shahrawat (India) 315 THE ATHEROGENIC PROFILE PREDOMINANT LIPOPROTEIN PROFILE IN CARDIOVASCULAR DISEASE 1145 S. Prof. Dr. Oravec, K. Dr. Gruber, A. Prof. Dr. Dukat, P. Ass. Prof. Gavornik, L. Ass. Prof. Gaspar, E. Dr. Dostal (Slovakia) 316 IMPACT OF NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AND NEUTROPHIL COUNTS IN THE LUDWIGSHAFEN RISK AND CARDIOVASCULART HEALTH STUDY 1146 R. Woitas, H. Scharnagl, M.E. Kleber, G.E. Delgado, T.B. Grammer, M. Pichler, B.K. Krämer, W. März, T. Stojakovic (Austria) 317 INCREASED LEVELS OF YKL-40 ARE ASSOCIATED WITH ALL-CAUSE MORTALITY IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE 1147 C.T. Herz, M.L. Tscharre, C. Höbaus, G. Pesau, F. Obendorf, R. Koppensteiner, G.H. Schernthaner (Austria) 318 RELATIONSHIP OF INFLAMMATORY BIOMARKERS, PTX3 WITH SEVERITY OF PERIPHERAL ARTERIAL DISEASE 1148 K. Igari (Japan)

88 Poster Walks tuesday 319 GALECTIN 3 AND THE REMODELING OF ARTERIAL WALL IN PATIENTS WITH METABOLIC SYNDROME 1149 V. Ionin, D. Brovin, E. Bazhenova, T. Karonova, E. Polyakova, O. Belyaeva, E. Baranova, E. Shlyachto (Russia) 320 RELATION OF PLASMA COPEPTIN LEVELS AND WAIST CIRCUMFERENCE IN NON-DİABETIC ACUTE ST-SEGMENT ELEVATION MYOCARDİAL INFARCTION PATIENTS 1150 K. Cosansu, A. Turer Cabbar, H.A. Cakmak (Turkey) 321 CORRELATION OF PIGMENT EPITHELIUM-DERIVED FACTOR WITH OXIDATIVE AND INFLAMMATORY MARKERS IN OBESE, NON-DIABETIC PATIENTS 1151 I. Juhász, I. Seres, A. Szentpéteri, E.V. Varga, S. Somodi, P. Fülöp, H. Lőrincz, G. Paragh (Hungary) 322 AORTIC VALVE STENOSIS IN ASSOCIATION WITH INFLAMMATORY PROCESS AND BIOCHEMICAL MARKERS J. Lūriņš, A. Visocka, V. Mackēvičs, P. Tretjakovs (Latvia) 323 ASSOCIATIONS OF LIPOCALIN 2 WITH MARKERS OF INFLAMMATION AND OXIDANT STATUS IN OBESE NON-DIABETIC PATIENTS 1153 P. Fülöp, H. Lőrincz, S. Somodi, M. Harangi, I. Seres, G. Paragh (Hungary) 324 FIRST TRIMESTER SERUM CONCENTRATIONS OF AFAMIN ARE ASSOCIATED WITH THE DEVELOPMENT OF PREECLAMPSIA AND GESTATIONAL DIABETES MELLITUS IN PREGNANT WOMEN 1154 A. Tramontana, B. Dieplinger, G. Stangl, E. Hafner, H. Dieplinger (Austria) 325 IS RED BLOOD CELL GLUTATHIONE A BETTER MARKER FOR CORONARY ARTERY DISEASE THAN PLASMA GLUTATHIONE? 1155 A. Lima, R. Ferin, E. Santos, A. Fontes, S. Ferreira, C. Almeida, D. Martins, J. Baptista, M.L. Pavão (Portugal) 326 CHANGES BRAIN NATRIURETIC PEPTIDE (BNP) LEVELS IMPROVE RISK PREDICTION OF SHORT-TERM MORTALITY FOLLOWING ACUTE MYOCARDIAL INFARCTION COMPARED TO GRACE SCORE: A BRASILIA HEART STUDY SUBANALYSIS 1156 L.S. Carvalho, L.A. Bogniotti, O.L. Almeida, J.C. Quinaglia e Silva, L. Trindade, G. Oliveira, A. Sposito (Brazil) 327 GENETIC DETERMINANTS CONTROLLING LIPID DEPOSITS IN DIFFERENT WILD TYPE STRAINS OF ZEBRAFISH (DANIO RERIO) 1157 K. Vishnolia, K. Tarhbalouti, P. Ciba, C. Kruse, Z. Aherrahrou, J. Erdmann (Germany) 328 CELL-DERIVED MICROPARTICLES AS MARKERS OF ENDOTHELIAL FUNCTION, INFLAMMATION AND COAGULATION IN PATIENTS WITH SLEEP APNEA-HYPOPNEA SYNDROME: A SYSTEMATIC REVIEW 1158 A.J. Vallejo-Vaz, R. Muñoz-Hernández, J. Villar, P. Stiefel (United Kingdom) 329 ANTIOXIDANT ENZYMES IN PATIENTS WITH ATHEROSCLEROSIS 1159 J. Bogdanska, D. Labudovic, S. Alabakovska, S. Cekovska, K. Tosheska Trajkovska, S. Jovanova (FYR Macedonia) 330 THE NUMBER OF REQUESTS FOR HIGH SENSITIVE TROPONIN I MEASUREMENT AND THE NUMBER OF PATIENTS DIAGNOSED WITH ACUTE MYOCARDIAL INFARCTION 1160 L. Majnaric, M. Mikic, S. Bekic, S. Guljas (Croatia) 331 CAROTID ATHEROSCLEROSIS IN A VERY ELDERLY POPULATION: ROLE OF AGEING AND OTHER CARDIOVASCULAR RISK FACTORS 1161 F. Spannella, F. Giulietti, G. Cocci, P. Giordano, M. Ricci, E. Espinosa, R. Sarzani (Italy) 332 BIOMARKER DISCOVERY BY PLASMA PROTEOMICS IN FAMILIAL LMNA DILATED CARDIOMYOPATHY 1162 I. Izquierdo, D. De Gonzalo-Calvo, V. Llorente-Cortes, I. Rosa, R. Brugada, C. Oscar, A. Perez-Serra, J. Broncano, A. Luna, J. Vazquez-Alfageme, J.R. Gonzalez-Juanatey, A. Mangas, A. Garcia, R. Toro (Spain) 333 BLOOD PRESSURE FLUCTUATIONS AS A LEADING LINK IN THE DEVELOPMENT OF COMPLICATIONS OF ATHEROSCLEROSIS 1163 A. Kebryakov, P. Bondarenko, M. Ermina, M. Ivanov, N. Koplyarova, A. Yadernaya, A. Mishchenko (Russia) Genetics, Nutrition, Biomarkers: Guidelines and Miscellaneous 334 ACC/AHA GUIDELINES SUPERIOR TO ESC/EAS GUIDELINES FOR PRIMARY PREVENTION WITH STATINS: THE COPENHAGEN GENERAL POPULATION STUDY 1164 M.B. Mortensen, B.G. Nordestgaard, S. Afzal, E. Falk (Denmark) 335 PREDICTING THE IMPACT OF THE ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS FOR SECONDARY PREVENTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE 1165 A. Merezhanova, E. Tarlovskaya, B. Nechaeva, A. Semenkin, S. Malchikova (Russia) 336 APPLICATION OF A MULTILEVEL HIERARCHICAL MODEL TO CORRELATE TOTAL CHOLESTEROL IN EIGHT DIFFERENT SETTINGS 1166 A. Pereira, F. Guarnieri, A.P.Q. Mello, R. Santos Filho, T.L.R. Martinez (Brazil) 337 PROPOSAL OF A NEW APPROACH TO ACCESS CHOLESTEROL RANGES ACCORDING TO DIFFERENT CONDITIONS 1167 A. Pereira, F. Guarnieri, A.P.Q. Mello, R. Santos Filho, T.L.R. Martinez (Brazil)

89 Poster Walks tuesday 338 PREDICTING FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS QUALITY OF LIFE AND SELF-ASSESSED HEALTH: ILLNESS BELIEFS, BELIEFS ABOUT MEDICATION, AND HEALTH LITERACY 1168 M. Hagger, J. Pang, G.F. Watts (Australia) 339 METABOLIC DISTURBANCES AND RISK OF CANCER IN THE 25 YEARS FOLLOW-UP OF THE "VENTIMIGLIA HEART STUDY" EPIDEMIOLOGICAL PROJECT D. Noto, A.B. Cefalù, C.M. Barbagallo, A. Giammanco, F. Fayer, O. Palesano, G.I. Altieri, R. Spina, V. Valenti, M. Pagano, G. Cavera, M.R. Averna (Italy) 340 ESTRADIOL TREATMENTS CHANGE THE LIPID PROFILE IN NATURALLY MENOPAUSAL RATS FROM DIFFERENT AGE GROUPS: A THERAPEUTIC POTENTIAL DRUG FOR ATHEROSCLEROSIS 1170 P. Kumar, N. Baquer (India) 341 HYPONATREMIA : A RISK FACTOR OF OVERT HEPATIC ENCEPHALOPATHY 1171 S. Khedher, A. Maoui, K. Bouzid, S. Lahiani, A. Bartkiz, M. Salem, J. Abdelmoula (Tunisia) 342 HYPONATREMIA, A PREDICTING FACTOR OF MORTALITY IN CIRRHOTIC PATIENT 1172 K. Bouzid, S. Khedher, A. Maoui, S. Lahiani, A. Bartkiz, M. Salem, J. Abdelmoula (Tunisia) 343 ANDROGEN-DEPRIVATION THERAPY-INDUCED ATHEROSCLEROSIS IN PROSTATE CANCER: DIFFERENCES BETWEEN GNRH-AGONIST AND ANTAGONIST 1173 W. Duivenvoorden, S. Hopmans, G. Werstuck, J. Pinthus (Canada) 344 RELIABILITY ASSESSMENT OF DETERMINATION OF PROCALCITONIN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS : ABOUT TWO CASES 1174 A. Bartkiz, K. Bouzid, S. Ghezaiel, S. Lahiani, S. Hammami, E. Talbi, A. Zannouri, M. Omrane, S. Barbouche, J. Abdelmoula (Tunisia) Abstract not Registered 400 WHAT WOULD YOU DO IF YOU WERE WITH AN EMBRYO-LIKE GIANT THROMBUS IN THE LEFT VENTRICLE: CASE REPORT 1175 Z. Aktop, E. Coskun (Turkey) 401 RELATIONSHIP BETWEEN CAROTID INTIMA-MEDIA THICKNESS AND THE WEIGHT GAIN 1176 T. Alexescu, I. Cheta, M. Handru, V. Negrean, L. Ciumarnean, I. Para (Romania) 402 EFFECTS OF OSTEOPATHIC MANIPULATIVE TREATMENT ON VASCULAR AND AUTONOMIC FUNCTIONS IN HEART PATIENTS: A RANDOMIZED, CLINICAL TRIAL 1177 F. Amatuzzi, A. Guervazoni, V. Marães, K. Bousquet, F. Stauffer, M.A. Catai, G. Chiappa, S. Thomaz, C. Nakata, R. Jácomo, M. Lucena, G. Cipriano Jr. (Brazil) 403 APPLANATION TONOMETRY PROPOSE DIFFERENT PHYSIOLOGIC MECHANISMS IN CHAGASIC VERSUS ISCHEMIC HEART FAILURE 1178 A. Lima, J. Vilela-Martin, L. Giollo, A.P. Silva, M.E. Otto, S. Marianne, V. Maldaner, G. Chiappa, G. Cipriano, F. Amatuzzi, G. Cipriano Jr (Brazil) 404 PREVALENCE OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AND IMPACT ON ACHIEVEMENT OF LIPID TARGETS DURING CARDIAC PREVENTION AND REHABILITATION PROGRAMMES IN ITALY: THE HEREDITY REGISTRY 1179 M. Ambrosetti, P. Faggiano, P.L. Temporelli, R. Griffo, R. Pedretti (Italy) 405 PEDIATRIC IMT ASSESSMENT 1180 E. Barabesi, O. Guardamagna, F. Abello (Italy) 406 RISK FACTORS FOR DEVELOPING DRUG-RELATED PROBLEMS IN PATIENTS WITH CARDIOVASCULAR DISEASES ATTENDING GONDAR UNIVERSITY HOSPITAL, ETHIOPIA 1181 A. Bhagavathula, O. Abubeker, A. Elnour, A. Shehab (Ethiopia) 407 CLINICAL UTILITY OF DABIGATRAN IN UNITED ARAB EMIRATES. A PHARMACOVIGILANCE STUDY 1182 A. Shehab, A. Elnour, A. Bhagavathula, S. Al Nuaimi (United Arab Emirates) 408 A MUFA RICH-DIET MAY REDUCE LIVER FAT CONTENT IN TYPE 2 DIABETES PATIENTS THROUGH AN ENHANCED POSTPRANDIAL FAT OXIDATION 1183 L. Bozzetto, G. Costabile, G. Annuzzi, D. Luongo, D. Naviglio, V. Cicala, M. Giorgini, C. Piantadosi, E. Griffo, P. Cipriano, A. Giacco, A. Rivellese (Italy) 409 AN ASSOCIATION STUDY OF EARLY-LIFE ARSENIC EXPOSURE ON THE RISK OF HYPERTENSION, HYPERGLYCEMIA, AND HYPERLIPIDEMIA 1184 H.Y. Chiou, S.Y. Kuo, F.I. Hsieh (Taiwan)

90 Poster Walks tuesday 410 NOVEL EFFECTS OF SARCOPENIC OSTEOARTHRITIS ON METABOLIC SYNDROME AND INSULIN RESISTANCE: THE NATIONAL SURVEY 1185 S.M. Chung, M.H. Hyun, H.S. Seo, D.J. Oh, C.G. Park, S.W. Rha, E.J. Kim, H.E. Lim, J.W. Kim, C.U. Choi, J.O. Na, S.K. Lee (Republic of Korea) 411 THE EXPRESSION OF MIR-125A-3P IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH CORONARY HEART DISEASE 1186 H.L. Dai, X.L. Yin, J. Xiao, X.F. Guang (China) 412 ENDOTHELIAL VASCULAR MOTOR FUNCTION IN ARTERIAL HYPERTENSIVE PATIENTS 1187 N. Demikhova, O. Chernatskaya, Y. Smiianova, O. Smiianova, L. Vynnychenko (Ukraine) 413 ROSUVASTATIN COMPARED TO ATORVASTATIN ON LIPID PROFILE AND APOLIPOPROTEIN LEVELS IN DYSLIPIDEMIC PATIENTS WITH ELEVATED LIPOPROTEIN (a) 1188 G. Derosa, D. Romano, A. D'Angelo, P. Maffioli (Italy) 414 RESPONSE TO AN ORAL FAT LOAD WITH A NON DAIRY CHEESE CREAM CONTAINING FERMENTED SOYBEAN EXTRACT SOY COMPARED TO A DAIRY CHEESE IN HEALTHY SUBJECTS 1189 G. Derosa, D. Romano, A. D'Angelo, P. Maffioli (Italy) 415 EFFECTS OF A NON DAIRY CHEESE CREAM CONTAINING FERMENTED SOYBEAN EXTRACT ON LIPID PROFILE AND LIPOPROTEINS IN DYSLIPIDEMIC PATIENTS 1190 G. Derosa, D. Romano, A. D'Angelo, P. Maffioli (Italy) 416 EVALUATION OF LIPID-LOWERING THERAPYPREFACINGACUTE CORONARY SYNDROME AND FATSDEPENDING ON CARDIOVASCULARRISK GROUP OF PATIENTS WITH ATRIAL FIBRILLATION 1191 Y. Dorofeeva, E. Tarlovskaya, S. Malcnikova (Russia) 417 RENOPREDICT: MULTIPLE BIOMARKER APPROACH TO IMPROVE THE PREDICTION OF MORTALITY IN DIALYSIS PATIENTS 1192 C. Drechsler, W. März, V. Krane, B. Kollerits, F. Kronenberg, C. Wanner (Germany) 421 ASSOCIATION OF IDEAL CARDIOVASCULAR HEALTH WITH SUBCLINICAL VASCULAR STRUCTURE FUNCTION AND ELASTICITY IN THE COMMUNITY. THE PARIS PROSPECTIVE STUDY B. Gaye, P. Boutouyrie, G. Parati, M.C. Perier, F. Thomas, C. Guibout, B. Pannier, X. Jouent, J.P. Empana (France) 422 CARDIOVASCULAR DISEASE RISK ASSESSMENT: TRIGLYCERIDE/ HIGH-DENSITY LIPOPROTEIN VERSUS METABOLIC SYNDROME CRITERIARUNNING TITLE: CVD RISK ASSESSMENT: TG/HDL VERSUS METS 1197 M. Gharipour, M. Sadeghi, P. Nezafati, N. Sarrafzadegan (Iran) 423 CARDIOVASCULAR RISK IN CHILDREN: THE CLINICAL RELEVANCE OF EARLY AND TIMELY STRATIFICATION AND TREATMENT 1198 I. Gomes, B. Cardoso, P. Loureiro, M. Bourbon, F. Pinto (Portugal) 424 THE MOST COMMON CARDIOVASCULAR RISK FACTORS IN ADOLESCENTS SIGNIFICANT FOR DEVELOPMENT OF CARDIOVASCULAR DISEASES IN ADULTHOOD 1199 G. Grujic Ilic (Serbia) 425 CLINICAL OUTCOMES OF MULTI-VESSEL CORONARY ARTERY SPASM ARE COMPARABLE TO SINGLE VESSEL SPASM ON RECOMMENDED OPTIMAL MEDICAL TREATMENTS: KOREA VASOSPASTIC ANGINA REGISTRY DATA ANALYSIS 1200 S.H. Han, O. Pyoung Chun, S. Dong Il, H. Sung Ho, A. Youngkeun, P. Keun Ho, K. Dong Soo, Y. Tae Hyun, C. Dong Ju, S. Jung Won, K. Hyuck Moon, L. Byoung Kwon, G. Hyeon Gheol, R. Seung Woon, J. Sang Ho, B. Sang Hong (Republic of Korea) 426 ABNORMAL METABOLIC CONDITIONS ARE INDEPENDENT RISK FACTORS FOR INCREASED ARTERIAL STIFFNESS INDEPENDENT OF AGE AND BLOOD PRESSURE 1201 S.H. Han, H. Hyo Sang, O. Pyung Chun, K. Kwang Kwon (Republic of Korea) 427 THE RATIO OF SKELETAL MUSCLE MASS TO VISCERAL FAT AREA IS A MAIN DETERMINANT LINKING CIRCULATING IRISIN TO METABOLIC PHENOTYPE 1202 Y.C. Hwang, P. Cheol-Young, Y. Byung-Soo (Republic of Korea) 418 PROGRANULIN MAY BE A BIOMARKER OF PERIPHERAL ATHEROSCLEROTIC DISEASE 1193 E. El Eter, H. Al Zamil, L. Al Dokhi, M. Al Omran (Egypt) 419 MATERNAL ENDOTHELIUM AND RISKS OF DEVELOPING CARDIOVASCULAR DISORDERS 1194 A. Fatima (Pakistan) 420 RELATIONSHIP BETWEEN THE LOCATION OF LESION AND THE ASSOCIATED ARRHYTHMIAS AND CONDUCTION ABNORMALITIES IN PATIENTS WITH MYOCARDIAL INFARCTION 1195 U. Ganiev, S. Khaitov, M. Kenjaev (Uzbekistan) 428 PLATELET RELEASE REACTIONS ARE MODIFIED IN VITAMIN D DEFICIENCY 1203 L. Kasatkina, I. Trikash (Ukraine) 429 RESPIRATORY FUNCTION OF LUNGS AT ISCHEMIC HEART DISEASE PATIENTS CONCOMITANT WITH TYPE 2 DIABETES MELLITUS 1204 S. Murtazaev, A. Mansurov, N. Sharapov, K. Khalikulov (Uzbekistan) 430 FREQUENCY OF STATIN DOWNTITRATION DURING OPEN LABEL EVOLOCUMAB TREATMENT IN THE OSLER-2 STUDIES 1205 M. Koren, Y. Ma, R. Somaratne, M. Bolognese (USA)

91 Poster Walks tuesday 431 HIGH LYMPHOCYTES AND LOW MEAN CORPUSCULAR VOLUME ARE ASSOCIATED WITH DIABETES, TRIGLYCERIDE-TO-HIGH-DENSITY- LIPOPROTEIN RATIO AND METABOLIC SYNDROME, IN PATIENTS AT HIGH RISK OF CORONARY ARTERY DISEASE 1206 B. LI, I. Trakarnwijitr, H. Adams, J. Layland, J. Garlick, A. Wilson (Australia) 432 NUMBER OF BLOOD PRESSURE MEASUREMENTS NEEDED TO ESTIMATE LONG TERM VISIT-TO-VISIT SYSTOLIC BLOOD PRESSURE VARIABILITY FOR PREDICTING 10-YEAR CARDIOVASCULAR RISK 1207 H.M. Lim, Y.C. Chia, S.M. Ching (Malaysia) 433 PLASMA TRIMETHYLLYSINE, TRIMETHYLAMINE-N-OXIDE, CARNITINE AND INCIDENT MYOCARDIAL INFARCTION IN PATIENTS WITH STABLE ANGINA PECTORIS 1208 K.H. Løland, H. Olset, G.F.T. Svingen, H. Schartum-Hansen, E.K. Pedersen, E. Strand, P.M. Ueland, A. Svardal, Ø. Bleie, J.E. Nordrehaug, O. Nygård (Norway) 434 IMPACT OF INSULIN RESISTANCE ON CARDIAC AND VASCULAR FUNCTION 1209 G. Manno, S. Novo, R. Russo, D. Buccheri, S. Dell'Oglio, P. Morreale, G. Vitale, G. Novo (Italy) 435 ASSOCIATION OF CAROTID ATHEROSCLEROSIS WITH CORONARY ARTERY DISEASE: A RETROSPECTIVE STUDY OF 589 PATIENTS 1210 D. Migliorino, A. Mignano, S. Evola, G. Novo, E. Corrado, S. Novo (Italy) 442 THE ROLE OF TRACKING OF BCL-2 AND CASPASE-3 ACTIVITY IN PLAQUE EVOLUTION IN ISCHEMIC HEART DISEASE PATIENTS 1217 T. Ristic, V. Djordjevic, V. Cosic (Serbia) 443 ASSOCIATION BETWEEN 677C>T POLYMORPHISM WITHIN METHYLENETETRAHYDROFOLATE REDUCTASE GENE AND POSTSTROKE HEMIPARESIS IN POLISH PEDIATRIC PATIENTS 1218 B. Sarecka-Hujar, I. Kopyta, I. Zak, E. Emich-Widera (Poland) 444 CAROTID INTIMAL-MEDIAL THICKNESS,PREVALENCE OF DOCUMENTED CORONARY AND CEREBRAL VASCULAR ATHEROSCLEROTIC DISEASES IN PATIENTS WITH ABDOMINAL AORTIC ANEURISM AND AORTO-ILIAC OCCLUSIVE DISEASE 1219 N. Sharashidze, I. Botchorishvili, Z. Pagava (Georgia) 445 ENDOTHELIAL FUNCTION ASSESSED BY PERIPHERAL ARTERIAL TONOMETRY IS NOT RELATED TO CARDIOVASCULAR RISK SCORE IN HEALTHY SUBJECTS 1220 Y.R. Sigurðardóttir, B.R. Stefánsdóttir, T. Aspelund, G. Þorgeirsson, V. Guðnason, L.B. Kristinsdóttir, K. Andersen (Iceland) 446 ASSESSMENT OF THE RISK OF PERIPHERAL ARTERIAL DISEASE IN PATIENTS WITH CORONARY ARTERY DISEASE 1221 K. Sirojiddin, A. Alavi, M. Kenjaev (Uzbekistan) 436 NIGELLA SATIVA AND THYMOQUINONE REDUCE GENE AND PROTEIN EXPRESSION OF INTERLEUKIN-6 VIA NUCLEAR FACTOR KAPPA B PATHWAY 1211 F. Mohtar, H. Nawawi, T. Rahman, G.R.A. Froemming (Malaysia) 437 OXIDATIVE-ANTIOXIDATIVE CHANGES OF LDL, CORONARY HEART DISEASE, SOME ATHEROSCLEROSIS RISK FACTORS AND 7-YEAR UNFAVORABLE LONG-TERM RESULTS IN MEN POPULATION OF NOVOSIBIRSK 1212 Y. Ragino, Y. Polonskaja, S. Malyutina, M. Voevoda (Russia) 438 ISCHEMIC HEART DISEASE MORTALITY AND ALCOHOL CONSUMPTION IN THE FORMER SOVIET REPUBLICS: A COMPARATIVE ANALYSIS OF TRENDS 1213 Y. Razvodovsky (Belarus) 439 ALCOHOL AND PREMATURE CARDIOVASCULAR MORTALITY IN BELARUS 1214 Y. Razvodovsky (Belarus) 440 LEG MINUS ARM PULSE WAVE VELOCITY MEASURED WITH A NEW DEVICE CORRELATES WITH CAROTID FEMORAL PULSE WAVE VELOCITY 1215 S. Rico Martin, J.F. Sánchez Muñoz-Torrero, J.F. Calderón García, J.M. De Nicolás Jiménez (Spain) 441 LEG MINUS ARM PULSE WAVE VELOCITY MEASURED WITH A NEW DEVICE CORRELATES WITH CORONARY CALCIUM SCORE 1216 J.F. Sanchez Munoz-torrero, S. Rico Martin, J.M. De Nicolas Jimenez, J.F. Calderon Garcia (Spain) 447 EFFECTS OF HIGH-DOSE ATORVASTATIN PRETREATMENT ON MYOCARDIAL STUNNING IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION 1222 K. Sirojiddin, D. Alimov, B. Mukhamedova, M. Kenjaev, R. Rakhimova (Uzbekistan) 448 EFFECT OF LOX1 RECEPTOR GENE EXPRESSION BY ORAl MgSO4 ADMINISTRATION TO CONTROL ATHEROSCLEROSIS IN STZ-INDUCED DIABETIC RAT 1223 N. Soltani, M. Fazali, F. Kharazmi, M. Kamran (Iran) 449 THE LEADING RISK FACTORS FOR DEVELOPMENT OF MYOCARDIAL INFARCTION IN ELDERLY PATIENTS 1224 I. Sukmanova, I. Zheltova (Russia) 450 GENDER-SPECIFIC RISK FACTORS OF MYOCARDIAL INFARCTION 1225 I. Sukmanova, I. Suspitsyna (Russia) 451 THE ROLE OF PSYCHOSOMATIC FACTORS AND HYPODYNAMIA IN THE DEVELOPMENT OF MYOCARDIAL INFARCTION IN MIDDLE AND ELDERLY WOMEN 1226 I. Suspitsyna, I. Sukmanova (Russia)

92 452 EFFECT OF ALPHA-LIPOIC ACID SUPPLEMENTATION ON OXIDATIVE STRESS MARKERS AND ANTIOXIDATIVE DEFENSE IN PATIENTS WITH DIABETIC NEUROPATHY 1227 F. Sztanek, I. Seres, H. Lőrincz, A. Molnár, G. Paragh (Hungary) 453 COMPARISON OF EFFECTIVENESS OF DIFFERENT ANTIPLATELET DOSES OF ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROME 1228 T.S. Tan Kurklu (Turkey) 454 PREVALENCE OF FAMILIAL HYPERCHOLESTEROLAEMIA IN PATIENTS WITH ISCHEMIC STROKE OR HIGH-RISK TIA 1229 T. Toell, L. Mayer, K. Willeit, M. Knoflach, S. Kiechl, J. Willeit (Austria) 84 th EAS CONGRESS May 29 - June 1, 2016 Innsbruck, Austria 455 Integrative Analysis of Gene Expression Network for Atherosclerosis-related disease and Nutraceuticals SUPPLEMENTS 1230 L. Torres, A. Obregon-Gonzalez, V. Padilla-Mata (Mexico) 456 EVALUATING MONITORED LEVELS OF TOTAL CHOLESTEROL AND APPLICATION OF LIPID-LOWERING THERAPY IN PATIENTS WITH DIABETES MELLITUS AND ISCHEMIC HEART DISEASE IN AN ACTUALLY AMBULATORY PRACTICE 1231 F. Valikulova, I. Fomin, A. Vaysberg, E. Gurvich, M. Boldina (Russia) 180 Index of Authors

93 INDEX A Abajo, M. 774 Abd Alla, J Abdelmoula, J. 858, 859, 867, 909, 1 091, 1 111, 1 171, 1 172, Abdijalilova, S. 567, 570, 571 Abdul Rahman, T. 923 Abdul Razak, S. 441, 716, 923, 965, 966 Abdulgamidov, M. 793 Abe, K. 583 Abedpour 721 Dehkordi, A. Abello, F. 987, 1 058, Abeysekera, A. 933 Abifadel, M. 946 Abubeker, O Achenbach, S. 377, Achmad, C. 576 Adam, S. 426 Adamcova, K. 889, 892 Adamek, V. 724 Adamkova, V. 724, 939, Adamova, I. 687 Adams, H. 723, Adamski, J. 290 Adorni, M.P. 697, 715 Adrian, G. 801 Adyrkhaev, Z. 793, 906, 911 Adzhemian, N. 606 Adzhiev, R. 685 Afanasieva, M. 679 Afanasieva, O. 551, 679, 685, 686, 687 Afonyushkin, T Afzal, S. 427, Ager, M. 942 Aghi, A AGOP, M. 575 Agrawal, D. 82 Agrogiannis, G Aguiar, P. 360 Aguilar Salinas, C. 959 Aguilar-Salinas, C. 945 Aherrahrou, Z Ahmad, R. 485, 486, 487 Ahmed, O. 89, Ahmed, S. 529 Aigner, E. 662 Aikawa, E. 42, 93 Aikawa, M. 42 Aittokallio, T. 378 Ajendra, J. 377 Akhvlediani, M. 844 Akin, I. 274 Akita, N. 375 Akiyama, T. 855 Akrami, A Akramova, D. 608 Aktan, M. 984 Akther, F. 508 Aktop, Z akturk, F. 826 Akyol, T. 984 Al Dokhi, L al mohy, Y. 798 Al Nuaimi, S Al Omran, M Al Zamil, H Al-Banna, R. 568 Alabakovska, S. 678, Alaeddin, A. 849 Alain, V.D. 283 Alavi, A Albareda, M Albasri, A. 891, 896, 887 Alberico L, C. 898 Alcantara, K. 522 Aldamiz- 129 Echevarria, G. Alegret, M. 508, Aleksandrova, K. 412 Alekseeva, O Alexandra, S. 830 Alexescu, T. 913, 992, Alexiev, A. 914, 917 Alfaro, F. 428 Ali, A.M. 485 Ali, M.Z. 820 Alimov, D Alkaaby, W. 666 Allanov, R. 752 Allaoui, F. 691 Allen, R. 268 Almaghraby, A. 587, 790 Almagro, F. 358, 921, 975 Almeida, C Almeida, O.L Almendros Afonso, 972 T.K. Almer, G. 894, 1 142, almusawi, A. 887, 891, 896 alnafakh, H. 887, 891, 896 Alomar, S.Y. 849 Alonso Moreno, 866 F.J. Alonso, R. 945 Alshehry, Z. 314 Alt, K. 223 Altamura, S. 102 Altieri, G.I. 954, Altieri, P. 553 Altunkeser, B. 984 Alvarez de 381, Sotomayor, M. Alvarez-León, E. 356 Alvarez-Llamas, G. 129 Alves, A.C. 943, 945, 955, 985, Alves, R. 799 Amadio, P. 222 Amarchand, R. 767 Amatuzzi, F , Ambadapadi, S. 107, Ambrosetti, M Amigó, N. 393, 434 Amin, R. 126, 655 Ammirati, E. 616 Ammori, B.J. 426 Amores-Arriaga, B. 505 Amouzadeh Ghadikolai, O. An, G.J. 512 An, K.J. 739 Ananthaseshan, S

94 INDEX Anastassopoulou, 813 J. Anđelković, K. 122 Andersen, K Andersen, O.M. 332 Andor, M Andrea, B. 707 Andrea, T. 475 Andreasen, A. 654 Andreasen, J.J. 654 Andréasson, A.C. 446 Andreev, V. 830 Angeles-Martínez, 356, 528 J. Angelin, B. 336 Angelino, D. 697 Angelopoulou, S. 794 Ann, T. 855 Annuzzi, G Ansheles, A.A. 947 Ansmidte, O. 694 Anto Michel, N. 224, 470 Antonini-Canterin, 599 F. Antonopoulou, S Antonov, K. 917 Antonucci, A. 725 Antunes, H Antunes, M. 993 Anwar, A. 658 Aoyama, N. 747 Aprami, T. 576 Aquila, G Aquilera, J. 434 Aragon, V Aragona, C.O. 496, 506, 588, 675, Arakelyan, A Araz, T Arca, M. 121 Arefieva, T. 551, 679 Ares Jr., M. 269 Argimón, J. 944 Argyrou, C Arisaka, O. 390 Ariza, M.J. 428 Armitage, J.M. 51 Arnaboldi, L. 450, 491, Arnesen, H Arnhard, K. 477 Arnoldi, A. 386 Arola, J. 915 Aronov, D. 982, 998 Arpad Faludi, A. 972 Arrondo, J.L.R. 637 Arroyo, D. 774 Arsenault, B. 119, 387 Arsiwala, T. 127 Artemieva, N. 687 Artemova, A. 850 Artemova, N. 613 Arutyunova, M. 860 Arzt, C. 448 Asai, A. 886 Asaji, M. 63 Asako, K. 457 Ascaso, J. 975 Ascaso, J.F. 358, 766, 921 Ascerov, N. 793 Ashavaid, T Ashford, M. 289 Ashor, A Aspelund, T Ass. Prof. Gaspar, L. Ass. Prof. Gavornik, P. Asselbergs, F.W. 240 Asset, G. 246 Assinger, A. 448 Assmann, G. 66 Astanina, K. 492 Astrakov, S. 644, 964 Astrakova, K. 644, 964 Atanasovska, B. 113 Atangwho, I Atkin-Smith, G. 489 Attia, N. 638 Auer, S. 662 Aurelian, S.M. 609, 792 Auwerx, J. 127 Auzky, O. 515, 871 Avdeeva, I. 590 Averkova, A. 785 Averna, M. 11, 121, 232, 388, 954 Averna, M.R Ayami, S. 63 Ayaori, M. 693, 700, Ayca, B. 777 Azevedo, O Azevedo, P Azevedo, S. 955, 985 Azinheira, J. 843 B Babadjanov, B. 861 Babets, A. 577 Baccar, H. 858, 859, 867, Baccara-Dinet, 463 M.T. Bachti, E Badimon, L Baena- 425 Fustegueras, J.A. Baena, M. 508, Baeten, D. 547 Baetta, R. 472 Bagheri, B. 566 Bahlous, A Baila-Rueda, L. 115, 765, 971 Bairaktari, E. 709 Bakker, L. 90 Bakker, S.J.L Bakrania, A Balakhonova, T. 551, 582, 679 Balandina, Y. 776 Balashenka, N. 581 Balatskaya, N. 606 Balder, W. 413 Balla, J. 467 Ballantyne, C. 61 Baltatzi, M. 736 Balu, N. 248 Bałys, M , Balzarotti, G. 431 Ban, Z. 285 Banach, M. 259, 672 Bañares, V. 945 Banchs, H.L. 553 Bao, W. 119 Baptista, J Baquer, N. 847, Barabesi, E. 987, Baragetti, A. 238, 616, 898, Baragetti, I. 898 Baral, B. 659 Barale, C. 276 Baranova, E. 740, 890, Barany, P. 47 Baranyi, A Barbagallo, C.M. 954, Barbarash, O. 520, 573, Barbeiro, D Barbieri, S. 222 Barbouche, S Bardova, K. 889, 892 Barichello, M. 725 Barinova, V Barkas, F. 432, 753, 928, 977, 978, Barlow, C. 314, 449 Barnes, E. 314 Barrett, P.H.R. 394, 471 Barros, P. 985 Bartelt, A. 48 Barter, P. 119 Barter, P.J. 342 Bartkiz, A. 867, 909, 1 091, 1 111, 1 171, 1 172, Bartolini-Gritti, B. 307 Baruah, P. 40, 459 Bassani Borges, J. 972 Bassendine, M. 369 Bast, A Battista, S. 692 Baudin, B. 638 Bauer, R. 622 Baumann, S. 274 Baumgartner, J. 418 Baumgartner, S , Bautembach- 956 Minkowska, J. Bawelski, M. 585 Bayly, G. 969, Bays, H. 389 Bazhenova, E. 740, 890, Bchir, N. 867 Bea-Sanz, A.M. 115 Bea, A. 765 Bea, A.M. 971 Beacham, L. 61 Becher, B. 127 Becher, T. 274 Beck, W. 641 Bednarska- 956 Makaruk, M. Beer, J.H. 127 Begum, H. 223 Behl-Gilhotra, R. 362 Behrendt, M. 446 Bekers, O Bekiari, E. 617, 618 Bekic, S Bekkering, S. 106, 270, 556 Belagha, J. 859 Belevich, I. 204 Belhadj Hassen, H. 858 Bell, D. 355 Belovol, A. 869 Beltowski, J. 468 Beltrami-Moreira, 93 M. Belyaeva, O Ben Abdallah, N. 858, 859, 867, 909, Ben Ahmed, H. 858, 859, 867, Benaiges, D Benczur, B. 414 Benghozi, R. 714 Benítez, S. 876 Benito-Vicente, A. 637, 985, Benjathummarak, 569 S. Benn, M. 123, 429, Benoist, J.F. 691 Bento, D Benvegnù, L Berbée, J. 90, 556 Berdiqulov, J. 572, Berestetskaya, Y. 687 Berg Schmidt, E. 654 Berg-Schmidt, E Berg, G. 995 Berge, K.E Berge, R.K. 363, Bergheanu, S. 244 Bergthaler, A. 307 Berkovich, O. 890 Berliner, S. 563 Bermudez Pulgarin, B. Bernabeu, C. 494 Bernatova, I. 565, Bernelot Moens, S. 81, 106, 547 Bernelot Moens, 627 S.J. Bernfur, K. 408 Bernhagen, J. 291 Bernhard, D. 477 Bernini, F. 692, 697 Berrougui, H. 110 Berta, E. 612 Bertaccini, D. 283 Bertagnin, E. 671, 749 Berteotti, M. 616 Berti, A. 616 Bertinaria, M Bertocco, S. 725, Bertolini, S. 121 Bertsch, T. 368, 438, Beshay, M. 797 Besseling, J. 99, 359, 974 Betriu, À. 774 Bezrodnyi, V. 811 Bhagavathula, A , Bhasin, P. 780 Bianco, A Bianconi, V. 865 Biazzi, C. 898 Bielicki, J. 641 Biemann, R. 412 Biessen, E. 704 Biessen, E.A.L. 269 Bigolin, P

95 INDEX Bilgic, E. 294 Billon-Crossouard, 648 S. Binder, C , Binder, C.J. 36, 39, 307 Biolo, M Birner- 440 Gruenberger, R. Birringer, M. 383 Bispo, K Bittar, R. 365 biyik, I. 826 Björkbacka, H. 290 Bjorndal, B Blackhurst, D. 710 Blaha, M Blaha, V. 976, 1 026, Blanco-Vaca, F. 358, 384, 944 Blangero, J. 449 Blauw, L. 113 Bleie, Ø Bliden, K.P. 417 Block, T Blom, D. 976 Bobabekov, A. 851, 861 Bobbert, T. 989 Bobronnikova, L. 869 Bocskei, R. 414 Bode,. 224 Bode, C. 306, 470 Bodor, M. 612 Boehm, B.O , Boeing, H. 412 Boekholdt, S.M. 119, 627, 680 Boeva, O. 848 Bogdan, M. 509 Bogdanska, J. 678, Bogniotti, L.A Boileau, C. 946 Boldina, M Bolognese, M Bolotov, I. 510 Bonacina, F. 222, 458 Bonaldo, A. 725 Bonavita, E. 458 Bondarenko, P. 568, 728, 783, 850, Bonde, Y. 376 Boni, M. 849, 865 Bono, E Bonora, E. 312 Boodhoo, D. 536 Boon, M. 90, 111, 556 Boonen, H. 513 Boosani, C. 82 Boot, C. 988 Borén, J. 241, 10, 43, 647 Borges Jr, N. 799 Borggrefe, M. 274 Borghi, C. 380, 391, 671, 749 Bornstein, S.R. 682 Borowiec, M. 828 Borrallo, R.M. 938 Borst, J. 305 Boshtam, M. 721 Bosisio, R. 386 Bossano Prescott, 74, 322 E. Bossone, E. 599 Bosusco, A. 987, Bot, I. 307 Botchorishvili, I Botet-Montoya, 921 J.P. Botha, S. 619 Botirova, L. 571 Bottazzi, B. 222 Bottiglieri, T. 277 Boucher, P. 283 Boudes, P. 244 Boudier, C. 283 Boulanger, C.M. 200 Boura, P. 617, 618 Bourantas, C.V. 399 Bourbon, M. 360, 730, 857, 901, 943, 945, 955, 959, 985, 993, 996, 1 060, Bousquet, K Boutouyrie, P Bouziana, S. 794, Bouzid, K. 858, 859, 867, 909, 1 091, 1 111, 1 171, 1 172, Bouzourene, K Bowden, K. 455 Boya, P. 346 Boyd, M. 498 Boydens, C. 856 Boyle, J.R. 743 Boytsov, S. 629, 640, 663 Bozorboev, M. 744 Bozzetto, L Bozzolo, E. 616 Brænne, I. 240 Brambilla, M , Brambilla, S. 450 Brandon, J. 95 Brandt, A. 956 Bratseth, V Brea, Á. 975, 766 Breierova, E. 565, Brenner, M.B. 88 Bridges, I. 462, Brisson, D. 660, Brito Jr, F. 781 Brix, S. 285 Broncano, J Broncel, M. 518, 828 Brouwer, I. 56 Brovin, D Brown, A. 349 Brown, M.J. 207 Brown, M.S. 134 Browning, M. 916 Bruckert, E. 1, 53, 69, 229, 244, 365, 946, 976 Brugada, R Bruheim, I Brunet, A. 463 Bubnova, M. 982, 998 Buccellati, C Buccheri, D Buchal, R. 517 Buchmann, N. 935, 989 Buda, V Bueno, M. 944 Buerger, C. 305 Bugrova, O. 613, 848 Bujo, H. 330 Bülow Eschen, R. 654 Bundalo, M. 373 Bürger, C. 128 Burger, F. 407 Burko, N. 603, Burlachuk, V. 750 Burnett, J. 355 Burnett, J.R. 471 Burokiene, N Bursill, C. 704 Burtceva, E Busacca, P. 803 Busnelli, M. 131, 372, 511, 639, 689, Buszko, M. 351 Buurman, W. 113 Buza, I. 513 Buza, V. 782, Byazrova, F Byazrova, S. 473, 853 Byoung Kwon, L Byung-Soo, Y Bzduch, V C Cabré, C. 434 Cacciagiú, L. 995 Caceres Gestoso, 615 A. Cadamuro, J. 662 Cahill, P. 476 cai, A. 490 Cai, G. 447 Caidahl, K. 521 Cairo, V. 496, 506, 675, Caixàs, A. 944 Cakmak, H.A. 893, 1 083, Calabrese, G. 416 Calabresi, L. 47, 121, 650, 963, Calabrò, P. 924, 925 Calderón García, 1 216, J.F. Caliceti, C Caligiuri, G. 451, 474 Calosing, C. 118 Camejo, G. 47 Camera, M , 1 034, CAN, L.H. 951 CANET-SOULAS, E. 292 Cannon, C.P. 463 Canton, G. 248 Cantor, R.M. 241 Canzano, P , 1 034, Cao, L.L. 94 Capelozzi, V Capisizu, A. 609, 792 Capobianco, E. 825 Cappellano, G. 351 Capra, V Caramelli, B. 863 Carbone, F. 407 Cárdenas Vázquez, 945 A. Cardoso-Saldaña, 528 G. Cardoso, B Cardoso, G. 356 Cardouat, G. 281 Carerj, S. 599 Caretta, N. 725 Carey, A. 223 Carletti, R. 549 Carmeliet, P. 27, 140 Carnuta, M.G. 701, Caro Gomez, N. 614 Caro, N. 888, 904, 1 099, Carreau, V. 946 Caruso, D. 267 Caruso, S. 489 Carvalho, L.S Casale, M. 803 Cascales, M.D.M. 508 Casetta, I. 407 Caslake, M Cassorla, G. 545 Castagna, A. 626, 656 Castelnuovo, S. 963 Castelo-Branco, M. 592 Castiglioni, L Castillo Bernal, F.J. 835, 836, 837 Castro Jiménez, M.C , 836, 837 Catai, M.A Catanozi, S. 698, Catapano, A. 16, 19, 24, 26, 30, 132, 250, 252, 256, 258, 315, 321, 324, 472 Catapano, A.L. 222, 238, 347, 392, 431, 458, 554, 616, Cattan-Lévy, L. 474 Cattaneo, F. 450 Caussy, C. 625, Cavalca, V. 530 Cavalot, F. 276 Cavera, G cebe, H. 826 Cecchettini, A. 825 Cecconi, D. 626, 656 Cedó, L. 384 Cefalù, A.B. 121, 954, Čejková, S. 535 Cekovska, S Cena, C Cenarro, A. 115, 202, 765, 971 Cermenati, G. 267 Ceska, R. 962 Chabowski, A Chae, I.H Chae, J.K. 493 Chaisri, U. 569 Chalikias, G. 657 Chalubinski, M. 518, 801, 828 Chamney, S. 650 Chan, D. 355, 471 Chan, D.C. 394 Chan, J. 357, 885

96 INDEX Chan, K.C. 247 Chang, S.Y. 560 Channon, K. 62 Chao, T.H. 773 Chapman, J. 4, 8, 213 Charakida, M. 719 Charania, S. 502 Charrière, S. 625, Chasiotis, V. 736 Chatzigeorgiou, M. 762 Chatzizisis, Y. 93 Chaudhary, R. 417 Chaudhuri, S. 933 Chawla, P Chechetkin, A. 598, 602 Chee, Y.J. 881 Chen, C.H. 348 Chen, H. 107, Chen, H.T. 341 Chen, Y. 524 Chen, Y.R. 453 Cheng, L.I Cheol-Young, P Chernatskaya, O Cherng, J.Y Chernyavina, A. 604, 605 Chestnutt, J. 650 Cheta, I Chétiveaux, M. 648 Chew, D Chew, D.E chi, Y. 524 Chia-Yin, T Chia, Y.C Chiappa, G , Chiara, M. 372 Chiariello, C. 626 Chicheva, M Chiesa, G. 131, 372, 511, 639, 689, Chillarón, J.J Ching, S.M Chinnasamy, P. 94 Chiong, C. 881 Chiou, H.Y , Chiu, T.Y. 341 Chiva-Blanch, G Chlebus, K. 956 Chlopicki, S. 494 Chmara, M. 956 Chmelik, Z. 778 Cho, D.H. 884 Cho, H.C. 404, 564 Cho, J.Y. 738, 739, Cho, K.H. 559, 646, 829 Cho, S.A. 738, 739 Cho, Y.K Cho, Y.S Choe, N. 350, 371, Choi Wan, J.F. 994 Choi, B Choi, B.G Choi, B.H. 404, 564 Choi, B.M. 439 Choi, C.U. 120, 1 000, Choi, J.H. 761 Choi, J.Y Choi, M.H. 120 Choi, Y.J. 244 Chong-Yang, D. 902 Chora, J. 945 Chora, J.R. 955, Chou, C.H. 919 Chowdhury, M.M. 743 Christen, T. 293 Christie, B. 677 Christoffersen, C. 717 Christomanou, H Chroni, A. 652 Chrysohoou, C. 762, 846 Chuang, C.K. 210 Chudinovskikh, T Chung, S.M Chung, W.Y. 512, Chvostova, M. 568 Ciba, P Cibickova, L. 635 Cicala, V Cicero, A. 380, 391, Cicero, A.F.G. 671, 749 Cifani, N. 544, 549, 550 Ciffolilli, S. 383 Cigankov, V. 911 Cioroch, M. 62 Cipollari, E. 697 Cipriano Jr, G Cipriano Jr., G Cipriano, G Cipriano, P Ciumarnean, L Civeira, F. 115, 202, 358, 765, 766, 921, 971, 975 Clapp, W. 107 Clara, J. 48 Clouet Foraison, N. 634 Coassin, S Cobbaert, C. 578, 634 Cocci, G Cochran, B. 342 Codogno, I. 474 Colaço, I. 742, 941 Cole, A. 93 Colhoun, H. 308, 310 Colhoun, H.M. 246, 463 Colima Fausto, 959 A.G. Colli, S. 530 Colombo, G Coman, S. 775 Compte, M.T. 434 Conceição, R. 920 Concin, H. 770 Cong, K. 651 Connell, P Connor, T Conrad, D.H. 307 Constantin, G. 705 Constantin, G.I. 802 Constantinou, C. 688 CONTAMIN, H. 292 Conte, C. 496 Cook, E. 209 Cook, E.C.L. 664 Cooper, A Cooper, J. 934, 952 Corrado, E Corral, P. 945, 995 Corrao, G. 261 Corrêa-Giannella, 863 M.L. Corrêa-Giannella, 698 M.L.C. Correia, E Correig, X. 434 Corsini, A. 472, 337, 347, 419, 450, 491 Cosansu, K Cosentino, N. 530 Cosic, V Coskun, E Coskunpinar, E Cosor, O.C. 769 Cossette, M. 696 Costabile, G Coughlin, P.A. 743 Couture, P. 976 Craiem, D. 754 Cramb, R. 666, 930 Crasborn, M. 556 Crespín Crespín, M , 836, 837 Crestani, M. 267 Cristaldi, A. 995 Cristescu, C Croce, K. 93 Croyal, M. 648 Cruciani, G. 383 Cruz, D. 742, 941 Cuchel, M. 430 Cuenca, N. 938 Cuesta Torres, L.F. 342 Cuevas, A. 945 Curran, J. 449 Cursaru, A. 805 Cutuli, L. 222 Czarnecka, D. 931 Cziraki, A. 414 D D Acierno, L. 924, 925 D Addato, S. 380, 391, 671, 749 D Agostini, L. 671 D Angelo, A , 1 189, D Angelo, R. 346 D Erasmo, L. 121 D Agostini, L. 749 da Silva Rodrigues, 972 E. Dąbek, J , Dadabaeva, N. 744, 752 Dafnis, I. 652 Dahl, M. 834 Dähnhardt, D. 411 Dai, H.L Dalan, R. 881, 1 065, Dalla-Riva, J. 408 Dallegri, F. 407 Dallinga-Thie, G. 97, 260, 331 Dallinga-Thie, G.M. 286, Dalton, N. 455 Damasceno, N.R.T Dancer, M Danielsson, A. 290 Danzl, K. 477, 504 Darabi, M. 104, 711 Das, S. 676 Dascalescu, R. 609, 792 Daskalopoulou, 452 S.S. Dasseux, J.L. 714 Datta, H. 988 Dattilo, G. 803 Daunoravicius, Z Dauteuille, C. 104, 711 Davel, A. 827 Davì, G Davids, J Davidson, M. 464 de Boer, H. 269 de Boer, J.F. 804 De Boever, P. 502, 514 de Bruin, R.G. 269, 483 de Bruin, T. 464 De Fabiani, E. 267 De Faria, E. 922, 983 de Feyter, P.J. 399 De Geest, B. 126, 655 de Gonzalo Calvo, 202 D. De Gonzalo-Calvo, D. de Graaf, J. 244, 270 de Gregorio, C. 803 De los Santos 615 Moreno, A. De Meyer, G.R.Y. 198, 201, 343 De Michele, M. 544 de Mutsert, R. 113, 293 De Nicolás 1 216, Jiménez, J.M. de Roos, A. 113, 293 De Soysa, M. 936 De Vries, J.K. 413 de Vries, T. 399 De Vuono, S. 849, 865 de Winther, M. 556, 704 Deanfield, J. 719 Dechkhajorn, W. 569 Deev, A. 734, 735 Degoricija, V. 707 Dehoux, M. 474 Del Bo, C Del Core, M. 82 Del Porto, F. 544, 549, 550 Delatour, V. 634 Delbridge, L. 223 Deleanu, M. 488, 523, 701 Delgado-Coello, B. 64 Delgado, G.E Dell Oca, N. 945 Dell Oglio, S Dell Oca, N. 961 Dellera, F. 131, 372, 511, 639, 689, Demakova, N Dembinska-Kiec, 546, A. DeMicco, D. 119 Demikhova, N Demina, E. 890 Demina, M. 911 Demir, M. 984 Demircioglu, S. 984 Demopoulos, C

97 INDEX Demuth, I. 935, Denby, L Dengxuan, W. 902 Denisenko, M Denney, L. 667, 910 Dent, R. 392, 462, Deon, V Derfler, K. 960 Derosa, G , 1 189, Descamps, O. 976 Deschildre, C. 474 Deshpande, A Deshpande, S Després, J.P. 3, 7, 212, 214, 387 Dhar, I. 779 Dhawan, V. 722 Dhyani, A. 472, 554, Di Bella, G. 803 DI CATALDO, V. 292 Di Filippo, M , 625 di Gioia, C. 549 di Giuseppe, R. 412 Di Taranto, M.D. 958 Diana, S. 476 DiCioccio, A.T. 463 Dickerhof, N Didangelos, T. 736 Didenko, Y. 783 Dienova, J Dieplinger, B. 460, 882, Dieplinger, H. 17, 23, 31, 411, Dietel, B. 377, Dikkers, A. 47 Dimakopoulos, I Dimitriou, T. 977, 978, Dimova, L.G. 804 Dimulescu, D.R Dincgez Cakmak, 893 B. Dissanayake, S. 994 Dito, R. 544, 549, 550 Dixon, S. 401 Djaramshi, A. 269 Djeric, M. 870, Djokic, V. 821 Djordjevic, V Dlouha, D. 683, 939 Dobrolubov, M. 613 Doganci, S. 294 Doi, M. 586 DOKMEN, H. 951 Dokoza Terešak, S. 707 Doktorova, M. 622 Dolezelova, E. 480, 494 Domagala, T. 796, 840, 841, Domingo-Espin, J. 408 Domingues, C. 592 Dominguez 972 Crespo Hirata, R. Dominguez 972 Crespo Hirata, T. Donato, P. 592 Dong Il, S Dong Ju, C Dong Soo, K Doni, A. 222 Donn, R. 426 Donners, M. 704 Doppler, C. 477 Dorel P., S. 913 Dorofeeva, Y Dostal, E. 541, 720 Douglas, G. 62, 349 Douglas, S. 969 Doulamis, I. 382, Downie, P. 969, Doytcheva, P. 719 Dr. Dostal, E Dr. Gruber, K Dragut, R. 805 Drechsler, C Dressel, A. 396 Drettwan, D. 90 Drexel, H. 366, 731, 732, 733, 839, 879, 883, 991, 1 067, 1 136, 1 137, Dritsa, V. 813 Drogari, E Dronca, E. 913 Dropinski, J. 796, 840, 841 Drosos, I. 657 Druina, L. 598, 602 Du, X.J. 223 Du, Y. 339 Duarte, T. 742 Ducla Soares, J.L. 742, 941 Duijs, J. 269 Duivenvoorden, W Dumfarth, J. 477 Dumitrescu, A. 769, Dumitriu, I.E. 40, 459 Dunaeva, A. 907 Dunaway, C. 94 Durmus, R. 984 Durrington, P.N. 426 Dürschmied, D. 470 Duta-Mare, M.C. 443 Dwivedi, O. 354 Dwyer, T. 758 Dybvig, A. 684 E Eak Kyun, S Eastwood, J Ebenbauer, B. 418 Ebtehaj, S. 47, 699 Eckardt, K.U. 278 Edelberg, J. 246 Edholm, D Edsfeldt, A. 290 EFECTL Study 461 Investigators, G. Efstathiou, S Egbung, G Eggertsen, G. 376 Eha, J Ehrenborg, E. 203 Eichmann, T. 374 Eichmann, T.O. 284 Ekici, A Ekroos, K. 131, 275, 639 El Asmar, Z. 283 El Bounkari, O. 291 El Eter, E El Khoury, P. 946 El-Kersh, A. 797 El-Osta, A. 35, 239, 265, El-Zidy Ibrahim, N. 989 El-Zidy-Ibrahim, N. 935 Elbahey, M. 587, 790 Elbaz, M. 346 Elbitar, S. 946 Elena, M. 555 Elfaleh, E. 909 Eligini, S. 530 Elisaf, M. 432, 709, 753, 928, 977, 978, Elizova, N. 532, 632 Ellena, R. 651 Ellis, K. 355 Elnour, A , Emese, T. 475 Emich-Widera, E Emma, K. 47 Empana, J.P Emukhvari, M. 844 Endo, Y Engberg, S. 209 Enguita, F. 996 Enikő, B. 475 Enko, D Eom, G.H. 350, epstein, J Erdmann, J. 240, Eremic, N Eretova, Z. 683 Eriksson, M. 89, Eriksson, M.J. 521 Eriksson, P. 521 Ermina, M. 568, 728, 850, EROGLU, Z. 953, 951 Erridge, C. 525 Erskine, N. 757 Erturk, M. 893 Escalante, F. 959 Escolà-Gil, J.C. 384 Espinosa, E Essop, F. 502 Esteve, E. 944 Estruch-Alrich, M. 876 Etxebarria, A. 637, 985, Eun Seoung, L. 552 Evangelakos, I. 437 Evdokimenko, A. 500, 598, 602 Even, G. 474 Everson, F. 514 Evola, S. 819, Evola, V. 819 Exarchos, T. 818 Ezhov, M. 606, 685, 686, 687 Ezhov, M.V. 947 F Fabres Machado, 531 U. Fabris, F. 725, Faccini, J. 346 Fagg, W.S. 269 Faggiano, P Fahey, T. 980 Fainardi, E. 407 Fajkusova, L. 973 Falcou, A. 544 Falk, E Fang-I, H. 453, Faraj, T. 525 Farajian, P Farhoudi, M. 600 Faria, F. 742, 941 Faria, R Farinaro, E. 67 Farnier, M. 246, 389, 463, 976 Fatima, A Faus-Dader, M.J. 866 Faussner, A. 305 Favari, E. 697, Favretto, S. 599 Fayer, F. 954, fazali, M Febbraio, M. 223 Fedak, D. 903 Federico, V. 818 Felder, T. 662 Fellin, R. 121 Fellnerova, A. 939 Fenyo, I.M. 527 Ferin, R Ferlin, A. 725 Fernandez- 312 Hernando, C. Fernández- 637 Higuero, J.A. Fernández-Miró, M. Fernández, E. 774 Fernandez, G. 961 Ferrari, A. 267 Ferrari, R Ferreira, G.S. 698 Ferreira, J. 592 Ferreira, M.J. 592 Ferreira, R. 843 Ferreira, S Ferrer, R. 425 Ferri, L. 544, 549, 550 Ferri, N. 337, 347, 419, 472 Figueras, R. 944 Fikrova, P. 480, 494 Filatova, A. 551 Filipovic, N. 818 Filippova, A. 497 Filou, S. 688 Fimiani, F. 924, 925 Fiorelli, S. 530 Fiorentini, C. 818 Fiorino, E. 267 Fischer, A. 333 Fischer, A.W. 88 Fischer, M. 418 Fischer, S. 403, 682 Fiser, A. 94 Fitzpatrick, E. 476 Flachs, P. 889, 892 Fletcher, J. 545 Flores Le-Roux, J.A. Flugelman, M.Y. 932 Fogacci, F. 391, 671, 749 Föger, B. 219 Fomin, I

98 INDEX Fonseca, R. 843 Fontes, A Foody, J. 389 Forbes, C Foresta, C. 725 Fort, J.M. 425 Fortini, F Fortunato, G. 958 Foryst-Ludwig, A. 285 Fotiadis, D. 818 Fotiadis, D.I. 399 Fourie, C.M. 619 Fournier, N. 691 Fraass, U. 396 Fragopoulou, E Fragoso, J.M. 356 Fragouli, S. 382 France, M. 426 Franceschini, G. 650 Franck, G. 93 Franco-Cereceda, 521 A. Frank, S. 374, 422, 499, 707 Franz, R. 48 Franzese, C.J. 417 Frascaroli, C. 276 Fraser, B. 758 Fraunberger, P Freiberger, T. 962, 973 Frias, M. 710 Fried, S. 281 Frikke-Schmidt, R. 237, Frimmel, K. 565, 1 015, Frisdal, E. 365 Fritsch, H. 22 Fritsche, A. 412 Fritz, J. 770 Froemming, G.A. 485, 486, 487 Froemming, G.R.A Froio, A. 511 Froněk, J. 562, 535 Fruttero, R. 491 Frutuoso, J. 730, 901 Fu, J. 5, 9, 113 Fuentes, J Fuentes, L. 651 Fuertes, R. 434 Fuior, E.V. 527, Fujita, Y. 636 Fülöp, P. 435, 467, 702, 1 151, Furtmair, R Furukawa, L Furusyo, N. 579, 610, 727, 755, 756, 905 Fusaro, M Fusco, F Futema, M. 952 G Gabbasov, Z. 473, 853 Gabcova, D Gabriel, D. 827 Gabrielyan, D. 850 Gabrielyan, L. 850 Gaetano, C. 218, 221 Gafane, L. 619 Gafarov, V. 795 Gafarova, A. 795 Gafencu, A.V. 527, Gagulin, I. 795 Gaita, D. 769, Gaita, L. 769, Galabova, G. 245 Galicia, U Galimskaya, V. 589, 590 Galitsyna, E Gall, J. 365 Gallagher, J. 114 Galli, F. 383 Gallieni, M Gallivan, A. 952 Galy, B. 102 Gandra, S.R. 392, Ganesan, M. 986 Ganiev, U Ganiyev, U. 571 Ganzetti, G.S. 131, 372, 511, 639, 689, Gao, X. 881, 1 065, Gapon, L. 538, 557 Garaffa, C. 924, 925 Garaffa, E. 924, 925 Garces-Horna, V. 505 García Fuertes, D. 835, 836, 837 Garcia Garcia, H.M. 399 García León, A. 384 García-Arnés, J. 428 Garcia , Campanario, I. García-Casares, N. 428 García-García, I. 938 Garcia-Vaz, E. 114 Garcia, A Garcia, I. 904 Gareeva, D. 745 Garjani, A. 566 Garlanda, C. 222, 458 Garlaschelli, K. 238, 616, 898, Garlick, J. 723, Garnier, J.M. 283 Garolera, M. 938 Garzillo, C. 781 Gasbarrino, K. 452 Gasco, A. 491 Gąsior, Z , Gasko, R. 635 Gaspar, G. 857 Gaspar, L. 541 Gasperikova, D Gast, K.B. 293 Gaston, A.T. 474 Gaudet, D. 59, 244, 247, 300, 353, 660, 669, Gautier, E.L. 104 Gavriil, L Gavrilova, N. 629, 640, 663 Gaye, B Gebhard, C. 696 GELOEN, A. 292 Gelosa, P Genest, J. 714 Genis, A. 514 Genkel, V Gennaro, A. 818 Genser, B. 699 Gentili, A. 849 Georgiadis, I Georgousopoulou, 762, 846 E. Gerard, W. 449 Gerdes, N. 128, 305 Gergei, I. 396 Gerothanassis, I Gesheff, M.G. 417 Ghabili, K. 817 Ghaleb, Y. 946 Ghanaati, H. 580, 607 Gharipour, M , 806 Gheysens, O. 655 Ghezaiel, S. 858, 859, Ghezzi, M. 725 Ghoneem, A. 587 Ghorashi, S. 817 Ghosh Laskar, M. 336 Giacco, A Giacobbe, C. 958 Giammanco, A Giannella Neto, D. 863 Giannini, S Gibbs, J. 976 Gieger, C. 313 Gijbels, M. 704 Gilham, D. 118 Gill, S. 897 Gillard, J. 349 Gillery, P. 634 Gimenez-Lopez, I. 505 Gingell, R. 936, 990 Ginsberg, H. 714 Giollo, L Giordano, P Giorgini, M Giovannini, M. 671, 749 Gipe, D.A. 247 Giral, P. 365 Giralt, M. 434 Girona, J. 393 Giulietti, F Giuseppe Danilo, 238, 898 N. Giyazitdinova, E. 597, 726, 787, 788, 831, 979, 1 025, Gkougkourelas, I. 617, 618 Gkourogianni, A Glazunova, A. 860 Glei, M. 383 Glerup, S. 332 Głodzik, J. 585 Głogowska-Ligus, 1 071, J. Godber, I Göderle, L. 307 Goebel, G. 503 Goedecke, J. 710 Goedeke, L. 312 Goeritzer, M. 284, 622 Goettsch, C. 42 Goh, L.L , Gojazadeh, M. 817 Gojkovic-Bukarica, 821 L. Gojković, T. 436, 741, 874 Goldberg, R. 757 Goldstein, J.A. 401 Goliasch, G. 541 Golledge, J. 362 Golubenko, M Gomaraschi, M. 47, 386, Gomes, A. 592 Gomes, D Gomes, D.J. 698 Gomes, E.I. 983 Gomes, I Gomes, M. 270 Gomez -Villarejo, 904 D. Gomez, M.F. 114 Gonçalves, C. 799 GONCALVES, F. 522 Gonçalves, I. 290 Gonçalves, L. 592 Goncharova, I González Garcia, 959 J.R. Gonzalez Marines, 959 D. Gonzalez-Calero, 129 L. Gonzalez Juanatey, J.R. González-Santos, 428 P. Gonzalez, F.J. 375 González, M Goodwin, M. 694 Goossens, P. 704 Góralska, J. 546, Gordts, P. 44, 46 Gorzelak-Pabis, P. 518 Gorzelak, P. 801, 828 Goswami, N. 502, 514 Gottschling, K. 333 Goudevenos, I Goulas, A Goumas, G Gouni-Berthold, I. 669 Gouveia, C. 843 Govorin, A. 807 Gracia, M. 754, 774 Græsdal, A. 684 Graham, I. 319 Graier, W.F. 284 Grallert, H. 313 Grammer, T. 396, 937 Grammer, T.B. 409, Granata, A. 450 Grandi, E. 380, 671 Gratsiansky, N. 735 Grau, J. 944 Grechanyk, N. 497 Greco, D. 692, 715 Green, S. 673 Grenkowtiz, T. 935 Greter, M. 127 Greve, J.W. 113 Griffin, J. 969 Griffo, E Griffo, R Grigore, L. 238, 616, 898, Grigorie, M. 705 Grimm, M. 351 Gritskevich, A. 906, 911 Grivel, J.C. 548,

99 INDEX Groen, A.K. 210, 622 Gromova, E. 795 Grönlund, C. 596 Groop, L. 354 Groothoff, J. 968 Grosu, L. 805 Gruca, A Gruchala, M. 956 Grufman, H. 290 Grujic Ilic, G Grune, J. 285 Gu, J. 654 Guaita, S. 393 Guang, X.F Guaraldi, F. 958 Guardamagna, O. 958, 987, 1 058, 1 105, Guardigli, M Guarini, P. 626, 656 Guarnieri, F. 981, 1 166, Guðnason, V Guedes, J Guerado Espinosa, I. 835, 836, 837 Guerin, M. 365 Guerra, A Guerrasio, A. 276 Guerrini, U. 458 Guertin, M.C. 696 Guervazoni, A Guibout, C Guillas-Baudouin, 104 I. Guizoni, D. 827 Gulevskaya, T. 500, 500, 598, 602 Guljas, S Gulkevych, O. 811 Gunasekar, P. 82 Gundry, S. 519, Guo, W. 534 Gurbel, P.A. 417 Gurevich, V. 400 Gurevich, V.S. 718, 947 Gurlek, A. 715 Gurses, K.M. 294, 715 Gursky, O. 630, 708 Gurvich, E Gustafsen, C. 332 Gustafsson, P. 203 Gustafsson, U Gutiérrez-Cardo, 428 A. Guyer, K.E. 417 Gyrasis, C. 399 H Ha, K.H. 729 Haas, G.M. 368, 438, Haase, M. 448 Habibinejad, H Haddad, E Haenen, G Haerdtner, C. 306 Hafner, E Hagemeyer, C. 223, 273 Hagger, M Hahn, R.T. 492 Haikal, A. 910 Hakimjavadi, R. 476 Hakovirta, H. 423 Hale, A. 62 Halliday, C. 118 Hallström, S. 499 Halmurat, U Halon, D.A. 932 Haltmayer, M. 882 Hama, S. 426 Hamed, W. 797 Hammad, B. 587, 790 Hammami, S Han, S.H , Handru, M Hanna, E. 650 Harada-Shiba, M. 121, 344, 390, 949, 976 Harada, A. 338 Harangi, M. 435, 467, 612, 702, Hargrave, G. 498 Harrison, S.C. 743 Hart, L. 969 Hartgers, M.L. 359, 974 Hartvigsen, K. 307 Harvey, D. 952 Haschke-Becher, 662 E. Hashida, T Hatsukami, T. 248 Hattori, T. 899 Hatzitolios, A. 617, 618, 736, Hatzitolios, I.A. 794 Haupt, C. 708 Havik, S. 547 Havulinna, A.S. 410 Hayashi, J. 579, 610, 727, 755, 756, 905 Hayashi, T. 484, 838, 854 Hayes, P.D. 743 He, B. 83 Heeren, J. 88, 331, 333, 334 Heestermans, M Heikkilä, H. 354 Heikkilä, T. 690 Heimann, J Hein, L. 306 Heine, M. 88, 333 Heinemann, A Heinle, H. 821 Heinonen, S. 446 Heintjes, E. 760 Heinz, K. 477 Heinzel Gutenbrunner, M. Helk, O. 960, Henkel, V.V. 947 Hennig, B. 385, Henstridge, D. 223 Hentze, M.W. 102 Heras, M. 393 Herder, C. 411 Heredero, A. 129 Herings, R. 760 Hermann, M. 649 Hermans, M. 578 Hernandez Flores, 959 T. Hernández- 866 Mijares, A. Hernandez, M. 522 Hernández, M.P. 478 Herrera, M.D. 381, Herz, C. 507, 772 Herz, C.T. 771, Herz, J. 41, 91, 283, 469 Hetjens, S. 274 Heywood, S. 223 Hiebert, S.W. 267 Hilgendorf, I. 224, 306, 470 Hilvo, M. 131, 275, 639 Hinterreiter, F. 882 Hippe, D. 248 Hiraoka, Y Hirata, H. 700 Hirata, K. 338 Hiroyuki Hirata, M. 972 Hisakawa, N. 561 Hjellestad, I.D. 249 Hmaidi, W , Ho-Jun, J Ho, H.H. 348 Ho, J. 426 Ho, Y.C. 348 Höbaus, C. 507, 771, 772, Hobbs, H. 32 Hobkir, J. 916 Hoefer, I. 71 Hoefler, G. 284, 622 Hoeke, G. 90 Hoeksema, M. 704 Hoes, A.A.W. 317, 326 Hoffman, J. 385 Hoffmann, M.M. 409 Hofker, M. 113 Høgh, A. 834 Hoh, B.P. 681 Hohensinner, P. 418 Hollstein, T. 989, Holmes, E. 988 Holven, K.B. 957 Honarpour, N. 465, 976 Hong, B. 339, 695 Hong, S.J. 738, 739, Hong, S.P Hong, T.J. 761 hongyu, W. 809 Hoogenboezem, 481 M. Hoogeveen, R. 677 Hooper, A. 355 Hopmans, S Hoppstaedter, J. 492 Hörauf, A. 377 Hori, M. 949 Horinek, A. 962 Horn, J. 651 Horner, D.S. 372 Host, L. 283 Hottiger, M.O. 127 Hou, J. 873 Hou, L. 342 Hovingh, G.K. 119, 286, 359, 392, 627, 680, 974, 976 Hovingh, K. 331 Hovland, A. 466, 864 Howanietz, M.T. 771 Hoxha, M Hrelia, S Hryachkova, O. 573 Hrzenjak, A. 374 Hsieh, F.I , Hsin-Chiao, W. 453 Hsu, L.W. 105, Hsu, P.L. 445 Hu, M. 357, 885 Hua-Long, L. 902 Huang, C.F Hubacek, J. 724, 939, 962, Hubacek, J.A. 871 Huber, K. 418, 541 Hübner, M. 377 Huby, T. 104 Huckova, M Hudiakova, N. 842 Hughes, A.D. 312 Hughes, L. 988 Hughes, S.G. 669 Hui, D. 331 Huisman, H.W. 619 Huitema, L. 704 Hukkanen, M. 915 Hulett, M. 489 Humphries, S. 238, 934 Humphries, S.E. 952 Hung-Yi, C. 453, Hung, M.Y. 455, 673 Hunter, W. 82 Hur, S.K. 420 Hurme, R. 275, 639 Hurt-Camejo, E. 47 Husche, C Husebye, E.S. 249 Hussain, M.M. 622 Hutcheson, J. 42 Hutchings, A. 942 Huth, C. 411 Hutten, B. 968 Huttl, M. 661 Huynh, K. 314 Hwang, S.H. 738, 739 Hwang, Y.C Hyeon Gheol, G Hyo Sang, H Hyuck Moon, K Hyun Woo, P Hyun, M.H , I Iaconi, M. 549, 550 IBAROLLA, D. 292 Ibarretxe, D. 393 Ibe, N. 641 Iborra, R.T. 698 Ibrahim, Z. 923 Idzior-Waluś, B. 903, 931, 912 Igari, K Igelseder, B. 503 Igland, J. 957 Ijäs, P. 354 Ikaida, M. 620 Ikeda, Y. 561 Ikegami, Y. 537, Ikemura, N. 537, Ikewaki, K. 693, 700, Ikhlef, S

100 INDEX Ikonen, E. 915 Ilina, N. 606 Ilincic, B. 870, Illyes, M. 414 Ilyin, A. 860, 900 Imamura, S. 621 Imbalzano, E. 496, 506, 588, 675, 803, Ina, K. 484, 838, 854 Inazu, A. 948 Inci Coskun, E. 893 Ingrassia, V. 954 Inoue, Y. 855 Ionin, V Iqbal, J. 622 Irina, O. 538 Irino, Y. 338 Isermann, B. 412, 669 Ishida, T. 338 Ishizuka, M isikssacan, N. 826 Ismail, N.H. 485 Ismail, Z. 965 Isomäki, A. 915 Ito, H. 586 Ito, M Ito, Y. 620 Ivandaev, A. 793, 906, 911 Ivanoshchuk, D. 832, 929, 940, 964 Ivanov, M. 568, 728, 783, 850, Ivanova, O. 548, 555 Ivanova, R. 914, 917 Iwaniec, T. 840, 841, Izquierdo, I J Jaceldo-Siegl, K Jacob-Lenet, M.P. 474 Jacobs, F. 126 Jácomo, R Jafari Dinani, N. 721 Jafari, R. 918 Jakic, B. 351 Jalkanen, J. 423 Jalkanen, S. 423 James, R. 710 Janabaev, B. 851, 861 Janczura, M. 796, 840, 841, Jänis, M. 131 Jannes, C. 945 Janovska, P. 889 Jarauta, E. 765, 971 Jargin, S. 808 Jaroch, J. 599 Jasik, P. 903 Jauhiainen, M. 623, 111, 286, 354, 378, 384, 442, 652, 690 Jay-Christian, H. 476 Jayaraman, S. 630, 708 Jazet, I. 90 Jean-Charles, G. 555 Jebari, S Jelev, D. 917 Jelić Ivanović, Z. 122 Jelić-Ivanović, Z. 436, 741, 874 Jeney, V. 475 Jenkinson, F. 988 Jensen, E. 389 Jensen, G.B. 427 Jensen, S.L. 332 Jenty, M. 283 Jeon, S.M Jeong, S.J. 420, 444 Jeonggeun, M Jezkova, K. 494 Ji-Yan, C. 902 Jianbin, Z. 902 Jiang, L. 489 Jiang, Y. 822, 824 Jiang, Y.D. 764 jinbo, L. 809 Jinga, M. 805 Jingwen, L. 337 Jiyan, C. 490 Jo, Y.H. 560 Johansson, J. 118 Jokitalo, E. 204 Joksić, J. 122 Jon, S Jones, A.F. 666 Jones, G Jones, J. 889 Jones, R. 362 Jönsson-Rylander, 446 A.C. Jonung, T. 249 Joo, H.J. 738, 739, Joo, N.S Joosten, L. 106, 270 Joosten, S. 556 Jörg, H. 48 Jørgensen, A.B. 237 Joris, P.J Josa-Laorden, C. 505 Jouent, X Jovanova, S. 678, Ju Won, S. 552 Juhász, I Jukema, J.W. 245, 269, 293 Jukema, W. 113, 446, 578 Jula, A. 354 Julius, U. 403, 682 Julve, J. 384, 425, 944 Jumaa, H. 307 Jung Won, S Jung, C.H. 405, 737 Jung, S.I Juno, C. 245 Jurado, M.A. 938 Justiniano, H. 283 K Ka Wah, L. 952 Kaaroud, H. 909 Kader, T Kaiser, P. 789 Kajani, S. 534 Kakaletsis, N. 794 Käkelä, R. 378 Kakino, A. 636 Kalbousi, S. 638 Kalil, J. 522 Kalimanovska- 741, 874 Oštrić, D. Kalkan, A.K Kalkavouri, A. 736 Kalminaovska 122 Oštrić, D. Kals, J Kamenihina, I. 454 Kamiyama, Y Kammoun, H. 223 Kamphuisen, P.W. 413 Kamran, M Kang, B.G Kang, D.O. 120 Kanjuh, V. 821 Kanthasamy, V. 897 Kapoor, S. 780 Kapusta, M. 903, 912, 931 karakaya, O. 826 Kararigas, G. 76 Karasek, D. 635 Karatzas, K. 794 Karavia, E. 688 Karbiener, M. 894 Karciauskaite, D Kardassis, D. 130, 206, 437, 527, Kari, A. 220 Karimova, M. 209 Karlafti, E. 736 Karlsson, T. 367 Karolina, R. 801 Karonova, T Karpe, F. 85, 86, 89 Karpov, A. 454, 526, 542 Karpov, Y. 782, Karppinen, S.M. 915 Kasatkina, L Kaser, S. 503 Kashtalap, V. 573, Kasichayanula, S. 976 Kasim, S. 923 Kasim, S.S. 966 Kasimdjanova, G. 744 Kasimov, U. 851, 861 Kaski, J.C. 40, 459 Kaspi, A Kassner, U. 935, 989, Kastelein, J. 119, 244, 390 Kastelein, J.J. 463 Kastl, S. 541 Katano, H. 593 Katarzyna, G. 801 Kathiresan, S. 946 Katkó, M. 702 Kato, Y. 579, 610, 727, 755, 756, 905 Katsilambros, N Katsilambros, Ν. 382 Kaudewitz, D. 312 Kauhanen, D. 275 Kaun, C. 418, 720 Kawakami, K. 855 Kawasaki, M. 642 Kawase, R. 63, 395, 653 Kawashiri, M.A. 948 Kaya Kocabas, E. 953 Kaya, E. 294 Kayikcioglu, M. 953 Kayıkcıoglu, M. 951, 984 Kaynar, L. 984 Kazan, H. 269 Kazdova, L. 421, 661, 877, 895 Kebryakov, A. 728, Kedenko, I Kedenko, L. 411, 503, 662, Keenan, A. 889 Kelleher, C Kellici, T Kenjaev, M. 567, 570, 571, 1 195, 1 221, Kenjaev, S. 570 Kenny, R.A. 980 Kerr, A. 62 Kershaw, E. 285 Kessler, T. 240 Keun Ho, P Keun-Hwa, J. 552 Keyserling, C. 714 Khaitov, S Khalikulov, K Khalil, A. 110 Khallou-Laschet, J. 474 Khan, F. 114, 289 Khanal, M.P. 659 Kharazmi, F Khasanova, Z Khaw, K.T. 627, 680 Kheder, R. 916 Khedher, S , Khessairi, N. 859 Khiari, K. 858, 859, 867, 909 Khokhlov, L. 750 Khokhlov, R. 750 Khoury, É. 247 Khromova, A. 591, 603 Khurana, I. 239, Kianpour, P. 918 Kiechl, S. 312, 411, Kiemer, A.K. 492 Kikas, P. 657 Kikuchi, H. 457 Kim, B. 751 Kim, B.W. 761 Kim, C.G. 398 Kim, C.J. 999 Kim, D.J. 729 Kim, D.W. 398 Kim, E Kim, E.J. 120, 1 000, Kim, E.M. 350, 371 Kim, H.C. 729 Kim, H.J Kim, H.K. 120 Kim, H.L. 512, Kim, H.S Kim, J.M. 552 Kim, J.W. 120, 1 000, Kim, J.Y. 559 Kim, K.C. 404, 564 Kim, K.S Kim, M.A. 512, 999, Kim, M.H. 398 Kim, M.J. 404, 560, 564 Kim, N.H

101 INDEX Kim, S. 405, 444, 493, 737 Kim, S.G. 398 Kim, S.H. 512, Kim, S.M. 631 Kim, W.H. 493 Kim, Y.C Kim, Y.G Kim, Y.O. 439 Kim, Y.S. 493, 564 Kimura, S. 456 Kimura, Y. 457 Kingwell, B. 223, 314, 362 Kintscher, U. 285 Kinz, E Kirchmair, R. 422 Kiriazis, H. 223 Kiriyama, M. 338 Kirsch, A. 422, 499 Kirschner, A. 503 Kiseleva, T. 606 Kishimoto, Y. 537, Kiss, A. 789 Kiss, M. 307 Kitslaar, P.H. 399 Kivelä, A. 495 Kjellmo, C.A. 864 Kleber, M.E. 396, 409, Kleijnen, J Klephortova, I. 860 Klesareva, E. 551, 679 Klevstig, M. 647 Klimes, I Klinghammer, L Kloch-Badełek, M. 931 Klopfleisch, R. 285 Kłosiewicz- 956 Latoszek, L. Klotsche, J. 396 Klouras, E. 753, 928, 977, 978, Kluge, S. 383 Knezl, V. 565 Knoflach, M Ko, A. 241 Ko, J. 493 Kobayashi, J. 621 Kobayashi, M Kobayashi, T. 63, 395 Kocabas, E.K. 951 Kochueva, M. 869 Kocourkova, L Kocyigit, D. 294, 715 Koenig, W. 397 Kofoed, K. 211 Koike, T Kolb-Lenz, D. 443 Kolb, D. 622 Koliakos, G. 736 Kollerits, B. 411, Komatsu, T. 693, Kondo, K. 537, König, C Konno, S. 899 Konnov, M. 734, 735 Kono, H. 457 Kono, S. 461 Konstantin, D. 418 Konstantinides, S. 657 Konstantopoulos, 382, P. Kontogianni, V Kontush, A. 104, 711 Kooijman, S. 111, 210 Kook, H. 350, 371, Kook, T. 371 Koolwijk, P. 481 Kopecky, C. 699 Kopecky, J. 889, 892 Koplyarova, N Koppensteiner, R. 507, 771, 772, Kopru, C. 294 Kopyta, I Kopytova, A. 740 Korbelius, M. 335 Koren, M. 462, Koricanac, G. 373 Korkusuz, P. 294 Kormi, I. 410 Korneva, V. 997 Korou, L.M. 382, Koseki, M. 63, 395, 653 Koshurnikova, M. 582 Kostaki, S. 794 Kostara, C. 709 Kostner, G. 135, 263, 960 Kotoulas, C. 813 Kotseva, K. 73, 116, 769 Kotula-Horowitz, K. Kotur-Stevuljevic, J. 796, 840, 841, Koutoulakis, E. 813 Koutsouri, A Kouznetsova, T. 768 Kovalyov, L. 454 Kovalyova, M. 454 Kovanen, P. 65, 96, 111, 230, 354, 378 Kovanen, P.T. 204 Kowala, M. 449 Kozhanova, A. 793, 906, 911 Kozhevnikov, D. 400, 728 Koziolova, N. 604, 605 Kozireva, A. 728 Kozlov, K. 510 Kozlov, S. 473, 853 Králová Lesná, I. 515, 562, 535 Králová, A. 562, 535 Krämer, B.K Kraml, P. 517, 558 Krane, V Krapf, C. 351 Kratky, D. 279, 284, 335, 443, 622 Krempf, M. 648 Krempler, F Krishnan, A. 767 Kristensen, T. 211 Kristiansen, K. 889 Kristinsdóttir, L.B Krizak, J. 565, Kronenberg, F. 18, 28, 241, 278, 295, 309, 411, 1 079, Kroon, J. 81, 481 Krott, L.M. 88 Kruger, R. 619 Kruse, C Krychtiuk, K. 541 Kubalska, J. 956 Kubo, T. 338 Kucinskas, V Kucinskiene, Z.A Kuehn, C Kühn, C. 377 Kuiper, J. 307, 760 Kuivenhoven, J.A. 241, 287, 331, 413 Kukharchuk, V.V. 947 Kulbak, V Kulik, A. 584 Kulikowski, E. 118 Kulkarni, H. 449 Kumar, P. 847, Kumar, S. 449 Kume, N Kumon, Y. 561 Kuo, S.Y Kupchynskaya, O. 811 KURIATA, A. 577 Kurilshikov, A. 832 Kurtoglu, E. 984 Kurtz, C. 465, 976 Kuryata, A. 497 Kuryata, O. 786 Kurzejamska, E. 800 Kutikova, L. 359, 760 kutkiene, S. 784 Kuznetsov, V. 538, 557 Kuznettsova, T. 997 Kuzniewski, M. 903 Kuzuya, M. 484, 838, 854 Kvantaliani, T. 844 Kvapil, M. 871 Kvarnstrom, M. 464 Kvetnoi, I. 510 Kwang Kwon, K Kwang-Yeol, P. 552 Kwok, S. 426 Kwon, D.H. 350, 371, Kwon, H.M. 665 Kwon, S.U. 763 Kwon, S.W. 665 Kyounghoon, L Kypreos, K. 688 Kyselak, O. 950 Kyung-Hyun, C. 631 L La Spada, M.P. 954 Laajala, T.D. 378 Laake, K Laakso, M. 241 Laaksonen, R. 131, 275, 639 Labib, M. 933 Labrador-Barba, E. 866 Labudovic, D. 678, Lacambra-Blasco, 505 I. Lackman, I. 745 Laclaustra, M. 766 Lagares Carballo, 888 M. Lagares, M. 904 Lagerstedt, J. 408 Laguna, J.C. 508, Lahiani, S. 858, 859, 867, 909, 1 171, 1 172, Lahoz, C. 766, 921, 975 Lai, H.Y. 105 Lalive, P. 407 Lamari, A. 803 Lamb, H. 113 Lamb, H.J. 293 Lambert, G. 119, 209, 645 LAMBERTON, F. 292 Lamina, C. 411, Lamiquiz Moneo, I. 971 Lamiquiz-Moneo, I. 115, 765, 921 Lammertyn, L. 619 Lamminmäki, U. 690 Landlinger, C. 245 Langer, A Langrova, H Langslet, G. 244 Lanska, M Lanska, V. 724 Lappegård, K.T. 466, 864 Laringe, M. 924, 925 Larsson, L. 89 Larsson, M. 601 Laskaris, A. 846 Lass, A. 284 Laufs, U. 50, 381, 624 Laura, T. 118 Lauridsen, B. 211 Laurila, P.P. 111 Laurinavicius, A. 920 LAVENNE, F. 292 Lavie, G. 932 Lavier, J Lavoie, J.M. 643 Lawrence, T. 704 Lawson, A.J. 666 Lawson, N. 482 Layland, J. 723, Lazarczyk, M. 800 Lazzarato, L. 491 LE BARS, D. 292 le Cessie, S. 293 Le Goff, W. 104, 365 Leach, N. 913, 992 Lebedev, I. 520, Lebedeva, A. 548, 555, Lebedeva, N. 868, Lechleitner, M. 499 Lecorps, G. 463 Lecour, S. 710 Lecube, A. 425 Lee, E Lee, E.M. 120 Lee, E.Y. 559, 646 Lee, H.L. 512, Lee, H.W. 761 Lee, J.B Lee, J.E. 884 Lee, P.T. 773 Lee, S. 738, 739, 751 Lee, S.H. 493, Lee, S.K Lee, S.N. 748 Lee, S.R. 493 Lee, S.Y. 120 Lee, W.J. 405, 737 Lee, Y.B. 439 Lee, Y.S. 751,

102 INDEX Lee, Y.U. 350, 371, Leguina-Ruzzi, A. 478 Lehti, S. 204 Leighton, B. 446 Leiherer, A. 366, 731, 732, 733, 839, 879, 883, 991, 1 067, 1 136, 1 137, Leitersdorf, E. 714 Leitges, M. 704 Lek, M. 641 Leoncini, E Leopold, C. 622 Leow, M.K.S Lepore, S.M Leren, T.P. 957, Lesnik, P. 104, 365 Letourneur, D. 79, 271 Levels, J Levin, L. 757 Levin, M. 647 Ley, K. 38, 125 Lhomme, M. 104, 711 Li Tin, S.P. 994 LI, B. 723, Li, J. 524 Li, M. 524 Li, S. 545 Li, Y. 278 Li, Y.H. 773 Li, Z. 273 Liamis, G. 753, 977, 978 Libby, P. 93, 306 Liberopoulos, E. 753, 928, 977, 978, Licata, V. 954 Lichtenstein, A.H. 2, 6, 379 Licona-Rashid, M. 717 Liem, A. 760 Liepold, E. 368, 438, Liew, H , Lim, D.S. 738, 739, Lim, H.E , Lim, H.M Lim, W.H. 512, Lima, A , Limon, J. 956 Limongelli, G. 924, 925 Lin, S.H Lin, Y.C. 445 Lindahl, M. 408 Lindau, A. 306 Lindholm, B. 47 Lindholt, J.S. 834 Lindqvist, P. 595, 596 Lindsberg, P. 204, 354 Liorda, E. 736 Liptak, B. 565 Lira, A. 462 Lisa M., C. 48 Littman, K Liu, C. 695 Liu, C.S. 341 Liu, D. 362 liu, H. 809 Liu, J. 248 Liu, P. 695 Liu, P.Y. 105, Liu, Q. 524 Liu, X. 822, 823, 824 Liu, Y. 426, 902 Liwen, L. 490 Llargués, E. 944 Llorente-Cortés, V , 202 Lo Gullo, A. 496, 506, 675 Lo, W.Y. 810 Łoboz-Grudzień, 599 K. Logunova, N. 782 Logvinenko, A. 811, 812 Løland, K.H Lombardi, M. 491 Long, R. 267 Lopez Tinoco, E. 614 López, G.I. 995 Lopez, L.R. 277, 417 Lopukhova, V Loregger, A. 209 Lőrincz, H. 435, 467, 612, 702, 1 151, 1 153, Lorkowski, S. 383 Lorza, E. 827 Loßnitzer, D. 274 Loubarinhas, G Loureiro, P Lövgren, J. 690 Lu, R. 693 Lu, Y.J. 822 Lualdi, A , Lucas, A. 107, Lucena, M Lucius, B. 359, 760 Luczak, E. 518, 801 Ludger, S. 48 Luetjohann, D Luginova, Z. 582 Luigi, S Luirink, I. 390, 968 Luna, A Luna, P. 667 Lundbye- 654 Christensen, S. Lundstrom, T. 464 Luongo, D Lupattelli, G. 849, 865 Lūriņš, J Lüscher, T. 719 Lüscher, T.F. 127 Lutgens, E. 128, 302, 303, 305, 556 Lütjohann, D Luukkonen, P. 915 Lysne, V. 779 Lysunets, T. 786 M Ma, R. 885 Ma, X. 83 Ma, Y Maas, R. 278 Mabuchi, H. 948 Macchi, C. 337 Mach, F. 58, 60, 407 Machado-Lima, A. 531, 698 Machado, F. 961 Machado, U.F. 698 Machida, T. 621 Macia, A Macic-Dzankovic, 706 A. Maciej, B. 801 Maciejczyk, M. 585 Mackēvičs, V MacRae, L. 268 Madder, R.D. 401 Madero, M. 713 Madl, T. 443 Madreiter- 284 Sokolowski, C.T. Madsen, L. 889 Madsen, P. 332 Maegdefessel, L. 264, 266 Maffioli, P , 1 189, Mafra, J.M. 857 Magaña Torres, 959 M.T. Magaña-Torres, T. 945 Magdalena, C. 801 Magné, J. 203 Magni, P. 337, 386 Magnoni, M. 616 Magnussen, C. 758 Magomedov, R. 783 Mahvi, B Mai, A. 267 Maistry, T. 759 Majnaric, L. 967, Majumder, A.A.S. 820 Makarenkova, K. 929, 940 Makeeva, O Makino, H. 949 Makri, E. 617, 618 Maksimow, M. 423 Makuuchi, A Malagaris, I Malchikova, S Malcnikova, S Malczewska- Malec, M , 546, Maldaner, V Maldonado, N. 42 Malik, V. 216 Malinska, H. 421, 661, 877, 895 Mallat, Z. 307 Malyutina, S Mamareli, V. 813 Mamarelis, I. 813 Mamone, F. 496, 506, 675, Mancas, S. 769 Manchenko, O. 860 Manchurov, V Mancina, R.M Mandraffino, G. 496, 506, 588, 675, Manea, V. 862 Maneerat, Y. 569 Manfredi, A.A. 616 Manfredi, M. 626 Mangas, A. 888, 904, 1 099, 1 109, Mangels, N. 333 Mangelsdorf, D. 139 Mangge, H. 894, 1 142, Mannarino, E. 865 Manno, G Manolaki, N Manolio, T. 34 Mansilha, H Mansurov, A Mantovani, A. 222, 458 Manzato, E. 121, 725, Manzini, S. 131, 372, 511, 639, 689, Maoui, A , Mapelli, M , Marães, V Marcais, C. 625, Marchianò, S. 347 Marchini, T. 470 Marco-Benedi, V. 115, 765, 975 Marcovina, S. 669, 670 Marcovina, S.M. 394 Marengo, E. 626 Marenzi, G. 530 Margolis, L. 548, 555, mariani, P. 865 Marianne, S Mariano, C. 943, 993, Marin, R. 725 Marinova, C. 914, 917 Markov, A , Markova, I. 421, 661, 877 Markus, H. 48 Marlena, B. 801 Marmelo, B Marmontel, O. 625 Maroto, A.S. 129 Marott, S. 429 Marques 972 Gonçalves, R. Marques, B Marques, N Marsche, G. 374, 440, 707, Martín-Campos, 944 J.M. Martin-Lorenzo, M. 129 Martin, C. 637, 985, Martin, R. 244 Martinelli, N. 626, 656 Martínez-Marin, M. 505 Martinez-Marin, R. 505 Martínez-Ramírez, 713 M. Martínez-Vea, A. 434 Martinez, L.O. 101, 281 Martínez, M. 774 Martinez, P.J. 129 Martinez, T.L.R. 981, 1 166, Martinotti, S. 626 Martins, D Martynov, S. 860 Maryukhnich, E. 548 März, W. 396, 406, 409, 624, 937, 1 146, Mas-Oliva, J. 64 Masana, L. 121, 393, 944 Mase, M. 593

103 INDEX Masenko, V. 526, 542, 853 Mashele, N. 502 Masson, G. 93 Mastorakos, G. 382 Masuda, D. 395, 653, 845 Mata, P. 945 Matas, L. 944 Matchin, Y. 686 Mateo-Gallego, R. 115, 765, 766, 921, 971 Mateva, L. 914, 917 Mathisen, M. 864 Matikainen, N. 241 Matmurotov, Q. 851, 861 Matsuda, H. 395, 653 Matsuzawa, Y. 20, 361 Matter, C.M. 127 Matz L., R. 283 Maurer, G. 418, 541 Mauri, M. 938, 944 Mavromoustakos, T. Mawson, T. 93 Mayer, G. 643 Mayer, L Mayos, J. 944 Mayr, M. 312 Mazeikiene, A Mazzolai, L Mc Crimmon, R. 114 Mc Neilly, A. 114 McAhren, S. 449 McCann, A. 779 McCormick, S. 112, McCullough, P.A. 277 McDaniels, K. 704 McGillicuddy, F. 534, 694 Mchirgui, N McKendrick, J. 392 McKey, S McLoughlin, E. 719 McParland, J. 430 McWherter, C. 244 Md Yasin, M. 716, 965, 966 Meakin, P. 289 Medbury, H. 545 Medeiros Bastos, 972 G. Medeiros, A.M. 360, 943, 945, 955, 985, Mehegan, J Mehrad, H. 580, 600, 607, 611, 1 020, 1 037, Meikle, P. 223, 314, 362, 449, 658 Meiler, S. 128, 305 Meinitzer, A. 511, 1 142, Meisinger, C. 411 Meitinger, T. 240 Mekala, A.P. 536 Mele, L. 692 Melki, A. 867 Mellett, N. 314 Mellgren, G. 363, 367 Mello, A.P.Q. 814, 981, 1 166, Melnichenko, A. 632, 633 Melnikov, I. 473 Melnikov, M. 830 Mels, C.M. 619 Méndez-Acevedo, 64 K. Mensink, R. 340, Mensink, R.P. 103, 1 096, 1 100, Menzel, J. 412 Merezhanova, A Messa, P Messika-Zeitoun, 474 D. Messner, B. 477 Metelskaya, V. 629, 640, 663 Metso, J. 384, 623, 652 Mezzano, D. 478 Miarka, P. 903, 912 Michael, L. 449 Michalis, L.K. 399 Michel, J.B. 474 Michell, D. 268 Mickiewicz, A. 956 Mieth, M. 278 Migliorino, D Mignano, A Mijovic, R. 870 Mika, P. 584, 585 Mikellidi, A Mikhaleva, O. 900 Mikic, M Milaciu, M. 992 Milano, G. 450 Milanova, M. 791 Milicua, J.C.G. 637 Milionis, H. 432 Miljkovic, M. 436 Miller, D. 61 Miñambres, I. 876 Ming, X. 479 Minicocci, I. 121 Ministrini, S. 865 Minniti, M.E. 47 Mintz, G.S. 83 Miranda, M. 127 Mirchi, M. 817 Miroshnikova, V. 740, 890 Mishchenko, A Misiano, G. 954 Mistri, A.K Mitish, V. 793 Mitro, N. 267 Mitrofanov, K Mitroshkin, M. 686 Miu, P. 673 Miura, K. 537, Miwa, K. 338 Miyamoto, Y. 949 Miyashita, K. 621 Miyata, K. 537, Miyazawa, T. 886 Miyoshi, T. 586 Mlih, M. 283 Mo, F.E. 445 Mo, Z.C. 822, 823, 824 Mocan, M. 509 Moeton, M. 209 Mohd Ismail, A. 716 Mohd Kasim, N.A. 441, 485, 487, 716, 923, 965, 966 Mohd Mokhsin, N.A , 716, 965, 966 Mohd Nasir, N. 716, 923 Mohd Nor, F. 681 Mohtar, F Mohtashami, R. 918 Mokhort, T. 852 Mokhtar, S.S. 681 Mokhtari-Dizaji, M. 580, 607 Molahedh, Y , Mollaki, V Molnár, Á Mombelli, G. 963 Momiyama, Y. 537, Monier, S. 711 Monsalvo 614, Hernando, M. Monsalvo- 888 Hernando, M. Monsalvo, M. 615 Montani, J.P. 479 Montecucco, F. 407 Mora-Brugués, J. 384 Morales, C. 944 Morbini, M. 380, 391 Moregola, A. 458 Moreno, X Mori, K. 338 Mori, M. 948 Mori, T.A. 471 Moriarty, P. 667, 910 Moriarty, P.M. 668 Moriconi, A. 865 Morihara, R. 583 Morlotti, B. 386 Morreale, P Morris, A. 95, 385 Morshed, S. 107, Mortensen, M.B Morvan, M. 474 Moschen, A.R. 312 Moschetta, A. 205, 208 Mospan, M. 811 Mosteoru, S. 769, Mostoslavsky, R. 127 Motazacker, M.M. 241, 286, 331 Motilva, M.J Motta, B.M Moulin, P. 242, 625, Moura, V. 522 Mousavi, F. 566 Moxon, J. 362 Mucher, E. 346 Muckenthaler, M. 102 Mueller, P. 95 Mueller, T. 882 Muendlein, A. 366, 731, 839, 991, Muid, S. 441, 485, 923 Muinjonov, B. 597, 726, 787, 788, 831, 979, 1 025, Mukhamedova, B Mukhamedova, M. 572 Mulder, M. 717 Mullan, R. 650 Müller, G. 403 Munakata, M. 899 Mundal, L. 957 Mundra, P. 314 Muñoz Hernández, R. Muñoz, M. 434 Muntean, C Muntoni, S. 121 Murakami, K. 338 Murakami, M. 621 Muro, A.F. 554 Murphy, C. 980 Murrin, C Murtazaev, S Musayeva, Y Musikhina, N. 538, 557 Mussbacher, M. 448 Mut-Vitcu, G. 769 Muthuramu, I. 126, 655 Muxel, R. 241 Muzalevskaya, M.V. 718 Myhre, P Mysliwiec, M. 956 N Na, J.O , Nabika, T. 703, Nabrozidis, A. 428 Nachtigal, P. 480, 494 Naderi, G.A. 721 Naeimi Kararoudi, 865 M. Naessen, T. 601 Nafakhi, H. 887, 891, 896 Nagai, A. 703, Nagao, M. 886 Nagasaka, R Nagel, F. 789 Nagel, G. 770 Nagornova, K. 613 Nagy, E.V. 612 Nahapetyan, H. 346 Nahon, K. 90 Nahrendorf, M. 93 Nair, D. 952 Najib, S. 281 Naka, K.K. 399 Nakagawa, T Nakajima, K. 621 Nakamura, K. 586 Nakandakare, E Nakandakare, E.R. 531, 698 Nakanishi, C. 948 Nakano, Y. 583 Nakata, C Nakatani, K. 395 Nakaya, N. 461 Nakayama, T. 456 Nam, Y.S Nan, R. 805 Narain, R. 815, 816 Narayanaswami, V. 641, 651 Nascimento, T. 781 Nasias, D. 437 Näslund, U. 596 Natale, F. 924, 925 Naumenko, E. 852 Naumov, V. 454, 526, 542 Navarova, J. 565, Naviglio, D

104 INDEX Nawawi, H. 441, 485, 486, 487, 681, 716, 923, 965, 966, Nawrot, T. 502 Nayeri, H. 721 Nazarenko, M. 520, Nechaeva, B NEDELCIUC, I. 575 Neely, D. 369, 988 Negi, P. 690 Nègre-Salvayre, A. 711 Negrean, V. 913, 992, Neimark, A. 740 Nekaies, Y. 638 Nekrasova, T.V. 718 Nelson, J. 209 Nelson, J.K. 664 Nemeckova, I. 480, 494 Neroev, V. 606 Neskudla, T. 871 Nestel, P. 314, 658 Nestvold, T. 864 Netea, M. 106, 270 Neville, M. 89 Nezafati, P Nezami, N. 817 Nezic, D. 821 Ngo Sock, E.T. 643 Nguyen, S.D. 204, 378 Ni, C.W. 482 NICA, A.S. 574 Nicholls, S. 61 Nicoletti, A. 474 Niculescu, L.S. 701, Nielen, T. 270 Nielsen, S. 369 Nieves, J. 553 Nikiforov, N. 532 Nikitin, A. 868 Nikitin, A.G Nikitin, Y. 768 Nikitina, N , 1 074, Nikitskaya, E. 548, 555 Nikkola, E. 241 Nikolaev, M. 740 Nikolic, S. 870 Nikolova, A. 791 Nilsen, R.M. 249 Nilsson-Wolanin, 408 O. Nilsson, J. 290 Nilsson, S.K. 88 Ning, T. 902 Nishida, M. 63, 395, 653 Nishida, T. 693, Nishiuchi, J. 561 Nizomov, A. 567, 570, 571, 572, 1 018, Njølstad, P.R. 363, 367 Noale, M Nobécourt, E. 645, 648 Noels, H. 291 Noeva, E. 551 Noguchi, H. 456 Nohara, A. 948 Nolasco, P. 522 Nolte, I.M. 413 Nony, S. 625 Norata, D.G. 431, 554 Norata, G.D. 222, 301, 458, 616, 1063 Nordestgaard, B. 75, 211, 227, 237, 254, 429, 669, Nordestgaard, B.G. 123, 427, Nordrehaug, J.E Norioka, N Noto, D. 121, 954, Notsu, Y. 703, Novakova, D. 724 Novakovic, R. 821 Novikova, A. 568 Novikova, L. 454 Novitskaya, A. 573 Novo, G , Novo, S. 819, 1 209, Novoa, J.M. 494 Ntallas, I Nugraha, F. 576 Nurmuhammat, A Nussbaum, K. 127 Nusshold, C. 499 Nygård, O. 275, 779, Nygård, O.K. 363, 367 Nyman, E. 596 O O Reilly, M. 534, 694 Obendorf, F Oberkersch, R.E. 416 Obregon Gonzalez, A. Obrowsky, S. 335, 622 Odegova, A. 746 Ogawa, K Ogundipe, T. 514 Ogura, M. 344, 700, 949 Oguz, S.H. 715 Oh, D.J. 120, 1 000, Oh, G.T. 420, 444 Oh, P. 392 Oh, P.C Ohama, T. 395, 653 Ohguro, T. 561 Ohmori, R. 537, Ohta, N. 949 Ohta, T. 390 Ohta, Y. 583 Ohtake, A. 390 Oikawa, S. 461, 886 Okada, T. 63, 390, 395, 653 Okazaki, M. 653 Okruhlicova, L. 565, 1 015, Okutan, H. 984 Okuyan, E. 777 Oldoni, F. 331 Oleynikov, V. 589, 590, 591, 603, Oliveira, G Oliveira, H. 827 Oliveira, M. 843, Olivieri, O. 626, 656 Oliyarnyk, O. 421, 661, 877 Olkkonen, V. 111, 286, 495 Olset, H Omote, Y. 583 Omrane, M Onda, A. 457 Ongen, Z Ooi, E.M. 394 Öörni, K. 47, 100, 204, 378 opan, S. 826 Opie, L. 710 Oppitz-Plörer, C. 21 Opris, S. 705, 802 Orășan, O. 992 Oravec, S. 541, 720 Ordóñez Llanos, J. 630 Ordóñez-Llanos, J. 876 Orekhov, A. 532, 632, 633, 1 066, 1 073, 1 074, 1 075, 1 076, Orekhova, V , Orera-Peña, M.L. 866 Orgera, G. 550 Orhan, B. 833 Orlov, P. 929, 940 Oscar, C Ose, L. 957 Osipova, I. 557 Osokina, A. 551 Ossoli, A. 650 Oster, D. 492 Osto, E. 719 Ostolaza, H. 637, Ottino, J. 938 Otto, M.E Oueslati, I. 858, 859, 867, 909 Ouguerram, K. 648 Ouweneel, A.B Ovsyannikova, A. 832 Ozan Tiryakioglu, N. Ozcebe, O. 984 Ozerova, I. 629, 640, 663 Ozmen, F. 294 Ozsvar-Kozma, M. 307 P Paapstel, K Pacifico, A. 121 Pacioni, F Packard, C. 49 Packard, C.J Padilla-Mata, V Padroni, M. 407 Pagano, M Pagava, Z Pagel, P. 90 Paiva, A. 827 Pajukanta, P. 241 Palesano, O. 954, Palmen, J. 238 Palmisano, S. 671, 749 Palo, S. 706 Palomar Muñoz, C. 614 Palominos, M. 478 Palotie, A. 241 PALTINEANU, B. 539, 628 Panagiotakos, D. 762, 846 Panahi, Y. 918, Panchal, A. 667 Panderi, A Panetta, D. 818 Pang, J. 355, 471, Pannier, B Panov, D. 795 Panteleeva, A. 740, 890 Pantoura, M. 617, 618 Panzavolta, C Panzoldo, N.B. 983 Paone, S. 489 Papadopoulou Pozatzidou, D. Papadopoulou, A Papadopoulou, S.L. 399 Papavasiliou, K Para, I. 992, Paragh, G. 435, 467, 612, 702, 1 151, 1 153, Parati, G Pardina, E. 425 Parhofer, K.G. 394 Parikova, A. 683 Parini, P. 47, 89, 203, 370, Park, C.G. 120, 1 000, Park, C.Y. 405, 737 Park, D.G. 512 Park, J.H. 738, 739, Park, J.Y. 405, 737 Park, K.C. 404, 564 Park, K.H. 404, 564 Park, K.S. 564 Park, M. 594 Park, S.H. 420 Park, Y.W Parnet, P. 645 Parodi, O. 818 Parolini, C. 131, 372, 511, 639, 689, Parra, E.S. 983 Parvu, M. 775 Pashos, E. 430 Pasqualini, L. 865 Passarelli, M. 531, 698, Pasterk, L Pasterkamp, G. 311 Patankar, J.V. 622 Patel, M. 104 Patel, S Patel, V. 545 Patsch, S.M Patsch, W. 662, Pattison, J. 455 PATURET, A. 292 Paul, J.L. 691 Paulweber, B. 68, 272, 411, 503, 662, Paulweber, M. 503 Pauwels, B. 856 Pavanello, C. 121, 386, 963, Pavão, M.L Pavlaki, M. 657 Pavlouskova, J. 973 PAYZIN, S

105 INDEX Pchelin, I. 842 Pchelina, S. 740, 890 Pedersen, E.K Pedersen, E.R. 363, 367 Pedrelli, M. 47, 203 Pedretti, R Pedro-Botet, J. 766, Pedro-Botet, J.C. 975 Pego, M. 592 Peinado-Onsurbe, 425 J. Pelikanova, T. 871 Pellegatta, F Pellegrin, M Pellegrini, N. 697 Pello, E. 768 Pelosi, G. 818, 825 Peloso, G. 946 PENA, C. 539, 540, 574, 628 Penco, S. 963 Peng, H. 341 Peng, X.S. 822, 823, 824 Penning-van 760 Beest, F. Peralta, J. 449 Pereira-Flores, K. 478 Pereira, A. 943, 945, 981, 1 166, Pereira, J. 478 Pérez Cuellar, M. 630 Perez Guerrero, P. 615 Perez Isla, L. 945 Perez Ternero, C. 381, Perez-Calahorra, S. 115, 358, 765, 766, 921, 975 Perez-Calvo, J. 505 Pérez-Hernández, 528 N. Pérez-Hernánez, 356 N. Perez-Marques, F. 667 Pérez-Méndez, O. 713 Pérez-Pérez, A. 876 Perez-Ruiz, M.R. 971 Perez-Serra, A Perez, A. 888, 1 099, Perez, C. 888, 904, 1 099, Peric, M. 821 Perier, M.C Perin, M.A. 781 Perkmann, T. 307 Perrea, D. 382, Perrotta, S. 549, 550 Persègol, L. 711 Persson, A. 290 Pertsoulis, N. 545 Perveen, I. 529 Pery, T. 888 Pes, G. 121 Pesau, G Petelina, T. 538, 557 Peter, J Peter, K. 273, 402 Peters, A. 313, 411 Petersen, C.M. 332 Peterson, K.L. 455 Petrek, M Petrides, F. 119 Petriello, M. 385, Petrini, J. 521 Petrkova, J petrulioniene, Z. 784 petrylaite, M. 784 Pettersson, K. 690 Pfaffenberger, S. 541 Pfeiffer, L. 313 Phillips, H. 942 Piacentini, L Piantadosi, C Piccinocchi, G. 924, 925 Pichler, M Piemontese, A. 692 Pieper, L. 396 Piepoli, M. 316, 318, 325 Pieterman, E. 446 Pieterman, E.J. 245 Pietrzycka, A. 903 Pihlajaniemi, T. 915 Piir, A Piña-Aguilar, R Ping-Yan, C. 902 Pingitore, P Pinthus, J Pinto, F Pinto, P.R. 698 Pintus, P. 121 Piotrkowicz, J , PIRAQUIVE 292 AGUDELO, J. Pirazzi, C Pirhonen, J. 286, 915 Pirildar, S. 984 PIrisi, M. 599 Pischon, T. 412 Pistrosch, F. 403 Piťha, J. 515, 683, 1 068, 871 Pithova, P. 871 Pitsavos, C. 762, 846 Plana, N. 358, 393, 766, 921, 944, 975 Plat, J. 103, 340, 704, 1 096, 1 100, 1 103, Pláteník, J. 517, 558 Pleava, R. 769, Plebani, M Plevin, R. 498 Plösch, T. 804 Pocovi, M. 358 Podesser, B.K. 789 Podpalov, V. 581 Poelz, W. 882 Pogorelova, O. 551, 679 Poirier, S. 98 Pojskic, B. 706 Pojskic, L. 706 Pokrovskiy, A Pokrovsky, A. 793, 906, 911 Pokrovsky, S. 679, 685, 686, 687 Poledne, R. 535, 562, Poli, A. 692 Polis, A. 389 Polizzi, G. 819 Polonskaja, Y Polus, A. 546 Polyakova, E Polyakova, V. 510 Pompilio, G. 450 Ponde, C Pongratz, T. 541 Poon, I. 489 Pop, C. 862 Pop, L. 862 Popeijus, H. 340 Popeijus, H.E. 103 Popescu, A.C Popescu, H. 805 Popescu, R.M Popova, A.B. 947 Popovic, D Pordy, R. 247, 463 Porrini, M Porteous, C Posadas-Romero, 356, 528 C. Posadas-Sánchez, 356, 528 R. Postnov, A. 655, 1 076, Potekhina, A. 551, 679 Potočková, J. 517, 558 Potočnjak, I. 707 Pouwer, M. 245, 446 Povlsen, G.K. 513 Pozzi, C. 898 Prabhakaran, D. 767 PRADA, G. 540, 574 PRADA, S. 540, 574 Prager, M. 720 Pramfalk, C. 89, Prasongsukarn, K. 569 Prassl, R. 199, 894, 1 142, Praveen, P.A. 767 Pravenec, M. 421, 877 Pregartner, G. 707 Prehn, C. 290 Previato, L Princen, H. 446 Princen, H.M.G. 245 Prins, J. 269 Prof. Dr. Dukat, A Prof. Dr. Oravec, S Proietta, M. 544, 549, 550 Przepiorkowska- 903 Hoyer, B. Pu, J. 83 Puhm, F Pujato, M. 94 Pulakazhi Venu, 554 V.K. Pulatov, U. 851, 861 Pulikal, A. 815 Purnomowati, A. 576 Pussinen, P.J. 410 Puzdriak, P. 728, 783 Puzyrev, V. 520, 1 070, Pyanikin, S. 906 Pyatchenkov, M. 501 Pyatkova, I. 906, 911 Pylaeva, E. 551, 679 Pyoung Chun, O Pyung Chun, O Pyush, M. 658 Q Qin, J. 524 Quartuccio, S. 588 Que, X. 455 Quezada-Feijoo, M. Quinaglia e Silva, J.C. Quintao, E Quintao, E.C.R. 698 Quitterer, U Qureshi, A.R. 47 R Raal, F. 465 Raal, F.J. 976 Rabelink, T.J. 269, 483 RABES, J.P. 946 Rached, F. 781, 920 Rader, D. 430 Radovic, B. 284, 443 Radulian, G. 805 Radulović, B. 707 Radulović, S. 499 Radwan, M. 82 Raggi, P. 714 Ragino, Y. 644, 832, 929, 940, 964, Rahimian, R. 508 Rahman, T. 441, 485, 486, 487, 681, 716, 820, 965, 966, Rahmat, R. 441, 923 Rainer, S. 335 Rajani, R Rajkovic, J. 821 Rakhimbayeva, G Rakhimov, R. 752 Rakhimova, R Ramakrishnan, L. 712 Ramaswami, U. 934 Ramirez, C.M. 312 Ramli, A.S. 965, 966 Ramsvik, M.S Ranzato, E. 626 Raptis, N. 617, 618 Ras, R Rasente, Y. 416 Raslova, K Rather, R. 722 Rathmann, W. 411 Rathouska, J. 494 Rato, Q. 993 Raut, M. 659 Ray, K. 61 Ray, K.K. 253 Raz, O. 563 Razny, U. 546, Razvodovsky, Y , Real, J.T. 358 Reaven, P.D. 45, 117 Reblova, K. 973 Rebnord, E.W. 363 Reda, A. 797 Reddy, K.S. 767 Redezuk, G. 983 Redmond, E. 476 Redpath, G. 112 Rega-Kaun, G. 720 Regmi, P. 659 Reiber, J.H.C. 399 Reim, S

106 INDEX Rein, P. 366, 731, 732, 733, 839, 883, 991, 1 067, 1 136, 1 137, Reis de Azevedo 863 Rabello, F. Reis, A Reischl, E. 313 Reiz, B. 240 Religa, P. 800 Ren, K. 822, 823, 824 Rencova, E Renker, M. 274 Rensen, P. 90, 111, 113, 556 Rensen, P.C.N. 210, 293 Rensen, S. 113 Rentz, T. 827 Ress, C. 503 Ressia, A. 961 Retterstøl, K. 957, Revnic, C.R. 539, 540, 574, 628 REVNIC, F. 539, 540, 574, 628 Reyes, X. 945, 961 Rha, S.W. 120, 1 000, Rhainds, D. 696 Rhéaume, E. 696 Rhee, K.S. 493 Riascos-Bernal, D. 94 Ricci,. 337 Ricci, C. 419 Ricci, M Ricci, M.A. 849, 865 Richart, A. 223 Rico Martin, S , Riesmeyer, J. 61 Riga, M. 794 Riksen, N. 106, 270, 556 Riksen, N.P. 669 Ring-Dimitriou, S. 662 Ring, M. 521 Ringdal Pedersen, 275 E. Rinnerthaler, M. 662 Rioja, J. 428 Ripatti, S. 111, 235, 236 Risérus, U Riško, P. 517, 558 Riso, P Ristic, T Ritsch, A. 109, 340, Rivas, A. 630 Rivellese, A Rizzo, B Rizzo, P Robier, C Robinson, J.G. 246, 463 Robinson, T Rocchiccioli, S. 818, 825 Roche, H. 694 Rocio, T. 888 Roda, A Roden, M. 411 Rodriguez -Rosety, 888 M. Rodríguez Cubero, A. Rodríguez-de Miguel, M. 835, 836, Rodriguez-Leal, C. 888, 904, 1 099, Rodríguez-Pérez, 356, 528 J.M. Rodriguez-Rosety, 904 M. Roeters van 106, 121, 717 Lennep, J. Rogers, M. 42 Roglans, N. 508, Rohrer, L. 345 Rolando, B. 491 Romano, D , 1 189, Romanovskaya, E. 589, 590 Romeo, S Romero, E. 938 Romeu, M. 434 Romijn, F. 578 Roncales-Garcia 505 Blanco, F. Ronda, N. 697, 715 Ros, E. 975 Rosa, I Rosa, R. 796, Rosendaal, F. 113 Rosendaal, F.R. 293 Rosenson, R.S. 392 Rosłoniec, E. 584, 585 Rosqvist, F Ross, J Rossell, J. 425 Rossetti, L , 1 034, Rossi, N. 996 Rossini, M Rosticci, M. 380, 391, 749 Roth, A. 407 Roth, E.M. 463 Rothe, M. 285 Rotllan, N. 312 Rovati, G Roversi, G. 407 Roy, A. 712, 767 Rubio-Gracia, J. 505 Rudling, M. 336, 376, Rufinatscha, K. 503 Rui, L. 531 Ruiz-Estevez, B , 904, Ruiz-Laiglesia, F. 505 Rull, A. 630 Ruotolo, G. 61 Rus, H. 536 Rus, V. 536 Ruscica, M. 337, 386, 431 Russo, I. 276 Russo, R Rusu, E. 805 Rusu, F. 805 Rutten, J. 270 Ruuth, M. 378 Rvatcheva, A. 542 Ryan, R.O. 87, 288 Ryazankina, N Rye, K.A. 104, 119, 342, 704 Rymar, O. 832 Rynkiewicz, A. 956 Ryu, J.K Ryzhkova, A , S Sabanovic, S. 967 Saburova, O. 473, 853 Sachdev, V. 622 Sadeghi, M. 806, Sädevirta, S. 915 Saely, C. 366, 731, 732, 733, 839, 879, 883, 991, 1 067, 1 136, 1 137, Saemann, M.D. 699 Sáenz-Aranzubía, 358 P. Saez, C.G. 478 Safarova, M. 686 Sag, S. 984 Sagitov, I. 745 Saheb, S. 244 Sahebkar, A. 672, 918, Sahlin, S Sairyo, M. 395, 653 Saita, E. 537, Saitta, A. 496, 506, 588, 675, Sakata, Y. 63, 395, 653 Sakellarios, A. 399, 818 Sakly, M. 638 Sakri, F.H. 716 Saksi, J. 354 Sakurada, M Sala, A Salakhitdinov, S. 567 Salashenko, A Salatzki, J. 285 Salcioglu, O. 984 Saleh, Y. 587, 790 Salem, M , Salerno, A. 827 Salim, V. 677 Salinas, M. 93 SALMAN, N. 951 Salomaa, V. 410 Salvadori, P.A. 818 Salvayre, R. 711 Salyamova, L. 591, 603, Salzmann, K. 503 Salzmann, M. 448 Samani, N.J. 240 Samoka, A. 587, 790 Samperiz-Legarre, 505 P. Sampietro, T. 976 Sanak, M Sanchez Lopez, Y. 959 Sánchez Muñoz , Torrero, J.F. Sánchez Quesada, 630 J.L. Sánchez- 975, 358, 921 Hernández, R.M. Sanchez-Marteles, 505 M. Sanchez-Orellana, E. Sánchez-Quesada, 384, 876 J.L. Sanda, G.M. 488, 523, 701, Sandhu, M.S. 680 Sang Ho, J Sang Hong, B Sang-Don, P Sangüesa, G. 508, Sanjana, N. 262, 352 Sant Anna Melo, E. 863 Santer, D. 789 Santer, P. 312 Santilli, F Santoro dos Santos 863 Pereira, S. Santos Filho, R. 981, 1 166, Santos, D. 384 Santos, E Santos, F. 843 Santos, M. 592 Santos, R. 920, 945, 976 Sanz-Bescos, C. 505 Sapozhnikova, I. 878 Saraiva, C. 843 Sarantopoulos, A. 617, 618 Sardo, M.A. 496, 506, 675, Sarecka-Hujar, B Sarrafzadegan, N. 806, Sarzani, R Sasaki, J. 461 Sasaki, M. 693, Sasiela, W. 247 Sasiela, W.J. 246 Sassolas, A. 625 Satoh, N. 620 Satta, N. 407 Sattar, N Sausen, G. 93 Savolainen, M. 378 Savopoulos, C. 736, 794 Savostyanov, K. 785 Sawamura, T. 636 Sawant, R Sayfutdinov, R. 613, 848 Sazonova, M. 532, 1 066, 1 074, 1 075, Scarinzi, P. 725 Schaefer, A.K. 789 Schaeffer, C. 283 Schalij, M. 578 Schaltenberg, N. 48 Scharfmann, R. 645 Scharin Täng, M. 647 Scharnagel, H. 396 Scharnagl, H. 374, 409, 624, Schartum-Hansen, 367, H. Schatz, U. 682 Schauer, S. 284 Scheicher, B. 622 Scheideler, M. 894 Scheja, L. 88, 108 Schernthaner, G.H. 507, 771, 772, Schiavetto, E Schiffmann, R. 277 Schilcher, I. 374, 499 Schlager, S. 284, 443 Schlein, C. 88 Schmid, J.A. 448 Schmidinger, B

107 INDEX Schmidt, B. 396 Schmidt, N. 396, 937 Schmitz, C. 291 Schmölz, L. 383 Schneider, M. 278, 772 Schneider, W. 241 Schneider, W.J. 133, 649 Schnitzler, J. 81 Schoepf, U.J. 274 Schofield, J.D. 426 Scholler, E. 283 Schratter, G. 894 Schreier, L. 945, 995 Schulze, M.B. 412 Schunkert, H. 33, 240 Schutte, A.E. 619 Schwab, U. 378 Schwandt, P. 368, 438, Schwarzova, L. 939, 962 Scopece, A. 450 Scotti, I. 616 Scrimali, C. 954 Scrylev, S. 500, 598, 602 Sedova, E. 510 Segura, E. 888, 904, 1 099, Segurado, R Sehar, N. 667, 910 Seifert, R. 367 Sekerkova, A. 562 Seleem, M. 587, 790 Selice, R. 725 Selimovic, H. 706 Seljeflot, I Sella, S Semenkin, A Semenova, E. 998 Semenova, I. 740, 890 Seo, H.S. 120, 1 000, Seo, J.B. 512, Sequeira Duarte, J. 843 Seraceni, S. 407 Serban, M.C. 672 Seres, I. 435, 467, 612, 702, 1 151, 1 153, Sergienko, I.V. 947 Serrano Jr, C.V. 781 Serruys, P.W. 399 SERUSCLAT, A. 292 Seung Hwan, H Seung Woon, R Seyedikhosroshahi, 611 S.A. Shaari, S.A. 681 Shahrawat, R Shakhtshneider, E. 644, 832, 929, 940, 964 Shalaby, A. 797 Shalaeva, A. 744 Shalaeva, E. 752, 851, 861 Shaligram, S. 508 Shalimova, A. 869 Shamkhalova, M. 860, 868, 900 Shamkhalova, M.S Shapira, C. 932 Shapira, I. 563 Shaposhnik, I Sharapov, N Sharashidze, N Sharifi, M. 952 SHARMA, M. 112 Sharma, S. 815, 816 Sharma, V. 880, Sharpe, L. 209 Shchinova, A. 551, 679 Shchipakin, V. 500 Shehab, A , Shehu, J Shelkov, G. 400 Shelley, E. 980 Sheng, Q. 268 Sherbakova, E. 907 Shestakova, M. 860, 868, 900 Shestakova, M.V Shih, M.F Shimizu, M. 579, 610, 727, 755, 756, 905 Shimizu, R Shin, S. 350, 371, Shinohata, R. 621 Shiomi, M Shiotani, K. 693, Shipman, K. 930 Shipman, K.E. 666 Shiqun, C. 902 Shiri-Sverdlov, R. 113 Shishkin, A. 842 Shiue, L. 269 Shkurat, T Shlomin, V. 783 Shlyachto, E Shogenova, M. 454, 526, 542 Shokouhi, B. 817 Shpektor, A. 548, 555, Shrivastava, A Shuto, T Shuto, Y. 886 Si, S. 695 Siahmansur, T. 426 SIALVERA, T.E Sibinga, N. 94 Siebel, A. 223 Siepi, D. 849 Sifuentes Diaz, E. 614, 615 Sigurðardóttir, Y.R Sijbrands, E. 717 Silva, A.P Silva, I.T. 814 Silva, K.S. 698 Silva, R. 592 Sima, A.V. 488, 523, 701, Simental-Mendía, 672 L.E. Simes, J. 314 Simic-Ogrizovic, S. 436 Simionescu, M. 523, 527, 701, 1 082, Simionescu, N Simmelbauer, A. 102 Simon, A. 754 Simonelli, S. 650 Simonetti, P Simonova, Z. 776 Simonyi, G Sinelli, M. 491 Singh, A. 712 Singh, N. 655 Singh, S. 712 Sinisalo, J. 378 Sinke, R. 331 Sinyov, V , 1 074, Sirenko, O. 786 Sirirat, R Sirojiddin, K , Sironi, M. 222 Sirtori, C. 121, 963 Sirtori, C.R. 131, 386, 639, 689 Sisic, I. 706 Skeldal, S. 332 Skilton, M. 758 Škop, V. 421, 661, 895 Skoumas, I. 762, 846 Skroblin, P. 312 Skryabin, N. 520, Sleptcov, A. 520, Smiianova, O Smiianova, Y Smit, N. 578 Smith, W. 619 Smyth, S. 95 So, W.Y. 885 Sobenin, I. 532, 633, 1 066, 1 073, 1 074, 1 075, 1 076, Sobotka, L Söderlund, S. 241 Sodi, R Søfteland, E. 249 Sohrabi, B. 566 Sokolov, A. 501 Sol, W.M.P.J. 483 Soler, C. 944 Soler, J. 434 Solheim, S Solnica, B. 546, Solovieva, E. 582 Soltani, N Somaratne, R. 462, Somerville, R Sommariva, E. 450 Somodi, S , Song, H.C. 439 Song, K.H. 884 Soon Yong, S Sopic, M. 122 Soran, H. 426, 462, 976 Sorin Nicu, B. 509 Soronen, J. 111 Sorrentino, V. 664 Sorsa, T. 410 Soska, V. 950 Sotnikova, R Soyal, S. 662 Soyal, T. 294 Spang, J. 492 Spannella, F Spanou, M. 794 Spasojević 122 Kalimanovska, V. Spasojević- 436, 741, 874 Kalimanovska, V. Speidl, W. 541, 720 Sperlongano, S. 924, 925 Speziali, G. 656 Spina, R. 954, Spira, D. 935, 989 Spitz, C. 128, 305 Spolding, B Sposito, A Stadiotti, I. 450 Stadlbauer, V. 440 Staessen, J. 768 Staffler, G. 245 Ståhlman, M. 647 Stamatelopoulos, K. Stanciu, O. 609, 792 Stancu, C.S. 488, 523, 701, Stanek, V Stangl, G Stangl, H. 415 Stanik, J Stanikova, D Stanisz, A. 796, 840, 841 Stankovic, A. 373 Starodubtseva, I. 543 Staudacher, G. 503 Stauffer, F Stavek, P. 515, 871 Stavri, S Stef, M. 358 Stefan K., N. 48 Stefanadis, C. 762, 846 Stefanovic, A. 436 Stefánsdóttir, B.R Stein, E.A. 465, 976 Steinberg, A. 244 Steinhagen- Thiessen, E. 669, 935, 989, Stender, S. 211 Stenvinkel, P. 47 Stepanov, A Stern, C. 477 Stevens, A. 426 Stewart, F. 650 Steyrer, E. 328 Stiefel, P Stimjanin, E. 706 Stitziel, N. 946 Stivala, S. 127 Stöckl, D. 411 Stoekenbroek, R.M. 680 Stoijkovic, S. 418 Stojakovic, T. 374, 409, 624, Stokic, E. 870, Stoll, M. 945, 961 Stone, G.W. 399 Stosic, Z. 870, Stover, C. 916 Stramba-Badiale, 431 M. Strand, E. 363, 367, Straniero, S Straußfeld, E. 291 Stravinsky, J

108 INDEX Straznicky, N. 658 Strelow Thurow, H. 972 Strijdom, H. 502, 514 Stroes, E. 13, 77, 81, 106, 299, 464, 547, 714 Stroes, E.S. 669 Stroes, E.S.G. 392, 627, Strohmaier, S. 770 Stroniawska- 956 Woźniak, M. Stryeck, S. 443 Stulnig, T. 231 Stumpf, C. 377 Su, C.H. 348 Suarez-Tembra, M. 975 Suchanek, P. 515 Suciu, L Sudjana, P. 576 Sugihara, H. 886 Suh, J.W Suhre, K. 297 Sukhova, G. 93 Sukmanova, I , 1 225, Sullivan, D. 314 Sullivan, D.R. 471 Sulowicz, W. 903 Sumino, H. 621 Sun, J. 248 Sun, W. 677 Sun, Y.T. 516 Sundbom, M Sung Ho, H Sung Woo, K Sung, H.R. 564 Sunkara, M. 385 Suo, R. 823 Suoniemi, M. 639 Susekov, A. 582 Suspitsyna, I , Sutcliffe, M. 349 Suwa, J. 875 Suzuki, N. 537, Svardal, A. 363, Svetlikov, A. 400 Svingen, G.F.T. 363, 367, Svobodova, M. 889, 892 Swartz, E. 93 Sweeney, M. 118 Swiader, A. 346 Swier, V. 82 Swift, C. 277 Swirski, F. 93 Swirski, F.K. 306 Syed, A. 426 Sysi-Aho, M. 275 Szentimrei, R. 435 Szentpéteri, A. 435, 702, Sztanek, F T Ta, H. 273 Tabet, F. 119, 342 Taborsky, M Tada, H. 948 Tae Hyun, Y Tae-Hoon, K Taehoon, A Taghipour, H Taherkhanchi, B. 566 Takahashi, A. 949 Takemoto, Y Takiguchi, S. 693 Talbi, E , Talbot, C. 340, Tallada Iborra, R. 531 Tallgren, T. 690 Talmud, P.J. 238 Talukdar, S. 88 Tam, C. 885 Tam, L. 62 Tamanaha, T. 949 Tamás, F Tamborino, C. 407 Tami, J. 669, 670 Tamura, S Tan Kurklu, T.S Tanaka, N. 338 Tanaka, Y. 579, 610, 727, 755, 756, 905 Tanashyan, M. 500, 598, 602 Tang, L. 465, 976 Tang, Z.L. 822, 823, 824 Tankovskiy, V. 606 Tantry, U.S. 417 Tarasenko, N Tardif, J.C. 244, 696 Tardivel, S. 691 Tarhbalouti, K Tarlarini, C. 963 Tarlovskaya, E. 746, 878, 1 110, 1 165, Tarlovskaya, Y. 776 Tartari, S. 222 Tarzamni, M.K. 817 Tas, S. 704 Taskinen, M. 84, 217 Taskinen, M.R. 111, 241, 387, 463 Tatomir, A. 536 Tauchi-Brück, M. 377 Tauchi, M Taurino, M. 544, 549, 550 Tavares Bello, C. 843 Tavintharan, S. 994 Tawakol, A. 78, 80 TBA, 320, 433 Tegla, C.A. 536 Tejedor, M.T. 971 Tell, G. 275 Tell, G.S. 363, 367 Tellis, C. 928 Temizhan, A. 984 Temporelli, P.L Teng, Z. 349 Teodoro, W Teoh, Y.P. 936, 990 Teplov, A. 906 Terrand, J. 283 Terrin, M. 725 Tershakovec, A. 389 Tervahartiala, T. 410 Tesloianu, D. 575 Tesmenitsky, Y. 93 Tetik Vardarli, A. 953 Thakkar, H. 712 Thaler, B. 418 Thedrez, A. 645 Theodorou, K. 704 Thiersé, D. 283 Thiessen, E.S. 14, 668 Thomaidis, A. 657 Thomas, F Thomaz, S Thompson, P. 314 Thorand, B. 411 Thymiakou, E. 130 Tibolla, G. 347, 431, 472 Ticha, A Tichy, L. 962, 973 Tietge, U. 47, 699 Tietge, U.J.F. 804 Tikka, A. 623 Tilg, H. 312, 503 Timina, I. 906, 911 Timmerman, I. 481 Tinoco Racero, I. 615 Tinoco-Racero, I. 888, 1 099, Tinoco, I. 904 Tiran, B. 707 Tishko, V. 501 Titze, J.M. 54, 55 Titze, S. 278 Tixeira, R. 489 Toell, T Toh, R. 338 Tokgözoglu, L. 72, 255, 294, 296, 715, 984 Toledo, V Toma, L. 488, 701 Tomas, L. 290 Tomashevskaya, Y Tomassini, J. 389 Tomescu, M Tomilova, D. 782 Tomlinson, B. 357, 885 Tondo, C. 450 Toni, D. 544 Tonkin, A. 314 Tootsi, K Tori, M.O Torii, H Toro, R. 614, 904, 1 099, 1 109, Torres-Courchoud, 505 I. Torres, L Toseska- 678 Trajkovska, K. Tosheska Trajkovska, K. Toshev, B. 572, Toth, P. 389 Tothova, V. 724 Touqui, L. 704 Tousoulis, D. 762 Trabattoni, D , Tragante do Ó, V. 240 Trakarnwijitr, I. 723, Tramontana, A Tran, H. 757 Trapani, G. 588 Trautwein, E Trautwein, E.A Travnikova, E Trayhurn, P. 849 Trbušić, M. 707 Tregubov, A.V. 718 Tremblay, K. 353, 660, Tremoli, E. 222, 530, 1 033, 1 034, Trentini, A. 407 Trescher, K. 789 Tretjakovs, P Tribuntseva, L. 750 Trieb, M. 440 Triebswetter, S. 908 Trikash, I Trikha, D. 722 Trindade, L Tripepi, G Tripoten, M. 551, 679 Tritapepe, L. 549, 550 Trivella, M.G. 818, 825 Trnovska, J. 421, 661, 895 Trojak, A. 912 Trompet, S. 293 Trusca, V.G. 527, Trzeciak, J. 584 Tsai, W.C. 516, 773, 919 Tscharre, M.L Tschöp, M. 298 Tselepis, A. 928, 1 035, Tselios, K. 617, 618 Tselmin, S. 403, 682 Tseng, H.C. 533 Tsiantoulas, D. 307 Tsimihodimos, V. 432, 709 Tsimikas, S. 455, 627, 668, 669, 670, 673, 674, 680 Tsoukatos, D Tsoumani, M , Tsujita, M. 375 Tsunoda, T Tsyrulneva, N. 811 Tubeuf, E. 104 Tuckwell, K Tudorache, I.F. 527, Tuimala, J. 354 Tuomi, T.M. 354 Turer Cabbar, A turhan caglar, F.N. 826 Turnbull, A.V. 622 Tuseddo, J.C. 995 Tybjærg-Hansen, A. 237, 211, 427, 429, Tzakos, A Tzani, A. 382, Tziakas, D. 657 Tziomalos, K. 617, 618, 794, U Uboldi, P. 554 Ueda, T Ueland, P. 779 Ueland, P.M. 367, Ulbricht, C. 757 Ulianova, I. 860 Ulmer, H. 770 Umarov, A. 608 ungan, I. 826 Urazgildeeva, S. 400, 718 Usenko, T. 740, 890 Usui, S

109 INDEX Utermann, G. 234 Utkina, E. 687 Uto-Kondo, H. 693, 700, Uusitupa, M. 378 V Vagida, M Valdivielso, J.M. 774 Valdivielso, P. 766 Valenti, L Valenti, V. 954, Valikulova, F Valkov, I. 917 Vallejo-Vaz, A.J van Beek, L. 556 van Bockxmeer, 471 F.M. van Buul, J.D. 481 van Capelleveen, J. 286, 331, 627 van Dam, A. 556 van de Pavert, S.A. 481 Van de Voorde, J. 856 van den Berg, B.M. 483 van den Berg, S. 556 van den Hoek, A. 446 van den Munckhof, 270 I. van der Burgt, Y. 578 van der Hoorn, 245 J.W.A. van der Krieken, 103 S.E. van der Laarse, A. 578 van der Tuin, S. 113 van der Valk, F.M. 669 van der Veer, E. 269 van der Veer, E.P. 483 van der Vorst, E. 704 Van Eck, M. 704, van Esch, H. 269 Van Gaal, L. 215, 719 van Gils, J. 269 van Gils, J.M. 483 van Harmelen, V. 556 van Kooten, C. 269 van Leuven, S.I. 547 van Rooyen, J.M. 619 van Tits, L.J. 127 van Tuijl, J. 106 Van Veldhoven, P. 655 van Vlijmen, B.J.M van Zonneveld, A.J. 269, 483 Vandendaele, L. 856 Vanoli, D. 595, 596 Varava, A. 911 Varbo, A. 123 VARDARLI, A.T. 951 Varejckova, M. 480, 494 Varga, E.V. 435, Varga, V.E. 467, 612, 702 Vargas-Alarcón, G. 356, 528 Variya, B Varol, S. 777 Varret, M. 946 Vasconcelos, C. 843 Vasilieva, E. 548, 555, Vasilkova, O. 842 Vasilkova, V. 852 Vaslin-Reimann, S. 634 Vassalo, T. 742, 941 Vasudevan, A. 277 Vatrano, M. 588 Vaudo, G. 849 Vaverkova, H. 635, 962 Vaysberg, A Vazquez Cardenas, 959 A. Vazquez Alfageme, J. Vecera, R. 421 Vedie, B. 691 Veierød, M.B. 957 Vekić, J. 436, 741, 874 Velagapudi, S. 345 Veldhof, S. 399 Velosa, A.P Vendrame, S Venn, A. 758 Verbeek, R. 680 Verhoeven, A. 717 Verkade, H.J. 804 Veronese, N VERSET, M. 292 Verweij, S. 81, 106 Verwilligen, R.A.F Vesa, S.C. 913 Vianello, D. 725, 987 Vickers, K. 268 Vihervaara, T. 275, 378 Viklicky, O. 683 Vikulova, O. 868, 900 Vikulova, O.K Vila Belmonte, A. 766, 975 Vila, À. 944 Vila, L. 944, Vilela-Martin, J Viljoen, K Villanueva Fernández, E. 835, 836, 837 Villar, J Villarreal-Molina, T. 356, 528 Vinaixa, M. 434 Vincent, V. 712 Vinchi, F. 102 Vindis, C. 346 Viney, N.J. 668, 669, 670 Virzi, J. 407 Visek, J Vishnolia, K Visinoni, C. 898 Visocka, A Vitale, G Vitali, C. 386 Vitverova, B. 480, 494 Vivanco, F. 129 Vlachos, I. 382, Vlad, A Vladimirov, S. 741, 874 Vlaicu, S.I. 536 Voevoda, M. 644, 795, 832, 929, 940, 964, Voevoda, M.I. 947 Vogt, A. 970 Voicu, M Voidazan, S. 775 VOINEA, S. 539, 628 Volpe, R Volpi, N. 416 von Eckardstein, A. 257, 327, 329, 345, 714 Vonbank, A. 366, 731, 732, 733, 839, 879, 883, 991, 1 067, 1 136, 1 137, Vrablík, M. 243, 962, 778 Vrieling, F. 556 Vriz, O. 599 Vuilleumier, N. 364, 407 Vujic, N. 284, 335 Vynnychenko, L Vyzantiadis, T.A W Wade-Martins, R. 62 Wadsack, C. 872 Wahl, S. 313 Wakefield, D. 107 Waldenberger, M. 313 Walder, K Waldmann, E. 394 Wallert, M. 383 Walus-Miarka, M. 903, 912, 931 Wan Ahmad, 716 W.N.H. Wan, J. 873 Wang, A. 248 Wang, C.C. 704 Wang, F. 447, 873 Wang, H.J. 810 Wang, J.M. 105 Wang, K.Y. 456 Wang, L. 339 Wang, P. 447, 873 Wang, Q. 447 Wang, X. 402, 695 Wang, Y. 113, 210 Wanner, C. 699, Wanschel, A. 827 Wareham, N.J. 680 Wareham, N.T. 627 Wasag, B. 956 Wasiak, S. 118 Wasserman, S.M. 976 Waters, D. 119 Wattimena, D. 717 Watts, G. 355, 424 Watts, G.F. 394, 471, 672, 926, 927, Weber-Boyvat, M. 286 Weber, C. 128, 305 Weber, J. 127 Webster, I. 502 Weers, P. 641, 651 Wegscheider, M. 443 Weijers, E.M. 481 Weijler, A. 649 Weikert, C. 412 Weir, J. 362, 449 Welsh, P Wen, J.T Werner, C. 381, 624 Werngren, O. 203 Werstuck, G Werz, O. 383 West, H. 758 Westcott, C. 502, 514 Whittaker, A. 273 Wick, G. 351 Widhalm, K. 960, Więcek, M. 585 Wieczorek- 903 Surdacka, E. Wieffer, H.M. 392 Wiegman, A. 968 Wigren, M. 290 Wiklund, O. 136, 225, 251, Willeit, J. 312, 411, Willeit, K. 503, Willeit, P. 312 Willems van Dijk, 293 J.A.P. Willems van Dijk, K. 113, 210 Willenborg, C. 240 William, K. 248 Williams, H. 545 Wilson, A. 723, Wilson, R. 313 Winkels, H. 128, 305 Wittchen, H.U. 396 Wittenbecher, C. 412 Witztum, J.L. 455, 627, 668, 669, 670, 673, 680 Wohlfahrt, P. 515 Woitas, R Wojciechowska, W. 931 Wojdan, K. 518, 801, 828 Wojta, J. 418, 541, 720 Wolf, D. 224, 470 Wong, G. 314, 362 Wong, M.S. 994 Wong, N. 118 Wood, D. 769 Woong Chol, K Worm, J. 513 Worsfold, B.P. 743 Worth, G Worthmann, A. 48 Worthy, G Woudberg, N. 710 Wu, Y. 704 Wühle-Demuth, M X Xenaki, C Xia, S. 669, 670 Xiao, J Xida, L. 490 Xilifu, D Xiong, S.L. 823 Xu, Y. 695 Y Yadav, R. 426 Yadernaya, A. 568, 728, 850, Yagi, K. 948 Yahya, R. 717 Yakushiji, E. 693 Yamada, K. 593 Yamada, S. 456 Yamagishi, M. 948 Yamashita, S. 63, 395, 461, 653 Yamashita, T. 583 Yamazaki, Y Yanagida, T. 457 Yang-Yen, H.F. 341 Yang, C.M

110 216 Yang, F. 339 Yang, H. 464 Yang, L. 95 Yang, X. 627, 673 Yang, Z. 479 Yano, S. 703, Yarovaya, E. 629, 640 Yasuda, D Yayla Abide, C. 893 Yeang, C. 455, 673, 674 Yen, J.J.Y. 341 Yenercag, M. 984 Yersal, N. 294 Yet, S.F. 348 Yi, C. 210 Yi, G.H. 822, 823, 824 Yilmaz, H. 984 Yilmaz, M. 984 Yin, X. 312 Yin, X.L Yingling, Z. 490 Yki-Järvinen, H. 915 Ylä-Herttuala, S. 37 Yogo, M. 693 Yokota, T. 375 Yokoyama, S. 375, 531, 693 yongqiang, H. 809 Yoo, J.A. 829 Yoo, J.Y. 420 Yoshida, M. 948 Yoshikawa, J Yoshikawa, K. 338 Yoshino, G. 855 Yoshino, H. 855 Yoshiyama, M Youn, T.J Young, J.L. 493 Youngkeun, A Yu, C.W. 738, 739, Yu, T. 524 Yu, Y. 479, Yuan, C. 248 Yue, J. 823 Yurtaev, Y. 783 Yuschak, S. 416 Yvant-Charvet, L. 124, 304 Z Zabakhidze, N. 844 Zafrir, B. 932 Zagajewski, J. 840 Zagidullin, B Zagidullin, N. 745, 907, Zagidullin, S. 745, 907, Zagjewski, J Zago, V.H. 983 Zaibi, M.S. 849 Zak, I Zambon, A. 12, 226, 725, 987, Zambon, S. 121, 725, Zambonin, L Zamfirescu, A. 609, 792 Zamora, A. 944 Zampelas, A Zampetaki, A. 312 Zannis, V. 652 Zannouri, A Zanolin, D. 366, 731, 732, 733, 839, 879, 883, 991, 1 136, 1 137, Zanotti, I. 692 Zateyshchikov, D. 785 Zaytsev, D. 807 Zdzienicka, A Zechner, R. 92, 137 Zelarayán M 961 Zelcer, N. 209, 664 Zelinskiy, V. 830 Zeljković, A. 436, 741, 874 Zelzer, S , Zeng, L. 240 Zerr, A. 283 Zhang, H. 483 Zhang, J. 339 Zhang, P. 83 Zhang, Q.H. 822, 823, 824 Zhao, S. 268 Zhelankin, A. 532, 1 076, Zheleznyakova, A. 868 Zheltova, I Zhemchugov, A. 400 Zheng, H. 452 Zheng, K.H. 547 Zhetisheva, R. 454, 526, 542 Zhokhov, D. 850 Zhou, P. 447, 873 Zhu, W. 268 Zhu, Y. 653 Zhuang, L. 210 Zielinski, L.P. 743 Ziemann, M Zierfuss, B. 507 Zilmer, M Zimetti, F. 697, 715, Zimmer, A. 622 Zimmermann, R. 282, 284 Zimmet, P Zirlik, A. 224, 306, 470 Zito, C. 599 Zivanovic, V. 821 Zivkovic, M. 373 Zizkova, V Zo, J.H. 512, Zotikov, A. 793, 906, 911, Zouhar, P. 889 Zsíros, N. 467, 702 Zuk, M. 956 Zulkarneev, R Zuraeva, Z. 900 Zvintzou, E. 688 Zykov, K Þorgeirsson, G Νomikos, T th EAS CONGRESS May 29 - June 1, 2016 Innsbruck, Austria Recognition, Acknowledgements and Commercial Support

111 84 th EAS CONGRESS PCSK9 inhibitors: a conversation on selecting the right patients Programme Chair: Alberico Catapano, Italy ACKNOWLEDGEMENTS CORPORATE PARTNERS gold Level Corporate Partner Welcome and introduction Who is at greatest unmet need? Clinical perspective How effective are PCSK9 inhibitors in reducing LDL-C? Clinical perspective Alberico Catapano, Italy Michel Farnier, France Panel Erik Stroes, The Netherlands Panel Silver Level Corporate Partner Which patients find it hardest to achieve recommended LDL-C levels? - Familial hypercholesterolaemia Michel Farnier, France - Statin intolerance: gauss-3 data Erik Stroes, The Netherlands Clinical perspective Panel Bronze Level Corporate Partners Will lowering LDL-C with PCSK9 inhibitors reduce CV risk? Closing Q&a and panel discussion Chair s summary and close Alberico Catapano, Italy Panel Alberico Catapano, Italy joint Bronze partners Lunch bags will be provided Amgen (Europe) GmbH Dammstrasse 23 CH-6300 Zug Switzerland Amgen Inc. All rights reserved. EUHQ-NP a

112 84 th EAS CONGRESS ACKNOWLEDGEMENTS The Organising Committee and the EAS Executive Committee would like to express their gratitude and acknowledgement to the following companies for their generous support in the 84th EAS Congress: EXHIBITORS Platinum sponsors gold sponsors silver sponsors sponsors

113 84 th EAS CONGRESS Industry supported sessions Sunday, May 29, :30-13:30 Carl von Rokitansky (Brussel) Hall Monday, May 30, :00-14:30 Nikolai N. Anitschkow (Tirol) Hall Meet the Experts - The Medical Puzzle of HoFH PCSK9 inhibitors: a conversation on selecting the right patients Chairperson: Cesare Sirtori, Italy Chairperson: Alberico Catapano, Italy Jeanine Roeters Van Lennep, The Netherlands Claudia Stefanutti, Italy Marcello Arca, Italy 16:00-17:30 Nikolai N. Anitschkow (Tirol) Hall MOVING PCSK9 INHIBITION FORWARD: The Future of Evidence-Based CV Outcomes in High-Risk Primary and Secondary Prevention Patients Chairperson: Jean-Claude Tardif, Canada 16:00 - Welcome and Introductions Jean-Claude Tardif, Canada 16:05 - Case-Based Approach to Identifying High-Risk Primary and Secondary Prevention Patients Michel Farnier, France 16:25 - Current Guidelines for High-Risk Patients: The Need for Evidence-Based Decision Making to Address Remaining Unmet Need G Kees Hovingh, The Netherlands 16:45 - Cardiovascular Risk Reduction With PCSK9 Inhibition: Evidence-Based Long-Term CV Outcomes Jean-Claude Tardif, Canada 17:05 - Panel discussion/q&a 13:00 - Welcome and introduction Alberico Catapano, Italy 13:05 - Who is at greatest unmet need? Michel Farnier, France 13:15 - Clinical perspective Panel 13:20 - How effective are PCSK9 inhibitors in reducing LDL-C? Erik Stroes, The Netherlands 13:30 - Clinical perspective Panel Which patients find it hardest to achieve recommended LDL-C levels? 13:35 - Familial hypercholesterolaemia Michel Farnier, France 13:45 - Statin intolerance: GAUSS-3 data Erik Stroes, The Netherlands 13:55 - Clinical perspective Panel 14:05 - Will lowering LDL-C with PCSK9 inhibitors reduce CV risk? Alberico Catapano, Italy 14:15 - Closing Q&A and panel discussion Panel 14:25 - Chair s summary and close Alberico Catapano, Italy

114 84 th EAS CONGRESS 13:00-14:30 Karl Landsteiner (Innsbruck) Hall LDL-Cholesterol Update 2016 Chairpersons: Lale Tokgözoglu, Turkey Pepe Zamorano, Spain 13:00 - Welcome and Introduction What s Hot 2016 Lale Tokgözoglu, Turkey Pepe Zamorano, Spain 13:10 - The Clinical Reality Attaining Treatment Targets in 2016 Lale Tokgözoglu, Turkey 13:20 - What Do Recent Combination Studies Teach Us? The Most Recent Insights Peter Toth, USA 13:45 - Novel Findings on Genetics and Mendelian Randomization Heribert Schunkert, Germany 14:00 - The Role of Combination Therapy Defining Treatment Options for the Individual Patient Pepe Zamorano, Spain 14:15 - Panel Discussion Lale Tokgözoglu, Turkey Pepe Zamorano, Spain Tuesday, May 30, :00-14:30 Karl Landsteiner (Innsbruck) Hall PCSK9 therapeutics can we redefine the clinical management of hypercholesterolemia? Chairperson: John Chapman, France 13:00 - Introduction John Chapman, France 13:05 - PCSK9 therapeutics the evidence so far Eli Roth, USA 13:25 - PCSK9 therapeutics early insights from the correlation between LDL-C and cardiovascular events Kausik Ray, UK 13:45 - PCSK9 therapeutics - what do we have yet to learn? Ulrich Laufs, Germany 14:05 - Panel Discussion and Q&A John Chapman, France Eli Roth, USA Kausik Ray, UK Ulrich Laufs, Germany 14:25 - Closing remarks John Chapman, France

115 84 th EAS CONGRESS 14:00-14:45 Nikolai N. Anitschkow (Tirol) Hall 14:10-14:55 Carl von Rokitansky (Brussel) Hall Special Lecture: Novel Concept and Clinical Proof to Address Unmet Medical Needs for the Treatment of Rasidual Vascular Risk Chairpersons: Yuji Matsuzawa, Japan Jean-Charles Fruchart, France 14:00 Welcome and Introduction Yuji Matsuzawa, Japan Jean-Charles Fruchart, France 14:05 Novel generation of Peroxisome Proliferator-Activated Receptor alpha (PPARα) agonists: selective PPARα modulator (SPPARMα) Jean-Charles Fruchart, France 14:25 Clinical proof of concept of SPPARMα developed to be more effective and less harmful Shun Ishibashi, Japan CETP inhibition what s hot in 2016? Chairperson: Alberico Catapano, Italy 14:10 Opening by the chair Alberico Catapano, Italy 14:15 The pharmacologic basis: Recent insights into kinetics Gisette Reyes-Soffer, USA 14:25 Facts, Findings & Expectations Ulf Landmesser, Germany 14:35 Is there a need for a new small molecule? Wouter Jukema, The Netherlands 14:45 Round Table, Q&A Alberico Catapano, Italy 14:05-14:50 Wilhelm Auerswald (Strassburg) Hall MeEt the Expert: Introducing Sebelipase alfa, a novel treatment for LAL-D A case-based meet-the-expert session chaired by Professor Thomas Stulnig Experts will present cases on Lysosomal Acid Lipase Deficiency including early treatment results with Sebelipase alfa

116 84 th EAS CONGRESS Educational Grant Exhibition Information The following session is supported by an Educational Grant. Monday, May 30, 2016 EXHIBITION MAP N. Anitschkow hall 18:40-19:40 Keynote Lecture Supported by Amgen, AstraZeneca, MSD, Pfizer, Regenron and Sanofi. Chair: Chair: alberico Catapano (Italy) wolfgang J. Schneider (Austria) 18:40 How genes control cholesterol Michael S. Brown (USA) EXHIBITORS LIST Company Name Booth # Akcea Therapeutics 22 Alexion Pharma 2 Amgen 18 Denka Seiken 8 European Atherosclerosis Society 10 and 25 European FH Patient Network 5 FH SCORE 23 Fujifilm VisualSonics 12 Immuno-Biological Laboratories 7 Kaneka Pharma Europe 6 Meda Pharma 17 Merck MSD 1 Mercodia 24 Nebion 4 Numares Health 9 Randox 21 Sanofi Regeneron 20 Wisepress Medical Bookshop

117 84 th EAS CONGRESS List of Sponsors, Supporters & Exhibitors YOU VE ONLY JUST ARRIVED & ALREADY WE RE THINKING OF YOUR NEXT TRIP As the official airline network for EAS 2016, we d like to thank you for choosing the Star Alliance network and hope that all goes really well for you here today. Whilst you concentrate on the day s events, we hope you ll consider us the next time you need to attend a conference. With over 18,500 flights a day to 1,330 airports across 192 countries, our 28 member airlines will extend a wide choice of flights to any future conference you re planning to attend. And no matter which of those airlines frequent flyer programmes you belong to, you can earn and redeem miles across all of them. So the next time you want to concentrate all your energies on your conference, we hope you ll decide to leave the travel arrangements to us. Aegerion Aegerion Pharmaceuticals Inc One Main St, Suite 800 Cambridge MA USA Aegerion Pharmaceuticals, headquartered in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company was founded in 2005 with an initial focus of bringing new therapies to patients with severe lipid disorders and is now focused on research, development, commercialization of orphan drugs for the treatment of debilitating rare diseases. Akcea Therapeutics 55 Cambridge Parkway, Suite 100 Cambridge USA Booth #: 22 Akcea Therapeutics is a development and commercialization company focused on transforming the lives of patients with serious cardiometabolic lipid disorders. Established as a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., Akcea s portfolio spans multiple targets and disease states using advanced RNA-targeted antisense therapeutics. Akcea s investigational pipeline includes novel drugs designed to reduce several lipid risk factors, including LDL-Cholesterol, apoc-iii, triglycerides and Lp(a). Volanesorsen, Akcea s most advanced investigational drug, is in Phase 3 trials for ultra-orphan lipid disorders characterized by extremely high triglycerides and apoc-iii, including familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy (FPL). Information correct as of 03/

118 84 th EAS CONGRESS Alexion Pharma Giesshübelstrasse 30 Zürich 8045 Switzerland Booth #: 02 Alexion is a global biopharmaceutical company focused on developing and delivering lifetransforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people s lives depend on our work. AMgen DAMMSTRASSE 23 ZUG 6300 Switzerland Booth #: 23 Amgen s Commitment to Cardiovascular Disease Amgen is dedicated to addressing important scientific questions to advance care and improve the lives of patients with cardiovascular disease. Amgen has built a robust cardiology pipeline in an effort to address a number of today s important unmet patient needs, such as high cholesterol and heart failure. About Amgen Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people s lives. Amgen has grown to be the world s largest independent biotechnology company, reaching millions of patients around the world. AstraZeneca SE Mölndal, Pepparedsleden 1 Sweden AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. basf Carl-Bosch-Strasse 38 Ludwigshafen,Rhineland-Palatinate Germany website: BASF s Nutrition & Health division develops, produces and markets a comprehensive range of products and services for the human and animal nutrition, pharmaceutical as well as flavor and fragrance industries. The division strives to contribute to a better life through improving the nutrition, health and wellbeing of people across the world. Important human nutrition products are vitamins and carotenoids, plant sterols, emulsifiers and omega-3 fatty acids. Its feed additives such as vitamins, carotenoids, enzymes and organic acids make Nutrition &Health a worldwide leader for the animal nutrition market. The division provides the pharmaceutical industry with active ingredients such as caffeine and ibuprofen, as well as excipients and custom synthesis services. Furthermore, it produces aroma ingredients such as citral, geraniol and L-menthol for the flavor and fragrance industry. Amgen EU HQ Dammstr. 23 Zug 6301 Switzerland Booth #: 18 Amgen s Commitment to Cardiovascular Disease Amgen is dedicated to addressing important scientific questions to advance care and improve the lives of patients with cardiovascular disease. Amgen has built a robust cardiology pipeline in an effort to address a number of today s important unmet patient needs, such as high cholesterol and heart failure. About Amgen Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people s lives. Amgen has grown to be the world s largest Denka Seiken Co., ltd Nihonbashi Mitsui Tower, Nihonbashi-Muromachi Tokyo Japan Booth #: 08 Denka Seiken offers assays directly quantifying (without any sample pretreatment) lipid subfractions, and also latex-enhanced turbidimetric immunoassays for specific protein biomarkers to be run on automated chemistry analyzers. The range of lipid subfraction assays includes small dense LDL, HDL3, Remnant Lipoproteins and Triglycerides in LDL particles. The latex-enhanced turbidimetric immunoassays are available for Adiponectin, Lp(a), Cystatin C, hscrp, RF, Myoglobin, IgE, Ferritin, etc. independent biotechnology company, reaching millions of patients around the world

119 84 th EAS CONGRESS European Atherosclerosis SocieTY Mässans gata 18/ Box 5243 Gothenburg Sweden Booth #: 10 Advancing and exchanging knowledge of the causes, natural history, treatments and prevention of atherosclerotic disease. FH Europe 7 North Road Maidenhead SL6 1PE UK Booth #: 05 FH Europe is the European FH Patient Network, consisting of 20 European patient organisations. We actively work to secure early identification and diagnosis of FH patients to prevent early cardiovascular disease. Our vision is to identify all FH patients across Europe and for them to be optimally treated in order they may live a full and healthy life. We were founded in 2015 and have successfully achieved a number of activities, including launching a Call to Action at the European Parliament in Brussels, we contributed to videos and articles about FH, attended health care professional meetings to raise awareness of the network and held a meeting of all countries to share best practice. FUJIFILM VisualSonics 3080 Yonge Street Suite 6100 Toronto M4N3N1 Canada Booth #: 12 FUJIFILM VisualSonics, Inc is the undisputed world leader in high-resolution, microultrasound systems designed for cardiovascular research. Our Vevo systems operate at MHz, achieving up to 30 μm resolution, 5-10 times higher than any other ultrasound system. Our small animal handling platforms captures key physiological parameters including temperature, respiration, ECG and heart rate. These are integrated in real-time with echo images and data. VisualSonics platforms combine high-resolution, real-time, in vivo imaging at reasonable cost with ease-of-use and quantifiable results. Immuno-Biological Laboratories Co., Ltd. (IBL) Naka Aza-Higashida, Fujioka-Shi, Gunma Japan Booth #: 07 LipoSEARCH is a sophisticated comprehensive lipoprotein profiling service (using HPLCbased system) that can deliver a reliable and promising complete set of data on Cholesterol and Triglyceride profiled in 4 major classes (CM, VLDL, LDL and HDL) and 20 subclasses classified by particle size. In addition, it also can deliver number of the particles that is recognized as an important factor in recent international research of atherosclerosis and dyslipidemia. The proprietary system and service LipoSEARCH is operated and provided by Skylight Biotech Inc. who is owned by Immuno-Biological Laboratories Co., Ltd. located in Japan. Kaneka Pharma Europe N.V. Frankfurter Straße Eschborn Germany Booth #: 06 Kaneka Corporation is touching the lives of people all over the world with infinite possibilities of chemistry. By further enhancing our key of highly innovative technology in producing medical devices and building blocks for active pharmaceutical ingredients (API), macromolecules, fermentation and bioscience, Kaneka is exploring new possibilities beyond the traditional boundaries of chemistry. Kaneka Pharma Europe N.V. (KPE) is the independent subsidiary responsible for the European market. Lipoproteinapheresis (Lp(a), LDL), in which Kaneka is one of the pioneers since 1989, is beside the interventional products one of KPE s main business

120 84 th EAS CONGRESS Kowa 6-29, Nishiki 3-chome, Naka-ku, Nagoya, Aichi Nagoya Japan Kowa Company, Ltd. (Kowa) is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various manufacturing and trading activities in the fields of pharmaceuticals, life science, information technology, textiles, machinery and various consumer products. Especially, the pharmaceutical field is positioned as the key business segment; prescription (ethical drug), Over-the-Counter (OTC) / Consumer Healthcare / Dietary supplement and Medical equipment. Moreover, the pharmaceutical R&D division is focused on research and development for cardiovascular therapeutics (dyslipidemia, type 2 diabetes and atherosclerosis), ophthalmology and antiinflammatory agents. To visit Kowa Company, Ltd. s website, please visit eng MEDA PHARMA S.P.A. Via Valosa di Sopra, 9 Monza Italy Booth #: 17 Meda is a leading international pharma company with a broad product portfolio. The nutraceuticals developed fall into the same therapeutic categories in which Meda has a wealth of experience. The cardiovascular area of nutraceuticals is represented by Armolipid product line (patented), dietary supplements with natural substances for the control of lipids when integrated in an adequate diet for such purposes. The ingredients of Armolipid line derive from high quality natural extracts with very well documented activity. The production process follows pharmaceutical quality standards, every product is clinically tested and the results of clinical trials published in peer-reviewed international medical journals. Mercodia ab Sylveniusgatan 8A Uppsala Sweden Booth #: 24 Mercodia AB is a Swedish biotech company focusing on the development of immunoassays for research within the field of metabolic disorders. Our assays are applicable to both animal and human models and are used for research ranging from basic scientific studies to large pre-clinical and clinical phase trials. The company was founded in 1991 and is today a world-leading supplier of products to all major international markets. More than ninety percent of our production is exported from our facilities in Uppsala to approximately 100 different countries around the world. MSD 2000 Galloping Hill Road Kenilworth USA Booth #: 01 Today s MSD is a global healthcare leader working to help the world be well. MSD is known as Merck in the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. MSD. Be well. For more information, visit Mylan Building 4 Trident Place Mosquito Way Hatfield AL10 9UL UK Mylan is one of the world s leading global pharmaceutical companies. Our medicines include generic and brand name products in a variety of dosage forms and therapeutic categories, such as difficult-to-manufacture injectables, transdermal patches and HIV/AIDS antiretroviral therapies. The company has innovative research and development capabilities and is one of the world s largest active pharmaceutical ingredient manufacturers. Mylan applies one global quality standard to all of our medications regardless of where they are produced. Creating better health for a better world. That s what inspires Mylan in our mission to provide quality healthcare to the world s 7 billion people, one person at a time

121 84 th EAS CONGRESS numares ag Am BioPark 9 Regensburg Germany Booth #: 09 numares HEALTH develops innovative, in vitro diagnostic (IVD) tests running exclusively on the AXINON System. AXINON relies on numares proprietary MGS technology for generating reproducible, quality controlled metabolic information using nuclear magnetic resonance (NMR) spectroscopy. The AXINON software makes this information based on disease-specific metabolic profiles easily accessible for in vitro diagnostics. The integration of different tests into one system makes AXINON a highly flexible tool for various diagnostic questions. The new IVD test lipofit-s100 (CE) determines clinically proven lipoprotein parameters such as LDL-P and sdldl in high throughput. Further tests for various indications (e.g. nephrology, oncology) are in development. Raisio P.O. Box 101, FI Raisio, Finland Website: Benecol - proven to reduce cholesterol Raisio Group is an expert in plant-based nutrition with strong international and local food brands. Benecol is the expert brand in cholesterol reduction and a pioneer in the cholesterol lowering functional food category. Raisio Group produces the unique cholesterol-lowering ingredient, Plant stanol ester, and licenses the Benecol brand worldwide. Benecol products are manufactured and sold by local food companies in 30 countries on five continents. Over 70 clinical studies support the use of Benecol as an effective, easy and safe dietary tool to lower LDL-cholesterol. The cholesterol-lowering effect of Benecol is additive to those of a healthy diet and statin medication. Randox Biosciences 55 Diamond Road Crumlin BT29 4QY UK Booth #: 21 Randox Biosciences is dedicated to improving health worldwide through scientific discovery, drug development and diagnostics. We offer a range of molecular products that provide diagnostic, prognostic and predictive solutions across a variety of disease areas including cardiology (cardiac risk prediction) and inherited disease. Our Familial Hypercholesterolemia Arrays l & ll enable the simultaneous detection of 40 FH-causing mutations within the LDLR, ApoB and PCSK9 genes. Utilising our award winning Biochip Array Technology for multi-analyte screening of biological samples, our assays provide a complete patient profile from a single sample for rapid, accurate diagnosis. regeneron 777 Old Saw Mill River Road Tarrytown, NY USA Booth #: 20 Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases. sanofi 54, av. La Boétie Paris France Booth #: 20 Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY)

122 84 th EAS CONGRESS 84 th European Atherosclerosis Society Congress Wisepress Medical BookshoP 25 High Path London SW19 2JL UK Booth #: 26 Wisepress.com, Europe s leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers. Follow us on Twitter for the latest MEET-THE-EXPERT SESSION Introducing Sebelipase alfa, a novel treatment for LAL-D Placing the spotlight on Lysosomal Acid Lipase Deficiency A case-based Meet-the-Expert session chaired by Professor Thomas Stulnig (Vienna, Austria) Experts will present cases on Lysosomal Acid Lipase Deficiency including early treatment results 31 May 2016; 14:05 14:50 Wilhelm Auerswald (Strassburg) Hall, Congress und Messe Innsbruck, Innsbruck, Austria 240 EMEA/UNB-LAL/16/

123 notes 84 th EAS CONGRESS

124 notes 84 th EAS CONGRESS

125 notes 84 th EAS CONGRESS

126 notes EAS INTERNATIONAL EVENING The EAS International Evening Networking event in Innsbruck will take place at Congress Park Igls Tuesday, May 31, 2016 at 19:30 Tickets are subject to availability and can be purchased at the registration desk. Transportation Buses will leave from the front of the Congress Centre at 18:45 We look forward to welcoming you 248

127